1	Gene	gene	NN	_	3	com	_	_
2	expression	expression	NN	_	3	com	_	_
3	analysis	analysis	NN	_	4	dep	_	_
4	indicated	indicate	VBD	_	0	root	_	_
5	an	an	DT	_	6	det	_	_
6	association	association	NN	_	4	obj	_	_
7	between	between	IN	_	8	case	_	_
8	genotypes	genotype	NNS	_	6	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	variant	variant	NN	_	8	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	CHRNA5	chrna0	NN	_	15	com	_	_
15	expression	expression	NN	_	12	conj	_	_
16	in	in	IN	_	17	case	_	_
17	brain	brain	NN	_	4	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	peripheral	peripheral	JJ	_	20	attr	_	_
20	drug2	drug0	NN	_	17	conj	_	_
21	,	,	,	_	17	p	_	_
22	and	and	CC	_	17	cc	_	_
23	with	with	IN	_	28	case	_	_
24	the	the	DT	_	28	det	_	_
25	rs16969968	rs0	NN	_	28	attr	_	_
26	and	and	CC	_	25	cc	_	_
27	rs17477223	rs0	NN	_	25	conj	_	_
28	variants	variant	NNS	_	17	conj	_	_
29	in	in	IN	_	30	case	_	_
30	brain	brain	NN	_	28	ppmod	_	_
31	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	aim	aim	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	study	study	NN	_	2	ppmod	_	_
6	was	be	VBD	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	assess	assess	VB	_	6	comp	_	_
9	the	the	DT	_	10	det	_	_
10	effect	effect	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	the	the	DT	_	15	det	_	_
15	intake	intake	NN	_	12	conj	_	_
16	of	of	IN	_	19	case	_	_
17	saturated	saturated	JJ	_	19	attr	_	_
18	fatty	fatty	JJ	_	19	attr	_	_
19	acids	acid	NNS	_	15	ppmod	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	SFA	sfa	NNS	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	,	,	,	_	15	p	_	_
24	and	and	CC	_	15	cc	_	_
25	drug2	drug0	NN	_	12	conj	_	_
26	on	on	IN	_	29	case	_	_
27	serum	serum	NN	_	29	com	_	_
28	lipid	lipid	NN	_	29	com	_	_
29	levels	level	NNS	_	10	ppmod	_	_
30	in	in	IN	_	33	case	_	_
31	Lithuanian	lithuanian	JJ	_	33	attr	_	_
32	adult	adult	JJ	_	33	attr	_	_
33	population	population	NN	_	29	ppmod	_	_
34	.	.	.	_	6	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	11	dep	_	_
4	,	,	,	_	3	p	_	_
5	SFA	sfa	NN	_	6	com	_	_
6	intake	intake	NN	_	3	conj	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	drug2	drug0	NN	_	3	conj	_	_
10	were	be	VBD	_	11	aux	_	_
11	found	find	VBN	_	1	acl	_	_
12	to	to	TO	_	14	aux	_	_
13	be	be	VB	_	14	aux	_	_
14	associated	associate	VBN	_	11	comp	_	_
15	with	with	IN	_	18	case	_	_
16	blood	blood	NN	_	18	com	_	_
17	lipid	lipid	NN	_	18	com	_	_
18	levels	level	NNS	_	14	ppmod	_	_
19	in	in	IN	_	22	case	_	_
20	Lithuanian	lithuanian	JJ	_	22	attr	_	_
21	adult	adult	JJ	_	22	attr	_	_
22	population	population	NN	_	18	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	Analysis	analysis	NN	_	9	dep	_	_
2	of	of	IN	_	6	case	_	_
3	gene-diet	gene-diet	JJ	_	6	attr	_	_
4	and	and	CC	_	3	cc	_	_
5	gene-obesity	gene-obesity	JJ	_	3	conj	_	_
6	interactions	interaction	NNS	_	1	ppmod	_	_
7	did	do	VBD	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	confirm	confirm	VB	_	0	root	_	_
10	that	that	IN	_	23	mark	_	_
11	the	the	DT	_	12	det	_	_
12	effects	effect	NNS	_	23	dep	_	_
13	of	of	IN	_	14	case	_	_
14	diet	diet	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	on	on	IN	_	18	case	_	_
18	TC	tc	NN	_	12	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	LDL-C	ldl-c	NN	_	21	com	_	_
21	level	level	NN	_	18	conj	_	_
22	significantly	significantly	RB	_	23	adv	_	_
23	depended	depend	VBD	_	9	comp	_	_
24	on	on	IN	_	25	case	_	_
25	drug1	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	9	p	_	_

1	Inside	inside	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	region	region	NN	_	19	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	16.3	0	CD	_	6	num	_	_
6	kb	kb	NN	_	3	ppmod	_	_
7	,	,	,	_	19	p	_	_
8	LD	ld	NN	_	19	dep	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	r2	r0	NN	_	11	advnp	_	_
11	=	=	JJ	_	12	attr	_	_
12	0.14	0	CD	_	8	num	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	between	between	IN	_	15	case	_	_
15	drug1	drug0	NN	_	8	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	was	be	VBD	_	19	aux	_	_
19	observed	observe	VBN	_	0	root	_	_
20	in	in	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	19	p	_	_
23	but	but	CC	_	26	cc	_	_
24	not	not	RB	_	26	neg	_	_
25	in	in	IN	_	26	case	_	_
26	drug4	drug0	NN	_	19	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	in	in	IN	_	29	case	_	_
29	controls	control	NNS	_	26	conj	_	_
30	.	.	.	_	19	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	discovery	discovery	NN	_	6	com	_	_
6	population	population	NN	_	9	ppmod	_	_
7	,	,	,	_	9	p	_	_
8	we	we	PRP	_	9	dep	_	_
9	observed	observe	VBD	_	1	acl	_	_
10	an	an	DT	_	11	det	_	_
11	association	association	NN	_	9	obj	_	_
12	between	between	IN	_	16	case	_	_
13	SIRT2	sirt0	NN	_	16	com	_	_
14	drug1	drug0	NN	_	16	com	_	_
15	T	t	NN	_	16	com	_	_
16	allele	allele	NN	_	11	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug2	drug0	NN	_	16	conj	_	_
19	(	-lrb-	-LRB-	_	32	p	_	_
20	adjusted	adjust	VBN	_	21	attr	_	_
21	odds	odds	NNS	_	32	dep	_	_
22	ratio	ratio	NN	_	25	advnp	_	_
23	-LSB-OR	-lsb-or	NN	_	25	advnp	_	_
24	]	-rsb-	-RRB-	_	25	p	_	_
25	=	=	JJ	_	21	attr	_	_
26	1.23	0	CD	_	25	num	_	_
27	,	,	,	_	32	p	_	_
28	95	0	CD	_	32	num	_	_
29	%	%	NN	_	32	meta	_	_
30	confidence	confidence	RB	_	31	adv	_	_
31	interval	interval	JJ	_	32	attr	_	_
32	-LSB-CI	-lsb-ci	NN	_	18	prn	_	_
33	]	-rsb-	-RRB-	_	32	p	_	_
34	:	:	:	_	32	p	_	_
35	1.02-1.50	0	CD	_	32	num	_	_
36	,	,	,	_	32	p	_	_
37	P	p	NN	_	38	dep	_	_
38	=	=	JJ	_	32	advcl	_	_
39	.02	0	NN	_	38	obj	_	_
40	,	,	,	_	38	p	_	_
41	after	after	IN	_	42	case	_	_
42	correction	correction	NN	_	38	ppmod	_	_
43	for	for	IN	_	44	case	_	_
44	sex	sex	NN	_	42	ppmod	_	_
45	,	,	,	_	44	p	_	_
46	age	age	NN	_	44	conj	_	_
47	,	,	,	_	46	p	_	_
48	and	and	CC	_	46	cc	_	_
49	APOE	apoe	NN	_	51	com	_	_
50	e4	e0	NN	_	51	com	_	_
51	genotype	genotype	NN	_	44	conj	_	_
52	)	-rrb-	-RRB-	_	32	p	_	_
53	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	association	association	NN	_	10	dep	_	_
3	between	between	IN	_	4	case	_	_
4	drug2	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	SIRT2	sirt0	NN	_	9	com	_	_
7	drug1	drug0	NN	_	9	com	_	_
8	T	t	NN	_	9	com	_	_
9	allele	allele	NN	_	4	conj	_	_
10	was	be	VBD	_	0	root	_	_
11	only	only	RB	_	12	adv	_	_
12	present	present	JJ	_	10	dep	_	_
13	in	in	IN	_	16	case	_	_
14	APOE	apoe	NN	_	16	com	_	_
15	e4	e0	NN	_	16	com	_	_
16	noncarriers	noncarriers	NNS	_	12	ppmod	_	_
17	(	-lrb-	-LRB-	_	31	p	_	_
18	adjusted	adjust	VBN	_	31	dep	_	_
19	OR	or	CC	_	18	cc	_	_
20	=	=	JJ	_	18	conj	_	_
21	1.29	0	CD	_	25	num	_	_
22	,	,	,	_	25	p	_	_
23	95	0	CD	_	25	num	_	_
24	%	%	NN	_	25	meta	_	_
25	CI	ci	CD	_	20	num	_	_
26	:	:	:	_	31	p	_	_
27	1.03-1.61	0	CD	_	31	num	_	_
28	,	,	,	_	31	p	_	_
29	P	p	NN	_	30	advnp	_	_
30	=	=	JJ	_	31	attr	_	_
31	.03	0	CD	_	10	num	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	.	.	.	_	10	p	_	_

1	Over	over	IN	_	4	case	_	_
2	an	an	DT	_	4	det	_	_
3	average	average	JJ	_	4	attr	_	_
4	period	period	NN	_	17	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	three	#crd#	CD	_	7	num	_	_
7	years	year	NNS	_	4	ppmod	_	_
8	,	,	,	_	17	p	_	_
9	participants	participant	NNS	_	17	dep	_	_
10	with	with	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	risk-conferring	risk-conferring	JJ	_	14	attr	_	_
13	TT	tt	NN	_	14	com	_	_
14	genotype	genotype	NN	_	9	ppmod	_	_
15	at	at	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	were	be	VBD	_	0	root	_	_
18	more	more	RBR	_	19	adv	_	_
19	likely	likely	JJ	_	17	dep	_	_
20	to	to	TO	_	21	aux	_	_
21	have	have	VB	_	17	comp	_	_
22	progression	progression	NN	_	21	obj	_	_
23	from	from	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	to	to	TO	_	26	aux	_	_
26	drug3	drug0	NN	_	22	ppmod	_	_
27	than	than	IN	_	28	mark	_	_
28	were	be	VBD	_	21	comp	_	_
29	CC	cc	JJ	_	30	attr	_	_
30	homozygotes	homozygote	NNS	_	28	obj	_	_
31	(	-lrb-	-LRB-	_	46	p	_	_
32	hazard	hazard	NN	_	33	com	_	_
33	ratio	ratio	NN	_	46	dep	_	_
34	,	,	,	_	46	p	_	_
35	1.55	0	CD	_	46	num	_	_
36	;	;	:	_	46	p	_	_
37	95	0	CD	_	38	num	_	_
38	percent	percent	NN	_	46	dep	_	_
39	confidence	confidence	RB	_	40	adv	_	_
40	interval	interval	JJ	_	38	attr	_	_
41	,	,	,	_	46	p	_	_
42	1.20	0	CD	_	44	num	_	_
43	to	to	TO	_	44	attr	_	_
44	2.01	0	CD	_	46	num	_	_
45	;	;	:	_	46	p	_	_
46	P<0.001	p<0	NN	_	30	prn	_	_
47	)	-rrb-	-RRB-	_	46	p	_	_
48	.	.	.	_	17	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	frequency	frequency	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	did	do	VBD	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	differ	differ	VB	_	1	acl	_	_
10	between	between	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NNS	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	controls	control	NNS	_	13	conj	_	_
16	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	indicated	indicate	VBD	_	0	root	_	_
4	that	that	IN	_	13	mark	_	_
5	homozygous	homozygous	JJ	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	carriers	carrier	NNS	_	13	dep	_	_
8	aged	aged	JJ	_	7	attr	_	_
9	35	0	CD	_	10	num	_	_
10	years	year	NNS	_	8	advnp	_	_
11	or	or	CC	_	10	cc	_	_
12	older	old	JJR	_	10	conj	_	_
13	had	have	VBD	_	3	comp	_	_
14	worse	bad	JJR	_	15	attr	_	_
15	drug2	drug0	NN	_	13	obj	_	_
16	than	than	IN	_	18	case	_	_
17	heterozygous	heterozygous	JJ	_	18	attr	_	_
18	carriers	carrier	NNS	_	13	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	noncarriers	noncarriers	NNS	_	18	conj	_	_
21	.	.	.	_	3	p	_	_

1	Nine	#crd#	CD	_	2	num	_	_
2	loci	locus	NNS	_	5	dep	_	_
3	were	be	VBD	_	5	aux	_	_
4	statistically	statistically	RB	_	5	adv	_	_
5	associated	associate	VBN	_	0	root	_	_
6	with	with	IN	_	9	case	_	_
7	incident	incident	JJ	_	9	attr	_	_
8	drug10	drug0	NN	_	9	com	_	_
9	events	event	NNS	_	5	ppmod	_	_
10	in	in	IN	_	33	case	_	_
11	white	white	JJ	_	12	attr	_	_
12	participants	participant	NNS	_	33	attr	_	_
13	:	:	:	_	12	p	_	_
14	9p21	0p0	NN	_	12	appo	_	_
15	(	-lrb-	-LRB-	_	19	p	_	_
16	drug1	drug0	NN	_	19	dep	_	_
17	;	;	:	_	19	p	_	_
18	P=4.7	p=0	CD	_	19	num	_	_
19	*	*	NN	_	14	prn	_	_
20	10	0	CD	_	19	num	_	_
21	(	-lrb-	-LRB-	_	19	p	_	_
22	-41	0	CD	_	19	num	_	_
23	)	-rrb-	-RRB-	_	19	p	_	_
24	)	-rrb-	-RRB-	_	19	p	_	_
25	,	,	,	_	12	p	_	_
26	16q23.1	0q0	CD	_	12	appo	_	_
27	(	-lrb-	-LRB-	_	30	p	_	_
28	drug2	drug0	NN	_	30	dep	_	_
29	;	;	:	_	30	p	_	_
30	P=0.0004	p=0	NN	_	26	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	,	,	,	_	12	p	_	_
33	6p24.1	0p0	NN	_	9	ppmod	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	drug3	drug0	NN	_	33	prn	_	_
36	;	;	:	_	35	p	_	_
37	P=0.0002	p=0	CD	_	35	num	_	_
38	)	-rrb-	-RRB-	_	35	p	_	_
39	,	,	,	_	33	p	_	_
40	2q36.3	0q0	CD	_	33	conj	_	_
41	(	-lrb-	-LRB-	_	45	p	_	_
42	drug4	drug0	NN	_	45	dep	_	_
43	;	;	:	_	45	p	_	_
44	P=6.7	p=0	CD	_	45	num	_	_
45	*	*	NN	_	40	prn	_	_
46	10	0	CD	_	45	num	_	_
47	(	-lrb-	-LRB-	_	45	p	_	_
48	-6	0	CD	_	45	num	_	_
49	)	-rrb-	-RRB-	_	45	p	_	_
50	)	-rrb-	-RRB-	_	45	p	_	_
51	,	,	,	_	40	p	_	_
52	MTHFD1L	mthfd0l	NN	_	33	conj	_	_
53	(	-lrb-	-LRB-	_	57	p	_	_
54	drug5	drug0	NN	_	57	dep	_	_
55	,	,	,	_	57	p	_	_
56	P=5.1	p=0	NN	_	57	com	_	_
57	*	*	NN	_	52	prn	_	_
58	10	0	CD	_	57	num	_	_
59	(	-lrb-	-LRB-	_	60	p	_	_
60	-10	0	CD	_	57	num	_	_
61	)	-rrb-	-RRB-	_	60	p	_	_
62	)	-rrb-	-RRB-	_	57	p	_	_
63	,	,	,	_	52	p	_	_
64	APOE	apoe	NN	_	33	conj	_	_
65	(	-lrb-	-LRB-	_	69	p	_	_
66	drug6	drug0	NN	_	69	dep	_	_
67	;	;	:	_	69	p	_	_
68	P=2.7	p=0	CD	_	69	num	_	_
69	*	*	NN	_	64	prn	_	_
70	10	0	CD	_	69	num	_	_
71	(	-lrb-	-LRB-	_	69	p	_	_
72	-18	0	CD	_	69	num	_	_
73	)	-rrb-	-RRB-	_	69	p	_	_
74	)	-rrb-	-RRB-	_	69	p	_	_
75	,	,	,	_	64	p	_	_
76	ZNF627	znf0	NN	_	33	conj	_	_
77	(	-lrb-	-LRB-	_	81	p	_	_
78	drug7	drug0	NN	_	81	dep	_	_
79	;	;	:	_	81	p	_	_
80	P=5.0	p=0	CD	_	81	num	_	_
81	*	*	NN	_	76	prn	_	_
82	10	0	CD	_	81	num	_	_
83	(	-lrb-	-LRB-	_	81	p	_	_
84	-8	0	CD	_	81	num	_	_
85	)	-rrb-	-RRB-	_	81	p	_	_
86	)	-rrb-	-RRB-	_	81	p	_	_
87	,	,	,	_	76	p	_	_
88	CXCL12	cxcl0	NN	_	33	conj	_	_
89	(	-lrb-	-LRB-	_	93	p	_	_
90	drug8	drug0	NN	_	93	dep	_	_
91	;	;	:	_	93	p	_	_
92	P=1.4	p=0	CD	_	93	num	_	_
93	*	*	NN	_	88	prn	_	_
94	10	0	CD	_	93	num	_	_
95	(	-lrb-	-LRB-	_	93	p	_	_
96	-6	0	CD	_	93	num	_	_
97	)	-rrb-	-RRB-	_	93	p	_	_
98	)	-rrb-	-RRB-	_	93	p	_	_
99	and	and	CC	_	88	cc	_	_
100	LPL	lpl	NN	_	33	conj	_	_
101	(	-lrb-	-LRB-	_	105	p	_	_
102	drug9	drug0	NN	_	105	dep	_	_
103	;	;	:	_	105	p	_	_
104	P=2.7	p=0	CD	_	105	num	_	_
105	*	*	NN	_	100	prn	_	_
106	10	0	CD	_	105	num	_	_
107	(	-lrb-	-LRB-	_	105	p	_	_
108	-17	0	CD	_	105	num	_	_
109	)	-rrb-	-RRB-	_	105	p	_	_
110	)	-rrb-	-RRB-	_	105	p	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Apolipoprotein	apolipoprotein	NN	_	4	com	_	_
4	E	e	NN	_	9	attr	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	APOE	apoe	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	functional	functional	JJ	_	9	attr	_	_
9	haplotypes	haplotype	NNS	_	19	dep	_	_
10	determined	determine	VBN	_	9	acl	_	_
11	by	by	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	SNPs	snp	NNS	_	12	conj	_	_
16	have	have	VBP	_	19	aux	_	_
17	been	be	VBN	_	19	aux	_	_
18	extensively	extensively	RB	_	19	adv	_	_
19	studied	study	VBN	_	1	acl	_	_
20	and	and	CC	_	19	cc	_	_
21	found	find	VBN	_	19	conj	_	_
22	to	to	TO	_	23	aux	_	_
23	be	be	VB	_	21	comp	_	_
24	one	#crd#	CD	_	23	obj	_	_
25	of	of	IN	_	29	case	_	_
26	the	the	DT	_	29	det	_	_
27	most	most	RBS	_	28	adv	_	_
28	consistent	consistent	JJ	_	29	attr	_	_
29	association	association	NN	_	24	ppmod	_	_
30	in	in	IN	_	33	case	_	_
31	human	human	JJ	_	33	attr	_	_
32	drug3	drug0	NN	_	33	com	_	_
33	studies	study	NNS	_	29	ppmod	_	_
34	.	.	.	_	1	p	_	_

1	There	there	EX	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	also	also	RB	_	2	adv	_	_
4	no	no	DT	_	6	det	_	_
5	significant	significant	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	2	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	E4	e0	NN	_	11	com	_	_
11	carriers	carrier	NNS	_	8	conj	_	_
12	on	on	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	development	development	NN	_	6	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	2	p	_	_
18	but	but	CC	_	2	cc	_	_
19	multivariate	multivariate	JJ	_	22	attr	_	_
20	logistic	logistic	JJ	_	22	attr	_	_
21	regression	regression	NN	_	22	com	_	_
22	testing	testing	NN	_	23	dep	_	_
23	revealed	reveal	VBD	_	2	conj	_	_
24	that	that	IN	_	35	mark	_	_
25	the	the	DT	_	26	det	_	_
26	duration	duration	NN	_	35	dep	_	_
27	of	of	IN	_	28	case	_	_
28	drug3	drug0	NN	_	26	ppmod	_	_
29	and	and	CC	_	28	cc	_	_
30	triglyceride	triglyceride	NN	_	34	attr	_	_
31	and	and	CC	_	30	cc	_	_
32	hemoglobin	hemoglobin	NN	_	33	com	_	_
33	A1c	a0c	NN	_	30	conj	_	_
34	concentrations	concentration	NNS	_	28	conj	_	_
35	had	have	VBD	_	23	comp	_	_
36	independent	independent	JJ	_	37	attr	_	_
37	effects	effect	NNS	_	35	obj	_	_
38	on	on	IN	_	40	case	_	_
39	the	the	DT	_	40	det	_	_
40	development	development	NN	_	35	ppmod	_	_
41	of	of	IN	_	42	case	_	_
42	drug4	drug0	NN	_	40	ppmod	_	_
43	.	.	.	_	23	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Significant	significant	JJ	_	4	attr	_	_
4	associations	association	NNS	_	8	dep	_	_
5	with	with	IN	_	6	case	_	_
6	drug4	drug0	NN	_	4	ppmod	_	_
7	were	be	VBD	_	8	aux	_	_
8	observed	observe	VBN	_	1	acl	_	_
9	for	for	IN	_	10	case	_	_
10	genotypes	genotype	NNS	_	8	ppmod	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	A/T	a/t	NN	_	10	attr	_	_
13	(	-lrb-	-LRB-	_	21	p	_	_
14	odds	odds	NNS	_	21	dep	_	_
15	ratio	ratio	NN	_	14	attr	_	_
16	-LSB-OR	-lsb-or	NN	_	15	appo	_	_
17	]	-rsb-	-RRB-	_	21	p	_	_
18	,	,	,	_	21	p	_	_
19	2.1	0	CD	_	21	num	_	_
20	;	;	:	_	21	p	_	_
21	95	0	CD	_	12	num	_	_
22	%	%	NN	_	21	meta	_	_
23	confidence	confidence	RB	_	24	adv	_	_
24	interval	interval	JJ	_	21	attr	_	_
25	-LSB-CI	-lsb-ci	NN	_	21	appo	_	_
26	]	-rsb-	-RRB-	_	21	p	_	_
27	,	,	,	_	28	p	_	_
28	1.0-4.5	0	CD	_	12	num	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	,	,	,	_	12	p	_	_
31	drug2	drug0	NN	_	32	com	_	_
32	T/C	t/c	NN	_	12	conj	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	OR	or	NN	_	32	prn	_	_
35	,	,	,	_	34	p	_	_
36	4.4	0	CD	_	40	num	_	_
37	;	;	:	_	40	p	_	_
38	95	0	CD	_	40	num	_	_
39	%	%	NN	_	40	meta	_	_
40	CI	ci	CD	_	34	appo	_	_
41	,	,	,	_	34	p	_	_
42	1.9-10.2	0	CD	_	34	appo	_	_
43	)	-rrb-	-RRB-	_	34	p	_	_
44	,	,	,	_	32	p	_	_
45	and	and	CC	_	32	cc	_	_
46	drug3	drug0	NN	_	12	conj	_	_
47	(	-lrb-	-LRB-	_	56	p	_	_
48	OR	or	CC	_	56	cc	_	_
49	,	,	,	_	56	p	_	_
50	4.1	0	CD	_	56	num	_	_
51	;	;	:	_	56	p	_	_
52	95	0	CD	_	54	num	_	_
53	%	%	NN	_	54	meta	_	_
54	CI	ci	NN	_	56	dep	_	_
55	,	,	,	_	56	p	_	_
56	1.6-10.9	0	CD	_	8	num	_	_
57	)	-rrb-	-RRB-	_	56	p	_	_

1	The	the	DT	_	4	det	_	_
2	nicotinic	nicotinic	JJ	_	4	attr	_	_
3	acetylcholine	acetylcholine	NN	_	4	com	_	_
4	receptor	receptor	NN	_	5	com	_	_
5	polymorphism	polymorphism	NN	_	13	dep	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug1	drug0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	on	on	IN	_	10	case	_	_
10	chromosome	chromosome	NN	_	5	ppmod	_	_
11	15q25	0q0	CD	_	10	num	_	_
12	is	be	VBZ	_	13	aux	_	_
13	associated	associate	VBN	_	0	root	_	_
14	with	with	IN	_	16	case	_	_
15	major	major	JJ	_	16	attr	_	_
16	drug2	drug0	NN	_	13	ppmod	_	_
17	in	in	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	general	general	JJ	_	20	attr	_	_
20	population	population	NN	_	16	ppmod	_	_
21	with	with	IN	_	24	case	_	_
22	additional	additional	JJ	_	24	attr	_	_
23	increased	increase	VBN	_	24	attr	_	_
24	risk	risk	NN	_	20	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	COPD	copd	NN	_	24	ppmod	_	_
27	as	as	RB	_	28	com	_	_
28	well	well	RB	_	20	cc	_	_
29	as	as	IN	_	28	com	_	_
30	drug3	drug0	NN	_	20	conj	_	_
31	.	.	.	_	13	p	_	_

1	Although	although	IN	_	3	mark	_	_
2	there	there	EX	_	3	dep	_	_
3	was	be	VBD	_	21	advcl	_	_
4	only	only	RB	_	5	adv	_	_
5	moderate	moderate	JJ	_	7	attr	_	_
6	linkage	linkage	NN	_	7	com	_	_
7	disequilibrium	disequilibrium	NN	_	3	obj	_	_
8	between	between	IN	_	9	case	_	_
9	drug1	drug0	NN	_	3	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	the	the	DT	_	16	det	_	_
12	ApoE	apoe	NN	_	16	attr	_	_
13	e4	e0	NN	_	16	attr	_	_
14	defining	define	VBG	_	16	attr	_	_
15	SNP	snp	NN	_	16	com	_	_
16	drug2	drug0	NN	_	9	conj	_	_
17	,	,	,	_	21	p	_	_
18	we	we	PRP	_	21	dep	_	_
19	could	could	MD	_	21	modal	_	_
20	not	not	RB	_	21	neg	_	_
21	find	find	VB	_	0	root	_	_
22	an	an	DT	_	24	det	_	_
23	APOE-independent	apoe-independent	JJ	_	24	attr	_	_
24	effect	effect	NN	_	21	obj	_	_
25	of	of	IN	_	26	case	_	_
26	drug3	drug0	NN	_	24	ppmod	_	_
27	on	on	IN	_	28	case	_	_
28	drug4	drug0	NN	_	24	ppmod	_	_
29	,	,	,	_	28	p	_	_
30	either	either	CC	_	28	cc	_	_
31	in	in	IN	_	36	case	_	_
32	cross-sectional	cross-sectional	JJ	_	36	attr	_	_
33	or	or	CC	_	32	cc	_	_
34	in	in	FW	_	35	adv	_	_
35	longitudinal	longitudinal	JJ	_	32	conj	_	_
36	analyses	analysis	NNS	_	28	conj	_	_
37	.	.	.	_	21	p	_	_

1	In	in	IN	_	2	case	_	_
2	conclusion	conclusion	NN	_	19	ppmod	_	_
3	,	,	,	_	19	p	_	_
4	the	the	DT	_	6	det	_	_
5	major	major	JJ	_	6	attr	_	_
6	locus	locus	NN	_	19	dep	_	_
7	determining	determine	VBG	_	6	acl	_	_
8	familial	familial	JJ	_	9	attr	_	_
9	drug2	drug0	NN	_	7	obj	_	_
10	up	up	IN	_	13	case	_	_
11	to	to	TO	_	13	aux	_	_
12	high	high	JJ	_	13	attr	_	_
13	age	age	NN	_	7	ppmod	_	_
14	as	as	IN	_	15	mark	_	_
15	detected	detect	VBN	_	13	acl	_	_
16	by	by	IN	_	17	case	_	_
17	GWAS	gwas	NN	_	15	ppmod	_	_
18	was	be	VBD	_	19	aux	_	_
19	marked	mark	VBN	_	0	root	_	_
20	by	by	IN	_	21	case	_	_
21	drug1	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	which	which	WDT	_	24	dep	_	_
24	tags	tag	NNS	_	21	relcl	_	_
25	the	the	DT	_	27	det	_	_
26	deleterious	deleterious	JJ	_	27	attr	_	_
27	effects	effect	NNS	_	24	obj	_	_
28	of	of	IN	_	32	case	_	_
29	the	the	DT	_	32	det	_	_
30	ApoE	apoe	NN	_	32	com	_	_
31	e4	e0	NN	_	32	com	_	_
32	allele	allele	NN	_	27	ppmod	_	_
33	.	.	.	_	19	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	After	after	IN	_	4	case	_	_
4	correcting	correct	VBG	_	43	ppmod	_	_
5	for	for	IN	_	7	case	_	_
6	multiple	multiple	JJ	_	7	attr	_	_
7	testing	testing	NN	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	p<0.05	p<0	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	and	and	CC	_	4	cc	_	_
12	accounting	account	VBG	_	4	conj	_	_
13	for	for	IN	_	15	case	_	_
14	significant	significant	JJ	_	15	attr	_	_
15	differences	difference	NNS	_	12	ppmod	_	_
16	in	in	IN	_	20	case	_	_
17	the	the	DT	_	20	det	_	_
18	association	association	NN	_	20	com	_	_
19	effect	effect	NN	_	20	com	_	_
20	sizes	size	NNS	_	15	ppmod	_	_
21	between	between	IN	_	22	case	_	_
22	subjects	subject	NNS	_	20	ppmod	_	_
23	with	with	IN	_	22	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	without	without	IN	_	26	case	_	_
26	drug4	drug0	NN	_	23	conj	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	p<0.05	p<0	NN	_	26	prn	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	,	,	,	_	43	p	_	_
31	variants	variant	NNS	_	43	dep	_	_
32	of	of	IN	_	33	case	_	_
33	APOA5	apoa0	NN	_	31	ppmod	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	drug1	drug0	NN	_	33	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	and	and	CC	_	33	cc	_	_
38	APOE	apoe	NN	_	33	conj	_	_
39	(	-lrb-	-LRB-	_	40	p	_	_
40	drug2	drug0	NN	_	38	prn	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	were	be	VBD	_	43	aux	_	_
43	associated	associate	VBN	_	1	acl	_	_
44	with	with	IN	_	45	case	_	_
45	HDL-C	hdl-c	NN	_	43	ppmod	_	_
46	and	and	CC	_	45	cc	_	_
47	LDL-C	ldl-c	NN	_	48	com	_	_
48	responses	response	NNS	_	45	conj	_	_
49	in	in	IN	_	51	case	_	_
50	MetS	met	NNS	_	51	com	_	_
51	subjects	subject	NNS	_	48	ppmod	_	_
52	,	,	,	_	43	p	_	_
53	while	while	IN	_	57	mark	_	_
54	APOA4	apoa0	NN	_	55	com	_	_
55	drug3	drug0	NN	_	57	dep	_	_
56	was	be	VBD	_	57	aux	_	_
57	associated	associate	VBN	_	43	comp	_	_
58	with	with	IN	_	60	case	_	_
59	TG	tg	NN	_	60	com	_	_
60	response	response	NN	_	57	ppmod	_	_
61	in	in	IN	_	63	case	_	_
62	non-MetS	non-mets	JJ	_	63	attr	_	_
63	subjects	subject	NNS	_	60	ppmod	_	_
64	.	.	.	_	1	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	findings	finding	NNS	_	3	dep	_	_
3	confirm	confirm	VBP	_	0	root	_	_
4	that	that	IN	_	8	mark	_	_
5	the	the	DT	_	7	det	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	gene	gene	NN	_	8	dep	_	_
8	represents	represent	VBZ	_	3	comp	_	_
9	an	an	DT	_	11	det	_	_
10	important	important	JJ	_	11	attr	_	_
11	locus	locus	NN	_	8	obj	_	_
12	for	for	IN	_	13	case	_	_
13	predicting	predict	VBG	_	11	ppmod	_	_
14	inherited	inherit	VBN	_	15	attr	_	_
15	susceptibility	susceptibility	NN	_	13	obj	_	_
16	to	to	TO	_	17	aux	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	Five	#crd#	CD	_	2	num	_	_
2	polymorphisms	polymorphism	NNS	_	20	dep	_	_
3	(	-lrb-	-LRB-	_	17	p	_	_
4	-491	0	CD	_	5	num	_	_
5	drug1	drug0	NN	_	17	dep	_	_
6	,	,	,	_	17	p	_	_
7	-427	0	NN	_	8	num	_	_
8	drug2	drug0	NN	_	17	dep	_	_
9	,	,	,	_	8	p	_	_
10	-219	0	CD	_	11	num	_	_
11	drug3	drug0	NN	_	8	conj	_	_
12	,	,	,	_	11	p	_	_
13	and	and	CC	_	11	cc	_	_
14	e	e	NN	_	15	com	_	_
15	drug4	drug0	NN	_	8	conj	_	_
16	-	-	:	_	17	p	_	_
17	drug5	drug0	NN	_	2	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	were	be	VBD	_	20	aux	_	_
20	studied	study	VBN	_	0	root	_	_
21	in	in	IN	_	24	case	_	_
22	1308	0	CD	_	24	num	_	_
23	drug6	drug0	NN	_	24	com	_	_
24	patients	patient	NNS	_	20	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	1082	0	NN	_	28	num	_	_
27	control	control	JJ	_	28	attr	_	_
28	individuals	individual	NNS	_	24	conj	_	_
29	from	from	IN	_	32	case	_	_
30	the	the	DT	_	32	det	_	_
31	Central-Northern	central-northern	NNP	_	32	com	_	_
32	Italy	italy	NNP	_	24	ppmod	_	_
33	.	.	.	_	20	p	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Apolipoprotein	apolipoprotein	NN	_	4	com	_	_
4	E	e	NN	_	8	attr	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	APOE	apoe	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	genotype	genotype	NN	_	22	dep	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	e2/e3/e4	e0/e0/e0	NN	_	8	prn	_	_
11	:	:	:	_	10	p	_	_
12	drug1	drug0	NN	_	14	com	_	_
13	e4	e0	NN	_	14	com	_	_
14	allele	allele	NN	_	10	appo	_	_
15	;	;	:	_	10	p	_	_
16	drug2	drug0	NN	_	18	com	_	_
17	e2	e0	NN	_	18	com	_	_
18	allele	allele	NN	_	10	appo	_	_
19	)	-rrb-	-RRB-	_	10	p	_	_
20	is	be	VBZ	_	22	aux	_	_
21	strongly	strongly	RB	_	22	adv	_	_
22	associated	associate	VBN	_	1	acl	_	_
23	with	with	IN	_	26	case	_	_
24	both	both	CC	_	26	cc	_	_
25	lipid	lipid	NN	_	26	com	_	_
26	levels	level	NNS	_	22	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	A	a	DT	_	29	det	_	_
29	drug3	drug0	NN	_	31	poss	_	_
30	's	's	POS	_	29	case	_	_
31	disease	disease	NN	_	26	conj	_	_
32	.	.	.	_	1	p	_	_

1	As	as	IN	_	2	mark	_	_
2	expected	expect	VBN	_	9	advcl	_	_
3	,	,	,	_	9	p	_	_
4	the	the	DT	_	8	det	_	_
5	most	most	RBS	_	6	com	_	_
6	strongly	strongly	RB	_	7	adv	_	_
7	associated	associate	VBN	_	8	attr	_	_
8	SNP	snp	NN	_	9	dep	_	_
9	was	be	VBD	_	0	root	_	_
10	the	the	DT	_	14	det	_	_
11	APOE	apoe	JJ	_	14	attr	_	_
12	e4	e0	NN	_	14	com	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	variant	variant	NN	_	9	obj	_	_
15	(	-lrb-	-LRB-	_	23	p	_	_
16	HR=2.47	hr=0	NNP	_	23	dep	_	_
17	-LSB-1.58	-lsb-0	CD	_	16	num	_	_
18	,	,	,	_	16	p	_	_
19	3.87	0	CD	_	16	num	_	_
20	]	-rsb-	-RRB-	_	16	p	_	_
21	,	,	,	_	23	p	_	_
22	p=7.52	p=0	CD	_	23	num	_	_
23	*	*	NN	_	14	prn	_	_
24	10	0	CD	_	23	num	_	_
25	(	-lrb-	-LRB-	_	23	p	_	_
26	-5	0	CD	_	23	num	_	_
27	)	-rrb-	-RRB-	_	23	p	_	_
28	)	-rrb-	-RRB-	_	23	p	_	_
29	,	,	,	_	9	p	_	_
30	although	although	IN	_	44	mark	_	_
31	variants	variant	NNS	_	44	dep	_	_
32	within	within	IN	_	37	case	_	_
33	the	the	DT	_	37	det	_	_
34	more	more	RBR	_	36	adv	_	_
35	recently	recently	RB	_	36	adv	_	_
36	implicated	implicate	VBN	_	37	attr	_	_
37	SORL1	sorl0	NN	_	31	ppmod	_	_
38	and	and	CC	_	37	cc	_	_
39	RUNX1	runx0	NN	_	40	com	_	_
40	genes	gene	NNS	_	37	conj	_	_
41	were	be	VBD	_	44	aux	_	_
42	also	also	RB	_	44	adv	_	_
43	strongly	strongly	RB	_	44	adv	_	_
44	associated	associate	VBN	_	9	comp	_	_
45	with	with	IN	_	46	case	_	_
46	drug2	drug0	NN	_	44	ppmod	_	_
47	in	in	IN	_	48	case	_	_
48	drug3	drug0	NN	_	46	ppmod	_	_
49	(	-lrb-	-LRB-	_	50	p	_	_
50	HR=0.54	hr=0	NN	_	48	prn	_	_
51	-LSB-0.37	-lsb-0	CD	_	50	num	_	_
52	,	,	,	_	50	p	_	_
53	0.80	0	CD	_	50	num	_	_
54	]	-rsb-	-RRB-	_	50	p	_	_
55	,	,	,	_	50	p	_	_
56	p=0.002	p=0	NN	_	50	attr	_	_
57	and	and	CC	_	56	cc	_	_
58	HR=1.61	hr=0	NN	_	56	conj	_	_
59	-LSB-1.15	-lsb-0	CD	_	58	num	_	_
60	,	,	,	_	58	p	_	_
61	2.26	0	CD	_	58	num	_	_
62	]	-rsb-	-RRB-	_	58	p	_	_
63	,	,	,	_	50	p	_	_
64	p=0.006	p=0	NN	_	50	attr	_	_
65	respectively	respectively	RB	_	50	adv	_	_
66	)	-rrb-	-RRB-	_	50	p	_	_
67	.	.	.	_	9	p	_	_

1	Disease	disease	NN	_	3	com	_	_
2	association	association	NN	_	3	com	_	_
3	analysis	analysis	NN	_	4	dep	_	_
4	revealed	reveal	VBD	_	0	root	_	_
5	a	a	DT	_	8	det	_	_
6	susceptibility	susceptibility	NN	_	8	com	_	_
7	haplotype	haplotype	NN	_	8	com	_	_
8	CGTC	cgtc	NN	_	4	obj	_	_
9	(	-lrb-	-LRB-	_	15	p	_	_
10	in	in	IN	_	11	case	_	_
11	order	order	NN	_	15	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	15	p	_	_
15	drug2	drug0	NN	_	8	prn	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	15	appo	_	_
18	,	,	,	_	15	p	_	_
19	drug4	drug0	NN	_	15	appo	_	_
20	)	-rrb-	-RRB-	_	15	p	_	_
21	and	and	CC	_	8	cc	_	_
22	the	the	DT	_	23	det	_	_
23	carriers	carrier	NNS	_	8	conj	_	_
24	of	of	IN	_	26	case	_	_
25	this	this	DT	_	26	det	_	_
26	haplotype	haplotype	NN	_	23	ppmod	_	_
27	has	have	VBZ	_	29	lv	_	_
28	higher	high	JJR	_	29	attr	_	_
29	risk	risk	NN	_	26	acl	_	_
30	of	of	IN	_	31	case	_	_
31	drug5	drug0	NN	_	29	ppmod	_	_
32	(	-lrb-	-LRB-	_	36	p	_	_
33	OR	or	CC	_	36	cc	_	_
34	3.53	0	CD	_	36	num	_	_
35	,	,	,	_	36	p	_	_
36	95	0	CD	_	31	num	_	_
37	%	%	NN	_	36	meta	_	_
38	CI	ci	NN	_	36	appo	_	_
39	1.21-11.0	0	CD	_	38	num	_	_
40	,	,	,	_	36	p	_	_
41	P=0.017	p=0	NN	_	36	appo	_	_
42	)	-rrb-	-RRB-	_	36	p	_	_
43	and	and	CC	_	31	cc	_	_
44	osteoporosis	osteoporosis	NN	_	31	conj	_	_
45	(	-lrb-	-LRB-	_	47	p	_	_
46	OR	or	CC	_	47	cc	_	_
47	3.61	0	NN	_	44	num	_	_
48	,	,	,	_	47	p	_	_
49	95	0	CD	_	52	num	_	_
50	%	%	NN	_	52	meta	_	_
51	CI	ci	JJ	_	52	attr	_	_
52	1.53-9.48	0	CD	_	47	appo	_	_
53	,	,	,	_	47	p	_	_
54	P=0.002	p=0	NN	_	47	appo	_	_
55	)	-rrb-	-RRB-	_	47	p	_	_
56	after	after	IN	_	57	case	_	_
57	adjusting	adjust	VBG	_	29	ppmod	_	_
58	the	the	DT	_	60	det	_	_
59	confounding	confounding	JJ	_	60	attr	_	_
60	effect	effect	NN	_	57	obj	_	_
61	of	of	IN	_	62	case	_	_
62	age	age	NN	_	60	ppmod	_	_
63	,	,	,	_	62	p	_	_
64	BMI	bmi	NN	_	62	conj	_	_
65	and	and	CC	_	64	cc	_	_
66	years	year	NNS	_	62	conj	_	_
67	since	since	IN	_	68	case	_	_
68	menopause	menopause	NN	_	66	ppmod	_	_
69	.	.	.	_	4	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	With	with	IN	_	7	case	_	_
4	multivariate	multivariate	JJ	_	7	attr	_	_
5	generalized	generalized	JJ	_	7	attr	_	_
6	linear	linear	NN	_	7	com	_	_
7	models	model	NNS	_	18	ppmod	_	_
8	,	,	,	_	18	p	_	_
9	the	the	DT	_	10	det	_	_
10	association	association	NN	_	18	dep	_	_
11	of	of	IN	_	13	case	_	_
12	TEF	tef	NN	_	13	com	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	with	with	IN	_	16	case	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	symptoms	symptom	NNS	_	10	ppmod	_	_
17	was	be	VBD	_	18	aux	_	_
18	confirmed	confirm	VBN	_	1	acl	_	_
19	.	.	.	_	1	p	_	_

1	Several	several	JJ	_	2	attr	_	_
2	markers	marker	NNS	_	17	dep	_	_
3	in	in	IN	_	5	case	_	_
4	strong	strong	JJ	_	5	attr	_	_
5	LD	ld	NN	_	2	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	r	r	NN	_	5	prn	_	_
8	(	-lrb-	-LRB-	_	7	p	_	_
9	2	0	CD	_	7	num	_	_
10	)	-rrb-	-RRB-	_	7	p	_	_
11	>	>	RB	_	12	adv	_	_
12	0.7	0	CD	_	7	num	_	_
13	)	-rrb-	-RRB-	_	7	p	_	_
14	with	with	IN	_	15	case	_	_
15	drug1	drug0	NN	_	5	ppmod	_	_
16	were	be	VBD	_	17	aux	_	_
17	found	find	VBN	_	0	root	_	_
18	to	to	TO	_	21	aux	_	_
19	be	be	VB	_	21	aux	_	_
20	significantly	significantly	RB	_	21	adv	_	_
21	associated	associate	VBN	_	17	comp	_	_
22	with	with	IN	_	24	case	_	_
23	drug2	drug0	NN	_	24	com	_	_
24	risk	risk	NN	_	21	ppmod	_	_
25	in	in	IN	_	29	case	_	_
26	recent	recent	JJ	_	29	attr	_	_
27	genome-wide	genome-wide	NN	_	29	com	_	_
28	association	association	NN	_	29	com	_	_
29	studies	study	NNS	_	24	ppmod	_	_
30	with	with	IN	_	33	case	_	_
31	similar	similar	JJ	_	33	attr	_	_
32	effect	effect	NN	_	33	com	_	_
33	sizes	size	NNS	_	29	ppmod	_	_
34	,	,	,	_	21	p	_	_
35	providing	provide	VBG	_	21	comp	_	_
36	independent	independent	JJ	_	37	attr	_	_
37	support	support	NN	_	35	obj	_	_
38	of	of	IN	_	41	case	_	_
39	the	the	DT	_	41	det	_	_
40	current	current	JJ	_	41	attr	_	_
41	findings	finding	NNS	_	37	ppmod	_	_
42	.	.	.	_	17	p	_	_

1	The	the	DT	_	2	det	_	_
2	frequency	frequency	NN	_	10	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	G	g	NN	_	6	com	_	_
6	genotype	genotype	NN	_	2	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	COMT	comt	NN	_	9	com	_	_
9	drug1	drug0	NN	_	2	ppmod	_	_
10	was	be	VBD	_	0	root	_	_
11	statistically	statistically	RB	_	12	adv	_	_
12	different	different	JJ	_	10	dep	_	_
13	between	between	IN	_	14	case	_	_
14	patients	patient	NNS	_	12	ppmod	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	14	cc	_	_
18	controls	control	NNS	_	14	conj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	P	p	NN	_	18	prn	_	_
21	=	=	JJ	_	20	attr	_	_
22	.04	0	CD	_	20	num	_	_
23	)	-rrb-	-RRB-	_	20	p	_	_
24	,	,	,	_	14	p	_	_
25	and	and	CC	_	14	cc	_	_
26	between	between	IN	_	27	case	_	_
27	patients	patient	NNS	_	14	conj	_	_
28	with	with	IN	_	29	case	_	_
29	drug3	drug0	NN	_	27	ppmod	_	_
30	and	and	CC	_	27	cc	_	_
31	controls	control	NNS	_	27	conj	_	_
32	(	-lrb-	-LRB-	_	35	p	_	_
33	P	p	NN	_	35	attr	_	_
34	=	=	JJ	_	35	attr	_	_
35	.02	0	NN	_	31	num	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	frequency	frequency	NN	_	10	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	A	a	NN	_	6	com	_	_
6	genotype	genotype	NN	_	2	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	PLCH1	plch0	NN	_	9	com	_	_
9	drug1	drug0	NN	_	2	ppmod	_	_
10	occurred	occur	VBD	_	0	root	_	_
11	more	more	RBR	_	12	com	_	_
12	frequently	frequently	RB	_	10	adv	_	_
13	in	in	IN	_	14	case	_	_
14	drug2	drug0	NN	_	10	ppmod	_	_
15	than	than	IN	_	17	case	_	_
16	in	in	IN	_	17	case	_	_
17	controls	control	NNS	_	10	ppmod	_	_
18	(	-lrb-	-LRB-	_	21	p	_	_
19	P	p	NN	_	21	attr	_	_
20	=	=	JJ	_	21	attr	_	_
21	.02	0	NN	_	17	num	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	.	.	.	_	10	p	_	_

1	The	the	DT	_	4	det	_	_
2	G/G	g/g	NN	_	4	attr	_	_
3	homozygous	homozygous	JJ	_	4	attr	_	_
4	genotype	genotype	NN	_	16	dep	_	_
5	in	in	IN	_	7	case	_	_
6	COMT	comt	NN	_	7	com	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	A/A	a/a	NN	_	11	attr	_	_
10	homozygous	homozygous	JJ	_	11	attr	_	_
11	genotype	genotype	NN	_	7	conj	_	_
12	in	in	IN	_	14	case	_	_
13	PLCH1	plch0	NN	_	14	com	_	_
14	drug2	drug0	NN	_	4	ppmod	_	_
15	were	be	VBD	_	16	aux	_	_
16	associated	associate	VBN	_	0	root	_	_
17	with	with	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug4	drug0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	respectively	respectively	RB	_	18	conj	_	_
23	(	-lrb-	-LRB-	_	28	p	_	_
24	odds	odds	NNS	_	25	com	_	_
25	ratio	ratio	NN	_	28	dep	_	_
26	-LSB-OR	-lsb-or	JJ	_	25	attr	_	_
27	]	-rsb-	-RRB-	_	28	p	_	_
28	0.61	0	CD	_	16	num	_	_
29	and	and	CC	_	28	cc	_	_
30	OR	or	CC	_	31	cc	_	_
31	2.01	0	CD	_	28	conj	_	_
32	,	,	,	_	31	p	_	_
33	respectively	respectively	RB	_	31	adv	_	_
34	)	-rrb-	-RRB-	_	28	p	_	_
35	.	.	.	_	16	p	_	_

1	In	in	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	study	study	NN	_	6	ppmod	_	_
4	,	,	,	_	6	p	_	_
5	we	we	PRP	_	6	dep	_	_
6	found	find	VBD	_	0	root	_	_
7	that	that	IN	_	14	mark	_	_
8	the	the	DT	_	11	det	_	_
9	COMT	comt	NN	_	11	com	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	SNP	snp	NN	_	14	dep	_	_
12	was	be	VBD	_	14	aux	_	_
13	significantly	significantly	RB	_	14	adv	_	_
14	associated	associate	VBN	_	6	comp	_	_
15	with	with	IN	_	18	case	_	_
16	a	a	DT	_	18	det	_	_
17	reduced	reduce	VBN	_	18	attr	_	_
18	risk	risk	NN	_	14	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	,	,	,	_	18	p	_	_
22	especially	especially	RB	_	18	adv	_	_
23	drug3	drug0	NN	_	18	appo	_	_
24	,	,	,	_	14	p	_	_
25	which	which	WDT	_	26	dep	_	_
26	suggests	suggest	VBZ	_	14	comp	_	_
27	that	that	IN	_	31	mark	_	_
28	this	this	DT	_	29	det	_	_
29	SNP	snp	NN	_	31	dep	_	_
30	may	may	MD	_	31	modal	_	_
31	have	have	VB	_	26	comp	_	_
32	a	a	DT	_	34	det	_	_
33	protective	protective	JJ	_	34	attr	_	_
34	effect	effect	NN	_	31	obj	_	_
35	.	.	.	_	6	p	_	_

1	Moreover	moreover	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	the	the	DT	_	6	det	_	_
4	PLCH1	plch0	NN	_	6	com	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	SNP	snp	NN	_	9	dep	_	_
7	was	be	VBD	_	9	aux	_	_
8	strongly	strongly	RB	_	9	adv	_	_
9	associated	associate	VBN	_	0	root	_	_
10	with	with	IN	_	13	case	_	_
11	an	an	DT	_	13	det	_	_
12	increased	increase	VBN	_	13	attr	_	_
13	risk	risk	NN	_	9	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	,	,	.	_	9	p	_	_

1	OBJECTIVE	objective	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	associated	associate	VBN	_	1	acl	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	athero-thrombosis	athero-thrombosis	NN	_	8	conj	_	_
11	however	however	WRB	_	23	adv	_	_
12	the	the	DT	_	13	det	_	_
13	association	association	NN	_	23	dep	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	AAA	aaa	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	has	have	VBZ	_	23	aux	_	_
20	not	not	RB	_	23	neg	_	_
21	been	be	VBN	_	23	aux	_	_
22	previously	previously	RB	_	23	adv	_	_
23	examined	examine	VBN	_	6	comp	_	_
24	.	.	.	_	1	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	We	we	PRP	_	4	dep	_	_
4	found	find	VBD	_	1	acl	_	_
5	no	no	DT	_	7	det	_	_
6	consistent	consistent	JJ	_	7	attr	_	_
7	association	association	NN	_	4	obj	_	_
8	between	between	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	.	.	.	_	1	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	As	as	IN	_	5	mark	_	_
4	previously	previously	RB	_	5	adv	_	_
5	reported	report	VBN	_	13	advcl	_	_
6	in	in	IN	_	7	case	_	_
7	Spain	spain	NN	_	5	ppmod	_	_
8	,	,	,	_	13	p	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	allele	allele	NN	_	13	dep	_	_
11	was	be	VBD	_	13	aux	_	_
12	strongly	strongly	RB	_	13	adv	_	_
13	associated	associate	VBN	_	1	acl	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	our	our	PRP$	_	18	poss	_	_
18	series	series	NN	_	13	ppmod	_	_
19	(	-lrb-	-LRB-	_	28	p	_	_
20	OR=2.88	or=0	CD	_	21	com	_	_
21	-LSB-95	-lsb-0	CD	_	28	num	_	_
22	%	%	NN	_	21	meta	_	_
23	C.I.	c.i.	NNP	_	21	appo	_	_
24	2.16-	0-	CD	_	23	num	_	_
25	3.84	0	CD	_	23	num	_	_
26	]	-rsb-	-RRB-	_	23	p	_	_
27	,	,	,	_	28	p	_	_
28	p=7.38E-11	p=0e-0	CD	_	13	num	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	.	.	.	_	1	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	results	result	NNS	_	3	dep	_	_
3	strengthen	strengthen	VBP	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	evidence	evidence	NN	_	3	obj	_	_
6	that	that	IN	_	14	mark	_	_
7	one	#crd#	CD	_	10	num	_	_
8	or	or	CC	_	7	cc	_	_
9	more	more	JJR	_	7	conj	_	_
10	variants	variant	NNS	_	14	dep	_	_
11	in	in	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	are	be	VBP	_	14	aux	_	_
14	associated	associate	VBN	_	5	acl	_	_
15	with	with	IN	_	17	case	_	_
16	increased	increase	VBN	_	17	attr	_	_
17	risk	risk	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	3	p	_	_

1	No	no	DT	_	3	det	_	_
2	combined	combined	JJ	_	3	attr	_	_
3	effect	effect	NN	_	11	dep	_	_
4	of	of	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	polymorphisms	polymorphism	NNS	_	3	ppmod	_	_
7	on	on	IN	_	9	case	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	phenotypes	phenotype	NNS	_	3	ppmod	_	_
10	was	be	VBD	_	11	aux	_	_
11	observed	observe	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	n't	not	RB	_	4	neg	_	_
4	affect	affect	VB	_	0	root	_	_
5	drug2	drug0	NN	_	4	obj	_	_
6	,	,	,	_	4	p	_	_
7	suggesting	suggest	VBG	_	4	comp	_	_
8	its	its	PRP$	_	11	poss	_	_
9	potential	potential	JJ	_	10	adv	_	_
10	modality-specific	modality-specific	JJ	_	11	attr	_	_
11	effects	effect	NNS	_	7	obj	_	_
12	on	on	IN	_	14	case	_	_
13	human	human	JJ	_	14	attr	_	_
14	pain	pain	NN	_	11	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	compared	compare	VBD	_	0	root	_	_
3	genotype	genotype	NN	_	4	com	_	_
4	frequencies	frequency	NNS	_	2	obj	_	_
5	in	in	IN	_	6	case	_	_
6	subjects	subject	NNS	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	those	those	DT	_	2	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	NGT	ngt	NN	_	10	ppmod	_	_
13	and	and	CC	_	2	cc	_	_
14	found	find	VBD	_	2	conj	_	_
15	marginal	marginal	JJ	_	16	attr	_	_
16	association	association	NN	_	14	obj	_	_
17	for	for	IN	_	18	case	_	_
18	drug1	drug0	NN	_	14	ppmod	_	_
19	(	-lrb-	-LRB-	_	24	p	_	_
20	P	p	NN	_	24	dep	_	_
21	=	=	JJ	_	20	attr	_	_
22	0.05	0	CD	_	21	num	_	_
23	;	;	:	_	24	p	_	_
24	odds	odds	NNS	_	18	prn	_	_
25	ratio	ratio	NN	_	24	attr	_	_
26	-LSB-OR	-lsb-or	JJ	_	28	attr	_	_
27	]	-rsb-	-RRB-	_	28	p	_	_
28	1.51	0	NN	_	25	appo	_	_
29	)	-rrb-	-RRB-	_	24	p	_	_
30	;	;	:	_	2	p	_	_

1	comparison	comparison	NN	_	13	dep	_	_
2	between	between	IN	_	5	case	_	_
3	NGT	ngt	JJ	_	5	attr	_	_
4	control	control	NN	_	5	com	_	_
5	subjects	subject	NNS	_	1	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	the	the	DT	_	12	det	_	_
8	combined	combined	JJ	_	12	attr	_	_
9	drug5	drug0	NN	_	12	com	_	_
10	/IGT	/igt	NN	_	12	com	_	_
11	case	case	NN	_	12	com	_	_
12	group	group	NN	_	5	conj	_	_
13	showed	show	VBD	_	0	root	_	_
14	strong	strong	JJ	_	15	attr	_	_
15	association	association	NN	_	13	obj	_	_
16	with	with	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	drug2	drug0	NN	_	17	conj	_	_
20	(	-lrb-	-LRB-	_	26	p	_	_
21	P	p	NN	_	26	dep	_	_
22	=	=	JJ	_	21	attr	_	_
23	0.008-0.01	0	CD	_	22	num	_	_
24	;	;	:	_	26	p	_	_
25	OR	or	CC	_	26	cc	_	_
26	1.53-1.57	0	CD	_	17	num	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	and	and	CC	_	15	cc	_	_
29	marginal	marginal	JJ	_	30	attr	_	_
30	association	association	NN	_	15	conj	_	_
31	with	with	IN	_	32	case	_	_
32	drug3	drug0	NN	_	30	ppmod	_	_
33	and	and	CC	_	32	cc	_	_
34	drug4	drug0	NN	_	32	conj	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	P	p	NN	_	32	prn	_	_
37	=	=	JJ	_	36	attr	_	_
38	0.07	0	CD	_	37	num	_	_
39	and	and	CC	_	36	cc	_	_
40	P	p	NN	_	36	conj	_	_
41	=	=	JJ	_	36	attr	_	_
42	0.04	0	CD	_	41	num	_	_
43	,	,	,	_	41	p	_	_
44	respectively	respectively	RB	_	41	adv	_	_
45	)	-rrb-	-RRB-	_	36	p	_	_
46	.	.	.	_	13	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	also	also	RB	_	3	adv	_	_
3	genotyped	genotyped	VBD	_	0	root	_	_
4	these	these	DT	_	5	det	_	_
5	SNPs	snp	NNS	_	3	obj	_	_
6	in	in	IN	_	10	case	_	_
7	nondiabetic	nondiabetic	JJ	_	9	adv	_	_
8	,	,	,	_	9	p	_	_
9	non-Amish	non-amish	JJ	_	10	attr	_	_
10	subjects	subject	NNS	_	3	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	n	n	NN	_	10	prn	_	_
13	=	=	JJ	_	12	attr	_	_
14	48	0	CD	_	12	num	_	_
15	)	-rrb-	-RRB-	_	12	p	_	_
16	,	,	,	_	10	p	_	_
17	in	in	IN	_	18	case	_	_
18	whom	whom	WP	_	24	ppmod	_	_
19	intravenous	intravenous	JJ	_	22	attr	_	_
20	glucose	glucose	NN	_	22	com	_	_
21	tolerance	tolerance	NN	_	22	com	_	_
22	tests	test	NNS	_	24	dep	_	_
23	were	be	VBD	_	24	aux	_	_
24	performed	performed	VBN	_	10	relcl	_	_
25	,	,	,	_	10	p	_	_
26	and	and	CC	_	3	cc	_	_
27	found	find	VBD	_	3	conj	_	_
28	an	an	DT	_	29	det	_	_
29	association	association	NN	_	27	obj	_	_
30	between	between	IN	_	31	case	_	_
31	drug1	drug0	NN	_	29	ppmod	_	_
32	and	and	CC	_	31	cc	_	_
33	drug2	drug0	NN	_	31	conj	_	_
34	and	and	CC	_	33	cc	_	_
35	drug3	drug0	NN	_	33	conj	_	_
36	(	-lrb-	-LRB-	_	37	p	_	_
37	P	p	NN	_	31	prn	_	_
38	=	=	JJ	_	37	attr	_	_
39	0.003	0	CD	_	37	num	_	_
40	and	and	CC	_	37	cc	_	_
41	P	p	NN	_	37	conj	_	_
42	=	=	VBG	_	41	acl	_	_
43	0.005	0	CD	_	42	obj	_	_
44	,	,	,	_	37	p	_	_
45	respectively	respectively	RB	_	37	adv	_	_
46	)	-rrb-	-RRB-	_	37	p	_	_
47	and	and	CC	_	31	cc	_	_
48	drug4	drug0	NN	_	31	conj	_	_
49	(	-lrb-	-LRB-	_	50	p	_	_
50	P	p	NN	_	48	prn	_	_
51	=	=	JJ	_	50	attr	_	_
52	0.04	0	CD	_	50	num	_	_
53	and	and	CC	_	50	cc	_	_
54	P	p	NN	_	50	conj	_	_
55	=	=	VBG	_	54	acl	_	_
56	0.007	0	CD	_	55	obj	_	_
57	,	,	,	_	50	p	_	_
58	respectively	respectively	RB	_	50	adv	_	_
59	)	-rrb-	-RRB-	_	50	p	_	_
60	.	.	.	_	3	p	_	_

1	Thus	thus	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	the	the	DT	_	5	det	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	polymorphism	polymorphism	NN	_	8	dep	_	_
6	is	be	VBZ	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	associated	associate	VBN	_	34	advcl	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	in	in	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	Caucasian	caucasian	NN	_	14	com	_	_
14	population	population	NN	_	10	ppmod	_	_
15	but	but	CC	_	8	cc	_	_
16	acts	act	VBZ	_	8	conj	_	_
17	as	as	IN	_	19	case	_	_
18	a	a	DT	_	19	det	_	_
19	modifier	modifier	NN	_	16	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	AAO	aao	NN	_	19	ppmod	_	_
23	in	in	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	with	with	IN	_	28	case	_	_
26	a	a	DT	_	28	det	_	_
27	sexual	sexual	JJ	_	28	attr	_	_
28	dimorphism	dimorphism	NN	_	22	ppmod	_	_
29	:	:	:	_	34	p	_	_
30	the	the	DT	_	32	det	_	_
31	Val	val	NN	_	32	com	_	_
32	allele	allele	NN	_	34	dep	_	_
33	is	be	VBZ	_	34	aux	_	_
34	associated	associate	VBN	_	0	root	_	_
35	with	with	IN	_	38	case	_	_
36	a	a	DT	_	38	det	_	_
37	younger	young	JJR	_	38	attr	_	_
38	AAO	aao	NN	_	34	ppmod	_	_
39	in	in	IN	_	40	case	_	_
40	men	man	NNS	_	38	ppmod	_	_
41	with	with	IN	_	43	case	_	_
42	idiopathic	idiopathic	JJ	_	43	attr	_	_
43	PD	pd	NN	_	40	ppmod	_	_
44	.	.	.	_	34	p	_	_

1	The	the	DT	_	4	det	_	_
2	drug1	drug0	NN	_	4	com	_	_
3	at-risk	at-risk	NN	_	4	com	_	_
4	allele	allele	NN	_	5	dep	_	_
5	associates	associate	VBZ	_	0	root	_	_
6	with	with	IN	_	8	case	_	_
7	decreased	decrease	VBN	_	8	attr	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	earlier	early	JJR	_	11	attr	_	_
11	age	age	NN	_	8	conj	_	_
12	at	at	IN	_	13	case	_	_
13	diagnosis	diagnosis	NN	_	11	ppmod	_	_
14	in	in	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	drug3	drug0	CD	_	17	num	_	_
17	subjects	subject	NNS	_	5	ppmod	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	P	p	NN	_	20	dep	_	_
20	=	=	JJ	_	17	prn	_	_
21	8.0	0	CD	_	22	num	_	_
22	x	x	NN	_	20	obj	_	_
23	10	0	CD	_	22	num	_	_
24	(	-lrb-	-LRB-	_	22	p	_	_
25	-3	0	CD	_	22	num	_	_
26	)	-rrb-	-RRB-	_	22	p	_	_
27	and	and	CC	_	20	cc	_	_
28	P	p	NN	_	29	dep	_	_
29	=	=	JJ	_	20	conj	_	_
30	3.8	0	CD	_	31	num	_	_
31	x	x	NN	_	29	obj	_	_
32	10	0	CD	_	31	num	_	_
33	(	-lrb-	-LRB-	_	31	p	_	_
34	-4	0	CD	_	31	num	_	_
35	)	-rrb-	-RRB-	_	31	p	_	_
36	,	,	,	_	29	p	_	_
37	respectively	respectively	RB	_	29	adv	_	_
38	)	-rrb-	-RRB-	_	20	p	_	_
39	,	,	,	_	17	p	_	_
40	which	which	WDT	_	42	dep	_	_
41	is	be	VBZ	_	42	aux	_	_
42	supported	support	VBN	_	17	relcl	_	_
43	by	by	IN	_	47	case	_	_
44	quantitative	quantitative	JJ	_	47	attr	_	_
45	family-based	family-based	JJ	_	47	attr	_	_
46	association	association	NN	_	47	com	_	_
47	tests	test	NNS	_	42	ppmod	_	_
48	.	.	.	_	5	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	seen	see	VBN	_	1	acl	_	_
6	to	to	TO	_	7	aux	_	_
7	show	show	VB	_	5	comp	_	_
8	a	a	DT	_	10	det	_	_
9	decreased	decrease	VBN	_	10	attr	_	_
10	risk	risk	NN	_	7	obj	_	_
11	for	for	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	Asian	asian	JJ	_	15	attr	_	_
15	population	population	NN	_	10	ppmod	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	polymorphisms	polymorphism	NNS	_	5	dep	_	_
5	demonstrated	demonstrate	VBD	_	0	root	_	_
6	an	an	DT	_	10	det	_	_
7	increased	increase	VBN	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	decreased	decrease	VBN	_	7	conj	_	_
10	risk	risk	NN	_	5	obj	_	_
11	for	for	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	5	p	_	_
14	respectively	respectively	RB	_	5	adv	_	_
15	.	.	.	_	5	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	We	we	PRP	_	4	dep	_	_
4	found	find	VBD	_	1	acl	_	_
5	no	no	DT	_	6	det	_	_
6	association	association	NN	_	4	obj	_	_
7	between	between	IN	_	9	case	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	status	status	NN	_	6	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	SNP	snp	NN	_	13	com	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	genotype	genotype	NN	_	9	conj	_	_
14	nor	nor	CC	_	4	cc	_	_
15	did	do	VBD	_	17	aux	_	_
16	we	we	PRP	_	17	obj	_	_
17	find	find	VB	_	4	conj	_	_
18	a	a	DT	_	20	det	_	_
19	significant	significant	JJ	_	20	attr	_	_
20	association	association	NN	_	17	obj	_	_
21	to	to	TO	_	23	aux	_	_
22	the	the	DT	_	23	det	_	_
23	degree	degree	NN	_	20	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug3	drug0	NNS	_	23	ppmod	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Although	although	IN	_	10	mark	_	_
4	prefrontal	prefrontal	JJ	_	5	attr	_	_
5	cortical	cortical	JJ	_	10	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	ventral	ventral	JJ	_	9	attr	_	_
8	striatal	striatal	JJ	_	9	attr	_	_
9	activity	activity	NN	_	5	conj	_	_
10	are	be	VBP	_	32	advcl	_	_
11	highly	highly	RB	_	12	adv	_	_
12	relevant	relevant	JJ	_	10	dep	_	_
13	for	for	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	10	p	_	_
16	and	and	CC	_	10	cc	_	_
17	under	under	IN	_	19	case	_	_
18	partial	partial	JJ	_	19	attr	_	_
19	control	control	NN	_	10	conj	_	_
20	of	of	IN	_	22	case	_	_
21	drug1	drug0	NN	_	22	com	_	_
22	genotype	genotype	NN	_	19	ppmod	_	_
23	,	,	,	_	32	p	_	_
24	no	no	DT	_	25	det	_	_
25	association	association	NN	_	32	dep	_	_
26	between	between	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	and	and	CC	_	27	cc	_	_
29	drug4	drug0	NN	_	30	com	_	_
30	behavior	behavior	NN	_	27	conj	_	_
31	was	be	VBD	_	32	aux	_	_
32	observed	observe	VBN	_	1	acl	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	data	datum	NNS	_	4	dep	_	_
3	strongly	strongly	RB	_	4	adv	_	_
4	confirm	confirm	VBP	_	0	root	_	_
5	that	that	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	gene	gene	NN	_	8	dep	_	_
8	contribute	contribute	VBP	_	4	comp	_	_
9	to	to	TO	_	11	aux	_	_
10	the	the	DT	_	11	det	_	_
11	risk	risk	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	In	in	IN	_	2	case	_	_
2	conclusion	conclusion	NN	_	6	ppmod	_	_
3	,	,	,	_	6	p	_	_
4	our	our	PRP$	_	5	poss	_	_
5	findings	finding	NNS	_	6	dep	_	_
6	provide	provide	VBP	_	0	root	_	_
7	evidence	evidence	NN	_	6	obj	_	_
8	that	that	IN	_	17	mark	_	_
9	in	in	IN	_	10	case	_	_
10	addition	addition	NN	_	17	ppmod	_	_
11	to	to	TO	_	13	aux	_	_
12	other	other	JJ	_	13	attr	_	_
13	genes	gene	NNS	_	10	ppmod	_	_
14	,	,	,	_	17	p	_	_
15	drug1	drug0	NN	_	17	dep	_	_
16	also	also	RB	_	17	adv	_	_
17	has	have	VBZ	_	7	acl	_	_
18	a	a	DT	_	20	det	_	_
19	significant	significant	JJ	_	20	attr	_	_
20	role	role	NN	_	17	obj	_	_
21	in	in	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	development	development	NN	_	17	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	,	,	,	_	6	p	_	_
27	and	and	CC	_	6	cc	_	_
28	demonstrate	demonstrate	VBP	_	6	conj	_	_
29	that	that	IN	_	40	mark	_	_
30	analysing	analyse	VBG	_	40	advcl	_	_
31	the	the	DT	_	34	det	_	_
32	complex	complex	JJ	_	34	attr	_	_
33	phenotype	phenotype	NN	_	34	com	_	_
34	associations	association	NNS	_	30	obj	_	_
35	of	of	IN	_	36	case	_	_
36	genes	gene	NNS	_	34	ppmod	_	_
37	by	by	IN	_	39	case	_	_
38	haplotype	haplotype	NN	_	39	com	_	_
39	tagging	tagging	NN	_	30	ppmod	_	_
40	is	be	VBZ	_	28	comp	_	_
41	a	a	DT	_	43	det	_	_
42	powerful	powerful	JJ	_	43	attr	_	_
43	method	method	NN	_	40	obj	_	_
44	.	.	.	_	6	p	_	_

1	In	in	IN	_	5	case	_	_
2	contrast	contrast	NN	_	5	advnp	_	_
3	to	to	TO	_	5	aux	_	_
4	previous	previous	JJ	_	5	attr	_	_
5	findings	finding	NNS	_	11	ppmod	_	_
6	,	,	,	_	11	p	_	_
7	analysis	analysis	NN	_	11	dep	_	_
8	by	by	IN	_	10	case	_	_
9	logistic	logistic	JJ	_	10	attr	_	_
10	regression	regression	NN	_	7	ppmod	_	_
11	failed	fail	VBD	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	find	find	VB	_	11	comp	_	_
14	any	any	DT	_	15	det	_	_
15	associations	association	NNS	_	13	obj	_	_
16	between	between	IN	_	20	case	_	_
17	drug1	drug0	JJ	_	20	attr	_	_
18	and	and	CC	_	17	cc	_	_
19	drug2	drug0	JJ	_	17	conj	_	_
20	symptoms	symptom	NNS	_	15	ppmod	_	_
21	.	.	.	_	11	p	_	_

1	Although	although	IN	_	8	mark	_	_
2	prefrontal	prefrontal	JJ	_	3	attr	_	_
3	cortical	cortical	JJ	_	8	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	ventral	ventral	JJ	_	7	attr	_	_
6	striatal	striatal	JJ	_	7	attr	_	_
7	activity	activity	NN	_	3	conj	_	_
8	are	be	VBP	_	29	advcl	_	_
9	highly	highly	RB	_	8	adv	_	_
10	relevant	relevant	JJ	_	8	dep	_	_
11	for	for	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	8	p	_	_
14	and	and	CC	_	8	cc	_	_
15	under	under	IN	_	17	case	_	_
16	partial	partial	JJ	_	17	attr	_	_
17	control	control	NN	_	8	conj	_	_
18	of	of	IN	_	20	case	_	_
19	drug1	drug0	NN	_	20	com	_	_
20	genotype	genotype	NN	_	17	ppmod	_	_
21	,	,	,	_	29	p	_	_
22	no	no	DT	_	23	det	_	_
23	association	association	NN	_	29	dep	_	_
24	between	between	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	drug4	drug0	NN	_	25	conj	_	_
28	was	be	VBD	_	29	aux	_	_
29	observed	observe	VBN	_	0	root	_	_
30	.	.	.	_	29	p	_	_

1	A	a	DT	_	3	det	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	association	association	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	observed	observe	VBN	_	0	root	_	_
6	between	between	IN	_	27	case	_	_
7	,	,	,	_	27	p	_	_
8	drug1	drug0	NN	_	27	attr	_	_
9	(	-lrb-	-LRB-	_	14	p	_	_
10	OR	or	CC	_	14	cc	_	_
11	=	=	JJ	_	14	attr	_	_
12	1.95	0	CD	_	11	num	_	_
13	,	,	,	_	14	p	_	_
14	C.I.	c.i.	NNP	_	8	prn	_	_
15	1.13-3.36	0	CD	_	14	num	_	_
16	)	-rrb-	-RRB-	_	14	p	_	_
17	and	and	CC	_	8	cc	_	_
18	drug2	drug0	NN	_	8	conj	_	_
19	(	-lrb-	-LRB-	_	24	p	_	_
20	OR	or	CC	_	24	cc	_	_
21	=	=	JJ	_	24	attr	_	_
22	2.39	0	CD	_	21	num	_	_
23	,	,	,	_	24	p	_	_
24	C.I.	c.i.	NNP	_	18	prn	_	_
25	1.24-4.24	0	CD	_	24	num	_	_
26	)	-rrb-	-RRB-	_	24	p	_	_
27	polymorphisms	polymorphism	NNS	_	5	ppmod	_	_
28	with	with	IN	_	30	case	_	_
29	the	the	DT	_	30	det	_	_
30	risk	risk	NN	_	5	ppmod	_	_
31	of	of	IN	_	32	case	_	_
32	drug3	drug0	NN	_	30	ppmod	_	_
33	.	.	.	_	5	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	observed	observe	VBN	_	0	root	_	_
3	a	a	DT	_	2	det	_	_
4	strong	strong	JJ	_	2	dep	_	_
5	association	association	NN	_	2	dep	_	_
6	drug4	drug0	NN	_	2	dep	_	_
7	with	with	IN	_	2	case	_	_
8	all	all	DT	_	2	det	_	_
9	the	the	DT	_	2	det	_	_
10	polymorphisms	polymorphism	NNS	_	2	dep	_	_
11	,	,	,	_	2	p	_	_
12	including	include	VBG	_	2	conj	_	_
13	drug1	drug0	NN	_	12	dep	_	_
14	(	-lrb-	-LRB-	_	12	p	_	_
15	odds	odds	NNS	_	12	dep	_	_
16	ratio	ratio	NN	_	12	dep	_	_
17	-LSB-OR	-lsb-or	JJ	_	12	dep	_	_
18	]	-rsb-	-RRB-	_	12	p	_	_
19	1.50	0	CD	_	12	num	_	_
20	-LSB-95	-lsb-0	CD	_	12	num	_	_
21	%	%	NN	_	12	meta	_	_
22	CI	ci	CD	_	12	num	_	_
23	=	=	JJ	_	12	dep	_	_
24	1.24-1.82	0	CD	_	12	num	_	_
25	]	-rsb-	-RRB-	_	12	p	_	_
26	,	,	,	_	12	p	_	_
27	p	p	NN	_	33	attr	_	_
28	=	=	JJ	_	33	attr	_	_
29	4.0	0	CD	_	33	num	_	_
30	x	x	NN	_	33	attr	_	_
31	10	0	CD	_	33	num	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	-5	0	CD	_	2	conj	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	)	-rrb-	-RRB-	_	33	p	_	_
36	,	,	,	_	33	p	_	_
37	drug2	drug0	NN	_	2	conj	_	_
38	(	-lrb-	-LRB-	_	37	p	_	_
39	OR	or	CC	_	37	cc	_	_
40	1.48	0	CD	_	45	num	_	_
41	-LSB-95	-lsb-0	CD	_	45	num	_	_
42	%	%	NN	_	45	meta	_	_
43	CI	ci	CD	_	45	num	_	_
44	=	=	JJ	_	45	attr	_	_
45	1.24-1.77	0	CD	_	2	conj	_	_
46	]	-rsb-	-RRB-	_	45	p	_	_
47	,	,	,	_	45	p	_	_
48	p	p	NN	_	54	attr	_	_
49	=	=	JJ	_	54	attr	_	_
50	2.0	0	CD	_	54	num	_	_
51	x	x	NN	_	54	attr	_	_
52	10	0	CD	_	54	num	_	_
53	(	-lrb-	-LRB-	_	54	p	_	_
54	-5	0	CD	_	2	conj	_	_
55	)	-rrb-	-RRB-	_	54	p	_	_
56	)	-rrb-	-RRB-	_	54	p	_	_
57	and	and	CC	_	54	cc	_	_
58	drug3	drug0	NN	_	2	conj	_	_
59	(	-lrb-	-LRB-	_	58	p	_	_
60	OR	or	CC	_	58	cc	_	_
61	1.46	0	CD	_	66	num	_	_
62	-LSB-95	-lsb-0	CD	_	66	num	_	_
63	%	%	NN	_	66	meta	_	_
64	CI	ci	CD	_	66	num	_	_
65	=	=	JJ	_	66	attr	_	_
66	1.22-1.75	0	CD	_	2	conj	_	_
67	]	-rsb-	-RRB-	_	66	p	_	_
68	,	,	,	_	66	p	_	_
69	p	p	NN	_	75	attr	_	_
70	=	=	JJ	_	75	attr	_	_
71	3.0	0	CD	_	75	num	_	_
72	x	x	NN	_	75	attr	_	_
73	10	0	CD	_	75	num	_	_
74	(	-lrb-	-LRB-	_	75	p	_	_
75	-5	0	CD	_	2	conj	_	_
76	)	-rrb-	-RRB-	_	75	p	_	_
77	)	-rrb-	-RRB-	_	75	p	_	_
78	.	.	.	_	75	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	found	find	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	association	association	NN	_	2	obj	_	_
5	of	of	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	TCF7L2	tcf0l0	NN	_	8	com	_	_
8	genotypes	genotype	NNS	_	4	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	age	age	NN	_	4	ppmod	_	_
11	at	at	IN	_	12	case	_	_
12	diagnosis	diagnosis	NN	_	2	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	BMI	bmi	NN	_	12	conj	_	_
15	or	or	CC	_	14	cc	_	_
16	WHR	whr	NN	_	12	conj	_	_
17	,	,	,	_	2	p	_	_
18	but	but	CC	_	2	cc	_	_
19	the	the	DT	_	21	det	_	_
20	risk	risk	NN	_	21	com	_	_
21	genotype	genotype	NN	_	25	dep	_	_
22	at	at	IN	_	23	case	_	_
23	drug1	drug0	NN	_	21	ppmod	_	_
24	was	be	VBD	_	25	aux	_	_
25	associated	associate	VBN	_	2	conj	_	_
26	with	with	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	p	p	NN	_	27	prn	_	_
30	=	=	JJ	_	29	attr	_	_
31	0.001	0	CD	_	29	num	_	_
32	)	-rrb-	-RRB-	_	29	p	_	_
33	,	,	,	_	27	p	_	_
34	drug3	drug0	NN	_	27	conj	_	_
35	(	-lrb-	-LRB-	_	38	p	_	_
36	p	p	NN	_	38	attr	_	_
37	=	=	JJ	_	38	attr	_	_
38	0.0002	0	NN	_	34	num	_	_
39	)	-rrb-	-RRB-	_	38	p	_	_
40	and	and	CC	_	34	cc	_	_
41	drug4	drug0	NN	_	43	com	_	_
42	model	model	NN	_	43	com	_	_
43	assessment	assessment	NN	_	27	conj	_	_
44	of	of	IN	_	45	case	_	_
45	drug5	drug0	NN	_	43	ppmod	_	_
46	(	-lrb-	-LRB-	_	51	p	_	_
47	HOMA-R	homa-r	NN	_	51	attr	_	_
48	;	;	:	_	51	p	_	_
49	p	p	NN	_	51	attr	_	_
50	=	=	JJ	_	51	attr	_	_
51	0.012	0	NN	_	45	num	_	_
52	)	-rrb-	-RRB-	_	51	p	_	_
53	in	in	IN	_	55	case	_	_
54	non-diabetic	non-diabetic	JJ	_	55	attr	_	_
55	subjects	subject	NNS	_	43	ppmod	_	_
56	.	.	.	_	25	p	_	_

1	However	however	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	we	we	PRP	_	4	dep	_	_
4	found	find	VBD	_	0	root	_	_
5	an	an	DT	_	6	det	_	_
6	association	association	NN	_	4	obj	_	_
7	between	between	IN	_	9	case	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	genotype	genotype	NN	_	6	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	Val/Val	val/val	JJ	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	and	and	CC	_	9	cc	_	_
14	A	a	DT	_	17	det	_	_
15	drug2	drug0	NN	_	17	com	_	_
16	carrier	carrier	NN	_	17	com	_	_
17	status	status	NN	_	9	conj	_	_
18	and	and	CC	_	6	cc	_	_
19	the	the	DT	_	20	det	_	_
20	risk	risk	NN	_	6	conj	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	drug4	drug0	NN	_	22	conj	_	_
25	.	.	.	_	4	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	polymorphisms	polymorphism	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	found	find	VBN	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	significantly	significantly	RB	_	9	adv	_	_
9	affect	affect	VB	_	6	comp	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	risk	risk	NN	_	9	obj	_	_
12	,	,	,	_	6	p	_	_
13	and	and	CC	_	6	cc	_	_
14	the	the	DT	_	16	det	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	polymorphism	polymorphism	NN	_	18	dep	_	_
17	helped	help	VBD	_	18	aux	_	_
18	determine	determine	VB	_	6	conj	_	_
19	drug4	drug0	NN	_	18	obj	_	_
20	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	association	association	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	drug2	drug0	NN	_	2	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	10	com	_	_
10	combination	combination	NN	_	7	conj	_	_
11	could	could	MD	_	12	modal	_	_
12	help	help	VB	_	0	root	_	_
13	to	to	TO	_	14	aux	_	_
14	explain	explain	VB	_	12	comp	_	_
15	the	the	DT	_	17	det	_	_
16	contradictory	contradictory	JJ	_	17	attr	_	_
17	results	result	NNS	_	14	obj	_	_
18	of	of	IN	_	20	case	_	_
19	previous	previous	JJ	_	20	attr	_	_
20	studies	study	NNS	_	17	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	There	there	EX	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	associations	association	NNS	_	2	obj	_	_
6	between	between	IN	_	8	case	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	genotypes	genotype	NNS	_	5	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	or	or	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	.	.	.	_	2	p	_	_

1	The	the	DT	_	3	det	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	allele	allele	NN	_	8	dep	_	_
4	of	of	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	COMT	comt	NN	_	7	com	_	_
7	gene	gene	NN	_	3	ppmod	_	_
8	confers	confer	VBZ	_	0	root	_	_
9	a	a	DT	_	12	det	_	_
10	significantly	significantly	RB	_	11	adv	_	_
11	increased	increase	VBN	_	12	attr	_	_
12	risk	risk	NN	_	8	obj	_	_
13	for	for	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	in	in	IN	_	18	case	_	_
18	drug4	drug0	NN	_	12	ppmod	_	_
19	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	show	show	VBP	_	0	root	_	_
4	a	a	DT	_	6	det	_	_
5	statistical	statistical	JJ	_	6	attr	_	_
6	association	association	NN	_	3	obj	_	_
7	and	and	CC	_	3	cc	_	_
8	suggest	suggest	VBP	_	3	conj	_	_
9	biological	biological	JJ	_	10	attr	_	_
10	plausibility	plausibility	NN	_	8	obj	_	_
11	that	that	IN	_	16	mark	_	_
12	the	the	DT	_	15	det	_	_
13	drug1	drug0	NN	_	15	com	_	_
14	T>C	t>c	NN	_	15	com	_	_
15	polymorphism	polymorphism	NN	_	16	dep	_	_
16	contributed	contribute	VBD	_	10	acl	_	_
17	to	to	TO	_	19	aux	_	_
18	increased	increase	VBN	_	19	attr	_	_
19	risks	risk	NNS	_	16	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	poor	poor	JJ	_	22	attr	_	_
22	prognosis	prognosis	NN	_	19	conj	_	_
23	of	of	IN	_	25	case	_	_
24	both	both	CC	_	25	cc	_	_
25	drug2	drug0	NN	_	19	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	drug3	drug0	NN	_	25	conj	_	_
28	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	increased	increase	VBN	_	3	attr	_	_
3	volumes	volume	NNS	_	17	dep	_	_
4	in	in	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	genu	genu	NN	_	3	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	splenium	splenium	NN	_	6	conj	_	_
9	and	and	CC	_	8	cc	_	_
10	total	total	JJ	_	11	attr	_	_
11	CC	cc	NN	_	6	conj	_	_
12	in	in	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	group	group	NN	_	6	ppmod	_	_
16	were	be	VBD	_	17	aux	_	_
17	associated	associate	VBN	_	0	root	_	_
18	with	with	IN	_	19	case	_	_
19	polymorphisms	polymorphism	NNS	_	17	ppmod	_	_
20	within	within	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	candidate	candidate	NN	_	23	com	_	_
23	genes	gene	NNS	_	19	ppmod	_	_
24	:	:	:	_	23	p	_	_
25	drug1	drug0	NN	_	23	appo	_	_
26	,	,	,	_	25	p	_	_
27	drug2	drug0	NN	_	25	conj	_	_
28	and	and	CC	_	27	cc	_	_
29	UFD1L	ufd0l	NN	_	25	conj	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	drug4	drug0	NN	_	29	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	.	.	.	_	17	p	_	_

1	The	the	DT	_	4	det	_	_
2	OPRM1	oprm0	NN	_	4	com	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	genotype	genotype	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	associated	associate	VBN	_	0	root	_	_
7	with	with	IN	_	31	case	_	_
8	patients	patient	NNS	_	31	attr	_	_
9	'	'	POS	_	8	case	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	ratings	rating	NNS	_	8	attr	_	_
12	at	at	IN	_	14	case	_	_
13	15	0	CD	_	14	num	_	_
14	min	min	NN	_	8	ppmod	_	_
15	in	in	IN	_	19	case	_	_
16	the	the	DT	_	19	det	_	_
17	postanesthesia	postanesthesia	NN	_	19	com	_	_
18	care	care	NN	_	19	com	_	_
19	unit	unit	NN	_	8	ppmod	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	PACU	pacu	NN	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	(	-lrb-	-LRB-	_	26	p	_	_
24	p	p	NN	_	25	advnp	_	_
25	=	=	JJ	_	26	attr	_	_
26	.01	0	CD	_	8	num	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	and	and	CC	_	8	cc	_	_
29	patients	patient	NNS	_	8	conj	_	_
30	'	'	POS	_	29	case	_	_
31	drug3	drug0	NN	_	6	ppmod	_	_
32	at	at	IN	_	34	case	_	_
33	15	0	CD	_	34	num	_	_
34	min	min	NN	_	31	ppmod	_	_
35	in	in	IN	_	37	case	_	_
36	the	the	DT	_	37	det	_	_
37	PACU	pacu	NNS	_	31	ppmod	_	_
38	(	-lrb-	-LRB-	_	41	p	_	_
39	p	p	NN	_	41	attr	_	_
40	=	=	JJ	_	41	attr	_	_
41	.02	0	NN	_	37	num	_	_
42	)	-rrb-	-RRB-	_	41	p	_	_
43	.	.	.	_	6	p	_	_

1	COMT	comt	NN	_	3	com	_	_
2	genotype	genotype	NN	_	3	com	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	associated	associate	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	in	in	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	first	#ord#	JJ	_	12	attr	_	_
11	45	0	CD	_	12	num	_	_
12	min	min	NN	_	7	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	PACU	pacu	NNS	_	12	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	p	p	NN	_	15	prn	_	_
18	=	=	JJ	_	17	attr	_	_
19	.04	0	CD	_	18	num	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	.	.	.	_	5	p	_	_

1	Our	our	PRP$	_	4	poss	_	_
2	haplotype	haplotype	NN	_	4	com	_	_
3	trend	trend	NN	_	4	com	_	_
4	analysis	analysis	NN	_	5	dep	_	_
5	identified	identify	VBD	_	0	root	_	_
6	a	a	DT	_	7	det	_	_
7	drug1	drug0	NN	_	5	obj	_	_
8	significantly	significantly	RB	_	9	adv	_	_
9	associated	associate	VBN	_	7	acl	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	p	p	NN	_	11	prn	_	_
14	=	=	JJ	_	13	attr	_	_
15	.0013	0	CD	_	13	num	_	_
16	)	-rrb-	-RRB-	_	13	p	_	_
17	,	,	,	_	11	p	_	_
18	drug3	drug0	NN	_	11	conj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	p	p	NN	_	18	prn	_	_
21	=	=	JJ	_	20	attr	_	_
22	.0024	0	CD	_	20	num	_	_
23	)	-rrb-	-RRB-	_	20	p	_	_
24	,	,	,	_	18	p	_	_
25	and	and	CC	_	18	cc	_	_
26	drug4	drug0	NN	_	11	conj	_	_
27	(	-lrb-	-LRB-	_	30	p	_	_
28	p	p	NN	_	30	attr	_	_
29	=	=	JJ	_	30	attr	_	_
30	.017	0	NN	_	26	num	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	.	.	.	_	5	p	_	_

1	Allele	allele	NN	_	4	com	_	_
2	G	g	NN	_	4	com	_	_
3	fromCOMT	fromcomt	NN	_	4	com	_	_
4	SNPs	snp	NNS	_	9	dep	_	_
5	drug1	drug0	NN	_	4	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	may	may	MD	_	9	modal	_	_
9	represent	represent	VB	_	0	root	_	_
10	reliable	reliable	JJ	_	12	attr	_	_
11	state-dependent	state-dependent	JJ	_	12	attr	_	_
12	predictors	predictor	NNS	_	9	obj	_	_
13	of	of	IN	_	15	case	_	_
14	global	global	JJ	_	15	attr	_	_
15	drug3	drug0	NN	_	12	ppmod	_	_
16	during	during	IN	_	20	case	_	_
17	manic	manic	JJ	_	20	attr	_	_
18	and	and	CC	_	17	cc	_	_
19	mixed	mixed	JJ	_	17	conj	_	_
20	episodes	episode	NNS	_	9	ppmod	_	_
21	in	in	IN	_	22	case	_	_
22	drug4	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	9	p	_	_

1	Moreover	moreover	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	the	the	DT	_	5	det	_	_
4	T	t	NN	_	5	com	_	_
5	allele	allele	NN	_	10	dep	_	_
6	at	at	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	was	be	VBD	_	10	aux	_	_
9	inversely	inversely	RB	_	10	adv	_	_
10	associated	associate	VBN	_	0	root	_	_
11	with	with	IN	_	16	case	_	_
12	log-transformed	log-transformed	JJ	_	14	adv	_	_
13	,	,	,	_	14	p	_	_
14	HOMA-	homa-	JJ	_	16	attr	_	_
15	%	%	NN	_	16	meta	_	_
16	B	b	NN	_	10	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	beta=-0.07	beta=-0	CD	_	16	num	_	_
19	,	,	,	_	18	p	_	_
20	p=0.005	p=0	CD	_	18	appo	_	_
21	)	-rrb-	-RRB-	_	18	p	_	_
22	as	as	IN	_	24	case	_	_
23	a	a	DT	_	24	det	_	_
24	measure	measure	NN	_	10	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	,	,	,	_	26	p	_	_
28	and	and	CC	_	26	cc	_	_
29	drug3	drug0	NN	_	26	conj	_	_
30	(	-lrb-	-LRB-	_	33	p	_	_
31	beta=-0.06	beta=-0	CD	_	33	num	_	_
32	,	,	,	_	33	p	_	_
33	p=0.02	p=0	CD	_	10	num	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	.	.	.	_	10	p	_	_

1	The	the	DT	_	4	det	_	_
2	nicotinic	nicotinic	JJ	_	4	attr	_	_
3	acetylcholine	acetylcholine	NN	_	4	com	_	_
4	receptor	receptor	NN	_	6	com	_	_
5	polymorphism	polymorphism	NN	_	6	com	_	_
6	drug1	drug0	NN	_	11	dep	_	_
7	on	on	IN	_	8	case	_	_
8	chromosome	chromosome	NN	_	6	ppmod	_	_
9	15q25	0q0	CD	_	8	num	_	_
10	is	be	VBZ	_	11	aux	_	_
11	associated	associate	VBN	_	0	root	_	_
12	with	with	IN	_	14	case	_	_
13	major	major	JJ	_	14	attr	_	_
14	drug2	drug0	NN	_	11	ppmod	_	_
15	in	in	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	general	general	JJ	_	18	attr	_	_
18	population	population	NN	_	14	ppmod	_	_
19	with	with	IN	_	22	case	_	_
20	additional	additional	JJ	_	22	attr	_	_
21	increased	increase	VBN	_	22	attr	_	_
22	risk	risk	NN	_	18	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	as	as	RB	_	26	com	_	_
26	well	well	RB	_	24	cc	_	_
27	as	as	IN	_	26	com	_	_
28	drug4	drug0	NN	_	24	conj	_	_
29	.	.	.	_	11	p	_	_

1	Variant	variant	JJ	_	2	attr	_	_
2	alleles	allele	NNS	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	polymorphisms	polymorphism	NNS	_	2	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	TLR2	tlr0	NN	_	7	com	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	drug3	drug0	NN	_	7	conj	_	_
13	demonstrated	demonstrate	VBD	_	0	root	_	_
14	a	a	DT	_	16	det	_	_
15	consistent	consistent	JJ	_	16	attr	_	_
16	association	association	NN	_	13	obj	_	_
17	with	with	IN	_	18	case	_	_
18	drug4	drug0	NN	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	21	p	_	_
20	p	p	NN	_	21	dep	_	_
21	=	=	JJ	_	13	prn	_	_
22	0.008	0	CD	_	21	obj	_	_
23	,	,	,	_	22	p	_	_
24	p	p	NN	_	22	conj	_	_
25	=	=	JJ	_	24	attr	_	_
26	0.006	0	CD	_	25	num	_	_
27	and	and	CC	_	24	cc	_	_
28	p	p	NN	_	22	conj	_	_
29	=	=	JJ	_	28	attr	_	_
30	0.029	0	CD	_	29	num	_	_
31	respectively	respectively	RB	_	30	adv	_	_
32	)	-rrb-	-RRB-	_	21	p	_	_
33	.	.	.	_	13	p	_	_

1	Variant	variant	JJ	_	2	attr	_	_
2	alleles	allele	NNS	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	polymorphisms	polymorphism	NNS	_	2	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	TLR2	tlr0	NN	_	7	com	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	drug3	drug0	NN	_	7	conj	_	_
13	demonstrated	demonstrate	VBD	_	0	root	_	_
14	a	a	DT	_	16	det	_	_
15	consistent	consistent	JJ	_	16	attr	_	_
16	association	association	NN	_	13	obj	_	_
17	with	with	IN	_	19	case	_	_
18	drug4	drug0	NN	_	19	com	_	_
19	severity	severity	NN	_	16	ppmod	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	p	p	NN	_	22	dep	_	_
22	=	=	JJ	_	13	prn	_	_
23	0.008	0	CD	_	22	obj	_	_
24	,	,	,	_	23	p	_	_
25	p	p	NN	_	23	conj	_	_
26	=	=	JJ	_	25	attr	_	_
27	0.006	0	CD	_	26	num	_	_
28	and	and	CC	_	25	cc	_	_
29	p	p	NN	_	23	conj	_	_
30	=	=	JJ	_	29	attr	_	_
31	0.029	0	CD	_	30	num	_	_
32	respectively	respectively	RB	_	31	adv	_	_
33	)	-rrb-	-RRB-	_	22	p	_	_

1	Patients	patient	NNS	_	0	root	_	_
2	homozygous	homozygous	JJ	_	3	attr	_	_
3	AA	aum	NNS	_	11	dep	_	_
4	for	for	IN	_	7	case	_	_
5	TLR1	tlr0	CD	_	7	num	_	_
6	polymorphism	polymorphism	NN	_	7	com	_	_
7	drug1	drug0	NN	_	3	ppmod	_	_
8	are	be	VBP	_	11	aux	_	_
9	more	more	RBR	_	10	com	_	_
10	frequently	frequently	RB	_	11	adv	_	_
11	associated	associate	VBN	_	1	acl	_	_
12	with	with	IN	_	14	case	_	_
13	faster	fast	JJR	_	14	attr	_	_
14	decline	decline	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	compared	compare	VBN	_	20	adv	_	_
18	to	to	TO	_	20	aux	_	_
19	heterozygous	heterozygous	JJ	_	20	attr	_	_
20	genotype	genotype	NN	_	14	ppmod	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	OR:7.33	or:0	NNP	_	11	prn	_	_
23	(	-lrb-	-LRB-	_	26	p	_	_
24	95	0	CD	_	26	num	_	_
25	%	%	NN	_	24	meta	_	_
26	CI:1.63-33.11	ci:0	CD	_	22	num	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	There	there	EX	_	4	dep	_	_
4	is	be	VBZ	_	1	acl	_	_
5	a	a	DT	_	7	det	_	_
6	close	close	JJ	_	7	attr	_	_
7	relationship	relationship	NN	_	4	obj	_	_
8	between	between	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	presence	presence	NN	_	7	ppmod	_	_
11	of	of	IN	_	14	case	_	_
12	TLR3	tlr0	NN	_	14	com	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	/CT	/ct	NN	_	10	ppmod	_	_
15	and	and	CC	_	7	cc	_	_
16	an	an	DT	_	18	det	_	_
17	increased	increase	VBN	_	18	attr	_	_
18	risk	risk	NN	_	7	conj	_	_
19	of	of	IN	_	20	case	_	_
20	pneumonia	pneumonia	NN	_	18	ppmod	_	_
21	in	in	IN	_	22	case	_	_
22	children	child	NNS	_	20	ppmod	_	_
23	infected	infect	VBN	_	22	acl	_	_
24	by	by	IN	_	31	case	_	_
25	the	the	DT	_	31	det	_	_
26	pandemic	pandemic	JJ	_	31	attr	_	_
27	A/	a/	NN	_	31	attr	_	_
28	drug2	drug0	NN	_	31	attr	_	_
29	/2009	0	NN	_	31	num	_	_
30	drug3	drug0	NN	_	31	com	_	_
31	virus	virus	NN	_	23	ppmod	_	_
32	.	.	.	_	1	p	_	_

1	METHODS	method	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Overall	overall	RB	_	12	adv	_	_
4	,	,	,	_	12	p	_	_
5	150	0	CD	_	6	num	_	_
6	patients	patient	NNS	_	12	dep	_	_
7	with	with	IN	_	8	case	_	_
8	drug6	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	ascites	ascites	NN	_	8	conj	_	_
11	were	be	VBD	_	12	aux	_	_
12	genotyped	genotyped	VBN	_	1	acl	_	_
13	for	for	IN	_	16	case	_	_
14	TLR2	tlr0	NN	_	16	com	_	_
15	gene	gene	NN	_	16	com	_	_
16	variants	variant	NNS	_	12	ppmod	_	_
17	drug1	drug0	NN	_	16	appo	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	drug2	drug0	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	,	,	,	_	17	p	_	_
22	drug3	drug0	NN	_	17	conj	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	drug4	drug0	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	,	,	,	_	22	p	_	_
27	Pro631His	pro0his	NN	_	17	conj	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	drug5	drug0	NN	_	27	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	and	and	CC	_	27	cc	_	_
32	the	the	DT	_	35	det	_	_
33	TLR2GT	tlr0gt	NN	_	35	com	_	_
34	microsatellite	microsatellite	NN	_	35	com	_	_
35	polymorphism	polymorphism	NN	_	17	conj	_	_
36	in	in	IN	_	37	case	_	_
37	intron	intron	NN	_	35	ppmod	_	_
38	2	0	CD	_	37	num	_	_
39	.	.	.	_	1	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	study	study	NN	_	5	dep	_	_
5	extends	extend	VBZ	_	1	acl	_	_
6	on	on	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	observation	observation	NN	_	5	ppmod	_	_
9	of	of	IN	_	13	case	_	_
10	a	a	DT	_	13	det	_	_
11	strong	strong	JJ	_	13	attr	_	_
12	multiethnic	multiethnic	JJ	_	13	attr	_	_
13	association	association	NN	_	8	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	polymorphisms	polymorphism	NNS	_	13	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	drug1	drug0	NN	_	15	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug2	drug0	NN	_	18	conj	_	_
21	with	with	IN	_	22	case	_	_
22	drug4	drug0	NN	_	18	ppmod	_	_
23	,	,	,	_	5	p	_	_
24	but	but	CC	_	5	cc	_	_
25	does	do	VBZ	_	27	aux	_	_
26	not	not	RB	_	27	neg	_	_
27	confirm	confirm	VB	_	5	conj	_	_
28	the	the	DT	_	29	det	_	_
29	association	association	NN	_	27	obj	_	_
30	of	of	IN	_	31	case	_	_
31	CPT1B/CHKB	cpt0b/chkb	NN	_	29	ppmod	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	drug3	drug0	NN	_	31	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	in	in	IN	_	38	case	_	_
36	the	the	DT	_	38	det	_	_
37	Chinese	chinese	JJ	_	38	attr	_	_
38	population	population	NN	_	29	ppmod	_	_
39	.	.	.	_	1	p	_	_

1	Common	common	JJ	_	2	attr	_	_
2	variation	variation	NN	_	7	dep	_	_
3	at	at	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	7	aux	_	_
6	robustly	robustly	RB	_	7	adv	_	_
7	associated	associate	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	smoking	smoking	NN	_	10	com	_	_
10	quantity	quantity	NN	_	7	ppmod	_	_
11	and	and	CC	_	7	cc	_	_
12	was	be	VBD	_	14	aux	_	_
13	recently	recently	RB	_	14	adv	_	_
14	shown	show	VBN	_	7	conj	_	_
15	to	to	TO	_	16	aux	_	_
16	influence	influence	VB	_	14	comp	_	_
17	drug2	drug0	NN	_	16	obj	_	_
18	during	during	IN	_	19	case	_	_
19	pregnancy	pregnancy	NN	_	16	ppmod	_	_
20	,	,	,	_	7	p	_	_
21	but	but	CC	_	7	cc	_	_
22	its	its	PRP$	_	23	poss	_	_
23	influence	influence	NN	_	27	dep	_	_
24	on	on	IN	_	26	case	_	_
25	birth	birth	NN	_	26	com	_	_
26	weight	weight	NN	_	23	ppmod	_	_
27	is	be	VBZ	_	7	conj	_	_
28	not	not	RB	_	27	neg	_	_
29	clear	clear	JJ	_	27	dep	_	_
30	.	.	.	_	7	p	_	_

1	Stepwise	stepwise	JJ	_	4	attr	_	_
2	multiple	multiple	JJ	_	4	attr	_	_
3	regression	regression	NN	_	4	com	_	_
4	analysis	analysis	NN	_	5	dep	_	_
5	revealed	reveal	VBD	_	0	root	_	_
6	that	that	IN	_	18	mark	_	_
7	the	the	DT	_	9	det	_	_
8	risk	risk	NN	_	9	com	_	_
9	allele	allele	NN	_	18	dep	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	C	c	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	for	for	IN	_	15	case	_	_
14	SNP	snp	NN	_	15	com	_	_
15	drug1	drug0	NN	_	9	ppmod	_	_
16	was	be	VBD	_	18	aux	_	_
17	significantly	significantly	RB	_	18	adv	_	_
18	associated	associate	VBN	_	5	comp	_	_
19	with	with	IN	_	23	case	_	_
20	decreased	decrease	VBN	_	23	attr	_	_
21	CPT1B	cpt0b	NN	_	23	com	_	_
22	mRNA	mrna	NN	_	23	com	_	_
23	expression	expression	NN	_	18	ppmod	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	P	p	NN	_	18	prn	_	_
26	=	=	JJ	_	25	attr	_	_
27	1.0	0	CD	_	28	num	_	_
28	*	*	NN	_	26	advnp	_	_
29	10	0	CD	_	28	num	_	_
30	(	-lrb-	-LRB-	_	28	p	_	_
31	-9	0	CD	_	28	num	_	_
32	)	-rrb-	-RRB-	_	28	p	_	_
33	)	-rrb-	-RRB-	_	25	p	_	_
34	,	,	,	_	18	p	_	_
35	and	and	CC	_	18	cc	_	_
36	the	the	DT	_	38	det	_	_
37	CPT1B	cpt0b	NN	_	38	com	_	_
38	expression	expression	NN	_	39	dep	_	_
39	was	be	VBD	_	18	conj	_	_
40	higher	high	JJR	_	39	dep	_	_
41	in	in	IN	_	44	case	_	_
42	the	the	DT	_	44	det	_	_
43	drug2	drug0	NN	_	44	com	_	_
44	patients	patient	NNS	_	40	ppmod	_	_
45	than	than	IN	_	48	case	_	_
46	in	in	IN	_	48	case	_	_
47	the	the	DT	_	48	det	_	_
48	controls	control	NNS	_	40	ppmod	_	_
49	(	-lrb-	-LRB-	_	50	p	_	_
50	P	p	NN	_	48	prn	_	_
51	=	=	JJ	_	50	attr	_	_
52	0.005	0	CD	_	50	num	_	_
53	)	-rrb-	-RRB-	_	50	p	_	_
54	.	.	.	_	5	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	6	dep	_	_
4	was	be	VBD	_	6	aux	_	_
5	significantly	significantly	RB	_	6	adv	_	_
6	associated	associate	VBN	_	1	acl	_	_
7	with	with	IN	_	9	case	_	_
8	SNP	snp	NN	_	9	com	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	P	p	NN	_	9	prn	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	allele	allele	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	=	=	VBG	_	11	acl	_	_
16	3.6x10	0x0	CD	_	18	num	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	-3	0	CD	_	15	obj	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	;	;	:	_	18	p	_	_
21	OR	or	CC	_	15	cc	_	_
22	=	=	VBG	_	15	conj	_	_
23	1.56	0	CD	_	22	obj	_	_
24	;	;	:	_	11	p	_	_
25	95	0	CD	_	27	num	_	_
26	%	%	NN	_	25	meta	_	_
27	c.i.	c.i.	NN	_	11	appo	_	_
28	:	:	:	_	27	p	_	_
29	1.12-2.15	0	CD	_	27	num	_	_
30	)	-rrb-	-RRB-	_	11	p	_	_
31	and	and	CC	_	9	cc	_	_
32	HLA-DRB1	hla-drb0	NN	_	35	com	_	_
33	*	*	NN	_	35	com	_	_
34	1501-DQB1	0-dqb0	NN	_	35	com	_	_
35	*	*	NN	_	37	attr	_	_
36	0602	0	NN	_	37	num	_	_
37	haplotype	haplotype	NN	_	9	conj	_	_
38	(	-lrb-	-LRB-	_	43	p	_	_
39	P	p	NN	_	43	advnp	_	_
40	(	-lrb-	-LRB-	_	43	p	_	_
41	positivity	positivity	NN	_	43	advnp	_	_
42	)	-rrb-	-RRB-	_	43	p	_	_
43	=	=	JJ	_	6	prn	_	_
44	9.2x10	0x0	CD	_	43	num	_	_
45	(	-lrb-	-LRB-	_	46	p	_	_
46	-11	0	NN	_	44	num	_	_
47	)	-rrb-	-RRB-	_	46	p	_	_
48	;	;	:	_	44	p	_	_
49	OR	or	CC	_	44	cc	_	_
50	=	=	JJ	_	55	attr	_	_
51	3.97	0	CD	_	53	num	_	_
52	;	;	:	_	53	p	_	_
53	95	0	CD	_	50	num	_	_
54	%	%	NN	_	53	meta	_	_
55	c.i.	c.i.	NN	_	44	conj	_	_
56	:	:	:	_	55	p	_	_
57	2.55-6.19	0	CD	_	55	num	_	_
58	)	-rrb-	-RRB-	_	43	p	_	_
59	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	,	,	,	_	1	p	_	_
3	a	a	DT	_	4	det	_	_
4	SNP	snp	NN	_	1	appo	_	_
5	located	located	JJ	_	4	attr	_	_
6	between	between	IN	_	7	case	_	_
7	CPT1B	cpt0b	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	CHKB	chkb	NN	_	7	conj	_	_
10	,	,	,	_	1	p	_	_
11	was	be	VBD	_	12	aux	_	_
12	associated	associate	VBN	_	0	root	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	Japanese	japanese	NN	_	14	ppmod	_	_
17	(	-lrb-	-LRB-	_	31	p	_	_
18	drug2	drug0	NN	_	19	com	_	_
19	-LSB-C	-lsb-c	NN	_	31	dep	_	_
20	]	-rsb-	-RRB-	_	31	p	_	_
21	,	,	,	_	31	p	_	_
22	odds	odds	NNS	_	23	com	_	_
23	ratio	ratio	NN	_	31	dep	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	OR	or	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	=	=	JJ	_	23	attr	_	_
28	1.79	0	CD	_	27	num	_	_
29	,	,	,	_	31	p	_	_
30	combined	combined	JJ	_	31	attr	_	_
31	P	p	NN	_	16	prn	_	_
32	=	=	JJ	_	31	attr	_	_
33	4.4	0	CD	_	32	num	_	_
34	x	x	CC	_	33	cc	_	_
35	10	0	CD	_	33	conj	_	_
36	(	-lrb-	-LRB-	_	37	p	_	_
37	-7	0	CD	_	33	num	_	_
38	)	-rrb-	-RRB-	_	37	p	_	_
39	)	-rrb-	-RRB-	_	31	p	_	_
40	and	and	CC	_	16	cc	_	_
41	other	other	JJ	_	43	attr	_	_
42	ancestry	ancestry	JJ	_	43	attr	_	_
43	groups	group	NNS	_	16	conj	_	_
44	(	-lrb-	-LRB-	_	49	p	_	_
45	OR	or	CC	_	49	cc	_	_
46	=	=	JJ	_	49	attr	_	_
47	1.40	0	NN	_	49	num	_	_
48	,	,	,	_	49	p	_	_
49	P	p	NN	_	12	prn	_	_
50	=	=	JJ	_	49	attr	_	_
51	0.02	0	CD	_	49	num	_	_
52	)	-rrb-	-RRB-	_	49	p	_	_
53	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	,	,	,	_	1	p	_	_
3	a	a	DT	_	4	det	_	_
4	SNP	snp	NN	_	1	appo	_	_
5	located	located	JJ	_	4	attr	_	_
6	between	between	IN	_	7	case	_	_
7	CPT1B	cpt0b	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	CHKB	chkb	NN	_	7	conj	_	_
10	,	,	,	_	1	p	_	_
11	was	be	VBD	_	12	aux	_	_
12	associated	associate	VBN	_	0	root	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	Japanese	japanese	NN	_	14	ppmod	_	_
17	(	-lrb-	-LRB-	_	31	p	_	_
18	drug2	drug0	NN	_	19	com	_	_
19	-LSB-C	-lsb-c	NN	_	31	dep	_	_
20	]	-rsb-	-RRB-	_	31	p	_	_
21	,	,	,	_	31	p	_	_
22	odds	odds	NNS	_	23	com	_	_
23	ratio	ratio	NN	_	31	dep	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	OR	or	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	=	=	JJ	_	23	attr	_	_
28	1.79	0	CD	_	27	num	_	_
29	,	,	,	_	31	p	_	_
30	combined	combined	JJ	_	31	attr	_	_
31	P	p	NN	_	16	prn	_	_
32	=	=	JJ	_	31	attr	_	_
33	4.4	0	CD	_	32	num	_	_
34	x	x	CC	_	33	cc	_	_
35	10	0	CD	_	33	conj	_	_
36	(	-lrb-	-LRB-	_	37	p	_	_
37	-7	0	CD	_	33	num	_	_
38	)	-rrb-	-RRB-	_	37	p	_	_
39	)	-rrb-	-RRB-	_	31	p	_	_
40	and	and	CC	_	16	cc	_	_
41	other	other	JJ	_	43	attr	_	_
42	ancestry	ancestry	JJ	_	43	attr	_	_
43	groups	group	NNS	_	16	conj	_	_
44	(	-lrb-	-LRB-	_	49	p	_	_
45	OR	or	CC	_	49	cc	_	_
46	=	=	JJ	_	49	attr	_	_
47	1.40	0	NN	_	49	num	_	_
48	,	,	,	_	49	p	_	_
49	P	p	NN	_	12	prn	_	_
50	=	=	JJ	_	49	attr	_	_
51	0.02	0	CD	_	49	num	_	_
52	)	-rrb-	-RRB-	_	49	p	_	_
53	.	.	.	_	12	p	_	_

1	Case-control	case-control	JJ	_	2	attr	_	_
2	comparisons	comparison	NNS	_	3	dep	_	_
3	revealed	reveal	VBD	_	0	root	_	_
4	higher	high	JJR	_	5	attr	_	_
5	prevalence	prevalence	NN	_	3	obj	_	_
6	of	of	IN	_	9	case	_	_
7	short	short	JJ	_	9	attr	_	_
8	CAG	cag	NN	_	9	com	_	_
9	alleles	allele	NNS	_	5	ppmod	_	_
10	as	as	RB	_	11	com	_	_
11	well	well	RB	_	9	cc	_	_
12	as	as	IN	_	11	com	_	_
13	of	of	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	A	a	NN	_	16	com	_	_
16	allele	allele	NN	_	9	conj	_	_
17	of	of	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	drug1	drug0	NN	_	20	com	_	_
20	SNP	snp	NN	_	16	ppmod	_	_
21	in	in	IN	_	24	case	_	_
22	female	female	JJ	_	24	attr	_	_
23	drug3	drug0	NN	_	24	com	_	_
24	cases	case	NNS	_	16	ppmod	_	_
25	than	than	IN	_	27	case	_	_
26	in	in	IN	_	27	case	_	_
27	controls	control	NNS	_	3	ppmod	_	_
28	,	,	,	_	3	p	_	_
29	but	but	CC	_	3	cc	_	_
30	revealed	reveal	VBD	_	3	conj	_	_
31	no	no	DT	_	33	det	_	_
32	significant	significant	JJ	_	33	attr	_	_
33	differences	difference	NNS	_	30	obj	_	_
34	with	with	IN	_	35	case	_	_
35	respect	respect	NN	_	30	ppmod	_	_
36	to	to	TO	_	38	aux	_	_
37	the	the	DT	_	38	det	_	_
38	drug2	drug0	NN	_	35	ppmod	_	_
39	.	.	.	_	3	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	identified	identify	VBD	_	14	advcl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	as	as	IN	_	6	mark	_	_
5	strongly	strongly	RB	_	6	adv	_	_
6	associated	associate	VBN	_	2	comp	_	_
7	with	with	IN	_	8	case	_	_
8	drug3	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	14	p	_	_
10	In	in	IN	_	11	case	_	_
11	particular	particular	JJ	_	14	ppmod	_	_
12	,	,	,	_	14	p	_	_
13	we	we	PRP	_	14	dep	_	_
14	found	find	VBD	_	0	root	_	_
15	that	that	IN	_	24	mark	_	_
16	drug2	drug0	NN	_	24	dep	_	_
17	located	located	JJ	_	16	attr	_	_
18	8	0	CD	_	19	num	_	_
19	kb	kb	NN	_	17	advnp	_	_
20	from	from	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	EDA2R	eda0r	NN	_	23	com	_	_
23	gene	gene	NN	_	19	ppmod	_	_
24	showed	show	VBD	_	14	comp	_	_
25	the	the	DT	_	27	det	_	_
26	best	good	JJS	_	27	attr	_	_
27	result	result	NN	_	24	obj	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	P=7.77e	p=0e	NN	_	27	prn	_	_
30	(	-lrb-	-LRB-	_	29	p	_	_
31	-7	0	CD	_	29	num	_	_
32	)	-rrb-	-RRB-	_	29	p	_	_
33	)	-rrb-	-RRB-	_	29	p	_	_
34	.	.	.	_	14	p	_	_

1	In	in	IN	_	4	case	_	_
2	conditional	conditional	JJ	_	4	attr	_	_
3	logistic	logistic	JJ	_	4	attr	_	_
4	regression	regression	NN	_	7	ppmod	_	_
5	,	,	,	_	7	p	_	_
6	there	there	EX	_	7	dep	_	_
7	was	be	VBD	_	0	root	_	_
8	no	no	DT	_	9	det	_	_
9	association	association	NN	_	7	obj	_	_
10	between	between	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	number	number	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	alleles	allele	NNS	_	12	ppmod	_	_
15	with	with	IN	_	17	case	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	>or=21	>or=0	NN	_	9	ppmod	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	or	or	CC	_	20	cc	_	_
20	>or=22	>or=0	CD	_	17	num	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	and	and	CC	_	9	cc	_	_
23	risk	risk	NN	_	9	conj	_	_
24	of	of	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	,	,	,	_	25	p	_	_
27	drug3	drug0	NN	_	25	conj	_	_
28	or	or	CC	_	27	cc	_	_
29	drug4	drug0	NN	_	25	conj	_	_
30	.	.	.	_	7	p	_	_

1	In	in	IN	_	2	case	_	_
2	2001	0	NN	_	5	ppmod	_	_
3	,	,	,	_	5	p	_	_
4	we	we	PRP	_	5	dep	_	_
5	published	publish	VBN	_	0	root	_	_
6	the	the	DT	_	9	det	_	_
7	first	#ord#	JJ	_	9	attr	_	_
8	significant	significant	JJ	_	9	attr	_	_
9	evidence	evidence	NN	_	5	obj	_	_
10	of	of	IN	_	13	case	_	_
11	a	a	DT	_	13	det	_	_
12	genetic	genetic	JJ	_	13	attr	_	_
13	association	association	NN	_	9	ppmod	_	_
14	between	between	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	a	a	DT	_	21	det	_	_
18	synonymous	synonymous	JJ	_	21	attr	_	_
19	coding	coding	NN	_	21	com	_	_
20	SNP	snp	NN	_	21	com	_	_
21	drug1	drug0	NN	_	15	conj	_	_
22	in	in	IN	_	26	case	_	_
23	the	the	DT	_	26	det	_	_
24	androgen	androgen	NN	_	26	com	_	_
25	receptor	receptor	NN	_	26	com	_	_
26	gene	gene	NN	_	21	ppmod	_	_
27	,	,	,	_	21	p	_	_
28	AR	ar	NN	_	21	appo	_	_
29	.	.	.	_	5	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	utilised	utilise	VBN	_	0	root	_	_
3	statistical	statistical	JJ	_	4	attr	_	_
4	methods	method	NNS	_	2	obj	_	_
5	appropriate	appropriate	JJ	_	4	attr	_	_
6	for	for	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	categorical	categorical	JJ	_	9	attr	_	_
9	nature	nature	NN	_	5	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	phenotype	phenotype	NN	_	9	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	familial	familial	JJ	_	15	attr	_	_
15	structure	structure	NN	_	12	conj	_	_
16	of	of	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	cohort	cohort	NN	_	12	ppmod	_	_
19	,	,	,	_	2	p	_	_
20	and	and	CC	_	2	cc	_	_
21	determined	determine	VBD	_	2	conj	_	_
22	that	that	IN	_	41	mark	_	_
23	whilst	whilst	IN	_	28	mark	_	_
24	SNP	snp	NN	_	25	com	_	_
25	drug1	drug0	NN	_	28	dep	_	_
26	was	be	VBD	_	28	aux	_	_
27	strongly	strongly	RB	_	28	adv	_	_
28	associated	associate	VBN	_	41	advcl	_	_
29	with	with	IN	_	30	case	_	_
30	drug2	drug0	NN	_	28	ppmod	_	_
31	(	-lrb-	-LRB-	_	33	p	_	_
32	P	p	NN	_	33	com	_	_
33	<	<	NN	_	30	prn	_	_
34	0.0001	0	CD	_	33	num	_	_
35	)	-rrb-	-RRB-	_	33	p	_	_
36	,	,	,	_	41	p	_	_
37	the	the	DT	_	40	det	_	_
38	GGN	ggn	JJ	_	40	attr	_	_
39	triplet	triplet	NN	_	40	com	_	_
40	repeat	repeat	NN	_	41	dep	_	_
41	was	be	VBD	_	21	comp	_	_
42	not	not	RB	_	41	neg	_	_
43	(	-lrb-	-LRB-	_	45	p	_	_
44	P	p	NN	_	45	dep	_	_
45	=	=	JJ	_	41	prn	_	_
46	0.13	0	CD	_	45	obj	_	_
47	)	-rrb-	-RRB-	_	45	p	_	_
48	.	.	.	_	2	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	genotyped	genotyped	VBD	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	CAG	cag	NN	_	5	com	_	_
5	microsatellite	microsatellite	NN	_	2	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	six	#crd#	CD	_	11	num	_	_
8	haplotype-tagging	haplotype-tagging	JJ	_	11	attr	_	_
9	single	single	JJ	_	11	attr	_	_
10	nucleotide	nucleotide	NN	_	11	com	_	_
11	polymorphisms	polymorphism	NNS	_	5	conj	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	drug1	drug0	NN	_	11	prn	_	_
14	,	,	,	_	13	p	_	_
15	drug2	drug0	NN	_	13	appo	_	_
16	,	,	,	_	13	p	_	_
17	drug3	drug0	NN	_	13	appo	_	_
18	,	,	,	_	13	p	_	_
19	drug4	drug0	NN	_	13	appo	_	_
20	,	,	,	_	13	p	_	_
21	drug5	drug0	NN	_	13	appo	_	_
22	,	,	,	_	13	p	_	_
23	drug6	drug0	NN	_	13	appo	_	_
24	)	-rrb-	-RRB-	_	13	p	_	_
25	of	of	IN	_	29	case	_	_
26	the	the	DT	_	29	det	_	_
27	androgen	androgen	NN	_	29	com	_	_
28	receptor	receptor	NN	_	29	com	_	_
29	gene	gene	NN	_	11	ppmod	_	_
30	in	in	IN	_	33	case	_	_
31	987	0	CD	_	33	num	_	_
32	drug7	drug0	NN	_	33	com	_	_
33	cases	case	NNS	_	2	ppmod	_	_
34	and	and	CC	_	33	cc	_	_
35	1,034	0	CD	_	36	num	_	_
36	controls	control	NNS	_	33	conj	_	_
37	from	from	IN	_	39	case	_	_
38	a	a	DT	_	39	det	_	_
39	study	study	NN	_	33	ppmod	_	_
40	conducted	conduct	VBN	_	39	acl	_	_
41	in	in	IN	_	43	case	_	_
42	New	new	JJ	_	43	attr	_	_
43	Hampshire	hampshire	NN	_	40	ppmod	_	_
44	and	and	CC	_	43	cc	_	_
45	eastern	eastern	JJ	_	46	attr	_	_
46	Massachusetts	massachusetts	NN	_	43	conj	_	_
47	between	between	IN	_	48	case	_	_
48	May	may	NN	_	43	ppmod	_	_
49	1992	0	CD	_	48	num	_	_
50	and	and	CC	_	48	cc	_	_
51	July	july	NNP	_	48	conj	_	_
52	2003	0	CD	_	51	num	_	_
53	.	.	.	_	2	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	observed	observe	VBD	_	0	root	_	_
3	that	that	IN	_	15	mark	_	_
4	carriage	carriage	NN	_	15	dep	_	_
5	of	of	IN	_	7	case	_	_
6	two	#crd#	CD	_	7	num	_	_
7	alleles	allele	NNS	_	4	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	>	>	NN	_	7	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	=	=	JJ	_	13	attr	_	_
12	22	0	CD	_	13	num	_	_
13	drug1	drug0	NN	_	9	conj	_	_
14	was	be	VBD	_	15	aux	_	_
15	associated	associate	VBN	_	2	comp	_	_
16	with	with	IN	_	19	case	_	_
17	an	an	DT	_	19	det	_	_
18	increased	increase	VBN	_	19	attr	_	_
19	risk	risk	NN	_	15	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	compared	compare	VBN	_	24	adv	_	_
23	with	with	IN	_	24	case	_	_
24	carriage	carriage	NN	_	15	ppmod	_	_
25	of	of	IN	_	27	case	_	_
26	two	#crd#	CD	_	27	num	_	_
27	alleles	allele	NNS	_	24	ppmod	_	_
28	with	with	IN	_	31	case	_	_
29	<22	<0	NN	_	31	com	_	_
30	CAG	cag	NN	_	31	com	_	_
31	repeats	repeat	NNS	_	27	ppmod	_	_
32	(	-lrb-	-LRB-	_	34	p	_	_
33	covariate-adjusted	covariate-adjusted	JJ	_	34	attr	_	_
34	odds	odds	NNS	_	15	prn	_	_
35	ratios	ratio	NNS	_	34	appo	_	_
36	,	,	,	_	34	p	_	_
37	1.31	0	CD	_	39	num	_	_
38	;	;	:	_	39	p	_	_
39	95	0	CD	_	42	num	_	_
40	%	%	NN	_	39	meta	_	_
41	confidence	confidence	NN	_	42	com	_	_
42	intervals	interval	NNS	_	34	appo	_	_
43	,	,	,	_	34	p	_	_
44	1.01-1.69	0	CD	_	34	appo	_	_
45	)	-rrb-	-RRB-	_	34	p	_	_
46	.	.	.	_	2	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	14	mark	_	_
5	possession	possession	NN	_	14	dep	_	_
6	of	of	IN	_	10	case	_	_
7	two	#crd#	CD	_	10	num	_	_
8	long	long	JJ	_	10	attr	_	_
9	AR	ar	NN	_	10	com	_	_
10	alleles	allele	NNS	_	5	ppmod	_	_
11	drug1	drug0	NN	_	10	attr	_	_
12	may	may	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	associated	associate	VBN	_	3	comp	_	_
15	with	with	IN	_	17	case	_	_
16	increased	increase	VBN	_	17	attr	_	_
17	risk	risk	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	compared	compare	VBN	_	22	adv	_	_
21	with	with	IN	_	22	case	_	_
22	women	woman	NNS	_	14	ppmod	_	_
23	with	with	IN	_	27	case	_	_
24	two	#crd#	CD	_	27	num	_	_
25	short	short	JJ	_	27	attr	_	_
26	AR	ar	NN	_	27	com	_	_
27	alleles	allele	NNS	_	22	ppmod	_	_
28	(	-lrb-	-LRB-	_	31	p	_	_
29	<22	<0	CD	_	31	num	_	_
30	CAG	cag	NN	_	31	com	_	_
31	repeats	repeat	NNS	_	27	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	.	.	.	_	3	p	_	_

1	Recently	recently	RB	_	20	adv	_	_
2	,	,	,	_	20	p	_	_
3	TCF7L2	tcf0l0	NN	_	4	com	_	_
4	variants	variant	NNS	_	20	dep	_	_
5	,	,	,	_	4	p	_	_
6	including	include	VBG	_	10	adv	_	_
7	the	the	DT	_	10	det	_	_
8	microsatellite	microsatellite	NN	_	10	com	_	_
9	marker	marker	NN	_	10	com	_	_
10	drug1	drug0	NN	_	4	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	the	the	DT	_	17	det	_	_
13	nearly	nearly	RB	_	14	com	_	_
14	perfectly	perfectly	RB	_	15	adv	_	_
15	linked	link	VBN	_	17	attr	_	_
16	SNP	snp	NN	_	17	com	_	_
17	drug2	drug0	NN	_	10	conj	_	_
18	,	,	,	_	4	p	_	_
19	were	be	VBD	_	20	aux	_	_
20	identified	identify	VBN	_	0	root	_	_
21	to	to	TO	_	22	aux	_	_
22	associate	associate	VB	_	20	comp	_	_
23	with	with	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_

1	The	the	DT	_	3	det	_	_
2	T	t	NN	_	3	com	_	_
3	allele	allele	NN	_	6	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	showed	show	VBD	_	0	root	_	_
7	an	an	DT	_	8	det	_	_
8	association	association	NN	_	6	obj	_	_
9	with	with	IN	_	11	case	_	_
10	borderline	borderline	NN	_	11	com	_	_
11	significance	significance	NN	_	8	ppmod	_	_
12	(	-lrb-	-LRB-	_	25	p	_	_
13	OR	or	CC	_	25	cc	_	_
14	=	=	JJ	_	25	attr	_	_
15	1.19	0	CD	_	25	num	_	_
16	,	,	,	_	25	p	_	_
17	95	0	CD	_	25	num	_	_
18	%	%	NN	_	25	meta	_	_
19	C.I.	c.i.	NN	_	25	attr	_	_
20	=	=	JJ	_	25	attr	_	_
21	1.01-1.42	0	CD	_	25	num	_	_
22	,	,	,	_	25	p	_	_
23	P	p	NN	_	25	attr	_	_
24	=	=	JJ	_	25	attr	_	_
25	0.04	0	CD	_	6	num	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	,	,	,	_	6	p	_	_
28	and	and	CC	_	6	cc	_	_
29	the	the	DT	_	31	det	_	_
30	Cochran-Armitage	cochran-armitage	JJ	_	31	attr	_	_
31	test	test	NN	_	34	dep	_	_
32	for	for	IN	_	33	case	_	_
33	trend	trend	NN	_	31	ppmod	_	_
34	revealed	reveal	VBD	_	6	conj	_	_
35	an	an	DT	_	38	det	_	_
36	allele	allele	NN	_	37	advnp	_	_
37	dose-dependent	dose-dependent	JJ	_	38	attr	_	_
38	association	association	NN	_	34	obj	_	_
39	of	of	IN	_	40	case	_	_
40	drug2	drug0	NN	_	38	ppmod	_	_
41	with	with	IN	_	42	case	_	_
42	drug3	drug0	NN	_	38	ppmod	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	Ptrend	ptrend	NN	_	42	prn	_	_
45	=	=	JJ	_	44	attr	_	_
46	0.04	0	CD	_	44	num	_	_
47	)	-rrb-	-RRB-	_	44	p	_	_
48	.	.	.	_	6	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	a	a	DT	_	6	det	_	_
5	possible	possible	JJ	_	6	attr	_	_
6	influence	influence	NN	_	3	obj	_	_
7	of	of	IN	_	9	case	_	_
8	TCF7L2	tcf0l0	NN	_	9	com	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	on	on	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	risk	risk	NN	_	6	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	Further	far	RB	_	39	adv	_	_
2	,	,	,	_	39	p	_	_
3	effects	effect	NNS	_	39	dep	_	_
4	of	of	IN	_	8	case	_	_
5	a	a	DT	_	8	det	_	_
6	stronger	strong	JJR	_	8	attr	_	_
7	beneficial	beneficial	JJ	_	8	attr	_	_
8	association	association	NN	_	3	ppmod	_	_
9	between	between	IN	_	11	case	_	_
10	n-3	n-0	NN	_	11	com	_	_
11	drug4	drug0	NN	_	8	ppmod	_	_
12	in	in	IN	_	13	case	_	_
13	RBCs	rbc	NNS	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	plasma	plasma	NN	_	17	com	_	_
16	lipid	lipid	NN	_	17	com	_	_
17	parameters-	parameters-	NN	_	13	conj	_	_
18	including	include	VBG	_	13	acl	_	_
19	lower	low	JJR	_	20	attr	_	_
20	totalcholesterol	totalcholesterol	NN	_	37	attr	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	TC	tc	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	,	,	,	_	20	p	_	_
25	drug5	drug0	NN	_	20	conj	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	LDL-C	ldl-c	NN	_	25	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	or	or	CC	_	25	cc	_	_
30	higher	high	JJR	_	33	attr	_	_
31	high-density	high-density	NN	_	33	com	_	_
32	lipoprotein	lipoprotein	NN	_	33	com	_	_
33	cholesterol	cholesterol	NN	_	20	conj	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	HDL-C	hdl-c	NN	_	20	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	concentrations-	concentrations-	NN	_	18	obj	_	_
38	were	be	VBD	_	39	aux	_	_
39	associated	associate	VBN	_	0	root	_	_
40	with	with	IN	_	47	case	_	_
41	AGT	agt	NN	_	47	attr	_	_
42	M235T	m0t	NN	_	47	attr	_	_
43	(	-lrb-	-LRB-	_	47	p	_	_
44	drug1	drug0	NN	_	47	attr	_	_
45	)	-rrb-	-RRB-	_	47	p	_	_
46	TT	tt	NN	_	47	com	_	_
47	genotype	genotype	NN	_	39	ppmod	_	_
48	,	,	,	_	47	p	_	_
49	CETP	cetp	NN	_	55	attr	_	_
50	G-971A	g-0a	NN	_	55	attr	_	_
51	(	-lrb-	-LRB-	_	55	p	_	_
52	drug2	drug0	NN	_	55	attr	_	_
53	)	-rrb-	-RRB-	_	55	p	_	_
54	AG	ag	NN	_	55	com	_	_
55	genotype	genotype	NN	_	47	conj	_	_
56	,	,	,	_	55	p	_	_
57	T	t	NN	_	59	com	_	_
58	allele	allele	NN	_	59	com	_	_
59	carriers	carrier	NNS	_	47	conj	_	_
60	of	of	IN	_	62	case	_	_
61	CETP	cetp	NN	_	62	com	_	_
62	C-4502T	c-0t	NN	_	59	ppmod	_	_
63	(	-lrb-	-LRB-	_	64	p	_	_
64	drug3	drug0	NN	_	62	prn	_	_
65	)	-rrb-	-RRB-	_	64	p	_	_
66	,	,	,	_	59	p	_	_
67	and	and	CC	_	59	cc	_	_
68	T	t	NN	_	70	com	_	_
69	allele	allele	NN	_	70	com	_	_
70	carriers	carrier	NNS	_	72	com	_	_
71	ofCETP	ofcetp	NN	_	72	com	_	_
72	Ile405Val	ile0val	NN	_	47	conj	_	_
73	(	-lrb-	-LRB-	_	74	p	_	_
74	rs5882	rs0	CD	_	72	num	_	_
75	)	-rrb-	-RRB-	_	74	p	_	_
76	.	.	.	_	39	p	_	_

1	Based	base	VBN	_	4	adv	_	_
2	on	on	IN	_	4	case	_	_
3	12	0	CD	_	4	num	_	_
4	studies	study	NNS	_	32	ppmod	_	_
5	with	with	IN	_	8	case	_	_
6	5,573	0	CD	_	8	num	_	_
7	MetS	met	NNS	_	8	com	_	_
8	cases	case	NNS	_	4	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	8,290	0	CD	_	11	num	_	_
11	controls	control	NNS	_	8	conj	_	_
12	from	from	IN	_	16	case	_	_
13	5	0	CD	_	16	num	_	_
14	East	east	JJ	_	16	attr	_	_
15	Asian	asian	NN	_	16	com	_	_
16	studies	study	NNS	_	8	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	5	0	CD	_	20	num	_	_
19	European	european	NN	_	20	com	_	_
20	studies	study	NNS	_	16	conj	_	_
21	and	and	CC	_	20	cc	_	_
22	2	0	CD	_	23	num	_	_
23	studies	study	NNS	_	16	conj	_	_
24	of	of	IN	_	27	case	_	_
25	other	other	JJ	_	27	attr	_	_
26	ethnic	ethnic	JJ	_	27	attr	_	_
27	groups	group	NNS	_	23	ppmod	_	_
28	,	,	,	_	32	p	_	_
29	the	the	DT	_	30	det	_	_
30	drug1	drug0	NN	_	32	dep	_	_
31	was	be	VBD	_	32	aux	_	_
32	associated	associate	VBN	_	0	root	_	_
33	with	with	IN	_	35	case	_	_
34	increased	increase	VBN	_	35	attr	_	_
35	risk	risk	NN	_	32	ppmod	_	_
36	of	of	IN	_	37	case	_	_
37	drug2	drug0	NN	_	35	ppmod	_	_
38	with	with	IN	_	40	case	_	_
39	an	an	DT	_	40	det	_	_
40	OR	or	NN	_	32	ppmod	_	_
41	(	-lrb-	-LRB-	_	44	p	_	_
42	95	0	CD	_	44	num	_	_
43	%	%	NN	_	44	meta	_	_
44	CI	ci	NN	_	40	prn	_	_
45	)	-rrb-	-RRB-	_	44	p	_	_
46	=	=	VBG	_	40	acl	_	_
47	1.33	0	CD	_	46	obj	_	_
48	(	-lrb-	-LRB-	_	51	p	_	_
49	1.16	0	CD	_	51	num	_	_
50	,	,	,	_	51	p	_	_
51	1.53	0	CD	_	47	num	_	_
52	)	-rrb-	-RRB-	_	51	p	_	_
53	in	in	IN	_	56	case	_	_
54	the	the	DT	_	56	det	_	_
55	overall	overall	JJ	_	56	attr	_	_
56	population	population	NN	_	47	ppmod	_	_
57	,	,	,	_	47	p	_	_
58	1.43	0	CD	_	47	conj	_	_
59	(	-lrb-	-LRB-	_	62	p	_	_
60	1.29	0	CD	_	62	num	_	_
61	,	,	,	_	62	p	_	_
62	1.58	0	CD	_	58	num	_	_
63	)	-rrb-	-RRB-	_	62	p	_	_
64	in	in	IN	_	66	case	_	_
65	East	east	JJ	_	66	attr	_	_
66	Asian	asian	NNP	_	58	ppmod	_	_
67	and	and	CC	_	58	cc	_	_
68	1.30	0	CD	_	47	conj	_	_
69	(	-lrb-	-LRB-	_	72	p	_	_
70	0.94	0	CD	_	72	num	_	_
71	,	,	,	_	72	p	_	_
72	1.78	0	CD	_	68	num	_	_
73	)	-rrb-	-RRB-	_	72	p	_	_
74	in	in	IN	_	76	case	_	_
75	European	european	NN	_	76	com	_	_
76	populations	population	NNS	_	68	ppmod	_	_
77	.	.	.	_	32	p	_	_

1	In	in	IN	_	2	case	_	_
2	conclusion	conclusion	NN	_	8	ppmod	_	_
3	,	,	,	_	8	p	_	_
4	the	the	DT	_	5	det	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	associated	associate	VBN	_	0	root	_	_
9	with	with	IN	_	11	case	_	_
10	elevated	elevated	JJ	_	11	attr	_	_
11	levels	level	NNS	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	fasting	fasting	JJ	_	14	attr	_	_
14	TG	tg	NN	_	11	ppmod	_	_
15	,	,	,	_	11	p	_	_
16	TC	tc	NN	_	11	appo	_	_
17	,	,	,	_	16	p	_	_
18	LDL-C	ldl-c	NN	_	16	conj	_	_
19	and	and	CC	_	18	cc	_	_
20	decreased	decrease	VBN	_	21	attr	_	_
21	HDL-C	hdl-c	NN	_	16	conj	_	_
22	,	,	,	_	11	p	_	_
23	and	and	CC	_	11	cc	_	_
24	increased	increase	VBN	_	25	attr	_	_
25	risk	risk	NN	_	11	conj	_	_
26	of	of	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	,	,	,	_	25	p	_	_
29	especially	especially	RB	_	25	adv	_	_
30	in	in	IN	_	32	case	_	_
31	East	east	JJ	_	32	attr	_	_
32	Asians	asian	NNS	_	25	ppmod	_	_
33	.	.	.	_	8	p	_	_

1	Conclusion	conclusion	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	This	this	DT	_	4	det	_	_
4	study	study	NN	_	5	dep	_	_
5	highlights	highlight	VBZ	_	1	acl	_	_
6	the	the	DT	_	10	det	_	_
7	gender-specific	gender-specific	JJ	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	weight-sensitive	weight-sensitive	JJ	_	7	conj	_	_
10	effects	effect	NNS	_	5	obj	_	_
11	of	of	IN	_	13	case	_	_
12	APOA5	apoa0	NN	_	13	com	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	on	on	IN	_	16	case	_	_
15	central	central	JJ	_	16	attr	_	_
16	drug2	drug0	NN	_	10	ppmod	_	_
17	in	in	IN	_	19	case	_	_
18	Taiwanese	taiwanese	NN	_	19	com	_	_
19	individuals	individual	NNS	_	16	ppmod	_	_
20	,	,	,	_	5	p	_	_
21	and	and	CC	_	25	cc	_	_
22	that	that	IN	_	25	mark	_	_
23	these	these	DT	_	24	det	_	_
24	effects	effect	NNS	_	25	dep	_	_
25	are	be	VBP	_	5	advcl	_	_
26	dyslipidemia-independent	dyslipidemia-independent	JJ	_	25	dep	_	_
27	and	and	CC	_	26	cc	_	_
28	weight-loss	weight-loss	JJ	_	29	adv	_	_
29	responsive	responsive	JJ	_	26	conj	_	_
30	.	.	.	_	1	p	_	_

1	Though	though	IN	_	7	mark	_	_
2	drug1	drug0	NN	_	5	attr	_	_
3	/C3/A4/A5	/c0/a0/a0	NN	_	5	attr	_	_
4	genetic	genetic	JJ	_	5	attr	_	_
5	polymorphisms	polymorphism	NNS	_	7	dep	_	_
6	are	be	VBP	_	7	aux	_	_
7	associated	associate	VBN	_	18	advcl	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	18	p	_	_
11	their	their	PRP$	_	12	poss	_	_
12	effect	effect	NN	_	18	dep	_	_
13	on	on	IN	_	15	case	_	_
14	central	central	JJ	_	15	attr	_	_
15	drug3	drug0	NN	_	12	ppmod	_	_
16	is	be	VBZ	_	18	aux	_	_
17	less	less	RBR	_	18	adv	_	_
18	known	know	VBN	_	0	root	_	_

1	The	the	DT	_	3	det	_	_
2	present	present	JJ	_	3	attr	_	_
3	study	study	NN	_	4	dep	_	_
4	demonstrated	demonstrate	VBD	_	0	root	_	_
5	that	that	IN	_	18	mark	_	_
6	carrying	carry	VBG	_	18	advcl	_	_
7	rare	rare	JJ	_	8	attr	_	_
8	alleles	allele	NNS	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	18	p	_	_
12	-1131T>C	0t>c	NN	_	18	dep	_	_
13	and	and	CC	_	12	cc	_	_
14	G185C	g0c	NN	_	12	conj	_	_
15	alone	alone	RB	_	18	adv	_	_
16	do	do	VBP	_	18	aux	_	_
17	not	not	RB	_	18	neg	_	_
18	constitute	constitute	VB	_	4	comp	_	_
19	a	a	DT	_	20	det	_	_
20	risk	risk	NN	_	18	obj	_	_
21	for	for	IN	_	23	case	_	_
22	ischemic	ischemic	JJ	_	23	attr	_	_
23	drug2	drug0	NN	_	20	ppmod	_	_
24	in	in	IN	_	28	case	_	_
25	the	the	DT	_	28	det	_	_
26	studied	study	VBN	_	28	attr	_	_
27	Turkish	turkish	JJ	_	28	attr	_	_
28	subjects	subject	NNS	_	23	ppmod	_	_
29	.	.	.	_	4	p	_	_

1	Multivariable	multivariable	JJ	_	4	attr	_	_
2	logistic	logistic	JJ	_	4	attr	_	_
3	regression	regression	NN	_	4	com	_	_
4	analysis	analysis	NN	_	17	dep	_	_
5	of	of	IN	_	7	case	_	_
6	combined	combined	JJ	_	7	attr	_	_
7	genotypes	genotype	NNS	_	4	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	adjustment	adjustment	NN	_	7	ppmod	_	_
10	for	for	IN	_	11	case	_	_
11	age	age	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	gender	gender	NN	_	11	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	mellitus	mellitus	NN	_	11	conj	_	_
17	revealed	reveal	VBD	_	0	root	_	_
18	that	that	IN	_	25	mark	_	_
19	drug1	drug0	NN	_	25	dep	_	_
20	and	and	CC	_	19	cc	_	_
21	drug2	drug0	NN	_	19	conj	_	_
22	significantly	significantly	RB	_	25	adv	_	_
23	and	and	CC	_	22	cc	_	_
24	synergistically	synergistically	RB	_	22	conj	_	_
25	affected	affect	VBD	_	17	comp	_	_
26	drug4	drug0	NN	_	25	obj	_	_
27	.	.	.	_	17	p	_	_

1	Genetic	genetic	JJ	_	2	attr	_	_
2	variants	variant	NNS	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	may	may	MD	_	9	modal	_	_
8	synergistically	synergistically	RB	_	9	adv	_	_
9	affect	affect	VB	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	prevalence	prevalence	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	in	in	IN	_	17	case	_	_
15	East	east	JJ	_	17	attr	_	_
16	Asian	asian	NN	_	17	com	_	_
17	populations	population	NNS	_	11	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	of	of	IN	_	20	case	_	_
20	drug4	drug0	NN	_	17	conj	_	_
21	in	in	IN	_	23	case	_	_
22	Japanese	japanese	JJ	_	23	attr	_	_
23	individuals	individual	NNS	_	20	ppmod	_	_
24	.	.	.	_	9	p	_	_

1	Our	our	PRP$	_	3	poss	_	_
2	cross-sectional	cross-sectional	JJ	_	3	attr	_	_
3	study	study	NN	_	4	dep	_	_
4	confirmed	confirm	VBD	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	essential	essential	JJ	_	7	attr	_	_
7	roles	role	NNS	_	4	obj	_	_
8	of	of	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	polymorphisms	polymorphism	NNS	_	7	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	,	,	,	_	10	p	_	_
15	drug2	drug0	NN	_	10	appo	_	_
16	and	and	CC	_	15	cc	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	in	in	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	lipid	lipid	NN	_	7	ppmod	_	_
21	or	or	CC	_	20	cc	_	_
22	drug4	drug0	NN	_	23	com	_	_
23	disorders	disorder	NNS	_	20	conj	_	_
24	,	,	,	_	4	p	_	_
25	and	and	CC	_	4	cc	_	_
26	suggested	suggest	VBD	_	4	conj	_	_
27	the	the	DT	_	28	det	_	_
28	importance	importance	NN	_	26	obj	_	_
29	of	of	IN	_	32	case	_	_
30	fat	fat	JJ	_	32	attr	_	_
31	intake	intake	JJ	_	32	attr	_	_
32	control	control	NN	_	28	ppmod	_	_
33	in	in	IN	_	36	case	_	_
34	the	the	DT	_	36	det	_	_
35	individualized	individualized	JJ	_	36	attr	_	_
36	prevention	prevention	NN	_	28	ppmod	_	_
37	of	of	IN	_	38	case	_	_
38	drug5	drug0	NN	_	36	ppmod	_	_
39	.	.	.	_	4	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	examined	examine	VBD	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	associations	association	NNS	_	3	obj	_	_
6	of	of	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	APOA5	apoa0	NN	_	9	com	_	_
9	T-1131C	t-0c	NN	_	5	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug1	drug0	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	,	,	,	_	9	p	_	_
14	G553T	g0t	NN	_	9	conj	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	drug2	drug0	NN	_	14	prn	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	appo	_	_
19	)	-rrb-	-RRB-	_	16	p	_	_
20	,	,	,	_	14	p	_	_
21	GCK	gck	NN	_	22	com	_	_
22	G-30A	g-0a	NN	_	9	conj	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	drug4	drug0	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	,	,	,	_	22	p	_	_
27	GCKR	gckr	NN	_	28	com	_	_
28	A/G	a/g	NN	_	9	conj	_	_
29	at	at	IN	_	30	case	_	_
30	intron16	intron0	NN	_	28	ppmod	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	drug5	drug0	NN	_	28	prn	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	and	and	CC	_	28	cc	_	_
35	T1403C	t0c	NNP	_	41	attr	_	_
36	(	-lrb-	-LRB-	_	41	p	_	_
37	Leu446Pro	leu0pro	NNP	_	41	attr	_	_
38	,	,	,	_	41	p	_	_
39	drug6	drug0	NN	_	41	attr	_	_
40	)	-rrb-	-RRB-	_	41	p	_	_
41	polymorphisms	polymorphism	NNS	_	9	conj	_	_
42	with	with	IN	_	43	case	_	_
43	drug7	drug0	NN	_	5	ppmod	_	_
44	and	and	CC	_	43	cc	_	_
45	drug8	drug0	NN	_	43	conj	_	_
46	in	in	IN	_	47	case	_	_
47	Japanese	japanese	NN	_	3	ppmod	_	_
48	,	,	,	_	3	p	_	_
49	considering	consider	VBG	_	3	comp	_	_
50	lifestyle	lifestyle	JJ	_	51	attr	_	_
51	factors	factor	NNS	_	49	obj	_	_

1	Moreover	moreover	RB	_	26	adv	_	_
2	,	,	,	_	26	p	_	_
3	a	a	DT	_	6	det	_	_
4	significant	significant	JJ	_	5	adv	_	_
5	positive	positive	JJ	_	6	attr	_	_
6	interaction	interaction	NN	_	26	dep	_	_
7	between	between	IN	_	10	case	_	_
8	drug1	drug0	NN	_	10	com	_	_
9	G/T+T/T	g/t+t/t	NN	_	10	com	_	_
10	genotypes	genotype	NNS	_	6	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	fat	fat	JJ	_	13	attr	_	_
13	intake	intake	NN	_	10	conj	_	_
14	>	>	VBG	_	10	acl	_	_
15	25	0	CD	_	14	obj	_	_
16	%	%	NN	_	15	meta	_	_
17	of	of	IN	_	19	case	_	_
18	total	total	JJ	_	19	attr	_	_
19	energy	energy	NN	_	15	ppmod	_	_
20	for	for	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	risk	risk	NN	_	14	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	was	be	VBD	_	26	aux	_	_
26	observed	observe	VBN	_	0	root	_	_
27	.	.	.	_	26	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	polymorphisms	polymorphism	NNS	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	serve	serve	VB	_	0	root	_	_
7	as	as	IN	_	8	case	_	_
8	biomarkers	biomarker	NNS	_	6	ppmod	_	_
9	in	in	IN	_	13	case	_	_
10	the	the	DT	_	13	det	_	_
11	South	south	NNP	_	13	com	_	_
12	Indian	indian	NNP	_	13	com	_	_
13	population	population	NN	_	8	ppmod	_	_
14	to	to	TO	_	15	aux	_	_
15	identify	identify	VB	_	6	comp	_	_
16	drug3	drug0	NN	_	17	com	_	_
17	patients	patient	NNS	_	15	obj	_	_
18	who	who	WP	_	19	dep	_	_
19	are	be	VBP	_	17	relcl	_	_
20	at	at	IN	_	21	case	_	_
21	risk	risk	NN	_	19	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	developing	develop	VBG	_	24	attr	_	_
24	drug4	drug0	NNS	_	21	ppmod	_	_
25	.	.	.	_	6	p	_	_

1	Two	#crd#	CD	_	2	num	_	_
2	SNPs	snp	NNS	_	11	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug1	drug0	NN	_	2	prn	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_
8	in	in	IN	_	9	case	_	_
9	IREB2	ireb0	NN	_	2	ppmod	_	_
10	were	be	VBD	_	11	aux	_	_
11	associated	associate	VBN	_	0	root	_	_
12	with	with	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	P=0.045	p=0	NN	_	13	prn	_	_
16	and	and	CC	_	15	cc	_	_
17	0.032	0	NN	_	15	conj	_	_
18	,	,	,	_	15	p	_	_
19	respectively	respectively	RB	_	15	adv	_	_
20	)	-rrb-	-RRB-	_	15	p	_	_
21	in	in	IN	_	22	case	_	_
22	non-smoker	non-smoker	NN	_	13	ppmod	_	_
23	.	.	.	_	11	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Our	our	PRP$	_	4	poss	_	_
4	findings	finding	NNS	_	5	dep	_	_
5	extend	extend	VBP	_	1	acl	_	_
6	and	and	CC	_	5	cc	_	_
7	add	add	VBP	_	5	conj	_	_
8	new	new	JJ	_	9	attr	_	_
9	information	information	NN	_	7	obj	_	_
10	to	to	TO	_	13	aux	_	_
11	the	the	DT	_	13	det	_	_
12	existing	existing	JJ	_	13	attr	_	_
13	data	datum	NNS	_	7	ppmod	_	_
14	regarding	regard	VBG	_	13	acl	_	_
15	the	the	DT	_	16	det	_	_
16	association	association	NN	_	14	obj	_	_
17	between	between	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	TG	tg	NN	_	21	com	_	_
21	regulation	regulation	NN	_	18	conj	_	_
22	during	during	IN	_	26	case	_	_
23	long-term	long-term	JJ	_	26	attr	_	_
24	atypical	atypical	JJ	_	26	attr	_	_
25	drug2	drug0	NN	_	26	com	_	_
26	treatment	treatment	NN	_	14	ppmod	_	_
27	.	.	.	_	1	p	_	_

1	significant	significant	JJ	_	2	attr	_	_
2	differences	difference	NNS	_	30	dep	_	_
3	in	in	IN	_	7	case	_	_
4	the	the	DT	_	7	det	_	_
5	association	association	NN	_	7	com	_	_
6	effect	effect	NN	_	7	com	_	_
7	sizes	size	NNS	_	2	ppmod	_	_
8	between	between	IN	_	9	case	_	_
9	subjects	subject	NNS	_	2	ppmod	_	_
10	with	with	IN	_	9	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	without	without	IN	_	13	case	_	_
13	MetS	met	NNS	_	10	conj	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	p<0.05	p<0	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	,	,	,	_	13	p	_	_
18	variants	variant	NNS	_	13	conj	_	_
19	of	of	IN	_	20	case	_	_
20	APOA5	apoa0	NN	_	18	ppmod	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	drug1	drug0	NN	_	18	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	and	and	CC	_	18	cc	_	_
25	APOE	apoe	NN	_	13	conj	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	drug2	drug0	NN	_	25	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	were	be	VBD	_	30	aux	_	_
30	associated	associate	VBN	_	0	root	_	_
31	with	with	IN	_	32	case	_	_
32	drug4	drug0	NN	_	30	ppmod	_	_
33	in	in	IN	_	35	case	_	_
34	drug5	drug0	NN	_	35	com	_	_
35	subjects	subject	NNS	_	32	ppmod	_	_
36	,	,	,	_	30	p	_	_
37	while	while	IN	_	43	mark	_	_
38	APOA4	apoa0	NN	_	43	dep	_	_
39	(	-lrb-	-LRB-	_	40	p	_	_
40	drug3	drug0	NN	_	38	prn	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	was	be	VBD	_	43	aux	_	_
43	associated	associate	VBN	_	30	comp	_	_
44	with	with	IN	_	45	case	_	_
45	drug6	drug0	NN	_	43	ppmod	_	_
46	in	in	IN	_	48	case	_	_
47	non-MetS	non-mets	JJ	_	48	attr	_	_
48	subjects	subject	NNS	_	45	ppmod	_	_
49	.	.	.	_	30	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	allele	allele	NN	_	15	dep	_	_
6	,	,	,	_	5	p	_	_
7	associated	associate	VBN	_	5	acl	_	_
8	with	with	IN	_	12	case	_	_
9	higher	high	JJR	_	12	attr	_	_
10	fasting	fasting	NN	_	12	com	_	_
11	triglyceride	triglyceride	NN	_	12	com	_	_
12	levels	level	NNS	_	7	ppmod	_	_
13	,	,	,	_	5	p	_	_
14	strongly	strongly	RB	_	15	adv	_	_
15	affects	affect	VBZ	_	1	acl	_	_
16	the	the	DT	_	17	det	_	_
17	risk	risk	NN	_	15	obj	_	_
18	for	for	IN	_	20	case	_	_
19	early-onset	early-onset	JJ	_	20	attr	_	_
20	drug2	drug0	NN	_	17	ppmod	_	_
21	,	,	,	_	15	p	_	_
22	even	even	RB	_	24	adv	_	_
23	after	after	IN	_	24	case	_	_
24	adjusting	adjust	VBG	_	15	ppmod	_	_
25	for	for	IN	_	26	case	_	_
26	triglycerides	triglyceride	NNS	_	24	ppmod	_	_
27	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	association	association	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	number	number	NN	_	2	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	drug2	drug0	JJ	_	11	attr	_	_
11	components	component	NNS	_	7	ppmod	_	_
12	was	be	VBD	_	0	root	_	_
13	significant	significant	JJ	_	12	dep	_	_
14	regardless	regardless	RB	_	13	adv	_	_
15	of	of	IN	_	16	case	_	_
16	age	age	NN	_	14	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	sex	sex	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	obesity	obesity	NN	_	16	conj	_	_
21	and	and	CC	_	20	cc	_	_
22	alcohol	alcohol	NN	_	23	com	_	_
23	drinking	drinking	NN	_	16	conj	_	_
24	,	,	,	_	12	p	_	_
25	but	but	CC	_	12	cc	_	_
26	almost	almost	RB	_	27	adv	_	_
27	disappeared	disappear	VBD	_	12	conj	_	_
28	after	after	IN	_	30	case	_	_
29	further	far	RB	_	30	adv	_	_
30	adjusting	adjust	VBG	_	27	ppmod	_	_
31	for	for	IN	_	33	case	_	_
32	plasma	plasma	NN	_	33	com	_	_
33	triglycerides	triglyceride	NNS	_	30	ppmod	_	_
34	.	.	.	_	12	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	While	while	IN	_	8	mark	_	_
4	previous	previous	JJ	_	5	attr	_	_
5	studies	study	NNS	_	8	dep	_	_
6	in	in	IN	_	7	case	_	_
7	adults	adult	NNS	_	5	ppmod	_	_
8	demonstrated	demonstrate	VBD	_	23	advcl	_	_
9	,	,	,	_	8	p	_	_
10	that	that	IN	_	16	mark	_	_
11	the	the	DT	_	15	det	_	_
12	drug1	drug0	NN	_	15	attr	_	_
13	-1131C	0c	NN	_	15	attr	_	_
14	minor	minor	JJ	_	15	attr	_	_
15	allele	allele	NN	_	16	dep	_	_
16	confers	confer	VBZ	_	8	comp	_	_
17	risk	risk	NN	_	16	obj	_	_
18	for	for	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	23	p	_	_
21	here	here	RB	_	23	adv	_	_
22	we	we	PRP	_	23	dep	_	_
23	show	show	VBP	_	1	acl	_	_
24	,	,	,	_	23	p	_	_
25	that	that	IN	_	28	mark	_	_
26	the	the	DT	_	28	det	_	_
27	susceptibility	susceptibility	NN	_	28	com	_	_
28	nature	nature	NN	_	23	comp	_	_
29	of	of	IN	_	31	case	_	_
30	this	this	DT	_	31	det	_	_
31	SNP	snp	NN	_	28	ppmod	_	_
32	restricted	restricted	JJ	_	31	attr	_	_
33	to	to	TO	_	38	aux	_	_
34	the	the	DT	_	38	det	_	_
35	APOA5	apoa0	NN	_	36	com	_	_
36	*	*	NN	_	38	attr	_	_
37	2	0	CD	_	36	num	_	_
38	haplotype	haplotype	NN	_	32	ppmod	_	_
39	in	in	IN	_	42	case	_	_
40	pediatric	pediatric	JJ	_	42	attr	_	_
41	obese	obese	JJ	_	42	attr	_	_
42	subjects	subject	NNS	_	38	ppmod	_	_
43	.	.	.	_	1	p	_	_

1	OBJECTIVE	objective	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Apolipoprotein	apolipoprotein	NN	_	4	com	_	_
4	A5	a0	NN	_	9	attr	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug1	drug0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	gene	gene	NN	_	9	com	_	_
9	variants	variant	NNS	_	12	dep	_	_
10	have	have	VBP	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	shown	show	VBN	_	29	advcl	_	_
13	to	to	TO	_	15	aux	_	_
14	be	be	VB	_	15	aux	_	_
15	associated	associate	VBN	_	12	comp	_	_
16	with	with	IN	_	19	case	_	_
17	elevated	elevated	JJ	_	19	attr	_	_
18	TG	tg	NN	_	19	com	_	_
19	levels	level	NNS	_	15	ppmod	_	_
20	;	;	:	_	29	p	_	_
21	the	the	DT	_	26	det	_	_
22	T-1131C	t-0c	NN	_	26	attr	_	_
23	(	-lrb-	-LRB-	_	26	p	_	_
24	drug2	drug0	NN	_	26	attr	_	_
25	)	-rrb-	-RRB-	_	26	p	_	_
26	variant	variant	NN	_	29	dep	_	_
27	has	have	VBZ	_	29	aux	_	_
28	been	be	VBN	_	29	aux	_	_
29	reported	report	VBN	_	1	acl	_	_
30	to	to	TO	_	31	aux	_	_
31	confer	confer	VB	_	29	comp	_	_
32	risk	risk	NN	_	31	obj	_	_
33	for	for	IN	_	35	case	_	_
34	the	the	DT	_	35	det	_	_
35	drug3	drug0	NN	_	32	ppmod	_	_
36	in	in	IN	_	38	case	_	_
37	adult	adult	JJ	_	38	attr	_	_
38	populations	population	NNS	_	35	ppmod	_	_
39	.	.	.	_	1	p	_	_

1	Single	single	JJ	_	3	attr	_	_
2	nucleotide	nucleotide	NN	_	3	com	_	_
3	polymorphisms	polymorphism	NNS	_	17	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	SNPs	snp	NNS	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	in	in	IN	_	14	case	_	_
8	the	the	DT	_	14	det	_	_
9	apolipoprotein	apolipoprotein	NN	_	14	attr	_	_
10	A5	a0	NN	_	14	attr	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	drug1	drug0	NN	_	14	attr	_	_
13	)	-rrb-	-RRB-	_	14	p	_	_
14	gene	gene	NN	_	3	ppmod	_	_
15	have	have	VBP	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	associated	associate	VBN	_	0	root	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	17	p	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug4	drug0	NN	_	7	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	HTG	htg	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	is	be	VBZ	_	1	acl	_	_
8	a	a	DT	_	12	det	_	_
9	well-established	well-established	JJ	_	12	attr	_	_
10	independent	independent	JJ	_	12	attr	_	_
11	risk	risk	NN	_	12	com	_	_
12	factor	factor	NN	_	7	obj	_	_
13	for	for	IN	_	15	case	_	_
14	drug5	drug0	NN	_	15	com	_	_
15	disease	disease	NN	_	12	ppmod	_	_
16	and	and	CC	_	7	cc	_	_
17	the	the	DT	_	18	det	_	_
18	influence	influence	NN	_	35	dep	_	_
19	of	of	IN	_	23	case	_	_
20	several	several	JJ	_	23	attr	_	_
21	geneti	geneti	NN	_	23	com	_	_
22	c	c	NN	_	23	com	_	_
23	variants	variant	NNS	_	18	ppmod	_	_
24	in	in	IN	_	25	case	_	_
25	genes	gene	NNS	_	23	ppmod	_	_
26	related	related	JJ	_	25	attr	_	_
27	with	with	IN	_	32	case	_	_
28	triglyceride	triglyceride	NN	_	32	attr	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	TG	tg	NN	_	28	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	metabolism	metabolism	NN	_	26	ppmod	_	_
33	has	have	VBZ	_	35	aux	_	_
34	been	be	VBN	_	35	aux	_	_
35	described	describe	VBN	_	7	conj	_	_
36	,	,	,	_	35	p	_	_
37	including	include	VBG	_	38	adv	_	_
38	drug1	drug0	NN	_	35	ppmod	_	_
39	,	,	,	_	38	p	_	_
40	drug2	drug0	NN	_	38	conj	_	_
41	and	and	CC	_	40	cc	_	_
42	drug3	drug0	NN	_	38	conj	_	_
43	.	.	.	_	1	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Our	our	PRP$	_	4	poss	_	_
4	results	result	NNS	_	5	dep	_	_
5	showed	show	VBD	_	1	acl	_	_
6	a	a	DT	_	10	det	_	_
7	significant	significant	JJ	_	10	attr	_	_
8	independent	independent	JJ	_	10	attr	_	_
9	additive	additive	JJ	_	10	attr	_	_
10	effect	effect	NN	_	5	obj	_	_
11	on	on	IN	_	12	case	_	_
12	drug5	drug0	NN	_	10	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	LPL	lpl	NN	_	16	com	_	_
16	polymorphisms	polymorphism	NNS	_	12	ppmod	_	_
17	drug1	drug0	NN	_	16	attr	_	_
18	,	,	,	_	17	p	_	_
19	drug2	drug0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug3	drug0	NN	_	17	conj	_	_
22	and	and	CC	_	21	cc	_	_
23	drug4	drug0	NN	_	17	conj	_	_
24	;	;	:	_	10	p	_	_
25	the	the	DT	_	26	det	_	_
26	S19W	s0w	NN	_	10	conj	_	_
27	and	and	CC	_	26	cc	_	_
28	-1131T/C	0t/c	NN	_	29	com	_	_
29	variants	variant	NNS	_	26	conj	_	_
30	of	of	IN	_	31	case	_	_
31	APOA5	apoa0	NN	_	26	ppmod	_	_
32	,	,	,	_	26	p	_	_
33	and	and	CC	_	26	cc	_	_
34	the	the	DT	_	36	det	_	_
35	epsilon4	epsilon0	NN	_	36	com	_	_
36	allele	allele	NN	_	10	conj	_	_
37	of	of	IN	_	38	case	_	_
38	APOE	apoe	NN	_	36	ppmod	_	_
39	in	in	IN	_	42	case	_	_
40	our	our	PRP$	_	42	poss	_	_
41	study	study	NN	_	42	com	_	_
42	population	population	NN	_	36	ppmod	_	_
43	.	.	.	_	1	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	12	mark	_	_
5	different	different	JJ	_	6	attr	_	_
6	SNPs	snp	NNS	_	12	dep	_	_
7	in	in	IN	_	9	case	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	polymorphisms	polymorphism	NNS	_	6	ppmod	_	_
10	may	may	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	associated	associate	VBN	_	3	comp	_	_
13	with	with	IN	_	15	case	_	_
14	triglyceride	triglyceride	NN	_	15	com	_	_
15	concentration	concentration	NN	_	12	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	in	in	IN	_	19	case	_	_
19	each	each	DT	_	15	ppmod	_	_
20	of	of	IN	_	23	case	_	_
21	these	these	DT	_	23	det	_	_
22	ethnic	ethnic	JJ	_	23	attr	_	_
23	origins	origin	NNS	_	19	ppmod	_	_
24	.	.	.	_	3	p	_	_

1	Homozygosity	homozygosity	NN	_	12	dep	_	_
2	for	for	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	minor	minor	JJ	_	5	attr	_	_
5	allele	allele	NN	_	1	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	TT	tt	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	of	of	IN	_	11	case	_	_
10	SNP	snp	NN	_	11	com	_	_
11	drug1	drug0	NN	_	5	ppmod	_	_
12	occurred	occur	VBD	_	0	root	_	_
13	in	in	IN	_	14	case	_	_
14	9	0	CD	_	12	ppmod	_	_
15	%	%	NN	_	14	meta	_	_
16	of	of	IN	_	17	case	_	_
17	individuals	individual	NNS	_	14	ppmod	_	_
18	and	and	CC	_	12	cc	_	_
19	was	be	VBD	_	20	aux	_	_
20	associated	associate	VBN	_	12	conj	_	_
21	with	with	IN	_	25	case	_	_
22	a	a	DT	_	25	det	_	_
23	31	0	CD	_	25	num	_	_
24	%	%	NN	_	23	meta	_	_
25	reduction	reduction	NN	_	20	ppmod	_	_
26	in	in	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	in	in	IN	_	31	case	_	_
29	a	a	DT	_	31	det	_	_
30	recessive	recessive	JJ	_	31	attr	_	_
31	model	model	NN	_	25	ppmod	_	_
32	.	.	.	_	12	p	_	_

1	whereas	whereas	IN	_	3	case	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	genotype	genotype	NN	_	6	dep	_	_
4	was	be	VBD	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	associated	associate	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	measures	measure	NNS	_	6	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	le	le	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	as	as	RB	_	6	adv	_	_
5	also	also	RB	_	6	adv	_	_
6	associated	associate	VBN	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	increased	increase	VBN	_	9	attr	_	_
9	prevalence	prevalence	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	Genotypes	genotype	NNS	_	6	dep	_	_
2	at	at	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	were	be	VBD	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	associated	associate	VBN	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	any	any	DT	_	9	det	_	_
9	drug2	drug0	NN	_	6	ppmod	_	_
10	.	.	.	_	6	p	_	_

1	Singlenucleotide	singlenucleotide	JJ	_	2	attr	_	_
2	polymorphisms	polymorphism	NNS	_	15	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	SNPs	snp	NNS	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	and	and	CC	_	2	cc	_	_
7	haplotypes	haplotype	NNS	_	2	conj	_	_
8	in	in	IN	_	13	case	_	_
9	the	the	DT	_	13	det	_	_
10	drug1	drug0	NN	_	13	com	_	_
11	/C3/A4/A5	/c0/a0/a0	NN	_	13	com	_	_
12	gene	gene	NN	_	13	com	_	_
13	cluster	cluster	NN	_	2	ppmod	_	_
14	are	be	VBP	_	15	aux	_	_
15	associated	associate	VBN	_	0	root	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	in	in	IN	_	19	case	_	_
19	Caucasians	caucasians	NN	_	17	ppmod	_	_
20	and	and	CC	_	17	cc	_	_
21	with	with	IN	_	22	case	_	_
22	elevatedtriglycerides	elevatedtriglycerides	NNS	_	17	conj	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	TG	tg	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	in	in	IN	_	29	case	_	_
27	various	various	JJ	_	29	attr	_	_
28	ethnic	ethnic	JJ	_	29	attr	_	_
29	groups	group	NNS	_	22	ppmod	_	_
30	.	.	.	_	15	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	found	find	VBD	_	79	advcl	_	_
3	that	that	IN	_	45	mark	_	_
4	:	:	:	_	31	p	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	i	i	NN	_	8	attr	_	_
7	)	-rrb-	-RRB-	_	8	p	_	_
8	genotypes	genotype	NNS	_	31	dep	_	_
9	,	,	,	_	8	p	_	_
10	including	include	VBG	_	11	adv	_	_
11	those	those	DT	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	S19W	s0w	NN	_	11	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	APOA5	apoa0	NN	_	19	com	_	_
17	-1131T	0t	NN	_	19	com	_	_
18	>	>	NN	_	19	com	_	_
19	C	c	NN	_	14	conj	_	_
20	,	,	,	_	19	p	_	_
21	APOE	apoe	NN	_	14	conj	_	_
22	,	,	,	_	21	p	_	_
23	GCKR	gckr	NN	_	14	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug2	drug0	NN	_	14	conj	_	_
26	and	and	CC	_	25	cc	_	_
27	TBL2/MLXIPL	tbl0/mlxipl	NN	_	14	conj	_	_
28	,	,	,	_	8	p	_	_
29	were	be	VBD	_	31	aux	_	_
30	significantly	significantly	RB	_	31	adv	_	_
31	associated	associate	VBN	_	39	comp	_	_
32	with	with	IN	_	34	case	_	_
33	severe	severe	JJ	_	34	attr	_	_
34	drug3	drug0	NN	_	31	ppmod	_	_
35	;	;	:	_	31	p	_	_
36	(	-lrb-	-LRB-	_	37	p	_	_
37	ii	ii	LS	_	31	meta	_	_
38	)	-rrb-	-RRB-	_	37	p	_	_
39	odds	odds	NNS	_	40	com	_	_
40	ratios	ratio	NNS	_	45	dep	_	_
41	for	for	IN	_	44	case	_	_
42	these	these	DT	_	44	det	_	_
43	genetic	genetic	JJ	_	44	attr	_	_
44	variables	variable	NNS	_	40	ppmod	_	_
45	were	be	VBD	_	2	comp	_	_
46	significant	significant	JJ	_	45	dep	_	_
47	in	in	IN	_	52	case	_	_
48	both	both	CC	_	49	cc	_	_
49	univariate	univariate	JJ	_	52	attr	_	_
50	and	and	CC	_	49	cc	_	_
51	multivariate	multivariate	JJ	_	49	conj	_	_
52	regressionanalyses	regressionanalyses	NNS	_	45	ppmod	_	_
53	,	,	,	_	45	p	_	_
54	irrespective	irrespective	RB	_	45	adv	_	_
55	of	of	IN	_	57	case	_	_
56	the	the	DT	_	57	det	_	_
57	presence	presence	NN	_	54	ppmod	_	_
58	or	or	CC	_	57	cc	_	_
59	absence	absence	NN	_	57	conj	_	_
60	of	of	IN	_	61	case	_	_
61	drug4	drug0	NN	_	57	ppmod	_	_
62	or	or	CC	_	61	cc	_	_
63	drug5	drug0	NN	_	61	conj	_	_
64	;	;	:	_	79	p	_	_
65	(	-lrb-	-LRB-	_	66	p	_	_
66	iii	iii	LS	_	79	meta	_	_
67	)	-rrb-	-RRB-	_	66	p	_	_
68	a	a	DT	_	71	det	_	_
69	significant	significant	JJ	_	71	attr	_	_
70	fraction-about	fraction-about	JJ	_	71	attr	_	_
71	one-quarter-of	one-quarter-of	NN	_	79	dep	_	_
72	the	the	DT	_	74	det	_	_
73	explained	explain	VBN	_	74	attr	_	_
74	variation	variation	NN	_	71	attr	_	_
75	in	in	IN	_	77	case	_	_
76	disease	disease	NN	_	77	com	_	_
77	status	status	NN	_	74	ppmod	_	_
78	was	be	VBD	_	79	aux	_	_
79	associated	associate	VBN	_	0	root	_	_
80	with	with	IN	_	82	case	_	_
81	these	these	DT	_	82	det	_	_
82	genotypes	genotype	NNS	_	79	ppmod	_	_
83	.	.	.	_	79	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	no	no	DT	_	4	det	_	_
4	relationships	relationship	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	found	find	VBN	_	0	root	_	_
7	between	between	IN	_	9	case	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	genotype	genotype	NN	_	6	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	in	in	IN	_	14	case	_	_
13	2	0	CD	_	14	num	_	_
14	cohorts	cohort	NNS	_	6	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	n=1648	n=0	NN	_	14	prn	_	_
17	and	and	CC	_	16	cc	_	_
18	n=1039	n=0	NN	_	16	conj	_	_
19	)	-rrb-	-RRB-	_	16	p	_	_
20	of	of	IN	_	23	case	_	_
21	healthy	healthy	JJ	_	23	attr	_	_
22	middle-aged	middle-aged	JJ	_	23	attr	_	_
23	carriers	carrier	NNS	_	14	ppmod	_	_
24	of	of	IN	_	28	case	_	_
25	the	the	DT	_	28	det	_	_
26	APOE	apoe	NN	_	28	com	_	_
27	e3/e3	e0/e0	NN	_	28	com	_	_
28	genotype	genotype	NN	_	23	ppmod	_	_
29	.	.	.	_	6	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	is	be	VBZ	_	1	acl	_	_
5	a	a	DT	_	7	det	_	_
6	functional	functional	JJ	_	7	attr	_	_
7	polymorphism	polymorphism	NN	_	4	obj	_	_
8	involved	involve	VBN	_	7	acl	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	regulation	regulation	NN	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	drug2	drug0	NN	_	11	ppmod	_	_
15	.	.	.	_	1	p	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Single	single	JJ	_	5	attr	_	_
4	nucleotide	nucleotide	NN	_	5	com	_	_
5	polymorphisms	polymorphism	NNS	_	38	dep	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	SNPs	snp	NNS	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	drug1	drug0	NN	_	5	appo	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	e4	e0	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	and	and	CC	_	9	cc	_	_
14	drug2	drug0	NN	_	9	conj	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	e2	e0	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	,	,	,	_	5	p	_	_
19	both	both	CC	_	5	cc	_	_
20	invoking	invoke	VBG	_	21	attr	_	_
21	changes	change	NNS	_	5	conj	_	_
22	in	in	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	amino-acid	amino-acid	JJ	_	25	attr	_	_
25	sequence	sequence	NN	_	21	ppmod	_	_
26	of	of	IN	_	33	case	_	_
27	the	the	DT	_	33	det	_	_
28	apolipoprotein	apolipoprotein	NN	_	33	attr	_	_
29	E	e	NN	_	33	attr	_	_
30	(	-lrb-	-LRB-	_	33	p	_	_
31	APOE	apoe	NN	_	33	attr	_	_
32	)	-rrb-	-RRB-	_	33	p	_	_
33	gene	gene	NN	_	25	ppmod	_	_
34	,	,	,	_	21	p	_	_
35	have	have	VBP	_	38	aux	_	_
36	previously	previously	RB	_	38	adv	_	_
37	been	be	VBN	_	38	aux	_	_
38	tested	test	VBN	_	1	acl	_	_
39	for	for	IN	_	40	case	_	_
40	association	association	NN	_	38	ppmod	_	_
41	with	with	IN	_	43	case	_	_
42	drug3	drug0	NN	_	43	com	_	_
43	risk	risk	NN	_	40	ppmod	_	_
44	.	.	.	_	1	p	_	_

1	Despite	despite	IN	_	3	case	_	_
2	sufficient	sufficient	JJ	_	3	attr	_	_
3	power	power	NN	_	21	ppmod	_	_
4	to	to	TO	_	5	aux	_	_
5	detect	detect	VB	_	3	acl	_	_
6	associations	association	NNS	_	5	obj	_	_
7	at	at	IN	_	10	case	_	_
8	genome-wide	genome-wide	NN	_	10	com	_	_
9	significance	significance	NN	_	10	com	_	_
10	thresholds	threshold	NNS	_	5	ppmod	_	_
11	across	across	IN	_	13	case	_	_
12	a	a	DT	_	13	det	_	_
13	range	range	NN	_	5	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	ORs	or	NNS	_	13	ppmod	_	_
16	,	,	,	_	21	p	_	_
17	our	our	PRP$	_	18	poss	_	_
18	analyses	analysis	NNS	_	21	dep	_	_
19	did	do	VBD	_	21	aux	_	_
20	not	not	RB	_	21	neg	_	_
21	support	support	VB	_	0	root	_	_
22	a	a	DT	_	23	det	_	_
23	role	role	NN	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug1	drug0	NN	_	23	ppmod	_	_
26	or	or	CC	_	25	cc	_	_
27	drug2	drug0	NN	_	25	conj	_	_
28	on	on	IN	_	29	case	_	_
29	drug3	drug0	NN	_	23	ppmod	_	_
30	.	.	.	_	21	p	_	_

1	Furthermore	furthermore	RB	_	26	adv	_	_
2	,	,	,	_	26	p	_	_
3	studies	study	NNS	_	26	dep	_	_
4	of	of	IN	_	6	case	_	_
5	APOE	apoe	NN	_	6	com	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug2	drug0	NN	_	6	appo	_	_
9	,	,	,	_	6	p	_	_
10	(	-lrb-	-LRB-	_	16	p	_	_
11	defining	define	VBG	_	13	attr	_	_
12	e2/e3/e4	e0/e0/e0	NN	_	13	com	_	_
13	alleles	allele	NNS	_	16	dep	_	_
14	;	;	:	_	16	p	_	_
15	12	0	CD	_	16	num	_	_
16	studies	study	NNS	_	6	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	and	and	CC	_	6	cc	_	_
19	APOB	apob	NN	_	20	com	_	_
20	drug3	drug0	NN	_	6	conj	_	_
21	(	-lrb-	-LRB-	_	23	p	_	_
22	eight	#crd#	CD	_	23	num	_	_
23	studies	study	NNS	_	20	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	were	be	VBD	_	26	aux	_	_
26	included	include	VBN	_	48	advcl	_	_
27	in	in	IN	_	28	case	_	_
28	meta-analyses	meta-analyses	NNS	_	26	ppmod	_	_
29	,	,	,	_	48	p	_	_
30	the	the	DT	_	33	det	_	_
31	observational	observational	JJ	_	33	attr	_	_
32	hazard	hazard	NN	_	33	com	_	_
33	ratio	ratio	NN	_	48	dep	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	HR	hr	NN	_	33	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	for	for	IN	_	39	case	_	_
38	symptomatic	symptomatic	JJ	_	39	attr	_	_
39	drug4	drug0	NN	_	33	ppmod	_	_
40	for	for	IN	_	45	case	_	_
41	the	the	DT	_	45	det	_	_
42	fifth	#ord#	JJ	_	45	attr	_	_
43	versus	versus	CC	_	42	cc	_	_
44	first	#ord#	JJ	_	42	conj	_	_
45	quintile	quintile	NN	_	33	ppmod	_	_
46	of	of	IN	_	47	case	_	_
47	LDL-C	ldl-c	NN	_	45	ppmod	_	_
48	was	be	VBD	_	0	root	_	_
49	0.94	0	CD	_	48	obj	_	_
50	(	-lrb-	-LRB-	_	56	p	_	_
51	95	0	CD	_	56	num	_	_
52	%	%	NN	_	51	meta	_	_
53	confidence	confidence	RB	_	54	adv	_	_
54	interval	interval	JJ	_	51	attr	_	_
55	:	:	:	_	56	p	_	_
56	0.76-1.17	0	CD	_	49	num	_	_
57	)	-rrb-	-RRB-	_	56	p	_	_
58	,	,	,	_	48	p	_	_
59	despite	despite	IN	_	64	case	_	_
60	a	a	DT	_	64	det	_	_
61	corresponding	corresponding	JJ	_	64	attr	_	_
62	134	0	CD	_	64	num	_	_
63	%	%	NN	_	62	meta	_	_
64	increase	increase	NN	_	48	ppmod	_	_
65	in	in	IN	_	66	case	_	_
66	LDL-C	ldl-c	NN	_	64	ppmod	_	_
67	.	.	.	_	48	p	_	_

1	There	there	EX	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	associations	association	NNS	_	2	obj	_	_
5	between	between	IN	_	7	case	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	polymorphisms	polymorphism	NNS	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	and	and	CC	_	11	cc	_	_
13	drug4	drug0	NN	_	9	conj	_	_

1	In	in	IN	_	3	case	_	_
2	drug2	drug0	NN	_	3	com	_	_
3	patients	patient	NNS	_	14	ppmod	_	_
4	,	,	,	_	14	p	_	_
5	genetic	genetic	JJ	_	6	attr	_	_
6	heterogeneity	heterogeneity	NN	_	14	dep	_	_
7	in	in	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	drug1	drug0	NN	_	11	attr	_	_
10	genomic	genomic	JJ	_	11	attr	_	_
11	region	region	NN	_	6	ppmod	_	_
12	is	be	VBZ	_	14	aux	_	_
13	significantly	significantly	RB	_	14	adv	_	_
14	associated	associate	VBN	_	0	root	_	_
15	with	with	IN	_	16	case	_	_
16	variation	variation	NN	_	14	ppmod	_	_
17	in	in	IN	_	19	case	_	_
18	serum	serum	NN	_	19	com	_	_
19	ApoE	apoe	NN	_	16	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	ApoB	apob	NN	_	22	com	_	_
22	levels	level	NNS	_	19	conj	_	_
23	,	,	,	_	16	p	_	_
24	and	and	CC	_	16	cc	_	_
25	also	also	RB	_	27	adv	_	_
26	with	with	IN	_	27	case	_	_
27	fibrosis	fibrosis	NN	_	16	conj	_	_
28	suggesting	suggest	VBG	_	14	comp	_	_
29	a	a	DT	_	31	det	_	_
30	pleiotropic	pleiotropic	JJ	_	31	attr	_	_
31	attribute	attribute	NN	_	28	obj	_	_
32	of	of	IN	_	35	case	_	_
33	this	this	DT	_	35	det	_	_
34	genomic	genomic	JJ	_	35	attr	_	_
35	region	region	NN	_	31	ppmod	_	_
36	.	.	.	_	14	p	_	_

1	The	the	DT	_	2	det	_	_
2	aim	aim	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	study	study	NN	_	2	ppmod	_	_
6	was	be	VBD	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	assess	assess	VB	_	6	comp	_	_
9	the	the	DT	_	10	det	_	_
10	effect	effect	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	the	the	DT	_	15	det	_	_
15	intake	intake	NN	_	12	conj	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	15	p	_	_
19	and	and	CC	_	15	cc	_	_
20	drug3	drug0	NN	_	12	conj	_	_
21	in	in	IN	_	24	case	_	_
22	Lithuanian	lithuanian	JJ	_	24	attr	_	_
23	adult	adult	JJ	_	24	attr	_	_
24	population	population	NN	_	10	ppmod	_	_
25	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	9	dep	_	_
2	,	,	,	_	1	p	_	_
3	SFA	sfa	NN	_	4	com	_	_
4	intake	intake	NN	_	1	conj	_	_
5	,	,	,	_	4	p	_	_
6	and	and	CC	_	4	cc	_	_
7	drug2	drug0	NN	_	1	conj	_	_
8	were	be	VBD	_	9	aux	_	_
9	found	find	VBN	_	0	root	_	_
10	to	to	TO	_	12	aux	_	_
11	be	be	VB	_	12	aux	_	_
12	associated	associate	VBN	_	9	comp	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	in	in	IN	_	18	case	_	_
16	Lithuanian	lithuanian	JJ	_	18	attr	_	_
17	adult	adult	JJ	_	18	attr	_	_
18	population	population	NN	_	14	ppmod	_	_
19	.	.	.	_	9	p	_	_

1	Multivariate	multivariate	JJ	_	2	attr	_	_
2	analysis	analysis	NN	_	3	dep	_	_
3	showed	show	VBD	_	0	root	_	_
4	association	association	NN	_	3	obj	_	_
5	between	between	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	,	,	,	_	3	p	_	_
10	independently	independently	RB	_	3	adv	_	_
11	from	from	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	effect	effect	NN	_	3	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	Pooled	pooled	JJ	_	3	attr	_	_
2	DNA	dna	NN	_	3	com	_	_
3	GWAS	gwas	NNS	_	4	dep	_	_
4	enabled	enable	VBD	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	identification	identification	NN	_	4	obj	_	_
7	of	of	IN	_	13	case	_	_
8	a	a	DT	_	13	det	_	_
9	novel	novel	JJ	_	13	attr	_	_
10	drug2	drug0	NN	_	13	com	_	_
11	candidate	candidate	NN	_	13	com	_	_
12	risk	risk	NN	_	13	com	_	_
13	variant	variant	NN	_	6	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug1	drug0	NN	_	13	appo	_	_
16	(	-lrb-	-LRB-	_	15	p	_	_
17	9q21.33	0q0	CD	_	15	num	_	_
18	)	-rrb-	-RRB-	_	15	p	_	_
19	,	,	,	_	13	p	_	_
20	tagging	tag	VBG	_	13	acl	_	_
21	a	a	DT	_	24	det	_	_
22	possible	possible	JJ	_	24	attr	_	_
23	genomic	genomic	JJ	_	24	attr	_	_
24	enhancer	enhancer	NN	_	20	obj	_	_
25	affecting	affect	VBG	_	24	acl	_	_
26	proximal	proximal	JJ	_	28	attr	_	_
27	transcribed	transcribe	VBN	_	28	attr	_	_
28	elements	element	NNS	_	25	obj	_	_
29	including	include	VBG	_	31	adv	_	_
30	DAPK1	dapk0	NN	_	31	com	_	_
31	gene	gene	NN	_	28	ppmod	_	_
32	.	.	.	_	4	p	_	_

1	the	the	DT	_	3	det	_	_
2	minor	minor	JJ	_	3	attr	_	_
3	alleles	allele	NNS	_	18	dep	_	_
4	of	of	IN	_	13	case	_	_
5	cholesteryl	cholesteryl	NN	_	13	attr	_	_
6	ester	ester	NN	_	13	attr	_	_
7	transfer	transfer	NN	_	13	attr	_	_
8	protein	protein	NN	_	13	attr	_	_
9	(	-lrb-	-LRB-	_	13	p	_	_
10	CETP	cetp	NN	_	13	attr	_	_
11	)	-rrb-	-RRB-	_	13	p	_	_
12	gene	gene	NN	_	13	com	_	_
13	SNPs	snp	NNS	_	3	ppmod	_	_
14	drug1	drug0	NN	_	13	appo	_	_
15	and	and	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	were	be	VBD	_	18	aux	_	_
18	associated	associate	VBN	_	0	root	_	_
19	with	with	IN	_	20	case	_	_
20	drug12	drug0	NN	_	18	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	with	with	IN	_	24	case	_	_
24	drug13	drug0	NN	_	20	ppmod	_	_
25	;	;	:	_	24	p	_	_
26	CETP	cetp	NN	_	27	com	_	_
27	SNPs	snp	NNS	_	24	conj	_	_
28	drug4	drug0	NN	_	27	appo	_	_
29	,	,	,	_	28	p	_	_
30	drug5	drug0	NN	_	28	conj	_	_
31	,	,	,	_	30	p	_	_
32	and	and	CC	_	30	cc	_	_
33	drug6	drug0	NN	_	28	conj	_	_
34	and	and	CC	_	33	cc	_	_
35	apolipoprotein	apolipoprotein	NN	_	42	attr	_	_
36	B	b	NN	_	42	attr	_	_
37	(	-lrb-	-LRB-	_	42	p	_	_
38	APOB	apob	NN	_	42	attr	_	_
39	)	-rrb-	-RRB-	_	42	p	_	_
40	gene	gene	NN	_	42	com	_	_
41	SNP	snp	NN	_	42	com	_	_
42	drug7	drug0	NN	_	28	conj	_	_
43	with	with	IN	_	44	case	_	_
44	drug14	drug0	NN	_	27	ppmod	_	_
45	;	;	:	_	27	p	_	_
46	APOE	apoe	JJ	_	48	attr	_	_
47	SNP	snp	NN	_	48	com	_	_
48	drug8	drug0	NN	_	24	conj	_	_
49	,	,	,	_	48	p	_	_
50	peroxisome	peroxisome	NN	_	59	attr	_	_
51	proliferator-activated	proliferator-activated	JJ	_	59	attr	_	_
52	receptor	receptor	NN	_	59	attr	_	_
53	gamma	gamma	NN	_	59	attr	_	_
54	(	-lrb-	-LRB-	_	59	p	_	_
55	PPARG	pparg	NN	_	59	attr	_	_
56	)	-rrb-	-RRB-	_	59	p	_	_
57	gene	gene	NN	_	59	com	_	_
58	SNP	snp	NN	_	59	com	_	_
59	drug9	drug0	NN	_	48	conj	_	_
60	with	with	IN	_	61	case	_	_
61	drug15	drug0	NN	_	59	ppmod	_	_
62	,	,	,	_	59	p	_	_
63	and	and	CC	_	59	cc	_	_
64	CETP	cetp	NN	_	66	com	_	_
65	SNP	snp	NN	_	66	com	_	_
66	drug10	drug0	NN	_	48	conj	_	_
67	with	with	IN	_	68	case	_	_
68	drug16	drug0	NN	_	48	ppmod	_	_
69	;	;	:	_	48	p	_	_
70	and	and	CC	_	48	cc	_	_
71	APOE/C1/C4/C2	apoe/c0/c0/c0	NN	_	74	com	_	_
72	cluster	cluster	NN	_	74	com	_	_
73	SNP	snp	NN	_	74	com	_	_
74	drug11	drug0	NN	_	24	conj	_	_
75	with	with	IN	_	78	case	_	_
76	lower	low	JJR	_	78	attr	_	_
77	serum	serum	NN	_	78	com	_	_
78	TG	tg	NN	_	74	ppmod	_	_
79	.	.	.	_	18	p	_	_

1	For	for	IN	_	2	case	_	_
2	example	example	NN	_	13	ppmod	_	_
3	,	,	,	_	13	p	_	_
4	the	the	DT	_	5	det	_	_
5	association	association	NN	_	13	dep	_	_
6	of	of	IN	_	7	case	_	_
7	polymorphisms	polymorphism	NNS	_	5	ppmod	_	_
8	drug1	drug0	NN	_	7	attr	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	with	with	IN	_	12	case	_	_
12	drug3	drug0	NN	_	5	ppmod	_	_
13	was	be	VBD	_	0	root	_	_
14	heterogeneous	heterogeneous	JJ	_	13	dep	_	_
15	between	between	IN	_	16	case	_	_
16	Caucasians	caucasians	NN	_	13	ppmod	_	_
17	(	-lrb-	-LRB-	_	26	p	_	_
18	OR	or	CC	_	26	cc	_	_
19	=	=	JJ	_	26	attr	_	_
20	1.32	0	CD	_	19	num	_	_
21	and	and	CC	_	20	cc	_	_
22	1.22	0	CD	_	20	conj	_	_
23	;	;	:	_	22	p	_	_
24	95	0	CD	_	20	conj	_	_
25	%	%	NN	_	20	meta	_	_
26	CI	ci	NN	_	16	prn	_	_
27	:	:	:	_	26	p	_	_
28	1.25-1.44	0	CD	_	26	appo	_	_
29	and	and	CC	_	28	cc	_	_
30	1.05-1.42	0	CD	_	28	conj	_	_
31	;	;	:	_	26	p	_	_
32	P<0.0005	p<0	CD	_	26	appo	_	_
33	and	and	CC	_	32	cc	_	_
34	0.008	0	CD	_	32	conj	_	_
35	,	,	,	_	26	p	_	_
36	respectively	respectively	RB	_	26	adv	_	_
37	)	-rrb-	-RRB-	_	26	p	_	_
38	and	and	CC	_	16	cc	_	_
39	East	east	JJ	_	40	attr	_	_
40	Asians	asian	NNS	_	16	conj	_	_
41	(	-lrb-	-LRB-	_	43	p	_	_
42	OR	or	CC	_	43	cc	_	_
43	=	=	JJ	_	40	prn	_	_
44	1.51	0	CD	_	43	num	_	_
45	and	and	CC	_	44	cc	_	_
46	1.03	0	CD	_	44	conj	_	_
47	;	;	:	_	44	p	_	_
48	95	0	CD	_	52	num	_	_
49	%	%	NN	_	52	meta	_	_
50	CI	ci	CD	_	52	num	_	_
51	:	:	:	_	52	p	_	_
52	0.76-3	0	CD	_	44	appo	_	_
53	and	and	CC	_	43	cc	_	_
54	0.47-2.27	0	NN	_	43	conj	_	_
55	;	;	:	_	43	p	_	_
56	P	p	NN	_	57	dep	_	_
57	=	=	JJ	_	43	advcl	_	_
58	0.237	0	CD	_	57	obj	_	_
59	and	and	CC	_	58	cc	_	_
60	0.934	0	NN	_	58	conj	_	_
61	,	,	,	_	57	p	_	_
62	respectively	respectively	RB	_	57	adv	_	_
63	)	-rrb-	-RRB-	_	43	p	_	_
64	under	under	IN	_	66	case	_	_
65	theallelic	theallelic	JJ	_	66	attr	_	_
66	model	model	NN	_	13	ppmod	_	_
67	,	,	,	_	13	p	_	_
68	and	and	CC	_	13	cc	_	_
69	this	this	DT	_	70	det	_	_
70	association	association	NN	_	73	dep	_	_
71	was	be	VBD	_	73	aux	_	_
72	relatively	relatively	RB	_	73	adv	_	_
73	strengthened	strengthen	VBN	_	13	conj	_	_
74	under	under	IN	_	77	case	_	_
75	the	the	DT	_	77	det	_	_
76	dominant	dominant	JJ	_	77	attr	_	_
77	model	model	NN	_	73	ppmod	_	_
78	.	.	.	_	13	p	_	_

1	Inside	inside	VBG	_	25	advcl	_	_
2	this	this	DT	_	3	det	_	_
3	region	region	NN	_	1	obj	_	_
4	of	of	IN	_	6	case	_	_
5	26.9	0	CD	_	6	num	_	_
6	kb	kb	NN	_	3	ppmod	_	_
7	,	,	,	_	25	p	_	_
8	LD	ld	NN	_	25	dep	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	r2	r0	NN	_	11	com	_	_
11	>	>	NN	_	8	prn	_	_
12	0.50	0	CD	_	11	num	_	_
13	)	-rrb-	-RRB-	_	11	p	_	_
14	between	between	IN	_	15	case	_	_
15	TOMM40	tomm0	NN	_	8	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	drug1	drug0	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	and	and	CC	_	15	cc	_	_
20	APOE	apoe	NN	_	15	conj	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	drug2	drug0	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	was	be	VBD	_	25	aux	_	_
25	observed	observe	VBN	_	0	root	_	_
26	in	in	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	and	and	CC	_	27	cc	_	_
29	in	in	IN	_	30	case	_	_
30	controls	control	NNS	_	27	conj	_	_
31	,	,	,	_	30	p	_	_
32	but	but	CC	_	30	cc	_	_
33	not	not	RB	_	35	neg	_	_
34	in	in	IN	_	35	case	_	_
35	drug4	drug0	NN	_	27	conj	_	_

1	The	the	DT	_	5	det	_	_
2	SIRT2	sirt0	NN	_	5	com	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	T	t	NN	_	5	com	_	_
5	allele	allele	NN	_	6	dep	_	_
6	deserves	deserve	VBZ	_	0	root	_	_
7	further	far	JJ	_	8	attr	_	_
8	investigation	investigation	NN	_	6	obj	_	_
9	as	as	IN	_	15	case	_	_
10	a	a	DT	_	15	det	_	_
11	novel	novel	JJ	_	15	attr	_	_
12	minor	minor	JJ	_	15	attr	_	_
13	genetic	genetic	JJ	_	15	attr	_	_
14	risk	risk	NN	_	15	com	_	_
15	factor	factor	NN	_	6	ppmod	_	_
16	for	for	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	in	in	IN	_	23	case	_	_
19	the	the	DT	_	23	det	_	_
20	APOE	apoe	NN	_	23	attr	_	_
21	e4-negative	e0-negative	JJ	_	23	attr	_	_
22	Caucasian	caucasian	NN	_	23	com	_	_
23	population	population	NN	_	15	ppmod	_	_
24	.	.	.	_	6	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	25	advcl	_	_
3	moderate	moderate	JJ	_	4	attr	_	_
4	consistency	consistency	NN	_	2	obj	_	_
5	between	between	IN	_	10	case	_	_
6	the	the	DT	_	10	det	_	_
7	cross-sectional	cross-sectional	JJ	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	longitudinal	longitudinal	JJ	_	7	conj	_	_
10	findings	finding	NNS	_	2	ppmod	_	_
11	,	,	,	_	2	p	_	_
12	with	with	IN	_	17	case	_	_
13	eight	#crd#	CD	_	17	num	_	_
14	SNP	snp	NN	_	17	attr	_	_
15	:	:	:	_	17	p	_	_
16	drug8	drug0	NN	_	17	com	_	_
17	associations	association	NNS	_	2	ppmod	_	_
18	consistently	consistently	RB	_	19	adv	_	_
19	identified	identify	VBN	_	17	acl	_	_
20	across	across	IN	_	23	case	_	_
21	both	both	DT	_	23	det	_	_
22	study	study	NN	_	23	com	_	_
23	designs	design	NNS	_	19	ppmod	_	_
24	:	:	:	_	25	p	_	_
25	-LSB-APOE.2	-lsb-apoe.0	CD	_	0	root	_	_
26	and	and	CC	_	25	cc	_	_
27	APOE.4	apoe.0	CD	_	29	num	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	drug1	drug0	NN	_	25	conj	_	_
30	and	and	CC	_	29	cc	_	_
31	drug2	drug0	NN	_	25	conj	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	]	-rsb-	-RRB-	_	31	p	_	_
34	:	:	:	_	31	p	_	_
35	TC	tc	NN	_	25	conj	_	_
36	;	;	:	_	37	p	_	_
37	HL/LIPC	hl/lipc	NN	_	35	prn	_	_
38	(	-lrb-	-LRB-	_	39	p	_	_
39	drug3	drug0	NN	_	37	prn	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	:	:	:	_	37	p	_	_
42	HDL	hdl	NN	_	37	appo	_	_
43	;	;	:	_	37	p	_	_
44	-LSB-APOB	-lsb-apob	NN	_	37	appo	_	_
45	(	-lrb-	-LRB-	_	46	p	_	_
46	drug4	drug0	NN	_	44	prn	_	_
47	)	-rrb-	-RRB-	_	46	p	_	_
48	,	,	,	_	37	p	_	_
49	APOE.2	apoe.0	CD	_	37	appo	_	_
50	and	and	CC	_	49	cc	_	_
51	APOE.4	apoe.0	CD	_	49	conj	_	_
52	(	-lrb-	-LRB-	_	53	p	_	_
53	drug5	drug0	NN	_	49	prn	_	_
54	and	and	CC	_	53	cc	_	_
55	drug6	drug0	NN	_	53	conj	_	_
56	)	-rrb-	-RRB-	_	53	p	_	_
57	]	-rsb-	-RRB-	_	53	p	_	_
58	:	:	:	_	37	p	_	_
59	LDL	ldl	NN	_	37	appo	_	_
60	;	;	:	_	37	p	_	_
61	-LSB-APOA5	-lsb-apoa0	NN	_	37	appo	_	_
62	(	-lrb-	-LRB-	_	63	p	_	_
63	drug7	drug0	NN	_	61	prn	_	_
64	)	-rrb-	-RRB-	_	63	p	_	_
65	and	and	CC	_	61	cc	_	_
66	APOC	apoc	NN	_	61	conj	_	_
67	III	iii	CD	_	66	num	_	_
68	(	-lrb-	-LRB-	_	69	p	_	_
69	drug9	drug0	NN	_	66	prn	_	_
70	)	-rrb-	-RRB-	_	69	p	_	_
71	]	-rsb-	-RRB-	_	37	p	_	_
72	:	:	:	_	35	p	_	_
73	TG	tg	NN	_	25	conj	_	_
74	.	.	.	_	25	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	frequency	frequency	NN	_	10	dep	_	_
5	of	of	IN	_	7	case	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	polymorphisms	polymorphism	NNS	_	4	ppmod	_	_
8	did	do	VBD	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	differ	differ	VB	_	1	acl	_	_
11	between	between	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NNS	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	controls	control	NNS	_	14	conj	_	_
17	.	.	.	_	1	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	present	present	JJ	_	4	attr	_	_
4	study	study	NN	_	7	ppmod	_	_
5	,	,	,	_	7	p	_	_
6	we	we	PRP	_	7	dep	_	_
7	investigated	investigate	VBD	_	0	root	_	_
8	whether	whether	IN	_	11	mark	_	_
9	drug1	drug0	NN	_	11	dep	_	_
10	was	be	VBD	_	11	aux	_	_
11	associated	associate	VBN	_	7	comp	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	in	in	IN	_	17	case	_	_
15	predominantly	predominantly	RB	_	16	adv	_	_
16	middle-aged	middle-aged	JJ	_	17	attr	_	_
17	persons	person	NNS	_	13	ppmod	_	_
18	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	indicated	indicate	VBD	_	0	root	_	_
4	that	that	IN	_	13	mark	_	_
5	homozygous	homozygous	JJ	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	carriers	carrier	NNS	_	13	dep	_	_
8	aged	aged	JJ	_	7	attr	_	_
9	35	0	CD	_	10	num	_	_
10	years	year	NNS	_	8	advnp	_	_
11	or	or	CC	_	10	cc	_	_
12	older	old	JJR	_	10	conj	_	_
13	had	have	VBD	_	3	comp	_	_
14	worse	bad	JJR	_	15	attr	_	_
15	drug2	drug0	NN	_	13	obj	_	_
16	than	than	IN	_	18	case	_	_
17	heterozygous	heterozygous	JJ	_	18	attr	_	_
18	carriers	carrier	NNS	_	13	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	noncarriers	noncarriers	NNS	_	18	conj	_	_
21	.	.	.	_	3	p	_	_

1	Collectively	collectively	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	these	these	DT	_	4	det	_	_
4	results	result	NNS	_	6	dep	_	_
5	also	also	RB	_	6	adv	_	_
6	suggest	suggest	VBP	_	0	root	_	_
7	and	and	CC	_	8	cc	_	_
8	claim	claim	NN	_	6	obj	_	_
9	for	for	IN	_	11	case	_	_
10	further	far	JJ	_	11	attr	_	_
11	investigations	investigation	NNS	_	8	ppmod	_	_
12	on	on	IN	_	15	case	_	_
13	drug1	drug0	NN	_	15	com	_	_
14	/HP	/hp	NN	_	15	com	_	_
15	interaction	interaction	NN	_	11	ppmod	_	_
16	in	in	IN	_	19	case	_	_
17	other	other	JJ	_	19	attr	_	_
18	age-related	age-related	JJ	_	19	attr	_	_
19	diseases	disease	NNS	_	8	ppmod	_	_
20	such	such	JJ	_	24	adv	_	_
21	as	as	IN	_	24	case	_	_
22	drug2	drug0	NN	_	24	attr	_	_
23	's	's	POS	_	24	case	_	_
24	disease	disease	NN	_	19	ppmod	_	_
25	,	,	,	_	24	p	_	_
26	drug3	drug0	NN	_	24	conj	_	_
27	and	and	CC	_	26	cc	_	_
28	drug4	drug0	NN	_	30	attr	_	_
29	's	's	POS	_	30	case	_	_
30	disease	disease	NN	_	24	conj	_	_
31	.	.	.	_	6	p	_	_

1	Apolipoprotein	apolipoprotein	NN	_	2	com	_	_
2	E	e	NN	_	7	attr	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	APOE	apoe	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	functional	functional	JJ	_	7	attr	_	_
7	haplotypes	haplotype	NNS	_	17	dep	_	_
8	determined	determine	VBN	_	7	acl	_	_
9	by	by	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	SNPs	snp	NNS	_	10	conj	_	_
14	have	have	VBP	_	17	aux	_	_
15	been	be	VBN	_	17	aux	_	_
16	extensively	extensively	RB	_	17	adv	_	_
17	studied	study	VBN	_	0	root	_	_
18	and	and	CC	_	17	cc	_	_
19	found	find	VBN	_	17	conj	_	_
20	to	to	TO	_	21	aux	_	_
21	be	be	VB	_	19	comp	_	_
22	one	#crd#	CD	_	21	obj	_	_
23	of	of	IN	_	27	case	_	_
24	the	the	DT	_	27	det	_	_
25	most	most	RBS	_	26	adv	_	_
26	consistent	consistent	JJ	_	27	attr	_	_
27	association	association	NN	_	22	ppmod	_	_
28	in	in	IN	_	31	case	_	_
29	human	human	JJ	_	31	attr	_	_
30	drug3	drug0	NN	_	31	com	_	_
31	studies	study	NNS	_	27	ppmod	_	_
32	.	.	.	_	17	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	haplotypes	haplotype	NNS	_	7	dep	_	_
5	are	be	VBP	_	7	aux	_	_
6	significantly	significantly	RB	_	7	adv	_	_
7	associated	associate	VBN	_	1	acl	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	our	our	PRP$	_	12	poss	_	_
12	population	population	NN	_	9	ppmod	_	_
13	.	.	.	_	1	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Although	although	IN	_	13	mark	_	_
4	the	the	DT	_	6	det	_	_
5	physiological	physiological	JJ	_	6	attr	_	_
6	role	role	NN	_	13	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	drug3	drug0	NN	_	6	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug4	drug0	NN	_	10	conj	_	_
13	needs	need	VBZ	_	19	advcl	_	_
14	further	far	JJ	_	15	attr	_	_
15	investigations	investigation	NNS	_	13	obj	_	_
16	,	,	,	_	19	p	_	_
17	our	our	PRP$	_	18	poss	_	_
18	results	result	NNS	_	19	dep	_	_
19	suggest	suggest	VBP	_	1	acl	_	_
20	an	an	DT	_	21	det	_	_
21	involvement	involvement	NN	_	19	obj	_	_
22	of	of	IN	_	26	case	_	_
23	the	the	DT	_	26	det	_	_
24	drug2	drug0	NN	_	26	com	_	_
25	gene	gene	NN	_	26	com	_	_
26	locus	locus	NN	_	21	ppmod	_	_
27	in	in	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	genetics	genetics	NNS	_	21	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	drug5	drug0	NN	_	29	ppmod	_	_
32	and	and	CC	_	31	cc	_	_
33	drug6	drug0	NN	_	31	conj	_	_
34	.	.	.	_	1	p	_	_

1	Individuals	individual	NNS	_	3	dep	_	_
2	were	be	VBD	_	3	aux	_	_
3	genotyped	genotyped	VBN	_	0	root	_	_
4	for	for	IN	_	6	case	_	_
5	PCSK9	pcsk0	NN	_	6	com	_	_
6	R46L	r0l	NN	_	3	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug1	drug0	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	,	,	,	_	6	p	_	_
11	ABCG8	abcg0	NN	_	12	com	_	_
12	D19H	d0h	NN	_	6	conj	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug2	drug0	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	,	,	,	_	12	p	_	_
17	and	and	CC	_	12	cc	_	_
18	APOE	apoe	NN	_	19	com	_	_
19	R112C	r0c	NNP	_	6	conj	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	drug3	drug0	NN	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	and	and	CC	_	19	cc	_	_
24	R158C	r0c	NN	_	28	attr	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	drug4	drug0	NN	_	28	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	polymorphisms	polymorphism	NNS	_	19	conj	_	_
29	,	,	,	_	3	p	_	_
30	all	all	DT	_	34	dep	_	_
31	of	of	IN	_	32	case	_	_
32	which	which	WDT	_	30	ppmod	_	_
33	are	be	VBP	_	34	aux	_	_
34	associated	associate	VBN	_	3	advcl	_	_
35	with	with	IN	_	37	case	_	_
36	lifelong	lifelong	RB	_	37	adv	_	_
37	drug5	drug0	NN	_	34	ppmod	_	_
38	.	.	.	_	3	p	_	_

1	This	this	DT	_	2	det	_	_
2	paper	paper	NN	_	3	dep	_	_
3	addresses	address	VBZ	_	0	root	_	_
4	a	a	DT	_	5	det	_	_
5	tenet	tenet	NN	_	3	dat	_	_
6	of	of	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	literature	literature	NN	_	5	ppmod	_	_
9	on	on	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	3	p	_	_
12	i.e.	i.e.	FW	_	3	ppmod	_	_
13	,	,	,	_	3	p	_	_
14	the	the	DT	_	15	det	_	_
15	relationship	relationship	NN	_	3	obj	_	_
16	between	between	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	effects	effect	NNS	_	15	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	e4	e0	NN	_	18	ppmod	_	_
22	,	,	,	_	18	p	_	_
23	one	#crd#	CD	_	18	conj	_	_
24	of	of	IN	_	29	case	_	_
25	the	the	DT	_	29	det	_	_
26	established	established	JJ	_	29	attr	_	_
27	genetic	genetic	JJ	_	29	attr	_	_
28	risk	risk	NN	_	29	com	_	_
29	factor	factor	NN	_	23	ppmod	_	_
30	for	for	IN	_	31	case	_	_
31	drug2	drug0	NN	_	29	ppmod	_	_
32	,	,	,	_	23	p	_	_
33	and	and	CC	_	23	cc	_	_
34	its	its	PRP$	_	36	poss	_	_
35	expression	expression	NN	_	36	com	_	_
36	levels	level	NNS	_	18	conj	_	_
37	as	as	IN	_	38	mark	_	_
38	determined	determine	VBN	_	15	acl	_	_
39	by	by	IN	_	42	case	_	_
40	APOE	apoe	NN	_	42	com	_	_
41	promoter	promoter	NN	_	42	com	_	_
42	polymorphisms	polymorphism	NNS	_	38	ppmod	_	_
43	.	.	.	_	3	p	_	_

1	Three	#crd#	CD	_	2	num	_	_
2	SNPs	snp	NNS	_	18	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug1	drug0	NN	_	2	prn	_	_
5	in	in	IN	_	6	case	_	_
6	IREB2	ireb0	NN	_	4	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	in	in	IN	_	10	case	_	_
10	LOC123688	loc0	NN	_	8	ppmod	_	_
11	,	,	,	_	8	p	_	_
12	and	and	CC	_	8	cc	_	_
13	drug3	drug0	NN	_	6	conj	_	_
14	in	in	IN	_	15	case	_	_
15	CHRNA3	chrna0	NN	_	13	ppmod	_	_
16	)	-rrb-	-RRB-	_	4	p	_	_
17	were	be	VBD	_	18	aux	_	_
18	associated	associate	VBN	_	0	root	_	_
19	with	with	IN	_	20	case	_	_
20	drug4	drug0	NN	_	18	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	predicted	predict	VBN	_	20	ppmod	_	_
23	in	in	IN	_	28	case	_	_
24	the	the	DT	_	28	det	_	_
25	AAT	aat	NN	_	28	attr	_	_
26	Genetic	genetic	JJ	_	27	attr	_	_
27	Modifiers	modifier	NNS	_	28	com	_	_
28	Study	study	NN	_	20	ppmod	_	_
29	.	.	.	_	18	p	_	_

1	Two	#crd#	CD	_	2	num	_	_
2	SNPs	snp	NNS	_	9	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug1	drug0	NN	_	2	prn	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_
8	were	be	VBD	_	9	aux	_	_
9	associated	associate	VBN	_	21	advcl	_	_
10	with	with	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	drug3	drug0	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	predicted	predict	VBN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug4	drug0	NNS	_	14	conj	_	_
17	;	;	:	_	21	p	_	_
18	SNP-by-gender	snp-by-gender	JJ	_	19	attr	_	_
19	interactions	interaction	NNS	_	21	dep	_	_
20	were	be	VBD	_	21	aux	_	_
21	observed	observe	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	In	in	IN	_	6	case	_	_
2	the	the	DT	_	6	det	_	_
3	UK	uk	NNP	_	5	com	_	_
4	National	national	NNP	_	5	com	_	_
5	Registry	registry	NNP	_	6	com	_	_
6	dataset	dataset	NN	_	11	ppmod	_	_
7	,	,	,	_	11	p	_	_
8	drug1	drug0	NN	_	11	dep	_	_
9	was	be	VBD	_	11	aux	_	_
10	significantly	significantly	RB	_	11	adv	_	_
11	associated	associate	VBN	_	23	advcl	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	in	in	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	male	male	JJ	_	17	attr	_	_
17	subgroup	subgroup	NN	_	13	ppmod	_	_
18	;	;	:	_	23	p	_	_
19	significant	significant	JJ	_	21	attr	_	_
20	SNP-by-smoking	snp-by-smoking	JJ	_	21	attr	_	_
21	interactions	interaction	NNS	_	23	dep	_	_
22	were	be	VBD	_	23	aux	_	_
23	observed	observe	VBN	_	0	root	_	_
24	.	.	.	_	23	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	investigated	investigate	VBD	_	0	root	_	_
3	thecausal	thecausal	JJ	_	4	attr	_	_
4	relationship	relationship	NN	_	2	obj	_	_
5	between	between	IN	_	6	case	_	_
6	drug2	drug0	NNS	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	symptoms	symptom	NNS	_	6	conj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	6	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug4	drug0	NN	_	10	conj	_	_
13	in	in	IN	_	17	case	_	_
14	the	the	DT	_	17	det	_	_
15	Norwegian	norwegian	NN	_	17	com	_	_
16	HUNT	hunt	NN	_	17	com	_	_
17	study	study	NN	_	10	ppmod	_	_
18	using	use	VBG	_	2	comp	_	_
19	the	the	DT	_	26	det	_	_
20	drug1	drug0	NN	_	26	attr	_	_
21	single	single	JJ	_	26	attr	_	_
22	nucleotidepolymorphism	nucleotidepolymorphism	NN	_	26	attr	_	_
23	(	-lrb-	-LRB-	_	26	p	_	_
24	SNP	snp	NN	_	26	attr	_	_
25	)	-rrb-	-RRB-	_	26	p	_	_
26	variant	variant	NN	_	18	obj	_	_
27	located	located	JJ	_	26	attr	_	_
28	in	in	IN	_	34	case	_	_
29	the	the	DT	_	32	det	_	_
30	nicotine	nicotine	NN	_	32	com	_	_
31	acetylcholine	acetylcholine	NN	_	32	com	_	_
32	receptor	receptor	NN	_	34	com	_	_
33	gene	gene	NN	_	34	com	_	_
34	cluster	cluster	NN	_	27	ppmod	_	_
35	on	on	IN	_	36	case	_	_
36	chromosome	chromosome	NN	_	34	ppmod	_	_
37	15	0	CD	_	36	num	_	_
38	as	as	IN	_	41	case	_	_
39	an	an	DT	_	41	det	_	_
40	instrumental	instrumental	JJ	_	41	attr	_	_
41	variable	variable	NN	_	18	ppmod	_	_
42	for	for	IN	_	43	case	_	_
43	smokingphenotypes	smokingphenotypes	NNS	_	41	ppmod	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	data	datum	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	compatible	compatible	JJ	_	3	dep	_	_
5	with	with	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	hypothesis	hypothesis	NN	_	4	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	a	a	DT	_	11	det	_	_
10	complex	complex	JJ	_	11	attr	_	_
11	role	role	NN	_	7	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	in	in	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	pathogenesis	pathogenesis	NN	_	11	ppmod	_	_
18	,	,	,	_	4	p	_	_
19	with	with	IN	_	23	case	_	_
20	positive	positive	JJ	_	23	attr	_	_
21	and	and	CC	_	20	cc	_	_
22	negative	negative	JJ	_	20	conj	_	_
23	effects	effect	NNS	_	4	ppmod	_	_
24	occurring	occur	VBG	_	23	acl	_	_
25	concomitantly	concomitantly	RB	_	24	adv	_	_
26	according	accord	VBG	_	30	adv	_	_
27	to	to	TO	_	30	aux	_	_
28	its	its	PRP$	_	30	poss	_	_
29	expression	expression	NN	_	30	com	_	_
30	levels	level	NNS	_	24	ppmod	_	_
31	and	and	CC	_	30	cc	_	_
32	its	its	PRP$	_	34	poss	_	_
33	protein-protein	protein-protein	JJ	_	34	attr	_	_
34	interactions	interaction	NNS	_	30	conj	_	_
35	largely	largely	RB	_	36	adv	_	_
36	unclarified	unclarified	VBN	_	34	acl	_	_
37	.	.	.	_	3	p	_	_

1	VKORC1	vkorc0	NN	_	3	attr	_	_
2	3673	0	NN	_	3	num	_	_
3	AA	aa	NN	_	38	dep	_	_
4	or	or	CC	_	3	cc	_	_
5	GA	ga	NN	_	6	com	_	_
6	genotype	genotype	NN	_	3	conj	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	P<0.0001	p<0	NN	_	3	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	,	,	,	_	3	p	_	_
11	one	#crd#	CD	_	15	num	_	_
12	or	or	CC	_	11	cc	_	_
13	two	#crd#	CD	_	11	conj	_	_
14	variant	variant	JJ	_	15	attr	_	_
15	alleles	allele	NNS	_	3	conj	_	_
16	of	of	IN	_	18	case	_	_
17	CYP2C9	cyp0c0	NN	_	18	com	_	_
18	gene	gene	NN	_	15	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	P=0.0004	p=0	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	,	,	,	_	15	p	_	_
23	drug1	drug0	NN	_	25	com	_	_
24	e2	e0	NN	_	25	com	_	_
25	haplotype	haplotype	NN	_	3	conj	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	P=0.01	p=0	NN	_	25	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	,	,	,	_	25	p	_	_
30	and	and	CC	_	25	cc	_	_
31	increasing	increase	VBG	_	32	attr	_	_
32	age	age	NN	_	3	conj	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	P<0.0001	p<0	NN	_	32	prn	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	were	be	VBD	_	38	aux	_	_
37	all	all	RB	_	38	adv	_	_
38	associated	associate	VBN	_	0	root	_	_
39	with	with	IN	_	42	case	_	_
40	lower	low	JJR	_	42	attr	_	_
41	warfarin	warfarin	NN	_	42	com	_	_
42	dose	dose	NN	_	38	ppmod	_	_
43	,	,	,	_	38	p	_	_
44	whereas	whereas	IN	_	54	mark	_	_
45	drug2	drug0	NN	_	54	dep	_	_
46	(	-lrb-	-LRB-	_	47	p	_	_
47	P=0.025	p=0	NN	_	45	prn	_	_
48	)	-rrb-	-RRB-	_	47	p	_	_
49	and	and	CC	_	45	cc	_	_
50	drug3	drug0	NN	_	45	conj	_	_
51	(	-lrb-	-LRB-	_	52	p	_	_
52	P=0.0059	p=0	NN	_	50	prn	_	_
53	)	-rrb-	-RRB-	_	52	p	_	_
54	showed	show	VBD	_	38	comp	_	_
55	association	association	NN	_	54	obj	_	_
56	with	with	IN	_	59	case	_	_
57	higher	high	JJR	_	59	attr	_	_
58	warfarin	warfarin	NN	_	59	com	_	_
59	doses	dose	NNS	_	55	ppmod	_	_
60	.	.	.	_	38	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	study	study	NN	_	5	dep	_	_
5	shows	show	VBZ	_	1	acl	_	_
6	that	that	IN	_	20	mark	_	_
7	drug1	drug0	NN	_	20	dep	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	polymorphisms	polymorphism	NNS	_	7	conj	_	_
11	,	,	,	_	10	p	_	_
12	APOE	apoe	NN	_	14	com	_	_
13	e2	e0	NN	_	14	com	_	_
14	variant	variant	NN	_	7	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	several	several	JJ	_	19	attr	_	_
18	clinical/demographic	clinical/demographic	JJ	_	19	attr	_	_
19	variables	variable	NNS	_	7	conj	_	_
20	are	be	VBP	_	5	comp	_	_
21	important	important	JJ	_	22	attr	_	_
22	determinants	determinant	NNS	_	20	obj	_	_
23	of	of	IN	_	26	case	_	_
24	drug3	drug0	NN	_	26	com	_	_
25	dose	dose	NN	_	26	com	_	_
26	requirements	requirement	NNS	_	22	ppmod	_	_
27	in	in	IN	_	29	case	_	_
28	Egyptian	egyptian	NN	_	29	com	_	_
29	patients	patient	NNS	_	22	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Although	although	IN	_	9	mark	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	genotype	genotype	NN	_	9	dep	_	_
6	does	do	VBZ	_	9	aux	_	_
7	have	have	VB	_	9	lv	_	_
8	strong	strong	JJ	_	9	attr	_	_
9	associations	association	NNS	_	19	advcl	_	_
10	with	with	IN	_	12	case	_	_
11	lipid	lipid	NN	_	12	com	_	_
12	levels	level	NNS	_	9	ppmod	_	_
13	in	in	IN	_	14	case	_	_
14	childhood	childhood	NN	_	9	ppmod	_	_
15	,	,	,	_	19	p	_	_
16	there	there	EX	_	19	dep	_	_
17	does	do	VBZ	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	seem	seem	VB	_	1	acl	_	_
20	to	to	TO	_	21	aux	_	_
21	be	be	VB	_	19	comp	_	_
22	meaningful	meaningful	JJ	_	23	attr	_	_
23	effects	effect	NNS	_	21	obj	_	_
24	on	on	IN	_	25	case	_	_
25	drug2	drug0	NNS	_	23	ppmod	_	_
26	,	,	,	_	19	p	_	_
27	suggesting	suggest	VBG	_	19	comp	_	_
28	that	that	IN	_	39	mark	_	_
29	any	any	DT	_	31	det	_	_
30	detrimental	detrimental	JJ	_	31	attr	_	_
31	effects	effect	NNS	_	39	dep	_	_
32	of	of	IN	_	35	case	_	_
33	the	the	DT	_	35	det	_	_
34	e4	e0	NN	_	35	com	_	_
35	allele	allele	NN	_	31	ppmod	_	_
36	on	on	IN	_	38	case	_	_
37	cognitive	cognitive	JJ	_	38	attr	_	_
38	function	function	NN	_	31	ppmod	_	_
39	are	be	VBP	_	27	comp	_	_
40	not	not	RB	_	39	neg	_	_
41	important	important	JJ	_	39	dep	_	_
42	until	until	IN	_	44	case	_	_
43	later	late	JJ	_	44	attr	_	_
44	life	life	NN	_	41	ppmod	_	_
45	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	alone	alone	RB	_	3	adv	_	_
3	is	be	VBZ	_	0	root	_	_
4	responsible	responsible	JJ	_	3	dep	_	_
5	for	for	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	association	association	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	APOE	apoe	NN	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	7	ppmod	_	_
12	;	;	:	_	3	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	present	present	JJ	_	5	attr	_	_
5	study	study	NN	_	6	dep	_	_
6	exposed	expose	VBD	_	1	acl	_	_
7	a	a	DT	_	10	det	_	_
8	susceptibility	susceptibility	NN	_	10	com	_	_
9	haplotype	haplotype	NN	_	10	com	_	_
10	drug1	drug0	NN	_	6	obj	_	_
11	,	,	,	_	6	p	_	_
12	within	within	IN	_	14	case	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	gene	gene	NN	_	6	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	which	which	WDT	_	18	dep	_	_
17	was	be	VBD	_	18	aux	_	_
18	found	find	VBN	_	14	relcl	_	_
19	to	to	TO	_	21	aux	_	_
20	be	be	VB	_	21	aux	_	_
21	associated	associate	VBN	_	18	comp	_	_
22	with	with	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	risk	risk	NN	_	23	conj	_	_
26	of	of	IN	_	27	case	_	_
27	drug4	drug0	NN	_	23	ppmod	_	_
28	and	and	CC	_	27	cc	_	_
29	drug5	drug0	NN	_	27	conj	_	_
30	in	in	IN	_	32	case	_	_
31	postmenopausal	postmenopausal	JJ	_	32	attr	_	_
32	females	female	NNS	_	27	ppmod	_	_
33	of	of	IN	_	34	case	_	_
34	India	india	NN	_	32	ppmod	_	_
35	.	.	.	_	1	p	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	association	association	NN	_	23	dep	_	_
5	of	of	IN	_	10	case	_	_
6	drug1	drug0	NN	_	10	attr	_	_
7	(	-lrb-	-LRB-	_	10	p	_	_
8	APOE	apoe	NN	_	10	attr	_	_
9	)	-rrb-	-RRB-	_	10	p	_	_
10	genotypes	genotype	NNS	_	4	ppmod	_	_
11	with	with	IN	_	14	case	_	_
12	bone	bone	NN	_	14	attr	_	_
13	mineral	mineral	JJ	_	14	attr	_	_
14	density	density	NN	_	4	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	BMD	bmd	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	and	and	CC	_	14	cc	_	_
19	risk	risk	NN	_	14	conj	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	have	have	VBP	_	23	aux	_	_
23	remained	remain	VBN	_	1	acl	_	_
24	unclear	unclear	JJ	_	23	dep	_	_
25	.	.	.	_	1	p	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Hypertriglyceridemia	hypertriglyceridemia	NN	_	7	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	HTG	htg	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	is	be	VBZ	_	1	acl	_	_
8	a	a	DT	_	12	det	_	_
9	well-established	well-established	JJ	_	12	attr	_	_
10	independent	independent	JJ	_	12	attr	_	_
11	risk	risk	NN	_	12	com	_	_
12	factor	factor	NN	_	7	obj	_	_
13	for	for	IN	_	15	case	_	_
14	drug4	drug0	JJ	_	15	attr	_	_
15	disease	disease	NN	_	12	ppmod	_	_
16	and	and	CC	_	7	cc	_	_
17	the	the	DT	_	18	det	_	_
18	influence	influence	NN	_	34	dep	_	_
19	of	of	IN	_	22	case	_	_
20	several	several	JJ	_	22	attr	_	_
21	genetic	genetic	JJ	_	22	attr	_	_
22	variants	variant	NNS	_	18	ppmod	_	_
23	in	in	IN	_	24	case	_	_
24	genes	gene	NNS	_	22	ppmod	_	_
25	related	related	JJ	_	24	attr	_	_
26	with	with	IN	_	31	case	_	_
27	triglyceride	triglyceride	NN	_	31	attr	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	TG	tg	NN	_	27	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	metabolism	metabolism	NN	_	25	ppmod	_	_
32	has	have	VBZ	_	34	aux	_	_
33	been	be	VBN	_	34	aux	_	_
34	described	describe	VBN	_	7	conj	_	_
35	,	,	,	_	34	p	_	_
36	including	include	VBG	_	37	adv	_	_
37	drug1	drug0	NN	_	34	ppmod	_	_
38	,	,	,	_	37	p	_	_
39	drug2	drug0	NN	_	37	conj	_	_
40	and	and	CC	_	39	cc	_	_
41	drug3	drug0	NN	_	37	conj	_	_
42	.	.	.	_	1	p	_	_

1	Among	among	IN	_	2	case	_	_
2	SNPs	snp	NNS	_	19	ppmod	_	_
3	tested	test	VBN	_	2	acl	_	_
4	with	with	IN	_	7	case	_	_
5	an	an	DT	_	7	det	_	_
6	allele	allele	NN	_	7	com	_	_
7	frequency	frequency	NN	_	3	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	at	at	IN	_	11	case	_	_
10	least	least	JJS	_	11	attr	_	_
11	5	0	CD	_	7	ppmod	_	_
12	%	%	NN	_	11	meta	_	_
13	,	,	,	_	19	p	_	_
14	only	only	JJ	_	15	attr	_	_
15	SNPs	snp	NNS	_	19	dep	_	_
16	in	in	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	are	be	VBP	_	19	aux	_	_
19	found	find	VBN	_	0	root	_	_
20	to	to	TO	_	21	aux	_	_
21	influence	influence	VB	_	19	comp	_	_
22	drug2	drug0	NN	_	21	obj	_	_
23	significantly	significantly	RB	_	21	adv	_	_
24	.	.	.	_	19	p	_	_

1	Of	of	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	3	0	CD	_	4	num	_	_
4	SNPs	snp	NNS	_	21	ppmod	_	_
5	most	most	RBS	_	6	com	_	_
6	significantly	significantly	RB	_	7	adv	_	_
7	associated	associate	VBN	_	4	acl	_	_
8	with	with	IN	_	9	case	_	_
9	MI	mi	NN	_	7	ppmod	_	_
10	,	,	,	_	21	p	_	_
11	drug1	drug0	NN	_	21	dep	_	_
12	,	,	,	_	11	p	_	_
13	which	which	WDT	_	14	dep	_	_
14	defines	define	VBZ	_	11	relcl	_	_
15	the	the	DT	_	18	det	_	_
16	Apo	apo	NN	_	18	com	_	_
17	E2	e0	NN	_	18	com	_	_
18	isoform	isoform	NN	_	14	obj	_	_
19	,	,	,	_	11	p	_	_
20	was	be	VBD	_	21	aux	_	_
21	associated	associate	VBN	_	0	root	_	_
22	with	with	IN	_	28	case	_	_
23	both	both	CC	_	28	cc	_	_
24	a	a	DT	_	28	det	_	_
25	lower	low	JJR	_	28	attr	_	_
26	Apo	apo	NN	_	28	com	_	_
27	B/A1	b/a0	NN	_	28	com	_	_
28	ratio	ratio	NN	_	21	ppmod	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	P=1.0x10	p=0x0	NN	_	28	prn	_	_
31	(	-lrb-	-LRB-	_	30	p	_	_
32	-7	0	CD	_	30	num	_	_
33	)	-rrb-	-RRB-	_	30	p	_	_
34	)	-rrb-	-RRB-	_	30	p	_	_
35	and	and	CC	_	28	cc	_	_
36	lower	low	JJR	_	38	attr	_	_
37	drug2	drug0	NN	_	38	com	_	_
38	risk	risk	NN	_	28	conj	_	_
39	(	-lrb-	-LRB-	_	40	p	_	_
40	P=0.0004	p=0	NN	_	21	prn	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	.	.	.	_	21	p	_	_

1	METHODS	method	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	We	we	PRP	_	4	dep	_	_
4	reviewed	review	VBN	_	1	acl	_	_
5	the	the	DT	_	6	det	_	_
6	literature	literature	NN	_	4	obj	_	_
7	relating	relate	VBG	_	6	acl	_	_
8	to	to	TO	_	10	aux	_	_
9	SNPs	snps	NN	_	10	com	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	and	and	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	,	,	,	_	1	p	_	_
16	and	and	CC	_	1	cc	_	_
17	clinical	clinical	JJ	_	20	attr	_	_
18	and	and	CC	_	17	cc	_	_
19	preclinical	preclinical	JJ	_	17	conj	_	_
20	studies	study	NNS	_	1	conj	_	_
21	,	,	,	_	20	p	_	_
22	which	which	WDT	_	23	dep	_	_
23	shed	shed	VB	_	20	relcl	_	_
24	light	light	NN	_	23	obj	_	_
25	on	on	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	mechanisms	mechanism	NNS	_	23	ppmod	_	_
28	underlying	underlie	VBG	_	27	acl	_	_
29	these	these	DT	_	30	det	_	_
30	associations	association	NNS	_	28	obj	_	_

1	Two	#crd#	CD	_	2	num	_	_
2	polymorphisms	polymorphism	NNS	_	23	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug1	drug0	NN	_	2	prn	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	appo	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_
8	that	that	WDT	_	9	dep	_	_
9	define	define	VBP	_	2	relcl	_	_
10	the	the	DT	_	17	det	_	_
11	epsilon2	epsilon0	NN	_	17	attr	_	_
12	,	,	,	_	11	p	_	_
13	epsilon3	epsilon0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	epsilon4	epsilon0	NN	_	11	conj	_	_
17	isoforms	isoforms	NNS	_	9	obj	_	_
18	of	of	IN	_	20	case	_	_
19	apolipoprotein	apolipoprotein	NN	_	20	com	_	_
20	E	e	NN	_	17	ppmod	_	_
21	were	be	VBD	_	23	aux	_	_
22	significantly	significantly	RB	_	23	adv	_	_
23	associated	associate	VBN	_	0	root	_	_
24	with	with	IN	_	26	case	_	_
25	percent	percent	JJ	_	26	attr	_	_
26	reduction	reduction	NN	_	23	ppmod	_	_
27	in	in	IN	_	28	case	_	_
28	drug3	drug0	NN	_	26	ppmod	_	_
29	(	-lrb-	-LRB-	_	47	p	_	_
30	epsilon2	epsilon0	NN	_	31	com	_	_
31	carriers	carrier	NNS	_	47	dep	_	_
32	53.8	0	CD	_	31	num	_	_
33	%	%	NN	_	31	meta	_	_
34	,	,	,	_	31	p	_	_
35	epsilon3/epsilon3	epsilon0/epsilon0	NN	_	31	conj	_	_
36	48.1	0	CD	_	35	num	_	_
37	%	%	NN	_	35	meta	_	_
38	,	,	,	_	35	p	_	_
39	and	and	CC	_	35	cc	_	_
40	epsilon4	epsilon0	NN	_	41	com	_	_
41	carriers	carrier	NNS	_	42	attr	_	_
42	46.4	0	CD	_	31	conj	_	_
43	%	%	NN	_	42	meta	_	_
44	,	,	,	_	31	p	_	_
45	respectively	respectively	RB	_	31	adv	_	_
46	,	,	,	_	47	p	_	_
47	P=0.00039	p=0	CD	_	23	num	_	_
48	)	-rrb-	-RRB-	_	47	p	_	_
49	and	and	CC	_	23	cc	_	_
50	replicated	replicate	VBD	_	23	conj	_	_
51	in	in	IN	_	53	case	_	_
52	the	the	DT	_	53	det	_	_
53	drug4	drug0	NN	_	50	ppmod	_	_
54	(	-lrb-	-LRB-	_	72	p	_	_
55	epsilon2	epsilon0	NN	_	56	com	_	_
56	carriers	carrier	NNS	_	57	attr	_	_
57	22.1	0	CD	_	72	num	_	_
58	%	%	NN	_	57	meta	_	_
59	,	,	,	_	57	p	_	_
60	epsilon3/epsilon3	epsilon0/epsilon0	NN	_	57	conj	_	_
61	21.8	0	CD	_	60	num	_	_
62	%	%	NN	_	60	meta	_	_
63	,	,	,	_	60	p	_	_
64	and	and	CC	_	60	cc	_	_
65	epsilon4	epsilon0	NN	_	66	com	_	_
66	carriers	carrier	NNS	_	67	attr	_	_
67	16.6	0	CD	_	57	conj	_	_
68	%	%	NN	_	67	meta	_	_
69	,	,	,	_	57	p	_	_
70	respectively	respectively	RB	_	57	adv	_	_
71	,	,	,	_	72	p	_	_
72	P=0.00038	p=0	CD	_	50	num	_	_
73	)	-rrb-	-RRB-	_	72	p	_	_
74	.	.	.	_	23	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	results	result	NNS	_	3	dep	_	_
3	support	support	VBP	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	hypothesis	hypothesis	NN	_	3	obj	_	_
6	that	that	IN	_	8	mark	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	influence	influence	VBP	_	5	acl	_	_
9	the	the	DT	_	10	det	_	_
10	prevalence	prevalence	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	possibly	possibly	RB	_	15	adv	_	_
15	overweight	overweight	NN	_	12	conj	_	_
16	in	in	IN	_	18	case	_	_
17	drug3	drug0	NN	_	18	com	_	_
18	patients	patient	NNS	_	10	ppmod	_	_
19	.	.	.	_	3	p	_	_

1	These	these	DT	_	2	det	_	_
2	associations	association	NNS	_	3	dep	_	_
3	warrant	warrant	VBP	_	0	root	_	_
4	prospective	prospective	JJ	_	5	attr	_	_
5	study	study	NN	_	3	obj	_	_
6	to	to	TO	_	7	aux	_	_
7	assess	assess	VB	_	5	acl	_	_
8	interaction	interaction	NN	_	7	obj	_	_
9	between	between	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	the	the	DT	_	13	det	_	_
13	propensity	propensity	NN	_	10	conj	_	_
14	of	of	IN	_	15	case	_	_
15	antipsychotics	antipsychotics	NN	_	13	ppmod	_	_
16	to	to	TO	_	17	aux	_	_
17	induce	induce	VB	_	13	acl	_	_
18	drug2	drug0	NN	_	17	obj	_	_
19	.	.	.	_	3	p	_	_

1	Lower	low	JJR	_	4	attr	_	_
2	lipid	lipid	NN	_	4	com	_	_
3	profile	profile	NN	_	4	com	_	_
4	values	value	NNS	_	19	dep	_	_
5	among	among	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	even	even	RB	_	6	adv	_	_
9	those	those	DT	_	6	appo	_	_
10	on	on	IN	_	12	case	_	_
11	lipid-rich	lipid-rich	JJ	_	12	attr	_	_
12	diets	diet	NNS	_	9	ppmod	_	_
13	associated	associate	VBN	_	12	acl	_	_
14	with	with	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	allele	allele	NN	_	13	ppmod	_	_
18	,	,	,	_	6	p	_	_
19	suggest	suggest	VBP	_	0	root	_	_
20	alterations	alteration	NNS	_	19	obj	_	_
21	in	in	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	lipid	lipid	NN	_	24	com	_	_
24	synthesis	synthesis	NN	_	20	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	metabolism	metabolism	NN	_	27	com	_	_
27	pathways	pathway	NNS	_	24	conj	_	_
28	in	in	IN	_	29	case	_	_
29	drug2	drug0	NN	_	24	ppmod	_	_
30	.	.	.	_	19	p	_	_

1	GAB2	gab0	NN	_	3	com	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	marker	marker	NN	_	6	dep	_	_
4	does	do	VBZ	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	modify	modify	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	risk	risk	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	in	in	IN	_	16	case	_	_
12	Spanish	spanish	NN	_	14	com	_	_
13	APOE	apoe	NN	_	14	com	_	_
14	epsilon	epsilon	NN	_	16	attr	_	_
15	4	0	CD	_	14	num	_	_
16	carriers	carrier	NNS	_	8	ppmod	_	_
17	.	.	.	_	6	p	_	_

1	OBJECTIVE	objective	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Although	although	IN	_	7	mark	_	_
4	several	several	JJ	_	5	attr	_	_
5	studies	study	NNS	_	7	dep	_	_
6	have	have	VBP	_	7	aux	_	_
7	reported	report	VBN	_	38	advcl	_	_
8	an	an	DT	_	9	det	_	_
9	association	association	NN	_	7	obj	_	_
10	between	between	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	OSA	osa	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	and	and	CC	_	11	cc	_	_
16	the	the	DT	_	18	det	_	_
17	chromosomal	chromosomal	JJ	_	18	attr	_	_
18	region	region	NN	_	11	conj	_	_
19	containing	contain	VBG	_	18	acl	_	_
20	the	the	DT	_	26	det	_	_
21	Apolipoprotein	apolipoprotein	NN	_	22	com	_	_
22	E	e	NN	_	26	attr	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	drug1	drug0	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	gene	gene	NN	_	19	obj	_	_
27	,	,	,	_	38	p	_	_
28	findings	finding	NNS	_	38	dep	_	_
29	about	about	IN	_	32	case	_	_
30	the	the	DT	_	32	det	_	_
31	exact	exact	JJ	_	32	attr	_	_
32	location	location	NN	_	28	ppmod	_	_
33	in	in	IN	_	36	case	_	_
34	the	the	DT	_	36	det	_	_
35	ApoE	apoe	NN	_	36	com	_	_
36	gene	gene	NN	_	32	ppmod	_	_
37	have	have	VBP	_	38	aux	_	_
38	been	be	VBN	_	1	acl	_	_
39	inconsistent	inconsistent	JJ	_	38	dep	_	_
40	.	.	.	_	1	p	_	_

1	The	the	DT	_	7	det	_	_
2	sliding	sliding	JJ	_	7	attr	_	_
3	window	window	NN	_	7	com	_	_
4	haplotype	haplotype	NN	_	7	com	_	_
5	trend	trend	NN	_	7	com	_	_
6	regression	regression	NN	_	7	com	_	_
7	test	test	NN	_	8	dep	_	_
8	revealed	reveal	VBD	_	0	root	_	_
9	that	that	IN	_	13	mark	_	_
10	SNP	snp	NN	_	11	com	_	_
11	drug1	drug0	NN	_	13	dep	_	_
12	was	be	VBD	_	13	aux	_	_
13	included	include	VBN	_	8	comp	_	_
14	in	in	IN	_	16	case	_	_
15	all	all	DT	_	16	det	_	_
16	haplotypes	haplotype	NNS	_	13	ppmod	_	_
17	that	that	WDT	_	20	dep	_	_
18	are	be	VBP	_	20	aux	_	_
19	significantly	significantly	RB	_	20	adv	_	_
20	associated	associate	VBN	_	16	relcl	_	_
21	with	with	IN	_	23	case	_	_
22	drug2	drug0	JJ	_	23	attr	_	_
23	status	status	NN	_	20	ppmod	_	_
24	.	.	.	_	8	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	setting	setting	NN	_	8	ppmod	_	_
5	,	,	,	_	8	p	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	could	could	MD	_	8	modal	_	_
8	offer	offer	VB	_	0	root	_	_
9	additional	additional	JJ	_	11	attr	_	_
10	biological	biological	JJ	_	11	attr	_	_
11	evidence	evidence	NN	_	8	obj	_	_
12	of	of	IN	_	17	case	_	_
13	whether	whether	IN	_	17	mark	_	_
14	a	a	DT	_	15	det	_	_
15	subject	subject	NN	_	17	dep	_	_
16	may	may	MD	_	17	modal	_	_
17	develop	develop	VB	_	11	ppmod	_	_
18	drug2	drug0	NN	_	17	obj	_	_
19	,	,	,	_	8	p	_	_
20	but	but	CC	_	8	cc	_	_
21	it	it	PRP	_	22	dep	_	_
22	is	be	VBZ	_	8	conj	_	_
23	not	not	RB	_	22	neg	_	_
24	robust	robust	JJ	_	22	dep	_	_
25	enough	enough	RB	_	24	adv	_	_
26	to	to	TO	_	27	aux	_	_
27	serve	serve	VB	_	24	comp	_	_
28	as	as	IN	_	31	case	_	_
29	an	an	DT	_	31	det	_	_
30	independent	independent	JJ	_	31	attr	_	_
31	screening	screening	NN	_	27	ppmod	_	_
32	or	or	CC	_	31	cc	_	_
33	predictive	predictive	JJ	_	34	attr	_	_
34	test	test	NN	_	31	conj	_	_
35	in	in	IN	_	36	case	_	_
36	thediagnosis	thediagnosis	NN	_	31	ppmod	_	_
37	of	of	IN	_	38	case	_	_
38	drug3	drug0	NN	_	36	ppmod	_	_

1	In	in	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	study	study	NN	_	6	ppmod	_	_
4	,	,	,	_	6	p	_	_
5	we	we	PRP	_	6	dep	_	_
6	investigated	investigate	VBD	_	0	root	_	_
7	whether	whether	IN	_	21	mark	_	_
8	variants	variant	NNS	_	21	dep	_	_
9	in	in	IN	_	14	case	_	_
10	three	#crd#	CD	_	14	num	_	_
11	key	key	JJ	_	14	attr	_	_
12	pigmentation	pigmentation	NN	_	14	com	_	_
13	genes-	genes-	NN	_	14	com	_	_
14	drug1	drug0	NN	_	8	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	drug3	drug0	NN	_	14	conj	_	_
20	--were	--were	VBD	_	21	aux	_	_
21	involved	involve	VBN	_	6	comp	_	_
22	in	in	IN	_	24	case	_	_
23	drug4	drug0	NN	_	24	com	_	_
24	predisposition	predisposition	NN	_	21	ppmod	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	variants	variant	NNS	_	1	conj	_	_
5	had	have	VBD	_	0	root	_	_
6	additive	additive	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	5	obj	_	_
8	on	on	IN	_	10	case	_	_
9	drug3	drug0	NN	_	10	com	_	_
10	risk	risk	NN	_	5	ppmod	_	_
11	,	,	,	_	5	p	_	_
12	and	and	CC	_	5	cc	_	_
13	after	after	IN	_	14	case	_	_
14	adjusting	adjust	VBG	_	21	ppmod	_	_
15	for	for	IN	_	17	case	_	_
16	pigmentation	pigmentation	NN	_	17	com	_	_
17	characteristics	characteristic	NNS	_	14	ppmod	_	_
18	,	,	,	_	21	p	_	_
19	the	the	DT	_	20	det	_	_
20	risk	risk	NN	_	21	dep	_	_
21	was	be	VBD	_	5	conj	_	_
22	persistent	persistent	JJ	_	21	dep	_	_
23	,	,	,	_	21	p	_	_
24	even	even	RB	_	28	adv	_	_
25	though	though	IN	_	28	mark	_	_
26	both	both	DT	_	27	det	_	_
27	genes	gene	NNS	_	28	dep	_	_
28	had	have	VBD	_	21	comp	_	_
29	a	a	DT	_	31	det	_	_
30	strong	strong	JJ	_	31	attr	_	_
31	impact	impact	NN	_	28	obj	_	_
32	on	on	IN	_	33	case	_	_
33	pigmentation	pigmentation	NN	_	28	ppmod	_	_

1	We	we	PRP	_	0	root	_	_
2	conducted	conduct	VBN	_	1	acl	_	_
3	additional	additional	JJ	_	4	attr	_	_
4	genotyping	genotyping	NN	_	2	obj	_	_
5	to	to	TO	_	6	aux	_	_
6	clarify	clarify	VB	_	2	comp	_	_
7	the	the	DT	_	8	det	_	_
8	role	role	NN	_	6	obj	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	locus	locus	NN	_	8	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	inheritance	inheritance	NN	_	8	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	other	other	JJ	_	21	attr	_	_
20	pigmentary	pigmentary	JJ	_	21	attr	_	_
21	traits	trait	NNS	_	17	conj	_	_
22	associated	associate	VBN	_	15	acl	_	_
23	with	with	IN	_	27	case	_	_
24	drug3	drug0	NN	_	27	com	_	_
25	risk	risk	NN	_	27	com	_	_
26	inwhite	inwhite	NN	_	27	com	_	_
27	populations	population	NNS	_	22	ppmod	_	_

1	The	the	DT	_	3	det	_	_
2	minor	minor	JJ	_	3	attr	_	_
3	alleles	allele	NNS	_	60	dep	_	_
4	of	of	IN	_	7	case	_	_
5	drug1	drug0	NN	_	7	com	_	_
6	T=	t=	NN	_	7	com	_	_
7	TF	tf	NN	_	3	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	TCF7L2	tcf0l0	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	7	p	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	T=TF	t=tf	NN	_	7	conj	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	TCF7L2	tcf0l0	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	,	,	,	_	13	p	_	_
18	drug3	drug0	NN	_	7	conj	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	-30G/A	0g/a	NN	_	22	dep	_	_
21	,	,	,	_	22	p	_	_
22	GCK	gck	NN	_	18	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	,	,	,	_	18	p	_	_
25	drug4	drug0	NN	_	7	conj	_	_
26	(	-lrb-	-LRB-	_	29	p	_	_
27	E23K	e0k	NN	_	29	dep	_	_
28	,	,	,	_	29	p	_	_
29	KCNJ11	kcnj0	NN	_	25	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	,	,	,	_	25	p	_	_
32	drug5	drug0	NN	_	7	conj	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	CDKAL1	cdkal0	NN	_	32	prn	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	,	,	,	_	32	p	_	_
37	drug6	drug0	NN	_	7	conj	_	_
38	(	-lrb-	-LRB-	_	39	p	_	_
39	IGF2BP2	igf0bp0	NN	_	37	prn	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	,	,	,	_	37	p	_	_
42	drug7	drug0	NN	_	7	conj	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	MTNR1B	mtnr0b	NN	_	42	prn	_	_
45	)	-rrb-	-RRB-	_	44	p	_	_
46	,	,	,	_	42	p	_	_
47	drug8	drug0	NN	_	7	conj	_	_
48	(	-lrb-	-LRB-	_	49	p	_	_
49	MTNR1B	mtnr0b	NN	_	47	prn	_	_
50	)	-rrb-	-RRB-	_	49	p	_	_
51	and	and	CC	_	47	cc	_	_
52	drug9	drug0	NN	_	7	conj	_	_
53	(	-lrb-	-LRB-	_	56	p	_	_
54	Gly972Arg	gly0arg	NNP	_	56	attr	_	_
55	,	,	,	_	56	p	_	_
56	IRS1	irs0	NNP	_	52	prn	_	_
57	)	-rrb-	-RRB-	_	56	p	_	_
58	were	be	VBD	_	60	aux	_	_
59	significantly	significantly	RB	_	60	adv	_	_
60	associated	associate	VBN	_	0	root	_	_
61	with	with	IN	_	64	case	_	_
62	a	a	DT	_	64	det	_	_
63	higher	high	JJR	_	64	attr	_	_
64	risk	risk	NN	_	60	ppmod	_	_
65	of	of	IN	_	66	case	_	_
66	drug10	drug0	NN	_	64	ppmod	_	_
67	.	.	.	_	60	p	_	_

1	Among	among	IN	_	2	case	_	_
2	them	them	PRP	_	8	ppmod	_	_
3	,	,	,	_	8	p	_	_
4	genetic	genetic	JJ	_	5	attr	_	_
5	variants	variant	NNS	_	8	dep	_	_
6	in	in	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	showed	show	VBD	_	0	root	_	_
9	the	the	DT	_	11	det	_	_
10	strongest	strong	JJS	_	11	attr	_	_
11	association	association	NN	_	8	obj	_	_
12	with	with	IN	_	14	case	_	_
13	drug4	drug0	NN	_	14	com	_	_
14	risk	risk	NN	_	11	ppmod	_	_
15	,	,	,	_	8	p	_	_
16	with	with	IN	_	17	case	_	_
17	ORs	or	NNS	_	8	ppmod	_	_
18	(	-lrb-	-LRB-	_	21	p	_	_
19	95	0	CD	_	21	num	_	_
20	%	%	NN	_	21	meta	_	_
21	CIs	cis	NN	_	17	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	of	of	IN	_	24	case	_	_
24	1.44	0	CD	_	17	ppmod	_	_
25	(	-lrb-	-LRB-	_	28	p	_	_
26	1.29-1.60	0	NN	_	28	num	_	_
27	,	,	,	_	28	p	_	_
28	P	p	NN	_	24	prn	_	_
29	<	<	JJ	_	28	attr	_	_
30	0.001	0	CD	_	28	num	_	_
31	)	-rrb-	-RRB-	_	28	p	_	_
32	per	per	IN	_	34	case	_	_
33	T	t	NN	_	34	com	_	_
34	allele	allele	NN	_	24	ppmod	_	_
35	of	of	IN	_	36	case	_	_
36	drug2	drug0	NN	_	34	ppmod	_	_
37	and	and	CC	_	24	cc	_	_
38	1.46	0	CD	_	24	conj	_	_
39	(	-lrb-	-LRB-	_	40	p	_	_
40	1.15-1.84	0	CD	_	38	num	_	_
41	,	,	,	_	40	p	_	_
42	P	p	NN	_	43	dep	_	_
43	=	=	JJ	_	40	advcl	_	_
44	0.002	0	CD	_	43	obj	_	_
45	)	-rrb-	-RRB-	_	40	p	_	_
46	per	per	IN	_	48	case	_	_
47	T	t	NN	_	48	com	_	_
48	allele	allele	NN	_	38	ppmod	_	_
49	of	of	IN	_	50	case	_	_
50	drug3	drug0	NN	_	48	ppmod	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Two	#crd#	CD	_	5	num	_	_
4	single-nucleotide	single-nucleotide	JJ	_	5	attr	_	_
5	polymorphisms	polymorphism	NNS	_	25	dep	_	_
6	,	,	,	_	5	p	_	_
7	drug1	drug0	NN	_	5	appo	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	5	p	_	_
11	located	located	JJ	_	5	attr	_	_
12	within	within	IN	_	18	case	_	_
13	the	the	DT	_	16	det	_	_
14	nicotinic	nicotinic	JJ	_	16	attr	_	_
15	acetylcholine	acetylcholine	NN	_	16	com	_	_
16	receptor	receptor	NN	_	18	com	_	_
17	gene	gene	NN	_	18	com	_	_
18	cluster	cluster	NN	_	11	ppmod	_	_
19	on	on	IN	_	22	case	_	_
20	chromosome	chromosome	NN	_	22	attr	_	_
21	15q25	0q0	CD	_	22	num	_	_
22	locus	locus	NN	_	18	ppmod	_	_
23	,	,	,	_	5	p	_	_
24	are	be	VBP	_	25	aux	_	_
25	associated	associate	VBN	_	1	acl	_	_
26	with	with	IN	_	27	case	_	_
27	heaviness	heaviness	NN	_	25	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	drug3	drug0	NN	_	27	ppmod	_	_
30	,	,	,	_	27	p	_	_
31	risk	risk	NN	_	27	conj	_	_
32	for	for	IN	_	33	case	_	_
33	drug4	drug0	NN	_	31	ppmod	_	_
34	,	,	,	_	31	p	_	_
35	and	and	CC	_	31	cc	_	_
36	other	other	JJ	_	39	attr	_	_
37	smoking-related	smoking-related	JJ	_	39	attr	_	_
38	health	health	NN	_	39	com	_	_
39	outcomes	outcome	NNS	_	27	conj	_	_
40	.	.	.	_	1	p	_	_

1	OBJECTIVE	objective	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	We	we	PRP	_	4	dep	_	_
4	aimed	aim	VBD	_	1	acl	_	_
5	to	to	TO	_	6	aux	_	_
6	replicate	replicate	VB	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	association	association	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	drug1	drug0	NN	_	8	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	IVS3C/T	ivs0c/t	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	and	and	CC	_	11	cc	_	_
16	drug2	drug0	NN	_	20	attr	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	IVS3C/T	ivs0c/t	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	polymorphisms	polymorphism	NNS	_	11	conj	_	_
21	of	of	IN	_	23	case	_	_
22	transcription	transcription	NN	_	23	com	_	_
23	factor	factor	NN	_	8	ppmod	_	_
24	7-like	0-like	JJ	_	23	attr	_	_
25	2	0	CD	_	23	num	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	TCF7L2	tcf0l0	NN	_	23	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	and	and	CC	_	23	cc	_	_
30	drug3	drug0	NN	_	23	conj	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	drug4	drug0	NN	_	30	prn	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	in	in	IN	_	37	case	_	_
35	Han	han	JJ	_	37	attr	_	_
36	Chinese	chinese	NN	_	37	com	_	_
37	people	people	NN	_	6	ppmod	_	_
38	in	in	IN	_	42	case	_	_
39	Henan	henan	NNP	_	42	attr	_	_
40	province	province	NNP	_	42	attr	_	_
41	,	,	,	_	42	p	_	_
42	China	china	NNP	_	37	ppmod	_	_
43	.	.	.	_	1	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	CC	cc	NN	_	5	com	_	_
5	genotype	genotype	NN	_	33	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	the	the	DT	_	9	det	_	_
8	recessive	recessive	JJ	_	9	attr	_	_
9	model	model	NN	_	5	conj	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	variant	variant	JJ	_	13	attr	_	_
13	drug1	drug0	NN	_	9	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	IVS3C/T	ivs0c/t	NN	_	5	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	and	and	CC	_	5	cc	_	_
18	CC	cc	JJ	_	19	attr	_	_
19	haplotype	haplotype	NN	_	5	conj	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	5	ppmod	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	IVS3C/T	ivs0c/t	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	and	and	CC	_	21	cc	_	_
26	drug3	drug0	NN	_	21	conj	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	IVS3C/T	ivs0c/t	NN	_	26	prn	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	in	in	IN	_	31	case	_	_
31	TCF7L2may	tcf0l0may	NN	_	5	ppmod	_	_
32	be	be	VB	_	33	aux	_	_
33	associated	associate	VBN	_	1	acl	_	_
34	with	with	IN	_	35	case	_	_
35	drug4	drug0	NN	_	33	ppmod	_	_
36	in	in	IN	_	39	case	_	_
37	Han	han	NN	_	39	com	_	_
38	Chinese	chinese	NN	_	39	com	_	_
39	people	people	NN	_	35	ppmod	_	_
40	in	in	IN	_	44	case	_	_
41	Henan	henan	NNP	_	44	attr	_	_
42	province	province	NNP	_	44	attr	_	_
43	,	,	,	_	44	p	_	_
44	China	china	NNP	_	39	ppmod	_	_
45	.	.	.	_	44	p	_	_
46	.	.	.	_	1	p	_	_

1	Here	here	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	we	we	PRP	_	4	dep	_	_
4	report	report	VBP	_	0	root	_	_
5	replication	replication	NN	_	4	obj	_	_
6	of	of	IN	_	7	case	_	_
7	association	association	NN	_	5	ppmod	_	_
8	between	between	IN	_	12	case	_	_
9	drug6	drug0	CD	_	12	num	_	_
10	and	and	CC	_	12	cc	_	_
11	three	#crd#	CD	_	12	num	_	_
12	SNPs	snp	NNS	_	7	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	case-control	case-control	JJ	_	12	ppmod	_	_
16	(	-lrb-	-LRB-	_	28	p	_	_
17	drug1	drug0	NN	_	28	dep	_	_
18	,	,	,	_	17	p	_	_
19	P=0.003	p=0	NN	_	17	appo	_	_
20	;	;	:	_	28	p	_	_
21	drug2	drug0	NN	_	28	dep	_	_
22	,	,	,	_	28	p	_	_
23	P=0.00002	p=0	NN	_	28	dep	_	_
24	;	;	:	_	28	p	_	_
25	and.	and.	NN	_	26	com	_	_
26	drug3	drug0	NN	_	28	dep	_	_
27	,	,	,	_	28	p	_	_
28	P=0.000004	p=0	NN	_	15	prn	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	and	and	CC	_	12	cc	_	_
31	two	#crd#	CD	_	32	num	_	_
32	SNPs	snp	NNS	_	12	conj	_	_
33	in	in	IN	_	45	case	_	_
34	the	the	DT	_	45	det	_	_
35	family-based	family-based	JJ	_	45	attr	_	_
36	(	-lrb-	-LRB-	_	37	p	_	_
37	drug4	drug0	NN	_	35	prn	_	_
38	,	,	,	_	37	p	_	_
39	P=0.01	p=0	NN	_	37	conj	_	_
40	and	and	CC	_	39	cc	_	_
41	drug5	drug0	NN	_	37	conj	_	_
42	,	,	,	_	37	p	_	_
43	P=0.04	p=0	NN	_	37	appo	_	_
44	)	-rrb-	-RRB-	_	37	p	_	_
45	samples	sample	NNS	_	32	ppmod	_	_
46	from	from	IN	_	48	case	_	_
47	northern	northern	NN	_	48	com	_	_
48	Sweden	sweden	NN	_	45	ppmod	_	_
49	.	.	.	_	4	p	_	_

1	This	this	DT	_	5	det	_	_
2	263	0	NN	_	5	num	_	_
3	indel	indel	NN	_	5	attr	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	is	be	VBZ	_	0	root	_	_
8	</ModMar>reported</ModMar>	</modmar>reported</modmar>	JJ	_	7	dep	_	_
9	to	to	TO	_	10	aux	_	_
10	be	be	VB	_	8	comp	_	_
11	in	in	IN	_	14	case	_	_
12	strong	strong	JJ	_	14	attr	_	_
13	linkage	linkage	NN	_	14	com	_	_
14	disequilibrium	disequilibrium	NN	_	10	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	LD	ld	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	with	with	IN	_	27	case	_	_
19	a	a	DT	_	22	det	_	_
20	single	single	JJ	_	22	attr	_	_
21	nucleotide	nucleotide	NN	_	22	com	_	_
22	polymorphism	polymorphism	NN	_	27	attr	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	SNP	snp	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	35	0	CD	_	27	num	_	_
27	kilobases	kilobases	NNS	_	14	ppmod	_	_
28	upstream	upstream	JJ	_	27	adv	_	_
29	of	of	IN	_	30	case	_	_
30	HLA-C	hla-c	NN	_	28	ppmod	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	-35T/C	0t/c	NN	_	30	prn	_	_
33	;	;	:	_	32	p	_	_
34	rs9264942	rs0	CD	_	32	num	_	_
35	)	-rrb-	-RRB-	_	32	p	_	_
36	in	in	IN	_	38	case	_	_
37	Caucasian	caucasian	NN	_	38	com	_	_
38	individuals	individual	NNS	_	30	ppmod	_	_
39	,	,	,	_	7	p	_	_
40	making	make	VBG	_	7	comp	_	_
41	this	this	DT	_	42	det	_	_
42	SNP	snp	NN	_	40	dat	_	_
43	a	a	DT	_	45	det	_	_
44	potential	potential	JJ	_	45	attr	_	_
45	marker	marker	NN	_	40	obj	_	_
46	for	for	IN	_	49	case	_	_
47	both	both	CC	_	49	cc	_	_
48	HLA-C	hla-c	NN	_	49	com	_	_
49	expression	expression	NN	_	45	ppmod	_	_
50	and	and	CC	_	49	cc	_	_
51	drug2	drug0	NN	_	53	com	_	_
52	disease	disease	NN	_	53	com	_	_
53	progression	progression	NN	_	49	conj	_	_

1	Two	#crd#	CD	_	2	num	_	_
2	polymorphisms	polymorphism	NNS	_	14	dep	_	_
3	affecting	affect	VBG	_	2	acl	_	_
4	HLA-Csurface	hla-csurface	NN	_	5	com	_	_
5	expression	expression	NN	_	3	obj	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug1	drug0	NN	_	5	prn	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	)	-rrb-	-RRB-	_	7	p	_	_
11	have	have	VBP	_	14	aux	_	_
12	recently	recently	RB	_	14	adv	_	_
13	been	be	VBN	_	14	aux	_	_
14	identified	identify	VBN	_	0	root	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	shown	show	VBN	_	14	conj	_	_
18	to	to	TO	_	19	aux	_	_
19	influence	influence	VB	_	17	comp	_	_
20	progression	progression	NN	_	19	obj	_	_
21	of	of	IN	_	23	case	_	_
22	drug3	drug0	NN	_	23	com	_	_
23	infection	infection	NN	_	20	ppmod	_	_
24	.	.	.	_	14	p	_	_

1	OBJECTIVE	objective	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Heterozygosity	heterozygosity	NN	_	45	dep	_	_
4	for	for	IN	_	9	case	_	_
5	a	a	DT	_	9	det	_	_
6	32	0	CD	_	8	num	_	_
7	base	base	NN	_	8	com	_	_
8	pair	pair	NN	_	9	com	_	_
9	deletion	deletion	NN	_	3	ppmod	_	_
10	in	in	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	CCR5	ccr0	NN	_	13	com	_	_
13	gene	gene	NN	_	9	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	CCR5wt/d32	ccr0wt/d0	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	and	and	CC	_	13	cc	_	_
18	the	the	DT	_	20	det	_	_
19	minor	minor	JJ	_	20	attr	_	_
20	alleles	allele	NNS	_	13	conj	_	_
21	of	of	IN	_	24	case	_	_
22	a	a	DT	_	24	det	_	_
23	single-nucleotide	single-nucleotide	JJ	_	24	attr	_	_
24	polymorphism	polymorphism	NN	_	20	ppmod	_	_
25	in	in	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	HCP5	hcp0	NN	_	28	com	_	_
28	gene	gene	NN	_	20	ppmod	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	drug1	drug0	NN	_	28	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	and	and	CC	_	28	cc	_	_
33	in	in	IN	_	37	case	_	_
34	the	the	DT	_	37	det	_	_
35	HLA-C	hla-c	JJ	_	37	attr	_	_
36	gene	gene	NN	_	37	com	_	_
37	region	region	NN	_	28	conj	_	_
38	(	-lrb-	-LRB-	_	39	p	_	_
39	-35HLA-C	0hla-c	NN	_	37	prn	_	_
40	;	;	:	_	39	p	_	_
41	drug2	drug0	NN	_	39	appo	_	_
42	)	-rrb-	-RRB-	_	39	p	_	_
43	has	have	VBZ	_	45	aux	_	_
44	been	be	VBN	_	45	aux	_	_
45	associated	associate	VBN	_	1	acl	_	_
46	with	with	IN	_	48	case	_	_
47	a	a	DT	_	48	det	_	_
48	drug3	drug0	NN	_	45	ppmod	_	_

1	A	a	DT	_	4	det	_	_
2	single	single	JJ	_	4	attr	_	_
3	nucleotide	nucleotide	NN	_	4	com	_	_
4	polymorphism	polymorphism	NN	_	9	attr	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	SNP	snp	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	35	0	CD	_	9	num	_	_
9	kb	kb	NN	_	19	dep	_	_
10	upstream	upstream	RB	_	9	adv	_	_
11	of	of	IN	_	12	case	_	_
12	HLA-C	hla-c	NN	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug1	drug0	NN	_	10	prn	_	_
15	;	;	:	_	14	p	_	_
16	termed	term	VBN	_	17	attr	_	_
17	-35	0	CD	_	14	num	_	_
18	)	-rrb-	-RRB-	_	14	p	_	_
19	associates	associate	VBZ	_	0	root	_	_
20	with	with	IN	_	21	case	_	_
21	control	control	NN	_	19	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug2	drug0	NN	_	21	ppmod	_	_
24	,	,	,	_	21	p	_	_
25	and	and	CC	_	21	cc	_	_
26	with	with	IN	_	27	case	_	_
27	levels	level	NNS	_	21	conj	_	_
28	of	of	IN	_	32	case	_	_
29	HLA-C	hla-c	JJ	_	32	attr	_	_
30	messenger	messenger	NN	_	32	com	_	_
31	RNA	rna	NN	_	32	com	_	_
32	transcripts	transcript	NNS	_	27	ppmod	_	_
33	and	and	CC	_	32	cc	_	_
34	cell-surface	cell-surface	JJ	_	35	attr	_	_
35	expression	expression	NN	_	32	conj	_	_
36	,	,	,	_	19	p	_	_
37	but	but	CC	_	19	cc	_	_
38	the	the	DT	_	39	det	_	_
39	mechanism	mechanism	NN	_	44	dep	_	_
40	underlying	underlie	VBG	_	39	acl	_	_
41	its	its	PRP$	_	43	poss	_	_
42	varied	varied	JJ	_	43	attr	_	_
43	expression	expression	NN	_	40	obj	_	_
44	is	be	VBZ	_	19	conj	_	_
45	unknown	unknown	JJ	_	44	dep	_	_
46	.	.	.	_	44	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Significant	significant	JJ	_	4	attr	_	_
4	associations	association	NNS	_	27	dep	_	_
5	between	between	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	minor	minor	JJ	_	9	attr	_	_
8	allele	allele	NN	_	9	com	_	_
9	variants	variant	NNS	_	4	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	SNPs	snp	NNS	_	9	ppmod	_	_
12	HLA-C	hla-c	NN	_	13	com	_	_
13	drug1	drug0	NN	_	11	attr	_	_
14	and	and	CC	_	13	cc	_	_
15	HCP5	hcp0	NN	_	16	com	_	_
16	drug2	drug0	NN	_	13	conj	_	_
17	and	and	CC	_	9	cc	_	_
18	a	a	DT	_	21	det	_	_
19	lower	low	JJR	_	21	attr	_	_
20	viral	viral	JJ	_	21	attr	_	_
21	load	load	NN	_	9	conj	_	_
22	at	at	IN	_	24	case	_	_
23	set	set	NN	_	24	com	_	_
24	point	point	NN	_	21	ppmod	_	_
25	could	could	MD	_	27	modal	_	_
26	be	be	VB	_	27	aux	_	_
27	replicated	replicate	VBN	_	1	acl	_	_
28	in	in	IN	_	30	case	_	_
29	the	the	DT	_	30	det	_	_
30	drug3	drug0	NN	_	27	ppmod	_	_
31	.	.	.	_	1	p	_	_

1	In	in	IN	_	5	case	_	_
2	adiposity-matched	adiposity-matched	JJ	_	4	adv	_	_
3	,	,	,	_	4	p	_	_
4	normal-weight	normal-weight	JJ	_	5	attr	_	_
5	humans	human	NNS	_	8	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	we	we	PRP	_	8	dep	_	_
8	showed	show	VBD	_	0	root	_	_
9	that	that	IN	_	20	mark	_	_
10	subjects	subject	NNS	_	20	dep	_	_
11	homozygous	homozygous	JJ	_	10	attr	_	_
12	for	for	IN	_	18	case	_	_
13	the	the	DT	_	18	det	_	_
14	FTO	fto	NN	_	18	com	_	_
15	drug2	drug0	NN	_	18	com	_	_
16	drug1	drug0	NN	_	18	com	_	_
17	A	a	NN	_	18	com	_	_
18	allele	allele	NN	_	11	ppmod	_	_
19	have	have	VBP	_	20	aux	_	_
20	dysregulated	dysregulated	VBN	_	8	comp	_	_
21	circulating	circulating	JJ	_	22	attr	_	_
22	levels	level	NNS	_	20	obj	_	_
23	of	of	IN	_	27	case	_	_
24	the	the	DT	_	27	det	_	_
25	orexigenic	orexigenic	JJ	_	27	attr	_	_
26	hormone	hormone	NN	_	27	com	_	_
27	acyl-ghrelin	acyl-ghrelin	NN	_	22	ppmod	_	_
28	and	and	CC	_	20	cc	_	_
29	attenuated	attenuate	VBN	_	20	conj	_	_
30	drug3	drug0	NN	_	29	obj	_	_
31	.	.	.	_	8	p	_	_

1	Through	through	IN	_	4	case	_	_
2	an	an	DT	_	4	det	_	_
3	exhaustive	exhaustive	JJ	_	4	attr	_	_
4	search	search	NN	_	24	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	pair-wise	pair-wise	JJ	_	7	attr	_	_
7	interactions	interaction	NNS	_	4	ppmod	_	_
8	and	and	CC	_	4	cc	_	_
9	a	a	DT	_	11	det	_	_
10	selected	select	VBN	_	11	attr	_	_
11	search	search	NN	_	4	conj	_	_
12	of	of	IN	_	13	case	_	_
13	three-	three-	CD	_	11	ppmod	_	_
14	to	to	TO	_	16	aux	_	_
15	five-way	five-way	JJ	_	16	attr	_	_
16	interactions	interaction	NNS	_	11	ppmod	_	_
17	conditioned	condition	VBN	_	16	acl	_	_
18	on	on	IN	_	21	case	_	_
19	significant	significant	JJ	_	21	attr	_	_
20	pair-wise	pair-wise	JJ	_	21	attr	_	_
21	results	result	NNS	_	17	ppmod	_	_
22	,	,	,	_	24	p	_	_
23	we	we	PRP	_	24	dep	_	_
24	identified	identify	VBD	_	0	root	_	_
25	24	0	CD	_	27	num	_	_
26	core	core	NN	_	27	com	_	_
27	SNPs	snp	NNS	_	24	obj	_	_
28	in	in	IN	_	30	case	_	_
29	six	#crd#	CD	_	30	num	_	_
30	genes	gene	NNS	_	27	ppmod	_	_
31	(	-lrb-	-LRB-	_	58	p	_	_
32	FTO	fto	NNP	_	58	dep	_	_
33	:	:	:	_	58	p	_	_
34	drug1	drug0	NN	_	58	dep	_	_
35	,	,	,	_	58	p	_	_
36	drug2	drug0	NN	_	58	attr	_	_
37	,	,	,	_	58	p	_	_
38	drug3	drug0	NN	_	58	attr	_	_
39	,	,	,	_	58	p	_	_
40	drug4	drug0	NN	_	58	attr	_	_
41	,	,	,	_	58	p	_	_
42	drug5	drug0	NN	_	58	attr	_	_
43	,	,	,	_	58	p	_	_
44	drug6	drug0	NN	_	58	attr	_	_
45	;	;	:	_	44	p	_	_
46	TSPAN8	tspan0	NN	_	44	appo	_	_
47	:	:	:	_	44	p	_	_
48	drug7	drug0	NN	_	44	appo	_	_
49	;	;	:	_	44	p	_	_
50	TCF7L2	tcf0l0	NN	_	44	appo	_	_
51	:	:	:	_	44	p	_	_
52	drug8	drug0	NN	_	44	appo	_	_
53	,	,	,	_	44	p	_	_
54	drug9	drug0	NN	_	44	appo	_	_
55	,	,	,	_	44	p	_	_
56	drug10	drug0	CD	_	44	appo	_	_
57	,	,	,	_	44	p	_	_
58	drug11	drug0	NN	_	30	prn	_	_
59	,	,	,	_	58	p	_	_
60	drug12	drug0	CD	_	58	appo	_	_
61	,	,	,	_	58	p	_	_
62	drug13	drug0	NN	_	58	appo	_	_
63	,	,	,	_	58	p	_	_
64	drug14	drug0	NN	_	58	appo	_	_
65	,	,	,	_	58	p	_	_
66	drug15	drug0	CD	_	58	appo	_	_
67	;	;	:	_	58	p	_	_
68	L3MBTL3	l0mbtl0	NN	_	58	appo	_	_
69	:	:	:	_	58	p	_	_
70	drug16	drug0	CD	_	58	appo	_	_
71	,	,	,	_	58	p	_	_
72	drug17	drug0	CD	_	58	appo	_	_
73	;	;	:	_	58	p	_	_
74	CELF4	celf0	NN	_	58	appo	_	_
75	:	:	:	_	58	p	_	_
76	drug18	drug0	CD	_	58	appo	_	_
77	,	,	,	_	58	p	_	_
78	drug19	drug0	CD	_	58	appo	_	_
79	;	;	:	_	58	p	_	_
80	RUNX1	runx0	NN	_	58	appo	_	_
81	:	:	:	_	58	p	_	_
82	drug20	drug0	CD	_	58	appo	_	_
83	,	,	,	_	58	p	_	_
84	drug21	drug0	NN	_	58	appo	_	_
85	,	,	,	_	58	p	_	_
86	drug22	drug0	NN	_	58	appo	_	_
87	,	,	,	_	58	p	_	_
88	drug23	drug0	NN	_	58	appo	_	_
89	,	,	,	_	58	p	_	_
90	drug24	drug0	CD	_	58	appo	_	_
91	)	-rrb-	-RRB-	_	58	p	_	_
92	that	that	WDT	_	93	dep	_	_
93	appear	appear	VBP	_	30	relcl	_	_
94	to	to	TO	_	95	aux	_	_
95	be	be	VB	_	93	comp	_	_
96	important	important	JJ	_	95	dep	_	_
97	for	for	IN	_	98	case	_	_
98	drug25	drug0	NN	_	96	ppmod	_	_
99	.	.	.	_	24	p	_	_

1	The	the	DT	_	2	det	_	_
2	increase	increase	NN	_	6	dep	_	_
3	in	in	IN	_	5	case	_	_
4	cotinine	cotinine	NN	_	5	com	_	_
5	levels	level	NNS	_	2	ppmod	_	_
6	indicated	indicate	VBD	_	0	root	_	_
7	an	an	DT	_	9	det	_	_
8	increased	increase	VBN	_	9	attr	_	_
9	risk	risk	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	with	with	IN	_	15	case	_	_
13	each	each	DT	_	15	det	_	_
14	additional	additional	JJ	_	15	attr	_	_
15	copy	copy	NN	_	9	ppmod	_	_
16	of	of	IN	_	22	case	_	_
17	the	the	DT	_	22	det	_	_
18	drug1	drug0	NN	_	22	attr	_	_
19	-	-	:	_	22	p	_	_
20	drug2	drug0	NN	_	22	com	_	_
21	risk	risk	NN	_	22	com	_	_
22	allele	allele	NN	_	15	ppmod	_	_

1	OBJECTIVE	objective	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	We	we	PRP	_	4	dep	_	_
4	investigated	investigate	VBD	_	1	acl	_	_
5	if	if	IN	_	9	mark	_	_
6	the	the	DT	_	8	det	_	_
7	FTO	fto	NN	_	8	com	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	associates	associate	VBZ	_	4	comp	_	_
10	with	with	IN	_	12	case	_	_
11	food	food	JJ	_	12	attr	_	_
12	preferences	preference	NNS	_	9	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	healthy	healthy	JJ	_	15	attr	_	_
15	adults	adult	NNS	_	12	ppmod	_	_
16	with	with	IN	_	18	case	_	_
17	no	no	NN	_	18	com	_	_
18	drug2	drug0	NN	_	15	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	drug3	drug0	NN	_	21	com	_	_
21	disease	disease	NN	_	18	conj	_	_
22	,	,	,	_	21	p	_	_
23	or	or	CC	_	21	cc	_	_
24	drug4	drug0	NN	_	18	conj	_	_
25	.	.	.	_	1	p	_	_

1	Conclusions	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	present	present	JJ	_	5	attr	_	_
5	study	study	NN	_	6	dep	_	_
6	demonstrated	demonstrate	VBD	_	1	acl	_	_
7	that	that	IN	_	15	mark	_	_
8	FTO	fto	NN	_	12	attr	_	_
9	drug1	drug0	JJ	_	12	attr	_	_
10	and	and	CC	_	9	cc	_	_
11	combined	combined	JJ	_	9	conj	_	_
12	SNPs	snp	NNS	_	15	dep	_	_
13	were	be	VBD	_	15	aux	_	_
14	significantly	significantly	RB	_	15	adv	_	_
15	associated	associate	VBN	_	6	comp	_	_
16	with	with	IN	_	17	case	_	_
17	risk	risk	NN	_	15	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	17	p	_	_
21	which	which	WDT	_	22	dep	_	_
22	seems	seem	VBZ	_	17	relcl	_	_
23	to	to	TO	_	24	aux	_	_
24	be	be	VB	_	22	comp	_	_
25	dependent	dependent	JJ	_	24	dep	_	_
26	on	on	IN	_	27	case	_	_
27	BMI	bmi	NN	_	25	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	present	present	JJ	_	5	attr	_	_
5	study	study	NN	_	6	dep	_	_
6	demonstrated	demonstrate	VBD	_	1	acl	_	_
7	that	that	IN	_	15	mark	_	_
8	FTO	fto	NN	_	12	attr	_	_
9	drug1	drug0	JJ	_	12	attr	_	_
10	and	and	CC	_	9	cc	_	_
11	combined	combined	JJ	_	9	conj	_	_
12	SNPs	snp	NNS	_	15	dep	_	_
13	were	be	VBD	_	15	aux	_	_
14	significantly	significantly	RB	_	15	adv	_	_
15	associated	associate	VBN	_	6	comp	_	_
16	with	with	IN	_	17	case	_	_
17	risk	risk	NN	_	15	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	17	p	_	_
21	which	which	WDT	_	22	dep	_	_
22	seems	seem	VBZ	_	17	relcl	_	_
23	to	to	TO	_	24	aux	_	_
24	be	be	VB	_	22	comp	_	_
25	dependent	dependent	JJ	_	24	dep	_	_
26	on	on	IN	_	27	case	_	_
27	BMI	bmi	NN	_	25	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	METHODS	method	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	All	all	DT	_	5	det	_	_
4	drug2	drug0	JJ	_	5	attr	_	_
5	patients	patient	NNS	_	6	dep	_	_
6	were	be	VBD	_	1	acl	_	_
7	genotypedfor	genotypedfor	JJ	_	16	attr	_	_
8	the	the	DT	_	12	det	_	_
9	FTO	fto	JJ	_	12	attr	_	_
10	single	single	JJ	_	12	attr	_	_
11	nucleotide	nucleotide	NN	_	12	com	_	_
12	polimorphysm	polimorphysm	NN	_	16	attr	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	SNP	snp	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	drug1	drug0	NN	_	6	obj	_	_
17	.	.	.	_	1	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	investigated	investigate	VBD	_	0	root	_	_
3	the	the	DT	_	7	det	_	_
4	drug1	drug0	NN	_	7	attr	_	_
5	single	single	JJ	_	7	attr	_	_
6	nucleotide	nucleotide	NN	_	7	com	_	_
7	polymorphism	polymorphism	NN	_	2	obj	_	_
8	in	in	IN	_	14	case	_	_
9	the	the	DT	_	14	det	_	_
10	nicotine	nicotine	NN	_	14	com	_	_
11	acetylcholine	acetylcholine	NN	_	14	com	_	_
12	receptor	receptor	NN	_	14	com	_	_
13	gene	gene	NN	_	14	com	_	_
14	cluster	cluster	NN	_	7	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	CHRNA5-CHRNA3-CHRNB4	chrna0-chrna0-chrnb0	NN	_	7	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	,	,	,	_	7	p	_	_
19	associated	associate	VBN	_	7	acl	_	_
20	with	with	IN	_	22	case	_	_
21	smoking	smoking	NN	_	22	com	_	_
22	phenotypes	phenotype	NNS	_	19	ppmod	_	_
23	,	,	,	_	7	p	_	_
24	to	to	TO	_	25	aux	_	_
25	determine	determine	VB	_	2	comp	_	_
26	whether	whether	IN	_	32	mark	_	_
27	women	woman	NNS	_	32	dep	_	_
28	who	who	WP	_	29	dep	_	_
29	continued	continue	VBD	_	27	relcl	_	_
30	to	to	TO	_	31	aux	_	_
31	smoke	smoke	NN	_	29	ppmod	_	_
32	were	be	VBD	_	25	comp	_	_
33	also	also	RB	_	32	adv	_	_
34	more	more	RBR	_	35	adv	_	_
35	likely	likely	JJ	_	32	dep	_	_
36	to	to	TO	_	37	aux	_	_
37	report	report	VBP	_	32	comp	_	_
38	a	a	DT	_	39	det	_	_
39	drug2	drug0	NN	_	37	obj	_	_
40	during	during	IN	_	41	case	_	_
41	pregnancy	pregnancy	NN	_	39	ppmod	_	_
42	.	.	.	_	2	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	found	find	VBD	_	0	root	_	_
3	among	among	IN	_	4	case	_	_
4	women	woman	NNS	_	15	ppmod	_	_
5	who	who	WP	_	6	dep	_	_
6	smoked	smoke	VBD	_	4	relcl	_	_
7	pre-pregnancy	pre-pregnancy	NN	_	6	obj	_	_
8	,	,	,	_	15	p	_	_
9	those	those	DT	_	15	dep	_	_
10	with	with	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	drug1	drug0	NN	_	14	com	_	_
13	T	t	NN	_	14	com	_	_
14	allele	allele	NN	_	9	ppmod	_	_
15	smoked	smoke	VBD	_	2	comp	_	_
16	more	more	RBR	_	15	adv	_	_
17	and	and	CC	_	15	cc	_	_
18	were	be	VBD	_	23	aux	_	_
19	less	less	RBR	_	20	com	_	_
20	likely	likely	RB	_	23	adv	_	_
21	to	to	TO	_	23	aux	_	_
22	quit	quit	VB	_	23	aux	_	_
23	drug2	drug0	VBN	_	15	conj	_	_
24	during	during	IN	_	25	case	_	_
25	pregnancy	pregnancy	NN	_	23	ppmod	_	_
26	,	,	,	_	23	p	_	_
27	but	but	CC	_	23	cc	_	_
28	were	be	VBD	_	23	conj	_	_
29	also	also	RB	_	28	adv	_	_
30	less	less	RBR	_	31	adv	_	_
31	likely	likely	JJ	_	28	dep	_	_
32	to	to	TO	_	33	aux	_	_
33	report	report	VBP	_	31	comp	_	_
34	high	high	JJ	_	35	attr	_	_
35	levels	level	NNS	_	33	obj	_	_
36	of	of	IN	_	37	case	_	_
37	drug3	drug0	NN	_	35	ppmod	_	_
38	at	at	IN	_	40	case	_	_
39	18	0	CD	_	40	num	_	_
40	weeks	week	NNS	_	33	ppmod	_	_
41	of	of	IN	_	42	case	_	_
42	pregnancy	pregnancy	NN	_	40	ppmod	_	_
43	(	-lrb-	-LRB-	_	59	p	_	_
44	per	per	IN	_	45	case	_	_
45	allele	allele	NN	_	59	ppmod	_	_
46	OR	or	CC	_	45	cc	_	_
47	=	=	JJ	_	55	attr	_	_
48	0.84	0	CD	_	52	num	_	_
49	,	,	,	_	52	p	_	_
50	95	0	CD	_	52	num	_	_
51	%	%	NN	_	52	meta	_	_
52	CI	ci	CD	_	47	num	_	_
53	0.72	0	CD	_	55	num	_	_
54	to	to	TO	_	55	attr	_	_
55	0.99	0	CD	_	45	conj	_	_
56	,	,	,	_	59	p	_	_
57	p	p	NN	_	59	attr	_	_
58	=	=	JJ	_	59	attr	_	_
59	0.034	0	NN	_	42	num	_	_
60	)	-rrb-	-RRB-	_	59	p	_	_
61	.	.	.	_	2	p	_	_

1	The	the	DT	_	4	det	_	_
2	drug1	drug0	JJ	_	4	attr	_	_
3	genetic	genetic	JJ	_	4	attr	_	_
4	variant	variant	NN	_	11	dep	_	_
5	within	within	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	CHRNA5-A3-B4	chrna0-a0-b0	NN	_	9	com	_	_
8	gene	gene	NN	_	9	com	_	_
9	cluster	cluster	NN	_	4	ppmod	_	_
10	is	be	VBZ	_	11	aux	_	_
11	associated	associate	VBN	_	0	root	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	11	cc	_	_
15	has	have	VBZ	_	18	aux	_	_
16	recently	recently	RB	_	18	adv	_	_
17	been	be	VBN	_	18	aux	_	_
18	reported	report	VBN	_	11	conj	_	_
19	to	to	TO	_	21	aux	_	_
20	be	be	VB	_	21	aux	_	_
21	associated	associate	VBN	_	18	comp	_	_
22	with	with	IN	_	23	case	_	_
23	likelihood	likelihood	NN	_	21	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	11	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	investigated	investigate	VBD	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	potential	potential	JJ	_	5	attr	_	_
5	association	association	NN	_	2	obj	_	_
6	of	of	IN	_	8	case	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	gLLLenotype	glllenotype	NN	_	5	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	reduced	reduce	VBN	_	11	attr	_	_
11	likelihood	likelihood	NN	_	5	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	2	0	CD	_	16	num	_	_
16	cohorts	cohort	NNS	_	11	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	treatment-seeking	treatment-seeking	JJ	_	19	attr	_	_
19	smokers	smoker	NNS	_	16	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	primary	primary	JJ	_	22	attr	_	_
22	care	care	NN	_	19	ppmod	_	_
23	in	in	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	United	united	JJ	_	26	attr	_	_
26	Kingdom	kingdom	NN	_	22	ppmod	_	_
27	.	.	.	_	2	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	evidence	evidence	NN	_	2	obj	_	_
4	of	of	IN	_	5	case	_	_
5	association	association	NN	_	3	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	genotype	genotype	NN	_	5	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	5	ppmod	_	_
11	in	in	IN	_	15	case	_	_
12	our	our	PRP$	_	15	poss	_	_
13	open-label	open-label	JJ	_	15	attr	_	_
14	trial	trial	NN	_	15	com	_	_
15	sample	sample	NN	_	2	ppmod	_	_
16	but	but	CC	_	15	cc	_	_
17	not	not	RB	_	16	com	_	_
18	our	our	PRP$	_	20	poss	_	_
19	placebo-controlled	placebo-controlled	JJ	_	20	attr	_	_
20	trial	trial	NN	_	21	com	_	_
21	sample	sample	NN	_	15	conj	_	_
22	.	.	.	_	2	p	_	_

1	Moreover	moreover	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	the	the	DT	_	5	det	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	variant	variant	NN	_	9	dep	_	_
6	may	may	MD	_	9	modal	_	_
7	not	not	RB	_	9	neg	_	_
8	merely	merely	RB	_	9	adv	_	_
9	operate	operate	VB	_	0	root	_	_
10	as	as	IN	_	12	case	_	_
11	a	a	DT	_	12	det	_	_
12	marker	marker	NN	_	9	ppmod	_	_
13	for	for	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	9	p	_	_

1	Nominally	nominally	RB	_	2	adv	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	associations	association	NNS	_	55	dep	_	_
4	with	with	IN	_	5	case	_	_
5	candidateSNPs	candidatesnps	NNS	_	3	ppmod	_	_
6	within	within	IN	_	8	case	_	_
7	cholinergic	cholinergic	JJ	_	8	attr	_	_
8	receptors	receptor	NNS	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	nicotinic	nicotinic	JJ	_	12	attr	_	_
11	,	,	,	_	12	p	_	_
12	alpha	alpha	NN	_	8	appo	_	_
13	3/5	0	CD	_	12	num	_	_
14	(	-lrb-	-LRB-	_	19	p	_	_
15	CHRNA3/CHRNA5	chrna0/chrna0	NN	_	19	dep	_	_
16	;	;	:	_	19	p	_	_
17	eg	eg	NN	_	19	dep	_	_
18	,	,	,	_	19	p	_	_
19	p=0.00011	p=0	NN	_	12	prn	_	_
20	for	for	IN	_	22	case	_	_
21	SNP	snp	NN	_	22	com	_	_
22	drug1	drug0	NN	_	19	ppmod	_	_
23	)	-rrb-	-RRB-	_	19	p	_	_
24	and	and	CC	_	12	cc	_	_
25	cytochrome	cytochrome	NN	_	26	com	_	_
26	P450	p0	NN	_	53	attr	_	_
27	,	,	,	_	26	p	_	_
28	family	family	NN	_	26	appo	_	_
29	2	0	CD	_	28	num	_	_
30	,	,	,	_	26	p	_	_
31	subfamily	subfamily	NN	_	32	com	_	_
32	A	a	NN	_	26	appo	_	_
33	,	,	,	_	26	p	_	_
34	polypeptide	polypeptide	NN	_	26	appo	_	_
35	6	0	CD	_	34	num	_	_
36	(	-lrb-	-LRB-	_	42	p	_	_
37	CYP2A6	cyp0a0	NN	_	42	dep	_	_
38	;	;	:	_	42	p	_	_
39	eg	eg	NN	_	42	dep	_	_
40	,	,	,	_	42	p	_	_
41	p=2.78	p=0	NN	_	42	com	_	_
42	*	*	NN	_	26	prn	_	_
43	10	0	CD	_	42	num	_	_
44	(	-lrb-	-LRB-	_	45	p	_	_
45	-5	0	CD	_	42	num	_	_
46	)	-rrb-	-RRB-	_	45	p	_	_
47	for	for	IN	_	51	case	_	_
48	a	a	DT	_	51	det	_	_
49	non-synonymous	non-synonymous	JJ	_	51	attr	_	_
50	SNP	snp	NN	_	51	com	_	_
51	drug2	drug0	NN	_	42	ppmod	_	_
52	)	-rrb-	-RRB-	_	42	p	_	_
53	regions	region	NNS	_	12	conj	_	_
54	were	be	VBD	_	55	aux	_	_
55	observed	observe	VBN	_	62	advcl	_	_
56	for	for	IN	_	57	case	_	_
57	drug3	drug0	NN	_	55	ppmod	_	_
58	,	,	,	_	62	p	_	_
59	however	however	RB	_	62	adv	_	_
60	only	only	RB	_	62	adv	_	_
61	CYP2A6	cyp0a0	NN	_	62	dep	_	_
62	showed	show	VBD	_	0	root	_	_
63	evidence	evidence	NN	_	62	obj	_	_
64	of	of	IN	_	66	case	_	_
65	significant	significant	JJ	_	66	attr	_	_
66	association	association	NN	_	63	ppmod	_	_
67	with	with	IN	_	68	case	_	_
68	drug4	drug0	NN	_	66	ppmod	_	_
69	.	.	.	_	62	p	_	_

1	A	a	DT	_	4	det	_	_
2	candidate	candidate	NN	_	4	com	_	_
3	SNP	snp	NN	_	4	com	_	_
4	drug1	drug0	NN	_	12	dep	_	_
5	in	in	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	was	be	VBD	_	12	aux	_	_
8	significantly	significantly	RB	_	12	adv	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	p=0.015	p=0	NN	_	12	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	associated	associate	VBN	_	0	root	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	12	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	examined	examine	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	associations	association	NNS	_	2	obj	_	_
5	between	between	IN	_	11	case	_	_
6	the	the	DT	_	9	det	_	_
7	nicotinic	nicotinic	JJ	_	9	attr	_	_
8	acetylcholine	acetylcholine	NN	_	9	com	_	_
9	receptor	receptor	NN	_	11	com	_	_
10	polymorphism	polymorphism	NN	_	11	com	_	_
11	drug1	drug0	NN	_	4	ppmod	_	_
12	on	on	IN	_	13	case	_	_
13	chromosome	chromosome	NN	_	11	ppmod	_	_
14	15q25	0q0	CD	_	13	num	_	_
15	marking	mark	VBG	_	13	acl	_	_
16	thegene	thegene	NN	_	18	com	_	_
17	cluster	cluster	NN	_	18	com	_	_
18	CHRNA3-CHRNB4-CHRNA5	chrna0-chrnb0-chrna0	NN	_	15	obj	_	_
19	,	,	,	_	18	p	_	_
20	drug2	drug0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	drug3	drug0	NN	_	18	conj	_	_
24	and	and	CC	_	23	cc	_	_
25	drug4	drug0	NN	_	23	conj	_	_
26	in	in	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	general	general	JJ	_	29	attr	_	_
29	population	population	NN	_	15	ppmod	_	_
30	.	.	.	_	2	p	_	_

1	Both	both	CC	_	3	cc	_	_
2	the	the	DT	_	3	det	_	_
3	T-allele	t-allele	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	3	cc	_	_
7	the	the	DT	_	8	det	_	_
8	T-allele	t-allele	NN	_	3	conj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	significantly	significantly	RB	_	12	adv	_	_
12	increase	increase	VBP	_	0	root	_	_
13	drug3	drug0	NN	_	14	com	_	_
14	risk	risk	NN	_	12	obj	_	_
15	with	with	IN	_	18	case	_	_
16	an	an	DT	_	18	det	_	_
17	allelic	allelic	JJ	_	18	attr	_	_
18	odds	odds	NNS	_	12	ppmod	_	_
19	ratio	ratio	NN	_	18	attr	_	_
20	(	-lrb-	-LRB-	_	19	p	_	_
21	OR	or	CC	_	19	cc	_	_
22	)	-rrb-	-RRB-	_	19	p	_	_
23	of	of	IN	_	24	case	_	_
24	1.69	0	CD	_	18	ppmod	_	_
25	(	-lrb-	-LRB-	_	28	p	_	_
26	95	0	CD	_	28	num	_	_
27	%	%	NN	_	28	meta	_	_
28	CI	ci	NN	_	24	prn	_	_
29	1.55-1.83	0	CD	_	28	num	_	_
30	)	-rrb-	-RRB-	_	28	p	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	P	p	NN	_	24	prn	_	_
33	=	=	JJ	_	32	attr	_	_
34	6.0	0	CD	_	33	num	_	_
35	x	x	CC	_	34	cc	_	_
36	10	0	CD	_	34	conj	_	_
37	(	-lrb-	-LRB-	_	38	p	_	_
38	-35	0	CD	_	34	num	_	_
39	)	-rrb-	-RRB-	_	38	p	_	_
40	)	-rrb-	-RRB-	_	32	p	_	_
41	and	and	CC	_	24	cc	_	_
42	1.60	0	CD	_	24	conj	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	1.47-1.74	0	NN	_	42	num	_	_
45	)	-rrb-	-RRB-	_	44	p	_	_
46	(	-lrb-	-LRB-	_	48	p	_	_
47	P	p	NN	_	48	dep	_	_
48	=	=	JJ	_	42	prn	_	_
49	7.6	0	CD	_	50	num	_	_
50	x	x	NN	_	48	obj	_	_
51	10	0	CD	_	50	num	_	_
52	(	-lrb-	-LRB-	_	50	p	_	_
53	-28	0	CD	_	50	num	_	_
54	)	-rrb-	-RRB-	_	50	p	_	_
55	)	-rrb-	-RRB-	_	48	p	_	_
56	,	,	,	_	24	p	_	_
57	respectively	respectively	RB	_	24	adv	_	_
58	.	.	.	_	12	p	_	_

1	The	the	DT	_	5	det	_	_
2	drug1	drug0	NN	_	5	com	_	_
3	T	t	NN	_	5	com	_	_
4	at-risk	at-risk	NN	_	5	com	_	_
5	allele	allele	NN	_	6	dep	_	_
6	associates	associate	VBZ	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	earlier	early	JJR	_	11	attr	_	_
11	age	age	NN	_	8	conj	_	_
12	at	at	IN	_	13	case	_	_
13	diagnosis	diagnosis	NN	_	11	ppmod	_	_
14	in	in	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	drug3	drug0	NN	_	17	com	_	_
17	subjects	subject	NNS	_	6	ppmod	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	P	p	NN	_	20	dep	_	_
20	=	=	JJ	_	17	prn	_	_
21	8.0	0	CD	_	22	num	_	_
22	x	x	NN	_	20	obj	_	_
23	10	0	CD	_	22	num	_	_
24	(	-lrb-	-LRB-	_	22	p	_	_
25	-3	0	CD	_	22	num	_	_
26	)	-rrb-	-RRB-	_	22	p	_	_
27	and	and	CC	_	20	cc	_	_
28	P	p	NN	_	29	dep	_	_
29	=	=	JJ	_	20	conj	_	_
30	3.8	0	CD	_	31	num	_	_
31	x	x	NN	_	29	obj	_	_
32	10	0	CD	_	31	num	_	_
33	(	-lrb-	-LRB-	_	31	p	_	_
34	-4	0	CD	_	31	num	_	_
35	)	-rrb-	-RRB-	_	31	p	_	_
36	,	,	,	_	29	p	_	_
37	respectively	respectively	RB	_	29	adv	_	_
38	)	-rrb-	-RRB-	_	20	p	_	_
39	,	,	,	_	17	p	_	_
40	which	which	WDT	_	41	dep	_	_
41	is	be	VBZ	_	17	relcl	_	_
42	supportedby	supportedby	JJ	_	46	attr	_	_
43	quantitative	quantitative	JJ	_	46	attr	_	_
44	family-based	family-based	JJ	_	46	attr	_	_
45	association	association	NN	_	46	com	_	_
46	tests	test	NNS	_	41	obj	_	_
47	.	.	.	_	6	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	genotyped	genotyped	VBD	_	0	root	_	_
3	four	#crd#	CD	_	2	obj	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	SNPs	snp	NNS	_	3	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug1	drug0	NN	_	3	prn	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	8	conj	_	_
13	,	,	,	_	12	p	_	_
14	and	and	CC	_	12	cc	_	_
15	drug4	drug0	NN	_	8	conj	_	_
16	)	-rrb-	-RRB-	_	8	p	_	_
17	in	in	IN	_	19	case	_	_
18	Amish	amish	NN	_	19	com	_	_
19	subjects	subject	NNS	_	2	ppmod	_	_
20	with	with	IN	_	21	case	_	_
21	drug5	drug0	NN	_	19	ppmod	_	_
22	(	-lrb-	-LRB-	_	25	p	_	_
23	n	n	NN	_	25	attr	_	_
24	=	=	JJ	_	25	attr	_	_
25	137	0	NN	_	21	num	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	,	,	,	_	21	p	_	_
28	drug6	drug0	NN	_	21	conj	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	IGT	igt	NN	_	28	prn	_	_
31	;	;	:	_	30	p	_	_
32	n	n	NN	_	33	dep	_	_
33	=	=	JJ	_	30	advcl	_	_
34	139	0	CD	_	33	obj	_	_
35	)	-rrb-	-RRB-	_	30	p	_	_
36	,	,	,	_	28	p	_	_
37	and	and	CC	_	28	cc	_	_
38	drug7	drug0	NN	_	21	conj	_	_
39	(	-lrb-	-LRB-	_	40	p	_	_
40	NGT	ngt	NN	_	38	prn	_	_
41	;	;	:	_	40	p	_	_
42	n	n	NN	_	43	dep	_	_
43	=	=	JJ	_	40	advcl	_	_
44	342	0	CD	_	43	obj	_	_
45	)	-rrb-	-RRB-	_	40	p	_	_
46	.	.	.	_	2	p	_	_

1	A-allele	a-allele	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	was	be	VBD	_	5	aux	_	_
5	associated	associate	VBN	_	0	root	_	_
6	with	with	IN	_	9	case	_	_
7	an	an	DT	_	9	det	_	_
8	increased	increase	VBN	_	9	attr	_	_
9	risk	risk	NN	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	regardless	regardless	RB	_	5	adv	_	_
13	of	of	IN	_	15	case	_	_
14	smoking	smoking	NN	_	15	com	_	_
15	exposure	exposure	NN	_	12	ppmod	_	_
16	(	-lrb-	-LRB-	_	27	p	_	_
17	pooled	pooled	JJ	_	22	attr	_	_
18	OR	or	CC	_	22	cc	_	_
19	=	=	JJ	_	22	attr	_	_
20	1.26	0	CD	_	22	num	_	_
21	,	,	,	_	22	p	_	_
22	95	0	CD	_	27	num	_	_
23	%	%	NN	_	22	meta	_	_
24	CI	ci	NN	_	22	appo	_	_
25	1.18-1.34	0	CD	_	24	num	_	_
26	,	,	,	_	27	p	_	_
27	p	p	NN	_	12	prn	_	_
28	<	<	RB	_	29	adv	_	_
29	10⁻⁵	0⁻⁵	JJ	_	27	attr	_	_
30	)	-rrb-	-RRB-	_	27	p	_	_
31	.	.	.	_	5	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	findings	finding	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	8	mark	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	in	in	IN	_	7	case	_	_
7	CHRNA	chrna	NN	_	5	ppmod	_	_
8	is	be	VBZ	_	3	comp	_	_
9	a	a	DT	_	11	det	_	_
10	susceptibility	susceptibility	NN	_	11	com	_	_
11	variant	variant	NN	_	8	obj	_	_
12	for	for	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	8	p	_	_
15	in	in	IN	_	16	case	_	_
16	terms	term	NNS	_	8	ppmod	_	_
17	of	of	IN	_	20	case	_	_
18	both	both	CC	_	20	cc	_	_
19	airway	airway	NN	_	20	com	_	_
20	obstruction	obstruction	NN	_	16	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	parenchyma	parenchyma	NN	_	23	com	_	_
23	destruction	destruction	NN	_	20	conj	_	_
24	.	.	.	_	3	p	_	_

1	Recently	recently	RB	_	20	adv	_	_
2	,	,	,	_	20	p	_	_
3	a	a	DT	_	5	det	_	_
4	microsatellite	microsatellite	NN	_	5	com	_	_
5	marker	marker	NN	_	20	dep	_	_
6	in	in	IN	_	9	case	_	_
7	intron	intron	NN	_	9	attr	_	_
8	3	0	CD	_	9	num	_	_
9	drug1	drug0	NN	_	5	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	five	#crd#	CD	_	15	num	_	_
12	correlated	correlated	JJ	_	15	attr	_	_
13	single	single	JJ	_	15	attr	_	_
14	nucleotide	nucleotide	NN	_	15	com	_	_
15	polymorphisms	polymorphism	NNS	_	9	conj	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	SNPs	snp	NNS	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	were	be	VBD	_	20	aux	_	_
20	identified	identify	VBN	_	0	root	_	_
21	in	in	IN	_	23	case	_	_
22	Icelandic	icelandic	JJ	_	23	attr	_	_
23	individuals	individual	NNS	_	20	ppmod	_	_
24	that	that	WDT	_	25	dep	_	_
25	showed	show	VBD	_	23	relcl	_	_
26	strong	strong	JJ	_	27	attr	_	_
27	association	association	NN	_	25	obj	_	_
28	with	with	IN	_	29	case	_	_
29	drug2	drug0	NN	_	27	ppmod	_	_
30	,	,	,	_	29	p	_	_
31	which	which	WDT	_	33	dep	_	_
32	was	be	VBD	_	33	aux	_	_
33	replicated	replicate	VBN	_	29	relcl	_	_
34	in	in	IN	_	38	case	_	_
35	Danish	danish	JJ	_	38	attr	_	_
36	and	and	CC	_	35	cc	_	_
37	European-American	european-american	JJ	_	35	conj	_	_
38	cohorts	cohort	NNS	_	33	ppmod	_	_
39	.	.	.	_	20	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	genotyped	genotyped	VBD	_	0	root	_	_
3	four	#crd#	CD	_	2	obj	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	SNPs	snp	NNS	_	3	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug1	drug0	NN	_	3	prn	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	8	conj	_	_
13	,	,	,	_	12	p	_	_
14	and	and	CC	_	12	cc	_	_
15	drug4	drug0	NN	_	8	conj	_	_
16	)	-rrb-	-RRB-	_	8	p	_	_
17	in	in	IN	_	19	case	_	_
18	Amish	amish	NN	_	19	com	_	_
19	subjects	subject	NNS	_	2	ppmod	_	_
20	with	with	IN	_	21	case	_	_
21	drug5	drug0	NN	_	19	ppmod	_	_
22	(	-lrb-	-LRB-	_	25	p	_	_
23	n	n	NN	_	25	attr	_	_
24	=	=	JJ	_	25	attr	_	_
25	137	0	NN	_	21	num	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	,	,	,	_	21	p	_	_
28	drug6	drug0	NN	_	21	conj	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	IGT	igt	NN	_	28	prn	_	_
31	;	;	:	_	30	p	_	_
32	n	n	NN	_	33	dep	_	_
33	=	=	JJ	_	30	advcl	_	_
34	139	0	CD	_	33	obj	_	_
35	)	-rrb-	-RRB-	_	30	p	_	_
36	,	,	,	_	28	p	_	_
37	and	and	CC	_	28	cc	_	_
38	drug7	drug0	NN	_	21	conj	_	_
39	(	-lrb-	-LRB-	_	40	p	_	_
40	NGT	ngt	NN	_	38	prn	_	_
41	;	;	:	_	40	p	_	_
42	n	n	NN	_	43	dep	_	_
43	=	=	JJ	_	40	advcl	_	_
44	342	0	CD	_	43	obj	_	_
45	)	-rrb-	-RRB-	_	40	p	_	_
46	.	.	.	_	2	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	compared	compare	VBD	_	0	root	_	_
3	genotype	genotype	NN	_	4	com	_	_
4	frequencies	frequency	NNS	_	2	obj	_	_
5	in	in	IN	_	6	case	_	_
6	subjects	subject	NNS	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	those	those	DT	_	2	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	NGT	ngt	NN	_	10	ppmod	_	_
13	and	and	CC	_	2	cc	_	_
14	found	find	VBD	_	2	conj	_	_
15	marginal	marginal	JJ	_	16	attr	_	_
16	association	association	NN	_	14	obj	_	_
17	for	for	IN	_	18	case	_	_
18	drug1	drug0	NN	_	14	ppmod	_	_
19	(	-lrb-	-LRB-	_	24	p	_	_
20	P	p	NN	_	24	dep	_	_
21	=	=	JJ	_	20	attr	_	_
22	0.05	0	CD	_	21	num	_	_
23	;	;	:	_	24	p	_	_
24	odds	odds	NNS	_	18	prn	_	_
25	ratio	ratio	NN	_	24	attr	_	_
26	-LSB-OR	-lsb-or	JJ	_	28	attr	_	_
27	]	-rsb-	-RRB-	_	28	p	_	_
28	1.51	0	NN	_	25	appo	_	_
29	)	-rrb-	-RRB-	_	24	p	_	_
30	;	;	:	_	2	p	_	_

1	comparison	comparison	NN	_	12	dep	_	_
2	between	between	IN	_	5	case	_	_
3	NGT	ngt	JJ	_	5	attr	_	_
4	control	control	NN	_	5	com	_	_
5	subjects	subject	NNS	_	1	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	the	the	DT	_	11	det	_	_
8	combined	combined	JJ	_	11	attr	_	_
9	drug5	drug0	NN	_	11	com	_	_
10	case	case	NN	_	11	com	_	_
11	group	group	NN	_	5	conj	_	_
12	showed	show	VBD	_	0	root	_	_
13	strong	strong	JJ	_	14	attr	_	_
14	association	association	NN	_	12	obj	_	_
15	with	with	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug2	drug0	NN	_	16	conj	_	_
19	(	-lrb-	-LRB-	_	25	p	_	_
20	P	p	NN	_	25	dep	_	_
21	=	=	JJ	_	20	attr	_	_
22	0.008-0.01	0	CD	_	21	num	_	_
23	;	;	:	_	25	p	_	_
24	OR	or	CC	_	25	cc	_	_
25	1.53-1.57	0	CD	_	16	num	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	and	and	CC	_	14	cc	_	_
28	marginal	marginal	JJ	_	29	attr	_	_
29	association	association	NN	_	14	conj	_	_
30	with	with	IN	_	31	case	_	_
31	drug3	drug0	NN	_	29	ppmod	_	_
32	and	and	CC	_	31	cc	_	_
33	drug4	drug0	NN	_	31	conj	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	P	p	NN	_	31	prn	_	_
36	=	=	JJ	_	35	attr	_	_
37	0.07	0	CD	_	36	num	_	_
38	and	and	CC	_	35	cc	_	_
39	P	p	NN	_	35	conj	_	_
40	=	=	JJ	_	35	attr	_	_
41	0.04	0	CD	_	40	num	_	_
42	,	,	,	_	40	p	_	_
43	respectively	respectively	RB	_	40	adv	_	_
44	)	-rrb-	-RRB-	_	35	p	_	_
45	.	.	.	_	12	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	also	also	RB	_	3	adv	_	_
3	genotyped	genotyped	VBD	_	0	root	_	_
4	these	these	DT	_	5	det	_	_
5	SNPs	snp	NNS	_	3	obj	_	_
6	in	in	IN	_	10	case	_	_
7	nondiabetic	nondiabetic	JJ	_	9	adv	_	_
8	,	,	,	_	9	p	_	_
9	non-Amish	non-amish	JJ	_	10	attr	_	_
10	subjects	subject	NNS	_	3	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	n	n	NN	_	10	prn	_	_
13	=	=	JJ	_	12	attr	_	_
14	48	0	CD	_	12	num	_	_
15	)	-rrb-	-RRB-	_	12	p	_	_
16	,	,	,	_	10	p	_	_
17	in	in	IN	_	18	case	_	_
18	whom	whom	WP	_	23	ppmod	_	_
19	intravenous	intravenous	JJ	_	21	attr	_	_
20	drug3	drug0	NN	_	21	com	_	_
21	tests	test	NNS	_	23	dep	_	_
22	were	be	VBD	_	23	aux	_	_
23	performed	performed	VBN	_	10	relcl	_	_
24	,	,	,	_	10	p	_	_
25	and	and	CC	_	3	cc	_	_
26	found	find	VBD	_	3	conj	_	_
27	an	an	DT	_	28	det	_	_
28	association	association	NN	_	26	obj	_	_
29	between	between	IN	_	30	case	_	_
30	drug1	drug0	NN	_	28	ppmod	_	_
31	and	and	CC	_	30	cc	_	_
32	drug2	drug0	NN	_	30	conj	_	_
33	and	and	CC	_	32	cc	_	_
34	drug4	drug0	NN	_	32	conj	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	P	p	NN	_	30	prn	_	_
37	=	=	JJ	_	36	attr	_	_
38	0.003	0	CD	_	36	num	_	_
39	and	and	CC	_	36	cc	_	_
40	P	p	NN	_	36	conj	_	_
41	=	=	VBG	_	40	acl	_	_
42	0.005	0	CD	_	41	obj	_	_
43	,	,	,	_	36	p	_	_
44	respectively	respectively	RB	_	36	adv	_	_
45	)	-rrb-	-RRB-	_	36	p	_	_
46	and	and	CC	_	30	cc	_	_
47	drug5	drug0	NN	_	30	conj	_	_
48	(	-lrb-	-LRB-	_	49	p	_	_
49	P	p	NN	_	47	prn	_	_
50	=	=	JJ	_	49	attr	_	_
51	0.04	0	CD	_	49	num	_	_
52	and	and	CC	_	49	cc	_	_
53	P	p	NN	_	49	conj	_	_
54	=	=	VBG	_	53	acl	_	_
55	0.007	0	CD	_	54	obj	_	_
56	,	,	,	_	49	p	_	_
57	respectively	respectively	RB	_	49	adv	_	_
58	)	-rrb-	-RRB-	_	49	p	_	_
59	.	.	.	_	3	p	_	_

1	we	we	PRP	_	2	dep	_	_
2	examined	examine	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	association	association	NN	_	2	obj	_	_
5	of	of	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	common	common	JJ	_	8	attr	_	_
8	variant	variant	NN	_	4	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	TCF7L2	tcf0l0	NN	_	12	com	_	_
12	gene	gene	NN	_	8	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug1	drug0	NN	_	8	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	with	with	IN	_	18	case	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	risk	risk	NN	_	4	ppmod	_	_
19	among	among	IN	_	20	case	_	_
20	Caucasians	caucasian	NNS	_	18	ppmod	_	_
21	.	.	.	_	2	p	_	_

1	Over	over	IN	_	4	case	_	_
2	an	an	DT	_	4	det	_	_
3	average	average	JJ	_	4	attr	_	_
4	period	period	NN	_	17	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	three	#crd#	CD	_	7	num	_	_
7	years	year	NNS	_	4	ppmod	_	_
8	,	,	,	_	17	p	_	_
9	participants	participant	NNS	_	17	dep	_	_
10	with	with	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	risk-conferring	risk-conferring	JJ	_	14	attr	_	_
13	TT	tt	NN	_	14	com	_	_
14	genotype	genotype	NN	_	9	ppmod	_	_
15	at	at	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	were	be	VBD	_	0	root	_	_
18	more	more	RBR	_	19	adv	_	_
19	likely	likely	JJ	_	17	dep	_	_
20	to	to	TO	_	21	aux	_	_
21	have	have	VB	_	17	comp	_	_
22	progression	progression	NN	_	21	obj	_	_
23	from	from	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	to	to	TO	_	26	aux	_	_
26	drug3	drug0	NN	_	22	ppmod	_	_
27	than	than	IN	_	28	mark	_	_
28	were	be	VBD	_	21	comp	_	_
29	CC	cc	JJ	_	30	attr	_	_
30	homozygotes	homozygote	NNS	_	28	obj	_	_
31	(	-lrb-	-LRB-	_	46	p	_	_
32	hazard	hazard	NN	_	33	com	_	_
33	ratio	ratio	NN	_	46	dep	_	_
34	,	,	,	_	46	p	_	_
35	1.55	0	CD	_	46	num	_	_
36	;	;	:	_	46	p	_	_
37	95	0	CD	_	38	num	_	_
38	percent	percent	NN	_	46	dep	_	_
39	confidence	confidence	RB	_	40	adv	_	_
40	interval	interval	JJ	_	38	attr	_	_
41	,	,	,	_	46	p	_	_
42	1.20	0	CD	_	44	num	_	_
43	to	to	TO	_	44	attr	_	_
44	2.01	0	CD	_	46	num	_	_
45	;	;	:	_	46	p	_	_
46	P<0.001	p<0	NN	_	30	prn	_	_
47	)	-rrb-	-RRB-	_	46	p	_	_
48	.	.	.	_	17	p	_	_

1	Common	common	JJ	_	2	attr	_	_
2	variants	variant	NNS	_	5	dep	_	_
3	in	in	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	seem	seem	VBP	_	0	root	_	_
6	to	to	TO	_	8	aux	_	_
7	be	be	VB	_	8	aux	_	_
8	associated	associate	VBN	_	5	comp	_	_
9	with	with	IN	_	12	case	_	_
10	an	an	DT	_	12	det	_	_
11	increased	increase	VBN	_	12	attr	_	_
12	risk	risk	NN	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	among	among	IN	_	16	case	_	_
16	persons	person	NNS	_	12	ppmod	_	_
17	with	with	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	SNP	snp	NN	_	3	com	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	was	be	VBD	_	6	aux	_	_
5	nominally	nominally	RB	_	6	adv	_	_
6	associated	associate	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	21	case	_	_
10	the	the	DT	_	21	det	_	_
11	initial	initial	JJ	_	21	attr	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	p	p	NN	_	21	prn	_	_
14	=	=	JJ	_	13	attr	_	_
15	0.08	0	CD	_	14	num	_	_
16	)	-rrb-	-RRB-	_	13	p	_	_
17	and	and	CC	_	21	cc	_	_
18	two	#crd#	CD	_	21	num	_	_
19	replication	replication	NN	_	21	com	_	_
20	sample	sample	NN	_	21	com	_	_
21	sets	set	NNS	_	8	ppmod	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	p	p	NN	_	24	dep	_	_
24	=	=	JJ	_	6	prn	_	_
25	0.05	0	CD	_	24	obj	_	_
26	and	and	CC	_	25	cc	_	_
27	0.06	0	CD	_	25	conj	_	_
28	)	-rrb-	-RRB-	_	24	p	_	_
29	.	.	.	_	6	p	_	_

1	For	for	IN	_	5	case	_	_
2	the	the	DT	_	5	det	_	_
3	combined	combined	JJ	_	5	attr	_	_
4	sample	sample	NN	_	5	com	_	_
5	set	set	NN	_	23	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	in	in	IN	_	8	case	_	_
8	which	which	WDT	_	11	ppmod	_	_
9	we	we	PRP	_	11	dep	_	_
10	successfully	successfully	RB	_	11	adv	_	_
11	genotyped	genotyped	VBD	_	5	relcl	_	_
12	1,174	0	NN	_	15	num	_	_
13	type	type	NN	_	15	attr	_	_
14	2	0	CD	_	15	num	_	_
15	diabetes	diabetes	NN	_	16	com	_	_
16	patients	patient	NNS	_	11	obj	_	_
17	and	and	CC	_	16	cc	_	_
18	823	0	CD	_	20	num	_	_
19	control	control	JJ	_	20	attr	_	_
20	subjects	subject	NNS	_	16	conj	_	_
21	,	,	,	_	23	p	_	_
22	drug1	drug0	NN	_	23	dep	_	_
23	showed	show	VBD	_	0	root	_	_
24	a	a	DT	_	26	det	_	_
25	significant	significant	JJ	_	26	attr	_	_
26	association	association	NN	_	23	obj	_	_
27	with	with	IN	_	28	case	_	_
28	drug2	drug0	NN	_	26	ppmod	_	_
29	(	-lrb-	-LRB-	_	40	p	_	_
30	odds	odds	NNS	_	31	com	_	_
31	ratio	ratio	NN	_	40	dep	_	_
32	=	=	JJ	_	31	attr	_	_
33	1.69	0	CD	_	34	com	_	_
34	-LSB-95	-lsb-0	CD	_	32	num	_	_
35	%	%	NN	_	34	meta	_	_
36	CI	ci	RB	_	37	adv	_	_
37	1.21-2.36	0	CD	_	34	num	_	_
38	]	-rsb-	-RRB-	_	40	p	_	_
39	,	,	,	_	40	p	_	_
40	p	p	NN	_	28	prn	_	_
41	=	=	JJ	_	40	attr	_	_
42	0.002	0	CD	_	40	num	_	_
43	)	-rrb-	-RRB-	_	40	p	_	_
44	with	with	IN	_	47	case	_	_
45	the	the	DT	_	47	det	_	_
46	same	same	JJ	_	47	attr	_	_
47	direction	direction	NN	_	26	ppmod	_	_
48	as	as	IN	_	51	case	_	_
49	the	the	DT	_	51	det	_	_
50	previous	previous	JJ	_	51	attr	_	_
51	reports	report	NNS	_	23	ppmod	_	_
52	in	in	IN	_	53	case	_	_
53	samples	sample	NNS	_	51	ppmod	_	_
54	from	from	IN	_	55	case	_	_
55	European	european	NNP	_	53	ppmod	_	_
56	and	and	CC	_	55	cc	_	_
57	European-origin	european-origin	NNP	_	58	com	_	_
58	populations	population	NNS	_	55	conj	_	_
59	.	.	.	_	23	p	_	_

1	The	the	DT	_	2	det	_	_
2	rest	rest	NN	_	16	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	five	#crd#	CD	_	6	num	_	_
6	SNPs	snp	NNS	_	2	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug1	drug0	NN	_	6	prn	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	8	conj	_	_
13	)	-rrb-	-RRB-	_	8	p	_	_
14	did	do	VBD	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	show	show	VB	_	0	root	_	_
17	any	any	DT	_	19	det	_	_
18	significant	significant	JJ	_	19	attr	_	_
19	associations	association	NNS	_	16	obj	_	_
20	with	with	IN	_	21	case	_	_
21	drug4	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	16	p	_	_

1	The	the	DT	_	3	det	_	_
2	consistent	consistent	JJ	_	3	attr	_	_
3	association	association	NN	_	20	dep	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	TCF7L2	tcf0l0	NN	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	in	in	IN	_	13	case	_	_
11	different	different	JJ	_	13	attr	_	_
12	ethnic	ethnic	JJ	_	13	attr	_	_
13	groups	group	NNS	_	7	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	including	include	VBG	_	18	adv	_	_
16	the	the	DT	_	18	det	_	_
17	Japanese	japanese	JJ	_	18	attr	_	_
18	population	population	NN	_	13	ppmod	_	_
19	,	,	,	_	13	p	_	_
20	suggests	suggest	VBZ	_	0	root	_	_
21	that	that	IN	_	23	mark	_	_
22	TCF7L2	tcf0l0	NN	_	23	dep	_	_
23	is	be	VBZ	_	20	comp	_	_
24	a	a	DT	_	27	det	_	_
25	common	common	JJ	_	27	attr	_	_
26	susceptibility	susceptibility	NN	_	27	com	_	_
27	gene	gene	NN	_	23	obj	_	_
28	for	for	IN	_	31	case	_	_
29	type	type	NN	_	31	attr	_	_
30	2	0	CD	_	31	num	_	_
31	diabetes	diabetes	NNS	_	27	ppmod	_	_
32	.	.	.	_	20	p	_	_

1	The	the	DT	_	3	det	_	_
2	minor	minor	JJ	_	3	attr	_	_
3	alleles	allele	NNS	_	57	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	TCF7L2	tcf0l0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	,	,	,	_	5	p	_	_
10	drug2	drug0	NN	_	5	conj	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	TCF7L2	tcf0l0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	,	,	,	_	10	p	_	_
15	drug3	drug0	NN	_	5	conj	_	_
16	(	-lrb-	-LRB-	_	19	p	_	_
17	-30G/A	0g/a	NN	_	19	dep	_	_
18	,	,	,	_	19	p	_	_
19	GCK	gck	NN	_	15	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	,	,	,	_	15	p	_	_
22	drug4	drug0	NN	_	5	conj	_	_
23	(	-lrb-	-LRB-	_	26	p	_	_
24	E23K	e0k	NN	_	26	dep	_	_
25	,	,	,	_	26	p	_	_
26	KCNJ11	kcnj0	NN	_	22	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	,	,	,	_	22	p	_	_
29	drug5	drug0	NN	_	5	conj	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	CDKAL1	cdkal0	NN	_	29	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	,	,	,	_	29	p	_	_
34	drug6	drug0	NN	_	5	conj	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	IGF2BP2	igf0bp0	NN	_	34	prn	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	,	,	,	_	34	p	_	_
39	drug7	drug0	NN	_	5	conj	_	_
40	(	-lrb-	-LRB-	_	41	p	_	_
41	MTNR1B	mtnr0b	NN	_	39	prn	_	_
42	)	-rrb-	-RRB-	_	41	p	_	_
43	,	,	,	_	39	p	_	_
44	drug8	drug0	NN	_	5	conj	_	_
45	(	-lrb-	-LRB-	_	46	p	_	_
46	MTNR1B	mtnr0b	NN	_	44	prn	_	_
47	)	-rrb-	-RRB-	_	46	p	_	_
48	and	and	CC	_	44	cc	_	_
49	drug9	drug0	NN	_	5	conj	_	_
50	(	-lrb-	-LRB-	_	53	p	_	_
51	Gly972Arg	gly0arg	NNP	_	53	attr	_	_
52	,	,	,	_	53	p	_	_
53	IRS1	irs0	NNP	_	49	prn	_	_
54	)	-rrb-	-RRB-	_	53	p	_	_
55	were	be	VBD	_	57	aux	_	_
56	significantly	significantly	RB	_	57	adv	_	_
57	associated	associate	VBN	_	0	root	_	_
58	with	with	IN	_	61	case	_	_
59	a	a	DT	_	61	det	_	_
60	higher	high	JJR	_	61	attr	_	_
61	risk	risk	NN	_	57	ppmod	_	_
62	of	of	IN	_	63	case	_	_
63	drug10	drug0	NN	_	61	ppmod	_	_
64	.	.	.	_	57	p	_	_

1	In	in	IN	_	2	case	_	_
2	summary	summary	NN	_	20	ppmod	_	_
3	,	,	,	_	20	p	_	_
4	by	by	IN	_	5	case	_	_
5	pooling	pool	VBG	_	20	ppmod	_	_
6	all	all	DT	_	9	det	_	_
7	available	available	JJ	_	9	attr	_	_
8	qualified	qualify	VBN	_	9	attr	_	_
9	data	datum	NNS	_	5	obj	_	_
10	from	from	IN	_	12	case	_	_
11	genetic	genetic	JJ	_	12	attr	_	_
12	studies	study	NNS	_	9	ppmod	_	_
13	on	on	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	,	,	,	_	20	p	_	_
18	we	we	PRP	_	20	dep	_	_
19	have	have	VBP	_	20	aux	_	_
20	confirmed	confirm	VBN	_	0	root	_	_
21	that	that	IN	_	25	mark	_	_
22	drug2	drug0	NN	_	25	dep	_	_
23	is	be	VBZ	_	25	aux	_	_
24	significantly	significantly	RB	_	25	adv	_	_
25	associated	associate	VBN	_	20	comp	_	_
26	with	with	IN	_	27	case	_	_
27	susceptibility	susceptibility	NN	_	25	ppmod	_	_
28	to	to	TO	_	29	aux	_	_
29	drug4	drug0	NN	_	27	ppmod	_	_
30	in	in	IN	_	33	case	_	_
31	the	the	DT	_	33	det	_	_
32	global	global	JJ	_	33	attr	_	_
33	population	population	NN	_	27	ppmod	_	_
34	.	.	.	_	20	p	_	_

1	In	in	IN	_	3	case	_	_
2	recent	recent	JJ	_	3	attr	_	_
3	years	year	NNS	_	9	ppmod	_	_
4	,	,	,	_	9	p	_	_
5	it	it	PRP	_	9	dep	_	_
6	has	have	VBZ	_	9	aux	_	_
7	been	be	VBN	_	9	aux	_	_
8	widely	widely	RB	_	9	adv	_	_
9	accepted	accept	VBN	_	0	root	_	_
10	that	that	IN	_	19	mark	_	_
11	transcription	transcription	NN	_	12	com	_	_
12	factor	factor	NN	_	19	dep	_	_
13	7-like	0-like	JJ	_	12	attr	_	_
14	2	0	CD	_	12	num	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	TCF7L2	tcf0l0	NN	_	12	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	is	be	VBZ	_	19	aux	_	_
19	associated	associate	VBN	_	9	comp	_	_
20	with	with	IN	_	25	case	_	_
21	type	type	NN	_	24	attr	_	_
22	2	0	CD	_	24	num	_	_
23	diabetes	diabetes	NN	_	24	com	_	_
24	mellitus	mellitus	NN	_	25	com	_	_
25	drug3	drug0	NN	_	19	ppmod	_	_
26	in	in	IN	_	29	case	_	_
27	multiple	multiple	JJ	_	29	attr	_	_
28	ethnic	ethnic	JJ	_	29	attr	_	_
29	groups	group	NNS	_	25	ppmod	_	_
30	,	,	,	_	29	p	_	_
31	especially	especially	RB	_	29	adv	_	_
32	its	its	PRP$	_	35	poss	_	_
33	single	single	JJ	_	35	attr	_	_
34	nucleotide	nucleotide	NN	_	35	com	_	_
35	polymorphisms	polymorphism	NNS	_	29	appo	_	_
36	of	of	IN	_	37	case	_	_
37	drug1	drug0	NN	_	35	ppmod	_	_
38	,	,	,	_	37	p	_	_
39	drug2	drug0	NN	_	37	conj	_	_
40	and	and	CC	_	39	cc	_	_
41	rs290487T/C	rs0t/c	NN	_	37	conj	_	_
42	.	.	.	_	9	p	_	_

1	In	in	IN	_	2	case	_	_
2	conclusion	conclusion	NN	_	6	ppmod	_	_
3	,	,	,	_	6	p	_	_
4	this	this	DT	_	5	det	_	_
5	study	study	NN	_	6	dep	_	_
6	indicated	indicate	VBD	_	0	root	_	_
7	that	that	IN	_	15	mark	_	_
8	the	the	DT	_	10	det	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	polymorphism	polymorphism	NN	_	15	dep	_	_
11	of	of	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	TCF7L2	tcf0l0	NN	_	14	com	_	_
14	gene	gene	NN	_	10	ppmod	_	_
15	had	have	VBD	_	6	comp	_	_
16	a	a	DT	_	18	det	_	_
17	significant	significant	JJ	_	18	attr	_	_
18	effect	effect	NN	_	15	obj	_	_
19	on	on	IN	_	21	case	_	_
20	drug4	drug0	NN	_	21	com	_	_
21	risk	risk	NN	_	15	ppmod	_	_
22	in	in	IN	_	25	case	_	_
23	Chinese	chinese	JJ	_	25	attr	_	_
24	Han	han	JJ	_	25	attr	_	_
25	population	population	NN	_	21	ppmod	_	_
26	,	,	,	_	15	p	_	_
27	with	with	IN	_	31	case	_	_
28	drug2	drug0	NN	_	31	attr	_	_
29	and	and	CC	_	28	cc	_	_
30	drug3	drug0	NN	_	28	conj	_	_
31	polymorphisms	polymorphism	NNS	_	15	ppmod	_	_
32	showing	show	VBG	_	31	acl	_	_
33	no	no	DT	_	35	det	_	_
34	significant	significant	JJ	_	35	attr	_	_
35	effect	effect	NN	_	32	obj	_	_
36	.	.	.	_	6	p	_	_

1	Subgroups	subgroup	NNS	_	2	com	_	_
2	analyses	analysis	NNS	_	3	dep	_	_
3	show	show	VBP	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	significant	significant	JJ	_	6	attr	_	_
6	associations	association	NNS	_	9	dep	_	_
7	are	be	VBP	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	found	find	VBN	_	3	comp	_	_
10	between	between	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	six	#crd#	CD	_	13	num	_	_
13	SNPs	snp	NNS	_	9	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	drug1	drug0	NN	_	13	prn	_	_
16	,	,	,	_	15	p	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug3	drug0	NN	_	15	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug4	drug0	NN	_	15	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug5	drug0	NN	_	15	conj	_	_
24	,	,	,	_	23	p	_	_
25	and	and	CC	_	23	cc	_	_
26	drug6	drug0	NN	_	15	conj	_	_
27	)	-rrb-	-RRB-	_	15	p	_	_
28	and	and	CC	_	13	cc	_	_
29	the	the	DT	_	30	det	_	_
30	drug7	drug0	NNS	_	13	conj	_	_
31	in	in	IN	_	34	case	_	_
32	some	some	DT	_	34	det	_	_
33	ethnic	ethnic	JJ	_	34	attr	_	_
34	populations	population	NNS	_	30	ppmod	_	_
35	.	.	.	_	3	p	_	_

1	The	the	DT	_	5	det	_	_
2	four	#crd#	CD	_	5	num	_	_
3	tested	test	VBN	_	5	attr	_	_
4	TCF7L2	tcf0l0	NN	_	5	com	_	_
5	variants	variant	NNS	_	6	dep	_	_
6	were	be	VBD	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	linkage	linkage	NN	_	9	com	_	_
9	disequilibrium	disequilibrium	NN	_	6	ppmod	_	_
10	,	,	,	_	6	p	_	_
11	and	and	CC	_	6	cc	_	_
12	4-locus	0-locus	JJ	_	23	attr	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug1	drug0	NN	_	23	prn	_	_
15	,	,	,	_	14	p	_	_
16	drug2	drug0	NN	_	14	appo	_	_
17	,	,	,	_	14	p	_	_
18	drug3	drug0	NN	_	14	appo	_	_
19	,	,	,	_	14	p	_	_
20	drug4	drug0	NN	_	14	appo	_	_
21	)	-rrb-	-RRB-	_	14	p	_	_
22	haplotype	haplotype	NN	_	23	com	_	_
23	analysis	analysis	NN	_	24	dep	_	_
24	demonstrated	demonstrate	VBD	_	6	conj	_	_
25	that	that	IN	_	30	mark	_	_
26	haplotype	haplotype	NN	_	27	com	_	_
27	1111	0	NN	_	30	num	_	_
28	was	be	VBD	_	30	aux	_	_
29	negatively	negatively	RB	_	30	adv	_	_
30	associated	associate	VBN	_	24	comp	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	Pc<0.001	pc<0	NN	_	30	prn	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	,	,	,	_	30	p	_	_
35	while	while	IN	_	48	mark	_	_
36	haplotypes	haplotype	NNS	_	48	dep	_	_
37	2222	0	CD	_	36	num	_	_
38	(	-lrb-	-LRB-	_	39	p	_	_
39	Pc=0.008	pc=0	CD	_	37	num	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	and	and	CC	_	37	cc	_	_
42	2211	0	CD	_	37	conj	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	Pc=0.020	pc=0	NN	_	42	prn	_	_
45	)	-rrb-	-RRB-	_	44	p	_	_
46	were	be	VBD	_	48	aux	_	_
47	positively	positively	RB	_	48	adv	_	_
48	associated	associate	VBN	_	30	comp	_	_
49	with	with	IN	_	51	case	_	_
50	drug5	drug0	NN	_	51	com	_	_
51	risk	risk	NN	_	48	ppmod	_	_
52	,	,	,	_	48	p	_	_
53	after	after	IN	_	54	case	_	_
54	controlling	control	VBG	_	48	ppmod	_	_
55	for	for	IN	_	57	case	_	_
56	a	a	DT	_	57	det	_	_
57	number	number	NN	_	54	ppmod	_	_
58	of	of	IN	_	59	case	_	_
59	covariates	covariate	NNS	_	57	ppmod	_	_
60	.	.	.	_	24	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	evaluated	evaluate	VBD	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	published	publish	VBN	_	5	attr	_	_
5	evidence	evidence	NN	_	2	obj	_	_
6	for	for	IN	_	7	case	_	_
7	association	association	NN	_	5	ppmod	_	_
8	between	between	IN	_	24	case	_	_
9	drug1	drug0	NN	_	24	attr	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	k	k	NN	_	9	prn	_	_
12	=	=	JJ	_	11	attr	_	_
13	27	0	CD	_	14	num	_	_
14	samples	sample	NNS	_	12	advnp	_	_
15	)	-rrb-	-RRB-	_	11	p	_	_
16	and	and	CC	_	9	cc	_	_
17	drug2	drug0	NN	_	9	conj	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	k	k	NN	_	17	prn	_	_
20	=	=	JJ	_	19	attr	_	_
21	44	0	CD	_	22	num	_	_
22	samples	sample	NNS	_	20	advnp	_	_
23	)	-rrb-	-RRB-	_	19	p	_	_
24	SNPs	snp	NNS	_	7	ppmod	_	_
25	with	with	IN	_	26	case	_	_
26	drug3	drug0	NN	_	7	ppmod	_	_
27	using	use	VBG	_	2	comp	_	_
28	meta-analytic	meta-analytic	JJ	_	29	attr	_	_
29	techniques	technique	NNS	_	27	obj	_	_
30	.	.	.	_	2	p	_	_

1	Meta-analysis	meta-analysis	NN	_	2	dep	_	_
2	indicated	indicate	VBD	_	0	root	_	_
3	compelling	compelling	JJ	_	4	attr	_	_
4	evidence	evidence	NN	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	an	an	DT	_	7	det	_	_
7	association	association	NN	_	4	ppmod	_	_
8	between	between	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	variants	variant	NNS	_	7	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NNS	_	11	conj	_	_
14	(	-lrb-	-LRB-	_	49	p	_	_
15	fixed	fixed	JJ	_	16	attr	_	_
16	effects	effect	NNS	_	49	dep	_	_
17	:	:	:	_	49	p	_	_
18	B	b	NN	_	49	dep	_	_
19	=	=	JJ	_	18	attr	_	_
20	0.91	0	CD	_	22	num	_	_
21	,	,	,	_	22	p	_	_
22	95	0	CD	_	24	num	_	_
23	%	%	NN	_	22	meta	_	_
24	CI	ci	NN	_	19	advnp	_	_
25	=	=	JJ	_	24	attr	_	_
26	0.77	0	CD	_	25	num	_	_
27	,	,	,	_	49	p	_	_
28	1.06	0	CD	_	49	num	_	_
29	,	,	,	_	49	p	_	_
30	p	p	NN	_	49	dep	_	_
31	<	<	JJ	_	30	attr	_	_
32	.001	0	CD	_	30	num	_	_
33	;	;	:	_	49	p	_	_
34	random	random	JJ	_	35	attr	_	_
35	effects	effect	NNS	_	49	dep	_	_
36	:	:	:	_	35	p	_	_
37	B	b	NN	_	35	appo	_	_
38	=	=	JJ	_	37	attr	_	_
39	1.01	0	CD	_	43	num	_	_
40	,	,	,	_	43	p	_	_
41	95	0	CD	_	43	num	_	_
42	%	%	NN	_	43	meta	_	_
43	CI	ci	NN	_	38	advnp	_	_
44	=	=	JJ	_	43	attr	_	_
45	0.81	0	CD	_	44	num	_	_
46	,	,	,	_	49	p	_	_
47	1.22	0	CD	_	49	num	_	_
48	,	,	,	_	49	p	_	_
49	p	p	NN	_	11	prn	_	_
50	<	<	JJ	_	49	attr	_	_
51	.001	0	CD	_	49	num	_	_
52	)	-rrb-	-RRB-	_	49	p	_	_
53	,	,	,	_	11	p	_	_
54	equivalent	equivalent	JJ	_	11	attr	_	_
55	to	to	TO	_	58	aux	_	_
56	a	a	DT	_	58	det	_	_
57	per-allele	per-allele	JJ	_	58	attr	_	_
58	effect	effect	NN	_	54	ppmod	_	_
59	of	of	IN	_	62	case	_	_
60	approximately	approximately	RB	_	61	adv	_	_
61	1	0	CD	_	62	num	_	_
62	cigarette/day	cigarette/day	NN	_	58	ppmod	_	_
63	.	.	.	_	2	p	_	_

1	Among	among	IN	_	2	case	_	_
2	women	woman	NNS	_	14	ppmod	_	_
3	with	with	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	history	history	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	14	p	_	_
9	the	the	DT	_	11	det	_	_
10	TT	tt	NN	_	11	com	_	_
11	genotype	genotype	NN	_	14	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	increased	increase	VBD	_	0	root	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	risk	risk	NN	_	14	obj	_	_
17	(	-lrb-	-LRB-	_	24	p	_	_
18	OR	or	CC	_	24	cc	_	_
19	,	,	,	_	24	p	_	_
20	2.46	0	CD	_	24	num	_	_
21	;	;	:	_	24	p	_	_
22	95	0	CD	_	24	num	_	_
23	%	%	NN	_	24	meta	_	_
24	CI	ci	NN	_	14	prn	_	_
25	1.28-4.73	0	CD	_	24	num	_	_
26	)	-rrb-	-RRB-	_	24	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Donor	donor	NN	_	6	com	_	_
4	TCF7L2	tcf0l0	NN	_	6	com	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	polymorphism	polymorphism	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	associated	associate	VBN	_	1	acl	_	_
9	with	with	IN	_	12	case	_	_
10	an	an	DT	_	12	det	_	_
11	increased	increase	VBN	_	12	attr	_	_
12	risk	risk	NN	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	after	after	IN	_	16	case	_	_
16	LT	lt	NN	_	12	ppmod	_	_
17	and	and	CC	_	8	cc	_	_
18	has	have	VBZ	_	8	conj	_	_
19	a	a	DT	_	22	det	_	_
20	potential	potential	JJ	_	22	attr	_	_
21	clinical	clinical	JJ	_	22	attr	_	_
22	value	value	NN	_	18	obj	_	_
23	for	for	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	prediction	prediction	NN	_	22	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	NODM	nodm	NN	_	25	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	The	the	DT	_	4	det	_	_
2	minor	minor	JJ	_	4	attr	_	_
3	T	t	NN	_	4	com	_	_
4	allele	allele	NN	_	9	dep	_	_
5	of	of	IN	_	7	case	_	_
6	TCF7L2	tcf0l0	NN	_	7	com	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	was	be	VBD	_	9	aux	_	_
9	found	find	VBN	_	0	root	_	_
10	to	to	TO	_	12	aux	_	_
11	significantly	significantly	RB	_	12	adv	_	_
12	increase	increase	VB	_	9	comp	_	_
13	the	the	DT	_	14	det	_	_
14	risk	risk	NN	_	12	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	12	p	_	_
18	with	with	IN	_	22	case	_	_
19	an	an	DT	_	22	det	_	_
20	allelic	allelic	JJ	_	21	attr	_	_
21	odds	odds	NNS	_	22	com	_	_
22	ratio	ratio	NN	_	12	ppmod	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	OR	or	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	of	of	IN	_	27	case	_	_
27	1.458	0	NN	_	22	ppmod	_	_
28	(	-lrb-	-LRB-	_	31	p	_	_
29	95	0	CD	_	31	num	_	_
30	%	%	NN	_	31	meta	_	_
31	CI	ci	NN	_	27	prn	_	_
32	1.108-1.918	0	CD	_	31	num	_	_
33	,	,	,	_	31	p	_	_
34	p	p	NN	_	35	dep	_	_
35	=	=	JJ	_	31	advcl	_	_
36	0.007	0	CD	_	35	obj	_	_
37	)	-rrb-	-RRB-	_	31	p	_	_
38	.	.	.	_	9	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	also	also	RB	_	3	adv	_	_
3	found	find	VBD	_	0	root	_	_
4	a	a	DT	_	6	det	_	_
5	strong	strong	JJ	_	6	attr	_	_
6	correlation	correlation	NN	_	3	obj	_	_
7	between	between	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	the	the	DT	_	12	det	_	_
12	presence	presence	NN	_	9	conj	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	P	p	NN	_	17	dep	_	_
17	=	=	JJ	_	6	prn	_	_
18	0.02	0	CD	_	17	obj	_	_
19	with	with	IN	_	24	case	_	_
20	a	a	DT	_	24	det	_	_
21	high	high	JJ	_	24	attr	_	_
22	OR	or	CC	_	21	cc	_	_
23	=	=	JJ	_	21	conj	_	_
24	8.28	0	NN	_	17	ppmod	_	_
25	)	-rrb-	-RRB-	_	17	p	_	_
26	.	.	.	_	3	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	conclude	conclude	VBP	_	0	root	_	_
3	that	that	IN	_	8	mark	_	_
4	drug1	drug0	NN	_	6	com	_	_
5	GTCF7L2	gtcf0l0	NN	_	6	com	_	_
6	variant	variant	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	associated	associate	VBN	_	2	comp	_	_
9	with	with	IN	_	11	case	_	_
10	peripheral	peripheral	JJ	_	11	attr	_	_
11	drug2	drug0	NNS	_	8	ppmod	_	_
12	in	in	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	but	but	CC	_	8	cc	_	_
15	this	this	DT	_	16	det	_	_
16	effect	effect	NN	_	19	dep	_	_
17	is	be	VBZ	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	seen	see	VBN	_	8	conj	_	_
20	in	in	IN	_	22	case	_	_
21	control	control	JJ	_	22	attr	_	_
22	women	woman	NNS	_	19	ppmod	_	_
23	.	.	.	_	2	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	TCF7L2	tcf0l0	NN	_	5	com	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	polymorphism	polymorphism	NN	_	6	dep	_	_
6	protects	protect	VBZ	_	1	acl	_	_
7	Mexican	mexican	NN	_	8	com	_	_
8	children	child	NNS	_	6	obj	_	_
9	from	from	IN	_	10	case	_	_
10	drug2	drug0	NN	_	6	ppmod	_	_
11	.	.	.	_	1	p	_	_

1	THADA	thada	JJ	_	2	attr	_	_
2	variant	variant	NN	_	7	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug1	drug0	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	was	be	VBD	_	7	aux	_	_
7	associated	associate	VBN	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	(	-lrb-	-LRB-	_	16	p	_	_
11	OR	or	CC	_	16	cc	_	_
12	1.5	0	CD	_	16	num	_	_
13	;	;	:	_	16	p	_	_
14	95	0	CD	_	16	num	_	_
15	%	%	NN	_	16	meta	_	_
16	CI	ci	NN	_	7	prn	_	_
17	1.04	0	CD	_	16	num	_	_
18	,	,	,	_	16	p	_	_
19	2.22	0	NN	_	16	appo	_	_
20	;	;	:	_	16	p	_	_
21	p	p	NN	_	16	appo	_	_
22	=	=	JJ	_	21	attr	_	_
23	0.03	0	CD	_	22	num	_	_
24	)	-rrb-	-RRB-	_	16	p	_	_
25	.	.	.	_	7	p	_	_

1	If	if	IN	_	14	mark	_	_
2	the	the	DT	_	3	det	_	_
3	application	application	NN	_	14	dep	_	_
4	of	of	IN	_	7	case	_	_
5	TCF7L2	tcf0l0	NN	_	7	com	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	SNPs	snp	NNS	_	3	ppmod	_	_
8	as	as	IN	_	10	case	_	_
9	a	a	DT	_	10	det	_	_
10	marker	marker	NN	_	3	ppmod	_	_
11	for	for	IN	_	12	case	_	_
12	drug2	drug0	NNS	_	10	ppmod	_	_
13	is	be	VBZ	_	14	aux	_	_
14	confirmed	confirm	VBN	_	27	advcl	_	_
15	by	by	IN	_	18	case	_	_
16	further	far	JJ	_	18	attr	_	_
17	independent	independent	JJ	_	18	attr	_	_
18	studies	study	NNS	_	14	ppmod	_	_
19	,	,	,	_	27	p	_	_
20	replacing	replace	VBG	_	27	advcl	_	_
21	tacrolimus	tacrolimus	NN	_	20	obj	_	_
22	with	with	IN	_	24	case	_	_
23	other	other	JJ	_	24	attr	_	_
24	immunosuppressants	immunosuppressant	NNS	_	20	ppmod	_	_
25	could	could	MD	_	27	modal	_	_
26	be	be	VB	_	27	aux	_	_
27	warranted	warrant	VBN	_	0	root	_	_
28	in	in	IN	_	29	case	_	_
29	patients	patient	NNS	_	27	ppmod	_	_
30	at	at	IN	_	32	case	_	_
31	high	high	JJ	_	32	attr	_	_
32	risk	risk	NN	_	29	ppmod	_	_
33	of	of	IN	_	34	case	_	_
34	drug3	drug0	NN	_	32	ppmod	_	_
35	,	,	,	_	27	p	_	_
36	as	as	IN	_	37	mark	_	_
37	diagnosed	diagnose	VBN	_	27	comp	_	_
38	by	by	IN	_	40	case	_	_
39	TCF7L2	tcf0l0	NN	_	40	com	_	_
40	genotyping	genotyping	NN	_	37	ppmod	_	_
41	.	.	.	_	27	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	16	ppmod	_	_
3	,	,	,	_	16	p	_	_
4	an	an	DT	_	5	det	_	_
5	association	association	NN	_	16	dep	_	_
6	of	of	IN	_	8	case	_	_
7	two	#crd#	CD	_	8	num	_	_
8	SNPs	snp	NNS	_	5	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	TCF7L2	tcf0l0	NN	_	12	com	_	_
12	gene	gene	NN	_	8	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	5	ppmod	_	_
15	was	be	VBD	_	16	aux	_	_
16	observed	observe	VBN	_	0	root	_	_
17	in	in	IN	_	19	case	_	_
18	both	both	DT	_	19	det	_	_
19	cities	city	NNS	_	16	ppmod	_	_
20	:	:	:	_	19	p	_	_
21	drug1	drug0	NN	_	19	appo	_	_
22	,	,	,	_	40	p	_	_
23	(	-lrb-	-LRB-	_	40	p	_	_
24	for	for	IN	_	25	case	_	_
25	Guerrero	guerrero	NN	_	40	ppmod	_	_
26	OR	or	CC	_	25	cc	_	_
27	=	=	JJ	_	31	attr	_	_
28	1.98	0	CD	_	27	num	_	_
29	CI95	ci0	CD	_	31	num	_	_
30	%	%	NN	_	31	meta	_	_
31	1.02-3.89	0	CD	_	25	conj	_	_
32	and	and	CC	_	25	cc	_	_
33	for	for	IN	_	34	case	_	_
34	Mexico	mexico	NNP	_	25	conj	_	_
35	OR	or	CC	_	34	cc	_	_
36	=	=	JJ	_	37	attr	_	_
37	1.94	0	CD	_	34	conj	_	_
38	CI95	ci0	CD	_	40	num	_	_
39	%	%	NN	_	40	meta	_	_
40	1.31-2.88	0	CD	_	21	num	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	and	and	CC	_	21	cc	_	_
43	drug2	drug0	NN	_	21	conj	_	_
44	(	-lrb-	-LRB-	_	46	p	_	_
45	OR	or	CC	_	46	cc	_	_
46	=	=	JJ	_	43	prn	_	_
47	1.79	0	CD	_	50	num	_	_
48	CI95	ci0	CD	_	50	num	_	_
49	%	%	NN	_	50	meta	_	_
50	1.08-2.97	0	CD	_	46	num	_	_
51	,	,	,	_	46	p	_	_
52	OR	or	CC	_	46	cc	_	_
53	=	=	JJ	_	46	conj	_	_
54	1.78	0	CD	_	53	num	_	_
55	CI95	ci0	CD	_	57	num	_	_
56	%	%	NN	_	57	meta	_	_
57	1.17-2.71	0	CD	_	54	appo	_	_
58	respectively	respectively	RB	_	54	adv	_	_
59	)	-rrb-	-RRB-	_	46	p	_	_
60	.	.	.	_	16	p	_	_

1	No	no	DT	_	2	det	_	_
2	interaction	interaction	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	between	between	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	HLA-DQB1	hla-dqb0	NN	_	10	com	_	_
9	*	*	NN	_	10	com	_	_
10	0602	0	NN	_	6	conj	_	_
11	,	,	,	_	6	p	_	_
12	which	which	WDT	_	14	dep	_	_
13	was	be	VBD	_	14	aux	_	_
14	shown	show	VBN	_	6	relcl	_	_
15	to	to	TO	_	18	aux	_	_
16	be	be	VB	_	18	aux	_	_
17	negatively	negatively	RB	_	18	adv	_	_
18	associated	associate	VBN	_	14	comp	_	_
19	with	with	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	in	in	IN	_	22	case	_	_
22	mothers	mother	NNS	_	20	ppmod	_	_
23	born	bear	VBN	_	22	acl	_	_
24	in	in	IN	_	25	case	_	_
25	Sweden	sweden	NN	_	23	ppmod	_	_
26	(	-lrb-	-LRB-	_	29	p	_	_
27	P	p	NN	_	29	attr	_	_
28	=	=	JJ	_	29	attr	_	_
29	0.010	0	NN	_	25	num	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	.	.	.	_	4	p	_	_

1	A	a	DT	_	3	det	_	_
2	genetic	genetic	JJ	_	3	attr	_	_
3	variant	variant	NN	_	20	dep	_	_
4	within	within	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	CHRNA5-CHRNA3-CHRNB4	chrna0-chrna0-chrnb0	JJ	_	7	attr	_	_
7	region	region	NN	_	3	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	drug1	drug0	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	3	p	_	_
12	previously	previously	RB	_	13	adv	_	_
13	associated	associate	VBN	_	3	acl	_	_
14	with	with	IN	_	16	case	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	quantity	quantity	NN	_	13	ppmod	_	_
17	,	,	,	_	3	p	_	_
18	was	be	VBD	_	20	aux	_	_
19	recently	recently	RB	_	20	adv	_	_
20	shown	show	VBN	_	0	root	_	_
21	to	to	TO	_	22	aux	_	_
22	interact	interact	VB	_	20	comp	_	_
23	with	with	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	on	on	IN	_	27	case	_	_
26	drug4	drug0	NN	_	27	com	_	_
27	predisposition	predisposition	NN	_	22	ppmod	_	_
28	.	.	.	_	20	p	_	_

1	The	the	DT	_	3	det	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	variant	variant	NN	_	7	dep	_	_
4	was	be	VBD	_	7	aux	_	_
5	not	not	RB	_	7	neg	_	_
6	significantly	significantly	RB	_	7	adv	_	_
7	associated	associate	VBN	_	24	advcl	_	_
8	with	with	IN	_	10	case	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	status	status	NN	_	7	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	snus	snus	NN	_	13	com	_	_
13	use	use	NN	_	10	conj	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	P	p	NN	_	16	com	_	_
16	>	>	NN	_	7	prn	_	_
17	0.05	0	CD	_	16	num	_	_
18	)	-rrb-	-RRB-	_	16	p	_	_
19	;	;	:	_	24	p	_	_
20	the	the	DT	_	22	det	_	_
21	T	t	NN	_	22	com	_	_
22	allele	allele	NN	_	24	dep	_	_
23	was	be	VBD	_	24	aux	_	_
24	associated	associate	VBN	_	0	root	_	_
25	with	with	IN	_	27	case	_	_
26	lower	low	JJR	_	27	attr	_	_
27	BMI	bmi	NN	_	24	ppmod	_	_
28	in	in	IN	_	31	case	_	_
29	the	the	DT	_	31	det	_	_
30	overall	overall	JJ	_	31	attr	_	_
31	cohort	cohort	NN	_	27	ppmod	_	_
32	(	-lrb-	-LRB-	_	41	p	_	_
33	b	b	NN	_	34	advnp	_	_
34	=	=	JJ	_	36	attr	_	_
35	-0.10	0	NN	_	36	num	_	_
36	kg/m	kg/m	NN	_	41	dep	_	_
37	(	-lrb-	-LRB-	_	38	p	_	_
38	2	0	CD	_	36	num	_	_
39	)	-rrb-	-RRB-	_	38	p	_	_
40	,	,	,	_	41	p	_	_
41	SE	se	NN	_	31	prn	_	_
42	=	=	JJ	_	41	attr	_	_
43	0.05	0	CD	_	42	num	_	_
44	;	;	:	_	41	p	_	_
45	P	p	NN	_	46	dep	_	_
46	=	=	JJ	_	41	advcl	_	_
47	0.03	0	CD	_	46	obj	_	_
48	)	-rrb-	-RRB-	_	41	p	_	_
49	and	and	CC	_	27	cc	_	_
50	with	with	IN	_	52	case	_	_
51	drug3	drug0	NN	_	52	com	_	_
52	quantity	quantity	NN	_	27	conj	_	_
53	in	in	IN	_	54	case	_	_
54	those	those	DT	_	52	ppmod	_	_
55	in	in	IN	_	56	case	_	_
56	whom	whom	WP	_	59	ppmod	_	_
57	this	this	DT	_	59	dep	_	_
58	was	be	VBD	_	59	aux	_	_
59	measured	measure	VBN	_	54	relcl	_	_
60	(	-lrb-	-LRB-	_	62	p	_	_
61	n	n	NN	_	62	dep	_	_
62	=	=	JJ	_	24	prn	_	_
63	5,304	0	CD	_	62	obj	_	_
64	)	-rrb-	-RRB-	_	62	p	_	_
65	(	-lrb-	-LRB-	_	74	p	_	_
66	b	b	NN	_	74	dep	_	_
67	=	=	JJ	_	66	attr	_	_
68	0.08	0	CD	_	67	num	_	_
69	,	,	,	_	74	p	_	_
70	SE	se	NN	_	74	dep	_	_
71	=	=	JJ	_	70	attr	_	_
72	0.01	0	CD	_	71	num	_	_
73	;	;	:	_	74	p	_	_
74	P	p	NN	_	24	prn	_	_
75	<	<	JJ	_	74	attr	_	_
76	0.0001	0	CD	_	74	num	_	_
77	)	-rrb-	-RRB-	_	74	p	_	_

1	The	the	DT	_	7	det	_	_
2	drug1	drug0	NN	_	7	attr	_	_
3	(	-lrb-	-LRB-	_	7	p	_	_
4	T	t	NN	_	7	attr	_	_
5	)	-rrb-	-RRB-	_	7	p	_	_
6	allele	allele	NN	_	7	com	_	_
7	genotype	genotype	NN	_	10	dep	_	_
8	was	be	VBD	_	10	aux	_	_
9	significantly	significantly	RB	_	10	adv	_	_
10	associated	associate	VBN	_	0	root	_	_
11	with	with	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	P	p	NN	_	10	prn	_	_
15	=	=	JJ	_	14	attr	_	_
16	0.003	0	CD	_	14	num	_	_
17	)	-rrb-	-RRB-	_	14	p	_	_
18	but	but	CC	_	10	cc	_	_
19	drug2	drug0	NN	_	24	attr	_	_
20	(	-lrb-	-LRB-	_	24	p	_	_
21	T	t	NN	_	24	attr	_	_
22	)	-rrb-	-RRB-	_	24	p	_	_
23	allele	allele	NN	_	24	com	_	_
24	genotype	genotype	NN	_	27	dep	_	_
25	was	be	VBD	_	27	aux	_	_
26	not	not	RB	_	27	neg	_	_
27	associated	associate	VBN	_	10	conj	_	_
28	with	with	IN	_	31	case	_	_
29	the	the	DT	_	31	det	_	_
30	clinico-pathologic	clinico-pathologic	JJ	_	31	attr	_	_
31	characteristics	characteristic	NNS	_	27	ppmod	_	_
32	.	.	.	_	10	p	_	_

1	Thus	thus	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	we	we	PRP	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	that	that	IN	_	12	mark	_	_
7	the	the	DT	_	8	det	_	_
8	drug1	drug0	NN	_	12	dep	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	markers	marker	NNS	_	8	conj	_	_
12	are	be	VBP	_	5	comp	_	_
13	independent	independent	JJ	_	17	attr	_	_
14	genetic	genetic	JJ	_	17	attr	_	_
15	drug3	drug0	NN	_	17	com	_	_
16	risk	risk	NN	_	17	com	_	_
17	factors	factor	NNS	_	12	obj	_	_
18	in	in	IN	_	21	case	_	_
19	a	a	DT	_	21	det	_	_
20	Russian	russian	JJ	_	21	attr	_	_
21	population	population	NN	_	17	ppmod	_	_
22	.	.	.	_	5	p	_	_

1	Thus	thus	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	we	we	PRP	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	that	that	IN	_	12	mark	_	_
7	the	the	DT	_	8	det	_	_
8	drug1	drug0	NN	_	12	dep	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	markers	marker	NNS	_	8	conj	_	_
12	are	be	VBP	_	5	comp	_	_
13	independent	independent	JJ	_	17	attr	_	_
14	genetic	genetic	JJ	_	17	attr	_	_
15	drug3	drug0	NN	_	17	com	_	_
16	risk	risk	NN	_	17	com	_	_
17	factors	factor	NNS	_	12	obj	_	_
18	in	in	IN	_	21	case	_	_
19	a	a	DT	_	21	det	_	_
20	Russian	russian	JJ	_	21	attr	_	_
21	population	population	NN	_	17	ppmod	_	_
22	.	.	.	_	5	p	_	_

1	The	the	DT	_	4	det	_	_
2	non-synonymous	non-synonymous	JJ	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	polymorphism	polymorphism	NN	_	10	dep	_	_
5	of	of	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	ADRB3	adrb0	NN	_	8	com	_	_
8	gene	gene	NN	_	4	ppmod	_	_
9	was	be	VBD	_	10	aux	_	_
10	associated	associate	VBN	_	0	root	_	_
11	with	with	IN	_	14	case	_	_
12	drug2	drug0	NNP	_	14	attr	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	Trpallele	trpallele	NNP	_	10	ppmod	_	_
15	,	,	,	_	10	p	_	_
16	OR	or	CC	_	10	cc	_	_
17	=	=	JJ	_	10	dep	_	_
18	0.62	0	NN	_	10	num	_	_
19	,	,	,	_	10	p	_	_
20	p	p	NN	_	10	dep	_	_
21	=	=	JJ	_	10	dep	_	_
22	0.001	0	CD	_	10	num	_	_
23	)	-rrb-	-RRB-	_	10	p	_	_
24	and	and	CC	_	10	cc	_	_
25	drug3	drug0	NN	_	10	dep	_	_
26	(	-lrb-	-LRB-	_	10	p	_	_
27	Trp	trp	NN	_	10	dep	_	_
28	allele	allele	NN	_	10	dep	_	_
29	,	,	,	_	10	p	_	_
30	OR	or	NN	_	10	dep	_	_
31	=	=	JJ	_	10	dep	_	_
32	0.74	0	CD	_	10	num	_	_
33	,	,	,	_	10	p	_	_
34	p	p	NN	_	36	attr	_	_
35	=	=	JJ	_	36	attr	_	_
36	0.018	0	CD	_	10	conj	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	.	.	.	_	36	p	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Single	single	JJ	_	5	attr	_	_
4	nucleotide	nucleotide	NN	_	5	com	_	_
5	polymiorphisms	polymiorphisms	NNS	_	18	dep	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	SNPs	snp	NNS	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	drug1	drug0	NN	_	5	appo	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	located	located	JJ	_	5	attr	_	_
13	within	within	IN	_	15	case	_	_
14	TCF7L2	tcf0l0	NN	_	15	com	_	_
15	gene	gene	NN	_	12	ppmod	_	_
16	have	have	VBP	_	18	aux	_	_
17	been	be	VBN	_	18	aux	_	_
18	identified	identify	VBN	_	1	acl	_	_
19	as	as	IN	_	25	case	_	_
20	the	the	DT	_	25	det	_	_
21	strongest	strong	JJS	_	25	attr	_	_
22	common	common	JJ	_	25	attr	_	_
23	genetic	genetic	JJ	_	25	attr	_	_
24	risk	risk	NN	_	25	com	_	_
25	factors	factor	NNS	_	18	ppmod	_	_
26	for	for	IN	_	27	case	_	_
27	development	development	NN	_	25	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	drug3	drug0	NN	_	27	ppmod	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	T2D	t0d	NN	_	29	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	.	.	.	_	1	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Although	although	IN	_	19	mark	_	_
4	the	the	DT	_	5	det	_	_
5	biology	biology	NN	_	19	dep	_	_
6	of	of	IN	_	10	case	_	_
7	the	the	DT	_	10	det	_	_
8	Wnt/beta-catenin	wnt/beta-catenin	NN	_	10	com	_	_
9	signaling	signaling	NN	_	10	com	_	_
10	pathway	pathway	NN	_	5	ppmod	_	_
11	and	and	CC	_	5	cc	_	_
12	prior	prior	JJ	_	13	attr	_	_
13	association	association	NN	_	5	conj	_	_
14	between	between	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	numerous	numerous	JJ	_	18	attr	_	_
18	phenotypes	phenotype	NNS	_	15	conj	_	_
19	warranted	warrant	VBN	_	36	advcl	_	_
20	examination	examination	NN	_	19	obj	_	_
21	of	of	IN	_	24	case	_	_
22	this	this	DT	_	24	det	_	_
23	TCF7L2	tcf0l0	NN	_	24	com	_	_
24	SNP	snp	NN	_	20	ppmod	_	_
25	,	,	,	_	36	p	_	_
26	no	no	DT	_	28	det	_	_
27	compelling	compelling	JJ	_	28	attr	_	_
28	evidence	evidence	NN	_	36	dep	_	_
29	for	for	IN	_	30	case	_	_
30	association	association	NN	_	28	ppmod	_	_
31	with	with	IN	_	32	case	_	_
32	breast	breast	NN	_	30	ppmod	_	_
33	or	or	CC	_	32	cc	_	_
34	drug2	drug0	NN	_	32	conj	_	_
35	was	be	VBD	_	36	aux	_	_
36	observed	observe	VBN	_	1	acl	_	_
37	.	.	.	_	1	p	_	_

1	However	however	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	the	the	DT	_	5	det	_	_
4	risk	risk	NN	_	5	com	_	_
5	allele	allele	NN	_	9	dep	_	_
6	at	at	IN	_	8	case	_	_
7	TCF7L2	tcf0l0	NN	_	8	com	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	was	be	VBD	_	0	root	_	_
10	more	more	RBR	_	11	adv	_	_
11	frequent	frequent	JJ	_	9	dep	_	_
12	in	in	IN	_	14	case	_	_
13	drug2	drug0	JJ	_	14	attr	_	_
14	subjects	subject	NNS	_	11	ppmod	_	_
15	than	than	IN	_	17	case	_	_
16	in	in	IN	_	17	case	_	_
17	controls	control	NNS	_	9	ppmod	_	_
18	when	when	WRB	_	20	adv	_	_
19	we	we	PRP	_	20	dep	_	_
20	restricted	restrict	VBN	_	9	comp	_	_
21	the	the	DT	_	22	det	_	_
22	analysis	analysis	NN	_	20	obj	_	_
23	to	to	TO	_	25	aux	_	_
24	the	the	DT	_	25	det	_	_
25	subjects	subject	NNS	_	20	ppmod	_	_
26	with	with	IN	_	28	case	_	_
27	lower	low	JJR	_	28	attr	_	_
28	weight-for-height	weight-for-height	NN	_	25	ppmod	_	_
29	than	than	IN	_	31	case	_	_
30	the	the	DT	_	31	det	_	_
31	median	median	NN	_	28	ppmod	_	_
32	of	of	IN	_	35	case	_	_
33	the	the	DT	_	35	det	_	_
34	PA	pa	NN	_	35	com	_	_
35	subjects	subject	NNS	_	31	ppmod	_	_
36	(	-lrb-	-LRB-	_	9	p	_	_

1	To	to	TO	_	2	aux	_	_
2	investigate	investigate	VB	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	expression	expression	NN	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	protein	protein	NN	_	4	ppmod	_	_
8	in	in	IN	_	11	case	_	_
9	normal	normal	JJ	_	11	attr	_	_
10	breast	breast	NN	_	11	com	_	_
11	tissue	tissue	NN	_	4	ppmod	_	_
12	,	,	,	_	2	p	_	_
13	and	and	CC	_	2	cc	_	_
14	examine	examine	VB	_	2	conj	_	_
15	the	the	DT	_	16	det	_	_
16	difference	difference	NN	_	14	obj	_	_
17	in	in	IN	_	19	case	_	_
18	ABCC11	abcc0	NN	_	19	com	_	_
19	mRNA	mrna	NN	_	16	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	proteinexpression	proteinexpression	NN	_	19	conj	_	_
22	between	between	IN	_	24	case	_	_
23	normal	normal	JJ	_	24	attr	_	_
24	breast	breast	NN	_	16	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	drug3	drug0	NN	_	27	com	_	_
27	tissues	tissue	NNS	_	24	conj	_	_
28	taking	take	VBG	_	24	acl	_	_
29	into	into	IN	_	32	case	_	_
30	account	account	NN	_	32	com	_	_
31	ABCC11	abcc0	NN	_	32	com	_	_
32	genotype	genotype	NN	_	28	ppmod	_	_
33	(	-lrb-	-LRB-	_	36	p	_	_
34	a	a	DT	_	36	det	_	_
35	functional	functional	JJ	_	36	attr	_	_
36	SNP	snp	NN	_	32	prn	_	_
37	,	,	,	_	36	p	_	_
38	drug1	drug0	NN	_	36	appo	_	_
39	)	-rrb-	-RRB-	_	36	p	_	_
40	and	and	CC	_	32	cc	_	_
41	estrogen	estrogen	NN	_	42	com	_	_
42	receptor	receptor	NN	_	46	attr	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	ER	er	NN	_	42	prn	_	_
45	)	-rrb-	-RRB-	_	44	p	_	_
46	status	status	NN	_	32	conj	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	present	present	JJ	_	4	attr	_	_
4	study	study	NN	_	24	ppmod	_	_
5	,	,	,	_	24	p	_	_
6	to	to	TO	_	7	aux	_	_
7	determine	determine	VB	_	24	advcl	_	_
8	whether	whether	IN	_	12	mark	_	_
9	the	the	DT	_	10	det	_	_
10	SNP	snp	NN	_	12	dep	_	_
11	can	can	MD	_	12	modal	_	_
12	serve	serve	VB	_	7	comp	_	_
13	as	as	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	diagnostic	diagnostic	JJ	_	16	attr	_	_
16	marker	marker	NN	_	12	ppmod	_	_
17	for	for	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	AO	ao	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	,	,	,	_	24	p	_	_
23	we	we	PRP	_	24	dep	_	_
24	examined	examine	VBD	_	0	root	_	_
25	genotypes	genotype	NNS	_	24	obj	_	_
26	at	at	IN	_	27	case	_	_
27	drug1	drug0	NN	_	25	ppmod	_	_
28	in	in	IN	_	32	case	_	_
29	79	0	CD	_	32	num	_	_
30	Japanese	japanese	JJ	_	32	attr	_	_
31	AO	ao	JJ	_	32	attr	_	_
32	individuals	individual	NNS	_	25	ppmod	_	_
33	.	.	.	_	24	p	_	_

1	In	in	IN	_	2	case	_	_
2	Europeans	europeans	NNP	_	11	ppmod	_	_
3	,	,	,	_	11	p	_	_
4	three	#crd#	CD	_	5	num	_	_
5	haplotypes	haplotype	NNS	_	11	dep	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	region	region	NN	_	5	ppmod	_	_
9	have	have	VBP	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	shown	show	VBN	_	0	root	_	_
12	to	to	TO	_	14	aux	_	_
13	be	be	VB	_	14	aux	_	_
14	associated	associate	VBN	_	11	comp	_	_
15	with	with	IN	_	17	case	_	_
16	eye	eye	NN	_	17	com	_	_
17	pigmentation	pigmentation	NN	_	14	ppmod	_	_
18	and	and	CC	_	11	cc	_	_
19	a	a	DT	_	21	det	_	_
20	missense	missense	NN	_	21	com	_	_
21	SNP	snp	NN	_	27	dep	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	drug1	drug0	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	has	have	VBZ	_	27	aux	_	_
26	been	be	VBN	_	27	aux	_	_
27	associated	associate	VBN	_	11	conj	_	_
28	with	with	IN	_	29	case	_	_
29	drug2	drug0	NN	_	27	ppmod	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	data	datum	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	10	mark	_	_
5	the	the	DT	_	6	det	_	_
6	haplotype	haplotype	NN	_	10	dep	_	_
7	restricted	restrict	VBN	_	6	acl	_	_
8	to	to	TO	_	9	aux	_	_
9	Europe	europe	NN	_	7	ppmod	_	_
10	is	be	VBZ	_	3	comp	_	_
11	the	the	DT	_	13	det	_	_
12	strongest	strong	JJS	_	13	attr	_	_
13	marker	marker	NN	_	10	obj	_	_
14	for	for	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	globally	globally	RB	_	10	adv	_	_
17	and	and	CC	_	3	cc	_	_
18	add	add	VBP	_	3	conj	_	_
19	further	far	JJ	_	21	attr	_	_
20	inferential	inferential	JJ	_	21	attr	_	_
21	evidence	evidence	NN	_	18	obj	_	_
22	that	that	IN	_	28	mark	_	_
23	the	the	DT	_	25	det	_	_
24	derived	derive	VBN	_	25	attr	_	_
25	allele	allele	NN	_	28	dep	_	_
26	of	of	IN	_	27	case	_	_
27	drug1	drug0	NN	_	25	ppmod	_	_
28	is	be	VBZ	_	21	acl	_	_
29	an	an	DT	_	33	det	_	_
30	East	east	JJ	_	33	attr	_	_
31	Asian	asian	NN	_	33	com	_	_
32	drug3	drug0	NN	_	33	com	_	_
33	allele	allele	NN	_	28	obj	_	_
34	.	.	.	_	3	p	_	_

1	Moreover	moreover	RB	_	23	adv	_	_
2	,	,	,	_	23	p	_	_
3	the	the	DT	_	5	det	_	_
4	TT	tt	NN	_	5	com	_	_
5	genotype	genotype	NN	_	23	dep	_	_
6	of	of	IN	_	19	case	_	_
7	the	the	DT	_	10	det	_	_
8	nicotinic	nicotinic	JJ	_	10	attr	_	_
9	acetylcholine	acetylcholine	NN	_	10	com	_	_
10	receptor	receptor	NN	_	19	attr	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	nAChR	nachr	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	a3-subunit	a0-subunit	NN	_	19	attr	_	_
15	(	-lrb-	-LRB-	_	19	p	_	_
16	CHRNA3	chrna0	NN	_	19	attr	_	_
17	)	-rrb-	-RRB-	_	19	p	_	_
18	drug1	drug0	NN	_	19	com	_	_
19	polymorphism	polymorphism	NN	_	5	ppmod	_	_
20	has	have	VBZ	_	23	aux	_	_
21	previously	previously	RB	_	23	adv	_	_
22	been	be	VBN	_	23	aux	_	_
23	associated	associate	VBN	_	0	root	_	_
24	with	with	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	drug3	drug0	NN	_	25	conj	_	_
28	.	.	.	_	23	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	found	find	VBD	_	0	root	_	_
3	that	that	IN	_	14	mark	_	_
4	the	the	DT	_	6	det	_	_
5	variant	variant	JJ	_	6	attr	_	_
6	allele	allele	NN	_	14	dep	_	_
7	of	of	IN	_	9	case	_	_
8	OCA2	oca0	NN	_	9	com	_	_
9	R419Q	r0q	NN	_	6	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug1	drug0	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	was	be	VBD	_	14	aux	_	_
14	associated	associate	VBN	_	2	comp	_	_
15	with	with	IN	_	17	case	_	_
16	increased	increase	VBN	_	17	attr	_	_
17	risk	risk	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	(	-lrb-	-LRB-	_	14	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	also	also	RB	_	2	adv	_	_
4	able	able	JJ	_	2	dep	_	_
5	to	to	TO	_	6	aux	_	_
6	demonstrate	demonstrate	VB	_	4	comp	_	_
7	the	the	DT	_	9	det	_	_
8	OCA2	oca0	NN	_	9	com	_	_
9	R419Q	r0q	NN	_	6	obj	_	_
10	,	,	,	_	9	p	_	_
11	drug1	drug0	NN	_	9	appo	_	_
12	,	,	,	_	9	p	_	_
13	coding	cod	VBG	_	9	acl	_	_
14	SNP	snp	NN	_	15	dep	_	_
15	acts	act	VBZ	_	13	comp	_	_
16	as	as	IN	_	19	case	_	_
17	a	a	DT	_	19	det	_	_
18	penetrance	penetrance	NN	_	19	com	_	_
19	modifier	modifier	NN	_	15	ppmod	_	_
20	of	of	IN	_	24	case	_	_
21	this	this	DT	_	24	det	_	_
22	new	new	JJ	_	24	attr	_	_
23	drug2	drug0	NN	_	24	com	_	_
24	SNP	snp	NN	_	19	ppmod	_	_
25	for	for	IN	_	27	case	_	_
26	eye	eye	NN	_	27	com	_	_
27	color	color	NN	_	19	ppmod	_	_
28	,	,	,	_	13	p	_	_
29	and	and	CC	_	13	cc	_	_
30	somewhat	somewhat	RB	_	13	conj	_	_
31	independently	independently	RB	_	30	adv	_	_
32	,	,	,	_	9	p	_	_
33	of	of	IN	_	35	case	_	_
34	drug3	drug0	NN	_	35	com	_	_
35	risk	risk	NN	_	9	ppmod	_	_
36	.	.	.	_	2	p	_	_

1	Conclusions	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Genetic	genetic	JJ	_	4	attr	_	_
4	variation	variation	NN	_	14	dep	_	_
5	of	of	IN	_	6	case	_	_
6	DRD2	drd0	NN	_	4	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	specifically	specifically	RB	_	11	adv	_	_
9	the	the	DT	_	11	det	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	polymorphism	polymorphism	NN	_	6	appo	_	_
12	,	,	,	_	6	p	_	_
13	may	may	MD	_	14	modal	_	_
14	produce	produce	VB	_	1	acl	_	_
15	an	an	DT	_	18	det	_	_
16	earlier	early	JJR	_	18	attr	_	_
17	clinical	clinical	JJ	_	18	attr	_	_
18	presentation	presentation	NN	_	14	obj	_	_
19	of	of	IN	_	23	case	_	_
20	drug2	drug0	NN	_	23	attr	_	_
21	disease	disease	NN	_	23	attr	_	_
22	neuropsychiatric	neuropsychiatric	JJ	_	23	attr	_	_
23	symptoms	symptom	NNS	_	18	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	signs	sign	NNS	_	23	conj	_	_
26	that	that	WDT	_	27	dep	_	_
27	occur	occur	VBP	_	23	relcl	_	_
28	in	in	IN	_	30	case	_	_
29	the	the	DT	_	30	det	_	_
30	course	course	NN	_	27	ppmod	_	_
31	of	of	IN	_	34	case	_	_
32	dopaminergic	dopaminergic	JJ	_	34	attr	_	_
33	system	system	NN	_	34	com	_	_
34	impairment	impairment	NN	_	30	ppmod	_	_
35	due	due	JJ	_	38	adv	_	_
36	to	to	TO	_	38	aux	_	_
37	copper	copper	NN	_	38	com	_	_
38	accumulation	accumulation	NN	_	27	ppmod	_	_
39	in	in	IN	_	41	case	_	_
40	the	the	DT	_	41	det	_	_
41	brain	brain	NN	_	38	ppmod	_	_
42	.	.	.	_	1	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	investigated	investigate	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	relationship	relationship	NN	_	2	obj	_	_
5	between	between	IN	_	7	case	_	_
6	drug4	drug0	JJ	_	7	attr	_	_
7	symptoms	symptom	NNS	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	dopamine	dopamine	NN	_	10	com	_	_
10	receptor	receptor	NN	_	22	attr	_	_
11	2	0	CD	_	10	num	_	_
12	DRD2	drd0	NN	_	22	attr	_	_
13	gene	gene	NN	_	22	attr	_	_
14	polymorphisms-141	polymorphisms-0	NN	_	22	attr	_	_
15	C	c	NN	_	22	attr	_	_
16	I/D	i/d	NN	_	22	attr	_	_
17	(	-lrb-	-LRB-	_	22	p	_	_
18	drug1	drug0	NN	_	22	attr	_	_
19	)	-rrb-	-RRB-	_	22	p	_	_
20	exon	exon	NN	_	22	attr	_	_
21	8	0	CD	_	22	num	_	_
22	G/A	g/a	NN	_	39	attr	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	drug2	drug0	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	and	and	CC	_	22	cc	_	_
27	ANKK1	ankk0	NN	_	38	attr	_	_
28	(	-lrb-	-LRB-	_	30	p	_	_
29	Ankyrin	ankyrin	NN	_	30	com	_	_
30	Repeat	repeat	NN	_	38	prn	_	_
31	and	and	CC	_	30	cc	_	_
32	Kinase	kinase	NN	_	34	com	_	_
33	Domain	domain	NN	_	34	com	_	_
34	Containing	containing	NN	_	30	conj	_	_
35	1	0	CD	_	34	num	_	_
36	)	-rrb-	-RRB-	_	30	p	_	_
37	gene	gene	NN	_	38	com	_	_
38	polymorphism	polymorphism	NN	_	22	conj	_	_
39	Taq1A	taq0a	NN	_	7	conj	_	_
40	(	-lrb-	-LRB-	_	41	p	_	_
41	drug3	drug0	NN	_	39	prn	_	_
42	)	-rrb-	-RRB-	_	41	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	4	dep	_	_
3	strongly	strongly	RB	_	4	adv	_	_
4	suggested	suggest	VBD	_	0	root	_	_
5	that	that	IN	_	13	mark	_	_
6	A1+	a0+	JJ	_	7	attr	_	_
7	variants	variant	NNS	_	13	dep	_	_
8	of	of	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	allele	allele	NN	_	7	ppmod	_	_
12	do	do	VBP	_	13	aux	_	_
13	confer	confer	VB	_	4	comp	_	_
14	an	an	DT	_	16	det	_	_
15	associated	associate	VBN	_	16	attr	_	_
16	risk	risk	NN	_	13	obj	_	_
17	for	for	IN	_	19	case	_	_
18	drug2	drug0	NN	_	19	com	_	_
19	inpatients	inpatient	NNS	_	16	ppmod	_	_
20	who	who	WP	_	22	dep	_	_
21	were	be	VBD	_	22	aux	_	_
22	treated	treat	VBN	_	19	relcl	_	_
23	with	with	IN	_	24	case	_	_
24	SGAs	sgas	NNS	_	22	ppmod	_	_
25	,	,	,	_	13	p	_	_
26	and	and	CC	_	13	cc	_	_
27	these	these	DT	_	28	det	_	_
28	variants	variant	NNS	_	30	dep	_	_
29	may	may	MD	_	30	modal	_	_
30	explain	explain	VB	_	13	conj	_	_
31	inconsistencies	inconsistency	NNS	_	30	obj	_	_
32	found	find	VBN	_	31	acl	_	_
33	across	across	IN	_	35	case	_	_
34	prior	prior	JJ	_	35	attr	_	_
35	studies	study	NNS	_	32	ppmod	_	_
36	,	,	,	_	30	p	_	_
37	when	when	WRB	_	38	adv	_	_
38	comparing	compare	VBG	_	30	comp	_	_
39	FGAs	fgas	NNS	_	38	obj	_	_
40	and	and	CC	_	39	cc	_	_
41	SGAs	sgas	NNS	_	39	conj	_	_
42	.	.	.	_	4	p	_	_

1	Eleven	#crd#	CD	_	5	num	_	_
2	tag	tag	NN	_	5	attr	_	_
3	single	single	JJ	_	5	attr	_	_
4	nucleotide	nucleotide	NN	_	5	com	_	_
5	polymorphisms	polymorphism	NNS	_	26	dep	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	SNPs	snp	NNS	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	in	in	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	PRCP	prcp	NN	_	12	com	_	_
12	gene	gene	NN	_	5	ppmod	_	_
13	and	and	CC	_	5	cc	_	_
14	four	#crd#	CD	_	16	num	_	_
15	tag	tag	NN	_	16	com	_	_
16	SNPs	snp	NNS	_	5	conj	_	_
17	and	and	CC	_	16	cc	_	_
18	G-1903A	g-0a	NN	_	20	com	_	_
19	drug1	drug0	NN	_	20	com	_	_
20	polymorphism	polymorphism	NN	_	16	conj	_	_
21	in	in	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	CMA1	cma0	NN	_	24	com	_	_
24	gene	gene	NN	_	16	ppmod	_	_
25	were	be	VBD	_	26	aux	_	_
26	genotyped	genotyped	VBN	_	0	root	_	_
27	in	in	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	drug2	drug0	NN	_	26	ppmod	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	n=1020	n=0	NN	_	29	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	using	use	VBG	_	26	comp	_	_
34	a	a	DT	_	40	det	_	_
35	polymerase	polymerase	NN	_	40	com	_	_
36	chain	chain	NN	_	40	com	_	_
37	reaction-restriction	reaction-restriction	NN	_	40	com	_	_
38	fragment	fragment	NN	_	40	com	_	_
39	length	length	NN	_	40	com	_	_
40	polymorphism	polymorphism	NN	_	41	com	_	_
41	method	method	NN	_	33	obj	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	present	present	JJ	_	5	attr	_	_
5	results	result	NNS	_	6	dep	_	_
6	indicated	indicate	VBD	_	1	acl	_	_
7	PRCP	prcp	IN	_	11	mark	_	_
8	drug1	drug0	NN	_	11	dep	_	_
9	can	can	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	considered	consider	VBN	_	6	comp	_	_
12	as	as	IN	_	14	case	_	_
13	a	a	DT	_	14	det	_	_
14	marker	marker	NN	_	11	ppmod	_	_
15	for	for	IN	_	31	case	_	_
16	EH	eh	NN	_	31	dep	_	_
17	and	and	CC	_	16	cc	_	_
18	Hap3	hap0	NN	_	19	com	_	_
19	GAGCACTAACA	gagcactaaca	NN	_	16	conj	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	PRCP	prcp	NN	_	16	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	and	and	CC	_	16	cc	_	_
24	Hap16	hap0	NN	_	25	com	_	_
25	TTTA	ttta	NN	_	16	conj	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	CMA1	cma0	NN	_	25	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	might	might	MD	_	31	modal	_	_
30	be	be	VB	_	31	aux	_	_
31	associated	associate	VBN	_	14	ppmod	_	_
32	with	with	IN	_	33	case	_	_
33	drug2	drug0	NN	_	31	ppmod	_	_
34	in	in	IN	_	37	case	_	_
35	Chinese	chinese	JJ	_	37	attr	_	_
36	Han	han	JJ	_	37	attr	_	_
37	population	population	NN	_	33	ppmod	_	_
38	.	.	.	_	1	p	_	_

1	Previous	previous	JJ	_	2	attr	_	_
2	studies	study	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	indicated	indicate	VBN	_	0	root	_	_
5	that	that	IN	_	12	mark	_	_
6	CMA1	cma0	NN	_	8	com	_	_
7	promoter	promoter	NN	_	8	com	_	_
8	polymorphism	polymorphism	NN	_	9	com	_	_
9	drug1	drug0	NN	_	12	dep	_	_
10	may	may	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	involved	involve	VBN	_	4	comp	_	_
13	in	in	IN	_	14	case	_	_
14	regulating	regulate	VBG	_	12	ppmod	_	_
15	immunoglobulin	immunoglobulin	NN	_	16	com	_	_
16	E	e	NN	_	20	attr	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	IgE	ige	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	levels	level	NNS	_	14	obj	_	_
21	in	in	IN	_	22	case	_	_
22	patients	patient	NNS	_	20	ppmod	_	_
23	with	with	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	,	,	,	_	12	p	_	_
26	and	and	CC	_	12	cc	_	_
27	it	it	PRP	_	29	dep	_	_
28	is	be	VBZ	_	29	aux	_	_
29	associated	associate	VBN	_	12	conj	_	_
30	with	with	IN	_	32	case	_	_
31	the	the	DT	_	32	det	_	_
32	progression	progression	NN	_	29	ppmod	_	_
33	of	of	IN	_	34	case	_	_
34	drug3	drug0	NN	_	32	ppmod	_	_
35	.	.	.	_	4	p	_	_

1	Polymorphism	polymorphism	NN	_	2	com	_	_
2	drug1	drug0	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	CMA1	cma0	NN	_	2	ppmod	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	associated	associate	VBN	_	0	root	_	_
8	with	with	IN	_	11	case	_	_
9	serum	serum	NN	_	11	com	_	_
10	IgE	ige	NN	_	11	com	_	_
11	level	level	NN	_	7	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	subjects	subject	NNS	_	11	ppmod	_	_
15	,	,	,	_	11	p	_	_
16	but	but	CC	_	11	cc	_	_
17	not	not	RB	_	20	neg	_	_
18	with	with	IN	_	20	case	_	_
19	chymase	chymase	NN	_	20	com	_	_
20	level	level	NN	_	11	conj	_	_
21	in	in	IN	_	23	case	_	_
22	both	both	DT	_	23	det	_	_
23	groups	group	NNS	_	20	ppmod	_	_
24	.	.	.	_	7	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Our	our	PRP$	_	4	poss	_	_
4	results	result	NNS	_	5	dep	_	_
5	suggest	suggest	VBP	_	1	acl	_	_
6	that	that	IN	_	12	mark	_	_
7	the	the	DT	_	10	det	_	_
8	CMA	cma	NN	_	10	com	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	polymorphism	polymorphism	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	associated	associate	VBN	_	5	comp	_	_
13	with	with	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	progression	progression	NN	_	12	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	drug2	drug0	NN	_	19	com	_	_
18	inKorean	inkorean	NN	_	19	com	_	_
19	patients	patient	NNS	_	15	ppmod	_	_
20	.	.	.	_	1	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	LEUVEN	leuven	NN	_	4	com	_	_
4	cohort	cohort	NN	_	15	ppmod	_	_
5	,	,	,	_	15	p	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	AA-carriers	aa-carriers	NNS	_	15	dep	_	_
8	and	and	CC	_	7	cc	_	_
9	rs8034191	rs0	NN	_	10	com	_	_
10	GG-carriers	gg-carriers	NNS	_	7	conj	_	_
11	had	have	VBD	_	15	lv	_	_
12	a	a	DT	_	15	det	_	_
13	two-fold	two-fold	RB	_	15	adv	_	_
14	increased	increase	VBN	_	15	attr	_	_
15	risk	risk	NN	_	0	root	_	_
16	to	to	TO	_	17	aux	_	_
17	suffer	suffer	VB	_	15	acl	_	_
18	from	from	IN	_	20	case	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	GOLD	gold	NN	_	17	ppmod	_	_
21	IV	iv	CD	_	20	num	_	_
22	(	-lrb-	-LRB-	_	15	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Results	result	NNS	_	4	dep	_	_
4	confirm	confirm	VBP	_	1	acl	_	_
5	previous	previous	JJ	_	6	attr	_	_
6	observations	observation	NNS	_	4	obj	_	_
7	of	of	IN	_	10	case	_	_
8	a	a	DT	_	10	det	_	_
9	significant	significant	JJ	_	10	attr	_	_
10	association	association	NN	_	6	ppmod	_	_
11	between	between	IN	_	16	case	_	_
12	the	the	DT	_	16	det	_	_
13	CMA1	cma0	NN	_	16	com	_	_
14	promoter	promoter	NN	_	16	com	_	_
15	polymorphism	polymorphism	NN	_	16	com	_	_
16	drug1	drug0	NN	_	10	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	atopic	atopic	JJ	_	19	attr	_	_
19	drug2	drug0	NN	_	16	conj	_	_
20	,	,	,	_	10	p	_	_
21	but	but	CC	_	10	cc	_	_
22	not	not	RB	_	21	com	_	_
23	with	with	IN	_	26	case	_	_
24	serum	serum	NN	_	26	com	_	_
25	IgE	ige	NN	_	26	com	_	_
26	levels	level	NNS	_	10	conj	_	_
27	,	,	,	_	26	p	_	_
28	and	and	CC	_	4	cc	_	_
29	support	support	VBP	_	4	conj	_	_
30	the	the	DT	_	31	det	_	_
31	hypothesis	hypothesis	NN	_	29	obj	_	_
32	that	that	IN	_	34	mark	_	_
33	CMA1	cma0	NN	_	34	dep	_	_
34	serves	serve	VBZ	_	31	acl	_	_
35	as	as	IN	_	37	case	_	_
36	candidate	candidate	NN	_	37	com	_	_
37	gene	gene	NN	_	34	ppmod	_	_
38	for	for	IN	_	40	case	_	_
39	atopic	atopic	JJ	_	40	attr	_	_
40	eczema	eczema	NN	_	37	ppmod	_	_
41	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	increased	increase	VBN	_	3	attr	_	_
3	risk	risk	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	brain	brain	NN	_	6	com	_	_
6	drug5	drug0	NN	_	3	ppmod	_	_
7	was	be	VBD	_	0	root	_	_
8	evident	evident	JJ	_	7	dep	_	_
9	for	for	IN	_	11	case	_	_
10	CYP1A1	cyp0a0	NN	_	11	com	_	_
11	drug1	drug0	NN	_	8	ppmod	_	_
12	(	-lrb-	-LRB-	_	25	p	_	_
13	P	p	NN	_	15	attr	_	_
14	=	=	JJ	_	15	attr	_	_
15	0.0028	0	NN	_	25	num	_	_
16	;	;	:	_	15	p	_	_
17	OR	or	CC	_	15	cc	_	_
18	=	=	JJ	_	23	attr	_	_
19	2.06	0	CD	_	21	num	_	_
20	;	;	:	_	21	p	_	_
21	95	0	CD	_	18	num	_	_
22	%	%	NN	_	21	meta	_	_
23	CI	ci	NN	_	15	conj	_	_
24	,	,	,	_	25	p	_	_
25	1.27-3.34	0	CD	_	11	num	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	and	and	CC	_	11	cc	_	_
28	minor	minor	JJ	_	29	attr	_	_
29	haplotypes	haplotype	NNS	_	11	conj	_	_
30	drug2	drug0	NN	_	29	appo	_	_
31	-	-	CC	_	30	cc	_	_
32	drug3	drug0	NN	_	30	conj	_	_
33	-	-	CC	_	32	cc	_	_
34	drug4	drug0	NN	_	32	conj	_	_
35	in	in	IN	_	36	case	_	_
36	females	female	NNS	_	32	ppmod	_	_
37	(	-lrb-	-LRB-	_	43	p	_	_
38	global	global	JJ	_	41	attr	_	_
39	haplotypeassociation	haplotypeassociation	NN	_	41	com	_	_
40	P	p	NN	_	41	com	_	_
41	value	value	NN	_	43	dep	_	_
42	,	,	,	_	43	p	_	_
43	0.0011	0	NN	_	36	num	_	_
44	)	-rrb-	-RRB-	_	43	p	_	_
45	.	.	.	_	7	p	_	_

1	Only	only	RB	_	2	adv	_	_
2	STK39	stk0	CD	_	3	num	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	was	be	VBD	_	6	aux	_	_
5	significantly	significantly	RB	_	6	adv	_	_
6	associated	associate	VBN	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	higher	high	JJR	_	9	attr	_	_
9	DBP	dbp	NN	_	6	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	P	p	NN	_	9	prn	_	_
12	=	=	JJ	_	11	attr	_	_
13	0.02	0	CD	_	11	num	_	_
14	)	-rrb-	-RRB-	_	11	p	_	_
15	in	in	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	drug2	drug0	JJ	_	18	attr	_	_
18	subjects	subject	NNS	_	9	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	association	association	NN	_	11	dep	_	_
3	between	between	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	susceptibility	susceptibility	NN	_	4	conj	_	_
8	has	have	VBZ	_	11	aux	_	_
9	been	be	VBN	_	11	aux	_	_
10	widely	widely	RB	_	11	adv	_	_
11	studied	study	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	polymorphism	polymorphism	NN	_	9	dep	_	_
5	of	of	IN	_	7	case	_	_
6	MTHFR	mthfr	NN	_	7	com	_	_
7	gene	gene	NN	_	4	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	increase	increase	VB	_	1	acl	_	_
10	the	the	DT	_	11	det	_	_
11	risk	risk	NN	_	9	obj	_	_
12	of	of	IN	_	14	case	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	cancer	cancer	NN	_	11	ppmod	_	_
15	in	in	IN	_	19	case	_	_
16	the	the	DT	_	19	det	_	_
17	complete	complete	JJ	_	19	attr	_	_
18	over-dominant	over-dominant	JJ	_	19	attr	_	_
19	model	model	NN	_	11	ppmod	_	_
20	.	.	.	_	1	p	_	_

1	The	the	DT	_	7	det	_	_
2	ACTN3	actn0	NN	_	7	attr	_	_
3	R577X	r0x	CD	_	7	num	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	drug1	drug0	NN	_	7	attr	_	_
6	)	-rrb-	-RRB-	_	7	p	_	_
7	polymorphism	polymorphism	NN	_	8	dep	_	_
8	determines	determine	VBZ	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	presence	presence	NN	_	8	obj	_	_
11	or	or	CC	_	10	cc	_	_
12	absence	absence	NN	_	10	conj	_	_
13	of	of	IN	_	15	case	_	_
14	functional	functional	JJ	_	15	attr	_	_
15	ACTN3	actn0	NN	_	10	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	which	which	WDT	_	19	dep	_	_
18	may	may	MD	_	19	modal	_	_
19	influence	influence	VB	_	15	relcl	_	_
20	the	the	DT	_	21	det	_	_
21	extent	extent	NN	_	19	obj	_	_
22	of	of	IN	_	24	case	_	_
23	exercise-induced	exercise-induced	JJ	_	24	attr	_	_
24	drug2	drug0	NNS	_	21	ppmod	_	_
25	.	.	.	_	8	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	conclude	conclude	VBP	_	0	root	_	_
3	that	that	IN	_	9	mark	_	_
4	HIF1A	hif0a	NN	_	6	com	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	polymorphism	polymorphism	NN	_	9	dep	_	_
7	by	by	IN	_	8	case	_	_
8	itself	itself	PRP	_	6	ppmod	_	_
9	is	be	VBZ	_	2	comp	_	_
10	not	not	RB	_	9	neg	_	_
11	critical	critical	JJ	_	9	dep	_	_
12	in	in	IN	_	13	case	_	_
13	determining	determine	VBG	_	11	ppmod	_	_
14	drug2	drug0	NN	_	13	obj	_	_
15	.	.	.	_	2	p	_	_

1	To	to	TO	_	2	aux	_	_
2	best	good	JJS	_	9	ppmod	_	_
3	of	of	IN	_	5	case	_	_
4	our	our	PRP$	_	5	poss	_	_
5	knowledge	knowledge	NN	_	2	ppmod	_	_
6	,	,	,	_	9	p	_	_
7	we	we	PRP	_	9	dep	_	_
8	first	#ord#	RB	_	9	adv	_	_
9	screened	screen	VBD	_	0	root	_	_
10	these	these	DT	_	11	det	_	_
11	variants	variant	NNS	_	9	obj	_	_
12	known	know	VBN	_	11	acl	_	_
13	to	to	TO	_	15	aux	_	_
14	be	be	VB	_	15	aux	_	_
15	associated	associate	VBN	_	12	comp	_	_
16	with	with	IN	_	18	case	_	_
17	drug10	drug0	NN	_	18	com	_	_
18	disease	disease	NN	_	15	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	E46K	e0k	NN	_	18	appo	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	drug1	drug0	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	in	in	IN	_	25	case	_	_
25	SNCA	snca	NN	_	20	ppmod	_	_
26	,	,	,	_	18	p	_	_
27	drug2	drug0	NN	_	18	appo	_	_
28	in	in	IN	_	29	case	_	_
29	LRRK2	lrrk0	NN	_	27	ppmod	_	_
30	,	,	,	_	29	p	_	_
31	drug3	drug0	NN	_	33	com	_	_
32	n	n	NN	_	33	com	_	_
33	PARK2	park0	NN	_	29	appo	_	_
34	,	,	,	_	29	p	_	_
35	drug4	drug0	NN	_	29	appo	_	_
36	in	in	IN	_	37	case	_	_
37	SLC41A1	slc0a0	NN	_	35	ppmod	_	_
38	,	,	,	_	29	p	_	_
39	drug5	drug0	NN	_	29	appo	_	_
40	,	,	,	_	29	p	_	_
41	drug6	drug0	NN	_	29	appo	_	_
42	,	,	,	_	29	p	_	_
43	G908R	g0r	NNP	_	29	appo	_	_
44	(	-lrb-	-LRB-	_	45	p	_	_
45	drug7	drug0	CD	_	43	num	_	_
46	)	-rrb-	-RRB-	_	45	p	_	_
47	,	,	,	_	29	p	_	_
48	1007fs	0fs	NN	_	29	appo	_	_
49	(	-lrb-	-LRB-	_	50	p	_	_
50	drug8	drug0	NN	_	48	prn	_	_
51	)	-rrb-	-RRB-	_	50	p	_	_
52	in	in	IN	_	53	case	_	_
53	NOD2	nod0	NN	_	27	ppmod	_	_
54	and	and	CC	_	53	cc	_	_
55	G2385R	g0r	NN	_	53	conj	_	_
56	(	-lrb-	-LRB-	_	57	p	_	_
57	drug9	drug0	NN	_	53	prn	_	_
58	)	-rrb-	-RRB-	_	57	p	_	_
59	in	in	IN	_	60	case	_	_
60	LRRK2	lrrk0	NN	_	53	ppmod	_	_
61	from	from	IN	_	64	case	_	_
62	southern	southern	NN	_	64	com	_	_
63	China	china	NN	_	64	com	_	_
64	population	population	NN	_	60	ppmod	_	_
65	.	.	.	_	9	p	_	_

1	drug5	drug0	NN	_	4	dep	_	_
2	were	be	VBD	_	4	aux	_	_
3	positively	positively	RB	_	4	adv	_	_
4	associated	associate	VBN	_	0	root	_	_
5	with	with	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	risk	risk	NN	_	8	com	_	_
8	alleles	allele	NNS	_	4	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	IL23R	il0r	NN	_	11	com	_	_
11	drug1	drug0	NN	_	8	ppmod	_	_
12	(	-lrb-	-LRB-	_	16	p	_	_
13	OR	or	CC	_	16	cc	_	_
14	=	=	JJ	_	16	attr	_	_
15	2.25	0	CD	_	14	num	_	_
16	-LSB-1.13-4.51	-lsb-0	CD	_	11	num	_	_
17	]	-rsb-	-RRB-	_	16	p	_	_
18	)	-rrb-	-RRB-	_	16	p	_	_
19	and	and	CC	_	11	cc	_	_
20	6q21	0q0	CD	_	21	num	_	_
21	drug2	drug0	NN	_	11	conj	_	_
22	(	-lrb-	-LRB-	_	26	p	_	_
23	OR	or	CC	_	26	cc	_	_
24	=	=	JJ	_	26	attr	_	_
25	1.60	0	CD	_	24	num	_	_
26	-LSB-1.10-2.34	-lsb-0	CD	_	21	num	_	_
27	]	-rsb-	-RRB-	_	26	p	_	_
28	and	and	CC	_	4	cc	_	_
29	negatively	negatively	RB	_	30	adv	_	_
30	associated	associate	VBN	_	4	conj	_	_
31	with	with	IN	_	34	case	_	_
32	the	the	DT	_	34	det	_	_
33	risk	risk	NN	_	34	com	_	_
34	alleles	allele	NNS	_	30	ppmod	_	_
35	of	of	IN	_	37	case	_	_
36	IRGM	irgm	NN	_	37	com	_	_
37	drug3	drug0	NN	_	34	ppmod	_	_
38	(	-lrb-	-LRB-	_	42	p	_	_
39	OR	or	CC	_	42	cc	_	_
40	=	=	JJ	_	42	attr	_	_
41	0.29	0	CD	_	40	num	_	_
42	-LSB-0.11-0.74	-lsb-0	CD	_	37	num	_	_
43	]	-rsb-	-RRB-	_	42	p	_	_
44	)	-rrb-	-RRB-	_	42	p	_	_
45	and	and	CC	_	37	cc	_	_
46	DEFB1	defb0	NN	_	47	com	_	_
47	drug4	drug0	NN	_	37	conj	_	_
48	(	-lrb-	-LRB-	_	52	p	_	_
49	OR	or	CC	_	52	cc	_	_
50	=	=	JJ	_	52	attr	_	_
51	0.50	0	CD	_	50	num	_	_
52	-LSB-0.30-0.80	-lsb-0	CD	_	47	num	_	_
53	]	-rsb-	-RRB-	_	52	p	_	_
54	)	-rrb-	-RRB-	_	52	p	_	_
55	.	.	.	_	4	p	_	_

1	In	in	IN	_	4	case	_	_
2	genotype-association	genotype-association	NN	_	4	com	_	_
3	SNP	snp	NN	_	4	com	_	_
4	analysis	analysis	NN	_	23	ppmod	_	_
5	,	,	,	_	23	p	_	_
6	all	all	DT	_	8	det	_	_
7	NOD2	nod0	NN	_	8	com	_	_
8	SNPs	snp	NNS	_	23	dep	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	drug1	drug0	NN	_	8	prn	_	_
11	,	,	,	_	10	p	_	_
12	drug2	drug0	NN	_	10	appo	_	_
13	,	,	,	_	10	p	_	_
14	drug3	drug0	NN	_	10	appo	_	_
15	)	-rrb-	-RRB-	_	10	p	_	_
16	and	and	CC	_	8	cc	_	_
17	the	the	DT	_	19	det	_	_
18	IL23r	il0r	NN	_	19	com	_	_
19	SNP	snp	NN	_	8	conj	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	drug4	drug0	NN	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	showed	show	VBD	_	0	root	_	_
24	a	a	DT	_	26	det	_	_
25	significant	significant	JJ	_	26	attr	_	_
26	association	association	NN	_	23	obj	_	_
27	to	to	TO	_	28	aux	_	_
28	drug5	drug0	NN	_	26	ppmod	_	_
29	(	-lrb-	-LRB-	_	31	p	_	_
30	p	p	NN	_	31	com	_	_
31	<	<	NN	_	28	prn	_	_
32	0.03	0	CD	_	31	num	_	_
33	)	-rrb-	-RRB-	_	31	p	_	_
34	.	.	.	_	23	p	_	_

1	Three	#crd#	CD	_	3	num	_	_
2	NOD2/CARD15	nod0/card0	NN	_	3	com	_	_
3	variants	variant	NNS	_	21	dep	_	_
4	,	,	,	_	3	p	_	_
5	namely	namely	RB	_	8	adv	_	_
6	two	#crd#	CD	_	8	num	_	_
7	missense	missense	NN	_	8	com	_	_
8	polymorphisms	polymorphism	NNS	_	3	conj	_	_
9	drug1	drug0	NN	_	8	attr	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	,	,	,	_	8	p	_	_
13	and	and	CC	_	8	cc	_	_
14	a	a	DT	_	16	det	_	_
15	frame	frame	NN	_	16	com	_	_
16	shift	shift	NN	_	18	com	_	_
17	polymorphism	polymorphism	NN	_	18	com	_	_
18	drug3	drug0	NN	_	3	conj	_	_
19	,	,	,	_	18	p	_	_
20	were	be	VBD	_	21	aux	_	_
21	associated	associate	VBN	_	0	root	_	_
22	with	with	IN	_	23	case	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	in	in	IN	_	26	case	_	_
25	Caucasian	caucasian	NN	_	26	com	_	_
26	populations	population	NNS	_	23	ppmod	_	_
27	.	.	.	_	21	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	analysis	analysis	NN	_	3	dep	_	_
3	revealed	reveal	VBD	_	0	root	_	_
4	that	that	IN	_	29	mark	_	_
5	effects	effect	NNS	_	29	dep	_	_
6	of	of	IN	_	9	case	_	_
7	two	#crd#	CD	_	9	num	_	_
8	linked	linked	JJ	_	9	attr	_	_
9	variants	variant	NNS	_	5	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug1	drug0	NN	_	9	prn	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	)	-rrb-	-RRB-	_	11	p	_	_
15	in	in	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	AGPHD1/CHRNA3	agphd0/chrna0	NN	_	18	com	_	_
18	cluster	cluster	NN	_	9	ppmod	_	_
19	on	on	IN	_	21	case	_	_
20	drug3	drug0	NN	_	21	com	_	_
21	development	development	NN	_	5	ppmod	_	_
22	are	be	VBP	_	29	aux	_	_
23	significantly	significantly	RB	_	29	adv	_	_
24	,	,	,	_	29	p	_	_
25	yet	yet	RB	_	29	adv	_	_
26	not	not	RB	_	29	neg	_	_
27	entirely	entirely	RB	_	29	adv	_	_
28	,	,	,	_	29	p	_	_
29	mediated	mediate	VBN	_	3	comp	_	_
30	by	by	IN	_	33	case	_	_
31	the	the	DT	_	33	det	_	_
32	smoking-related	smoking-related	JJ	_	33	attr	_	_
33	phenotypes	phenotype	NNS	_	29	ppmod	_	_

1	In	in	IN	_	3	case	_	_
2	association	association	NN	_	3	com	_	_
3	analysis	analysis	NN	_	6	ppmod	_	_
4	,	,	,	_	6	p	_	_
5	we	we	PRP	_	6	dep	_	_
6	found	find	VBD	_	0	root	_	_
7	statistically	statistically	RB	_	8	adv	_	_
8	significant	significant	JJ	_	9	attr	_	_
9	association	association	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	p	p	NN	_	11	prn	_	_
14	=0.001	0	NN	_	13	num	_	_
15	,	,	,	_	13	p	_	_
16	OR=3.011	or=0	NN	_	13	attr	_	_
17	,	,	,	_	13	p	_	_
18	CI95	ci0	CD	_	20	num	_	_
19	%	%	NN	_	20	meta	_	_
20	=1.494-6.071	0	CD	_	13	num	_	_
21	)	-rrb-	-RRB-	_	13	p	_	_
22	and	and	CC	_	11	cc	_	_
23	drug2	drug0	NN	_	40	attr	_	_
24	(	-lrb-	-LRB-	_	30	p	_	_
25	p=2.62	p=0	CD	_	30	num	_	_
26	*	*	NN	_	30	attr	_	_
27	10<formula>^	0<formula>^	NN	_	30	attr	_	_
28	{	-lcb-	NN	_	30	attr	_	_
29	-4	0	CD	_	30	num	_	_
30	}	-rcb-	NN	_	23	prn	_	_
31	</formula>	</formula>	CD	_	30	num	_	_
32	,	,	,	_	30	p	_	_
33	OR=14.117	or=0	CD	_	30	num	_	_
34	,	,	,	_	30	p	_	_
35	CI95	ci0	CD	_	37	num	_	_
36	%	%	NN	_	35	meta	_	_
37	=	=	JJ	_	30	advcl	_	_
38	1.884-105.799	0	CD	_	37	obj	_	_
39	)	-rrb-	-RRB-	_	30	p	_	_
40	polymorphisms	polymorphism	NNS	_	11	conj	_	_
41	with	with	IN	_	43	case	_	_
42	drug3	drug0	NN	_	43	com	_	_
43	patients	patient	NNS	_	9	ppmod	_	_
44	.	.	.	_	6	p	_	_

1	Whereas	whereas	IN	_	9	mark	_	_
2	the	the	DT	_	4	det	_	_
3	NOD2	nod0	NN	_	4	com	_	_
4	genotype	genotype	NN	_	9	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	are	be	VBP	_	9	aux	_	_
8	positively	positively	RB	_	9	adv	_	_
9	associated	associate	VBN	_	18	advcl	_	_
10	with	with	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	18	p	_	_
13	the	the	DT	_	15	det	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	genotype	genotype	NN	_	18	dep	_	_
16	is	be	VBZ	_	18	aux	_	_
17	positively	positively	RB	_	18	adv	_	_
18	associated	associate	VBN	_	0	root	_	_
19	with	with	IN	_	24	case	_	_
20	drug4	drug0	NN	_	24	attr	_	_
21	(	-lrb-	-LRB-	_	24	p	_	_
22	L2	l0	NN	_	24	attr	_	_
23	)	-rrb-	-RRB-	_	24	p	_	_
24	disease	disease	NN	_	18	ppmod	_	_
25	.	.	.	_	18	p	_	_

1	The	the	DT	_	2	det	_	_
2	association	association	NN	_	19	dep	_	_
3	between	between	IN	_	12	case	_	_
4	the	the	DT	_	12	det	_	_
5	Serine/threonine	serine/threonine	NN	_	12	attr	_	_
6	kinase	kinase	NN	_	12	attr	_	_
7	15	0	CD	_	12	num	_	_
8	(	-lrb-	-LRB-	_	12	p	_	_
9	STK15	stk0	NN	_	12	attr	_	_
10	)	-rrb-	-RRB-	_	12	p	_	_
11	F31I	f0i	NN	_	12	com	_	_
12	polymorphism	polymorphism	NN	_	2	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug1	drug0	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	and	and	CC	_	12	cc	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	susceptibility	susceptibility	NN	_	12	conj	_	_
19	remains	remain	VBZ	_	0	root	_	_
20	controversial	controversial	JJ	_	19	dep	_	_
21	.	.	.	_	19	p	_	_

1	Stratified	stratified	JJ	_	2	attr	_	_
2	analysis	analysis	NN	_	6	dep	_	_
3	by	by	IN	_	5	case	_	_
4	drug2	drug0	NN	_	5	com	_	_
5	type	type	NN	_	2	ppmod	_	_
6	revealed	reveal	VBD	_	0	root	_	_
7	that	that	IN	_	13	mark	_	_
8	the	the	DT	_	11	det	_	_
9	STK	stk	NN	_	11	com	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	polymorphism	polymorphism	NN	_	13	dep	_	_
12	may	may	MD	_	13	modal	_	_
13	contribute	contribute	VB	_	6	comp	_	_
14	to	to	TO	_	16	aux	_	_
15	the	the	DT	_	16	det	_	_
16	risk	risk	NN	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	CD	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	30	p	_	_
20	AA	aa	NN	_	30	dep	_	_
21	vs.	vs.	CC	_	20	cc	_	_
22	TT	tt	NN	_	20	conj	_	_
23	:	:	:	_	30	p	_	_
24	OR=1.21	or=0	CD	_	30	num	_	_
25	,	,	,	_	30	p	_	_
26	95	0	CD	_	28	num	_	_
27	%	%	NN	_	28	meta	_	_
28	CI=1.01-1.44	ci=0	CD	_	30	num	_	_
29	,	,	,	_	30	p	_	_
30	Pheterogeneity=0.002	pheterogeneity=0	CD	_	18	num	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	,	,	,	_	18	p	_	_
33	drug4	drug0	CD	_	18	conj	_	_
34	(	-lrb-	-LRB-	_	45	p	_	_
35	AA	aa	NN	_	45	dep	_	_
36	vs.	vs.	CC	_	35	cc	_	_
37	UNASSIGNED	unassigned	JJ	_	35	conj	_	_
38	:	:	:	_	45	p	_	_
39	OR=1.24	or=0	CD	_	45	num	_	_
40	,	,	,	_	45	p	_	_
41	95	0	CD	_	43	num	_	_
42	%	%	NN	_	43	meta	_	_
43	CI=1.05-1.47	ci=0	CD	_	45	num	_	_
44	,	,	,	_	45	p	_	_
45	Pheterogeneity=0.124	pheterogeneity=0	CD	_	33	num	_	_
46	)	-rrb-	-RRB-	_	45	p	_	_
47	,	,	,	_	33	p	_	_
48	and	and	CC	_	33	cc	_	_
49	drug5	drug0	CD	_	18	conj	_	_
50	(	-lrb-	-LRB-	_	61	p	_	_
51	AA	aa	NN	_	61	dep	_	_
52	vs.	vs.	CC	_	51	cc	_	_
53	UNASSIGNED	unassigned	JJ	_	51	conj	_	_
54	:	:	:	_	61	p	_	_
55	OR=1.19	or=0	NN	_	61	dep	_	_
56	,	,	,	_	55	p	_	_
57	95	0	CD	_	59	num	_	_
58	%	%	NN	_	59	meta	_	_
59	CI=1.02-1.39	ci=0	CD	_	55	appo	_	_
60	,	,	,	_	61	p	_	_
61	Pheterogeneity=0.148	pheterogeneity=0	CD	_	49	num	_	_
62	)	-rrb-	-RRB-	_	61	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	showed	show	VBD	_	0	root	_	_
4	that	that	IN	_	104	mark	_	_
5	four	#crd#	CD	_	6	num	_	_
6	SNPs	snp	NNS	_	104	dep	_	_
7	in	in	IN	_	8	case	_	_
8	AURKA	aurka	NN	_	6	ppmod	_	_
9	(	-lrb-	-LRB-	_	75	p	_	_
10	data	datum	NNS	_	75	dep	_	_
11	in	in	IN	_	13	case	_	_
12	recessive	recessive	JJ	_	13	attr	_	_
13	model	model	NN	_	10	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug1	drug0	NN	_	13	appo	_	_
16	:	:	:	_	15	p	_	_
17	OR	or	CC	_	15	cc	_	_
18	=	=	JJ	_	19	attr	_	_
19	2.19	0	NN	_	15	conj	_	_
20	,	,	,	_	75	p	_	_
21	95	0	CD	_	23	num	_	_
22	%	%	NN	_	23	meta	_	_
23	CI	ci	NN	_	75	dep	_	_
24	=	=	JJ	_	23	attr	_	_
25	1.03-4.66	0	CD	_	23	num	_	_
26	,	,	,	_	75	p	_	_
27	p	p	NN	_	75	dep	_	_
28	=	=	JJ	_	27	attr	_	_
29	0.0422	0	CD	_	27	num	_	_
30	;	;	:	_	27	p	_	_
31	drug2	drug0	NN	_	27	conj	_	_
32	:	:	:	_	31	p	_	_
33	OR	or	CC	_	31	cc	_	_
34	=	=	JJ	_	41	attr	_	_
35	0.38	0	CD	_	39	num	_	_
36	,	,	,	_	39	p	_	_
37	95	0	CD	_	39	num	_	_
38	%	%	NN	_	39	meta	_	_
39	CI	ci	CD	_	34	num	_	_
40	=	=	JJ	_	41	attr	_	_
41	0.18-0.82	0	NN	_	27	conj	_	_
42	,	,	,	_	41	p	_	_
43	p	p	NN	_	27	conj	_	_
44	=	=	JJ	_	43	attr	_	_
45	0.0141	0	CD	_	43	num	_	_
46	;	;	:	_	43	p	_	_
47	drug3	drug0	NN	_	27	conj	_	_
48	:	:	:	_	47	p	_	_
49	OR	or	CC	_	47	cc	_	_
50	=	=	JJ	_	55	attr	_	_
51	1.54	0	CD	_	55	num	_	_
52	,	,	,	_	55	p	_	_
53	95	0	CD	_	55	num	_	_
54	%	%	NN	_	55	meta	_	_
55	CI	ci	CD	_	27	conj	_	_
56	=	=	JJ	_	27	attr	_	_
57	1.18-2.00	0	CD	_	56	num	_	_
58	,	,	,	_	57	p	_	_
59	p	p	NN	_	57	appo	_	_
60	=	=	JJ	_	59	attr	_	_
61	0.0014	0	CD	_	59	num	_	_
62	;	;	:	_	59	p	_	_
63	drug4	drug0	NN	_	59	conj	_	_
64	:	:	:	_	63	p	_	_
65	OR	or	CC	_	63	cc	_	_
66	=	=	JJ	_	73	attr	_	_
67	0.68	0	CD	_	71	num	_	_
68	,	,	,	_	71	p	_	_
69	95	0	CD	_	71	num	_	_
70	%	%	NN	_	71	meta	_	_
71	CI	ci	CD	_	66	num	_	_
72	=	=	JJ	_	73	attr	_	_
73	0.47-0.98	0	NN	_	59	conj	_	_
74	,	,	,	_	75	p	_	_
75	p	p	NN	_	8	prn	_	_
76	=	=	JJ	_	75	attr	_	_
77	0.0380	0	CD	_	75	num	_	_
78	)	-rrb-	-RRB-	_	75	p	_	_
79	and	and	CC	_	8	cc	_	_
80	one	#crd#	CD	_	81	num	_	_
81	SNP	snp	NN	_	8	conj	_	_
82	in	in	IN	_	83	case	_	_
83	BRCA1	brca0	NN	_	81	ppmod	_	_
84	(	-lrb-	-LRB-	_	99	p	_	_
85	drug5	drug0	NN	_	99	dep	_	_
86	,	,	,	_	85	p	_	_
87	dominant	dominant	JJ	_	88	attr	_	_
88	model	model	NN	_	85	conj	_	_
89	OR	or	CC	_	88	cc	_	_
90	=	=	JJ	_	95	attr	_	_
91	1.35	0	CD	_	93	num	_	_
92	,	,	,	_	93	p	_	_
93	95	0	CD	_	90	num	_	_
94	%	%	NN	_	93	meta	_	_
95	CI	ci	NN	_	85	conj	_	_
96	=	=	JJ	_	95	attr	_	_
97	1.11-1.64	0	CD	_	95	num	_	_
98	,	,	,	_	99	p	_	_
99	p	p	NN	_	81	prn	_	_
100	=	=	JJ	_	99	attr	_	_
101	0.0030	0	CD	_	99	num	_	_
102	)	-rrb-	-RRB-	_	99	p	_	_
103	were	be	VBD	_	104	aux	_	_
104	associated	associate	VBN	_	3	comp	_	_
105	with	with	IN	_	107	case	_	_
106	drug6	drug0	NN	_	107	com	_	_
107	susceptibility	susceptibility	NN	_	104	ppmod	_	_
108	.	.	.	_	3	p	_	_

1	METHODS	method	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Six	#crd#	CD	_	6	num	_	_
4	single	single	JJ	_	6	attr	_	_
5	nucleotide	nucleotide	NN	_	6	com	_	_
6	polymorphisms	polymorphism	NNS	_	44	dep	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	SNPs	snp	NNS	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	AURKA	aurka	NN	_	6	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug1	drug0	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	,	,	,	_	12	p	_	_
17	ERBB2	erbb0	NN	_	12	conj	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	drug2	drug0	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	,	,	,	_	17	p	_	_
22	MDM2	mdm0	NN	_	12	conj	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	drug3	drug0	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	,	,	,	_	22	p	_	_
27	CDH1	cdh0	NN	_	12	conj	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	drug4	drug0	NN	_	27	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	,	,	,	_	27	p	_	_
32	CDKN2A	cdkn0a	NN	_	12	conj	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	drug5	drug0	NN	_	32	prn	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	,	,	,	_	32	p	_	_
37	and	and	CC	_	32	cc	_	_
38	TP73	tp0	CD	_	42	num	_	_
39	(	-lrb-	-LRB-	_	40	p	_	_
40	drug6	drug0	NN	_	42	prn	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	genes	gene	NNS	_	12	conj	_	_
43	were	be	VBD	_	44	aux	_	_
44	genotyped	genotyped	VBN	_	1	acl	_	_
45	in	in	IN	_	48	case	_	_
46	a	a	DT	_	48	det	_	_
47	consecutive	consecutive	JJ	_	48	attr	_	_
48	cohort	cohort	NN	_	44	ppmod	_	_
49	of	of	IN	_	52	case	_	_
50	346	0	CD	_	52	num	_	_
51	drug7	drug0	NN	_	52	com	_	_
52	patients	patient	NNS	_	48	ppmod	_	_
53	,	,	,	_	48	p	_	_
54	who	who	WP	_	56	dep	_	_
55	had	have	VBD	_	56	aux	_	_
56	underwent	undergo	VBD	_	48	relcl	_	_
57	surgical	surgical	JJ	_	58	attr	_	_
58	resection	resection	NN	_	56	obj	_	_
59	with	with	IN	_	61	case	_	_
60	curative	curative	JJ	_	61	attr	_	_
61	intent	intent	NN	_	58	ppmod	_	_
62	.	.	.	_	1	p	_	_

1	However	however	RB	_	22	adv	_	_
2	,	,	,	_	22	p	_	_
3	in	in	IN	_	6	case	_	_
4	a	a	DT	_	6	det	_	_
5	multivariate	multivariate	JJ	_	6	attr	_	_
6	analysis	analysis	NN	_	22	ppmod	_	_
7	,	,	,	_	22	p	_	_
8	patients	patient	NNS	_	22	dep	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NNS	_	8	ppmod	_	_
11	carrying	carry	VBG	_	10	acl	_	_
12	the	the	DT	_	19	det	_	_
13	heterozygous	heterozygous	JJ	_	19	attr	_	_
14	MDM2	mdm0	NN	_	19	attr	_	_
15	(	-lrb-	-LRB-	_	19	p	_	_
16	drug1	drug0	NN	_	19	attr	_	_
17	)	-rrb-	-RRB-	_	19	p	_	_
18	T/G	t/g	NN	_	19	com	_	_
19	genotype	genotype	NN	_	11	obj	_	_
20	had	have	VBD	_	22	aux	_	_
21	significantly	significantly	RB	_	22	adv	_	_
22	improved	improve	VBD	_	0	root	_	_
23	DFS	dfs	NN	_	22	obj	_	_
24	compared	compare	VBN	_	26	adv	_	_
25	with	with	IN	_	26	case	_	_
26	patients	patient	NNS	_	22	ppmod	_	_
27	carrying	carry	VBG	_	26	acl	_	_
28	the	the	DT	_	30	det	_	_
29	wild-type	wild-type	JJ	_	30	attr	_	_
30	genotype	genotype	NN	_	27	obj	_	_
31	(	-lrb-	-LRB-	_	34	p	_	_
32	adjusted	adjust	VBN	_	34	attr	_	_
33	hazard	hazard	NN	_	34	com	_	_
34	ratio	ratio	NN	_	30	prn	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	AHR	ahr	NN	_	34	prn	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	,	,	,	_	34	p	_	_
39	0.63	0	CD	_	34	appo	_	_
40	;	;	:	_	34	p	_	_
41	95	0	CD	_	44	num	_	_
42	%	%	NN	_	41	meta	_	_
43	confidence	confidence	NN	_	44	com	_	_
44	interval	interval	NN	_	34	appo	_	_
45	(	-lrb-	-LRB-	_	46	p	_	_
46	CI	ci	NNP	_	44	prn	_	_
47	)	-rrb-	-RRB-	_	46	p	_	_
48	-LSB-0.45-0.88	-lsb-0	CD	_	46	num	_	_
49	]	-rsb-	-RRB-	_	46	p	_	_
50	)	-rrb-	-RRB-	_	34	p	_	_
51	.	.	.	_	22	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	43	ppmod	_	_
3	,	,	,	_	43	p	_	_
4	higher	high	JJR	_	5	attr	_	_
5	frequencies	frequency	NNS	_	43	dep	_	_
6	of	of	IN	_	11	case	_	_
7	the	the	DT	_	11	det	_	_
8	MMP1	mmp0	NN	_	11	com	_	_
9	drug1	drug0	NN	_	11	com	_	_
10	2G	0g	NN	_	11	com	_	_
11	allele	allele	NN	_	5	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	p	p	NN	_	11	prn	_	_
14	=	=	VBG	_	13	acl	_	_
15	0.017	0	CD	_	14	obj	_	_
16	,	,	,	_	13	p	_	_
17	OR	or	CC	_	13	cc	_	_
18	1.49	0	CD	_	22	num	_	_
19	,	,	,	_	22	p	_	_
20	95	0	CD	_	22	num	_	_
21	%	%	NN	_	22	meta	_	_
22	CI	ci	NN	_	13	conj	_	_
23	1.06-2.08	0	CD	_	22	num	_	_
24	)	-rrb-	-RRB-	_	13	p	_	_
25	and	and	CC	_	11	cc	_	_
26	the	the	DT	_	32	det	_	_
27	MMP1/MMP3	mmp0/mmp0	NN	_	32	attr	_	_
28	drug2	drug0	NN	_	32	attr	_	_
29	/	/	:	_	32	p	_	_
30	drug3	drug0	NN	_	32	com	_	_
31	2G/G	0g/g	NN	_	32	com	_	_
32	haplotype	haplotype	NN	_	11	conj	_	_
33	(	-lrb-	-LRB-	_	35	p	_	_
34	OR	or	CC	_	35	cc	_	_
35	1.45	0	NN	_	32	num	_	_
36	,	,	,	_	35	p	_	_
37	95	0	CD	_	40	num	_	_
38	%	%	NN	_	40	meta	_	_
39	CI	ci	JJ	_	40	attr	_	_
40	1.01-2.10	0	CD	_	35	appo	_	_
41	)	-rrb-	-RRB-	_	35	p	_	_
42	were	be	VBD	_	43	aux	_	_
43	detected	detect	VBN	_	0	root	_	_
44	in	in	IN	_	46	case	_	_
45	drug4	drug0	NN	_	46	com	_	_
46	patients	patient	NNS	_	43	ppmod	_	_
47	than	than	IN	_	49	case	_	_
48	in	in	IN	_	49	case	_	_
49	controls	control	NNS	_	46	ppmod	_	_
50	(	-lrb-	-LRB-	_	51	p	_	_
51	n	n	NN	_	49	prn	_	_
52	=	=	JJ	_	51	attr	_	_
53	295	0	CD	_	51	num	_	_
54	)	-rrb-	-RRB-	_	51	p	_	_
55	.	.	.	_	43	p	_	_

1	The	the	DT	_	2	det	_	_
2	presence	presence	NN	_	13	dep	_	_
3	of	of	IN	_	8	case	_	_
4	the	the	DT	_	8	det	_	_
5	variant	variant	JJ	_	8	attr	_	_
6	allele	allele	NN	_	8	com	_	_
7	TNFA	tnfa	NN	_	8	com	_	_
8	c.-238A	c.-0a	NN	_	2	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	drug1	drug0	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	was	be	VBD	_	13	aux	_	_
13	associated	associate	VBN	_	0	root	_	_
14	with	with	IN	_	17	case	_	_
15	lower	low	JJR	_	17	attr	_	_
16	serum	serum	NN	_	17	com	_	_
17	levels	level	NNS	_	13	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	TNF-a	tnf-a	NN	_	17	ppmod	_	_
20	,	,	,	_	17	p	_	_
21	and	and	CC	_	17	cc	_	_
22	with	with	IN	_	25	case	_	_
23	significantly	significantly	RB	_	24	adv	_	_
24	decreased	decrease	VBN	_	25	attr	_	_
25	risk	risk	NN	_	17	conj	_	_
26	of	of	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	in	in	IN	_	30	case	_	_
29	both	both	DT	_	30	det	_	_
30	cohorts	cohort	NNS	_	27	ppmod	_	_
31	.	.	.	_	13	p	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Evidence	evidence	NN	_	5	dep	_	_
4	has	have	VBZ	_	5	aux	_	_
5	suggested	suggest	VBN	_	1	acl	_	_
6	that	that	IN	_	16	mark	_	_
7	tumour	tumour	NN	_	9	com	_	_
8	necrosis	necrosis	NN	_	9	com	_	_
9	factor	factor	NN	_	13	attr	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	TNF	tnf	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	-a	-a	NN	_	16	dep	_	_
14	may	may	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	involved	involve	VBN	_	5	comp	_	_
17	in	in	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	aetiology	aetiology	NN	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	psoriasis	psoriasis	NN	_	19	ppmod	_	_
22	,	,	,	_	16	p	_	_
23	but	but	CC	_	16	cc	_	_
24	the	the	DT	_	26	det	_	_
25	underlying	underlying	JJ	_	26	attr	_	_
26	association	association	NN	_	47	dep	_	_
27	of	of	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	TNF-a	tnf-a	NN	_	30	com	_	_
30	polymorphisms	polymorphism	NNS	_	26	ppmod	_	_
31	-238G/A	0g/a	NN	_	30	attr	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	drug1	drug0	NN	_	31	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	and	and	CC	_	31	cc	_	_
36	-308G/A	0g/a	NN	_	31	conj	_	_
37	(	-lrb-	-LRB-	_	38	p	_	_
38	drug2	drug0	NN	_	36	prn	_	_
39	)	-rrb-	-RRB-	_	38	p	_	_
40	with	with	IN	_	42	case	_	_
41	the	the	DT	_	42	det	_	_
42	risk	risk	NN	_	26	ppmod	_	_
43	of	of	IN	_	44	case	_	_
44	drug3	drug0	NN	_	42	ppmod	_	_
45	is	be	VBZ	_	47	aux	_	_
46	still	still	RB	_	47	adv	_	_
47	unconfirmed	unconfirmed	VBN	_	16	conj	_	_
48	.	.	.	_	1	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Risk	risk	NN	_	4	com	_	_
4	alleles	allele	NNS	_	14	dep	_	_
5	previously	previously	RB	_	6	adv	_	_
6	associated	associate	VBN	_	4	acl	_	_
7	with	with	IN	_	8	case	_	_
8	drug5	drug0	NN	_	6	ppmod	_	_
9	were	be	VBD	_	14	aux	_	_
10	significantly	significantly	RB	_	14	adv	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	P<0.05	p<0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	associated	associate	VBN	_	1	acl	_	_
15	with	with	IN	_	17	case	_	_
16	reduced	reduce	VBN	_	17	attr	_	_
17	abstinence	abstinence	NN	_	14	ppmod	_	_
18	in	in	IN	_	22	case	_	_
19	the	the	DT	_	22	det	_	_
20	PLA	pla	NN	_	22	com	_	_
21	pharmacotherapy	pharmacotherapy	NN	_	22	com	_	_
22	group	group	NN	_	17	ppmod	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	PG	pg	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	at	at	IN	_	29	case	_	_
27	6MO	0mo	NN	_	29	com	_	_
28	-LSB-for	-lsb-for	NN	_	29	com	_	_
29	drug1	drug0	NN	_	22	ppmod	_	_
30	,	,	,	_	29	p	_	_
31	odds	odds	NNS	_	32	com	_	_
32	ratio	ratio	NN	_	29	appo	_	_
33	(	-lrb-	-LRB-	_	41	p	_	_
34	95	0	CD	_	37	num	_	_
35	%	%	NN	_	37	meta	_	_
36	confidence	confidence	NN	_	37	com	_	_
37	interval	interval	NN	_	41	dep	_	_
38	)	-rrb-	-RRB-	_	41	p	_	_
39	0.41	0	CD	_	41	num	_	_
40	(	-lrb-	-LRB-	_	41	p	_	_
41	0.17-0.99	0	CD	_	32	num	_	_
42	)	-rrb-	-RRB-	_	41	p	_	_
43	]	-rsb-	-RRB-	_	41	p	_	_
44	,	,	,	_	29	p	_	_
45	and	and	CC	_	22	cc	_	_
46	at	at	IN	_	47	case	_	_
47	end	end	NN	_	22	conj	_	_
48	of	of	IN	_	49	case	_	_
49	treatment	treatment	NN	_	47	ppmod	_	_
50	and	and	CC	_	17	cc	_	_
51	at	at	IN	_	54	case	_	_
52	6MO	0mo	NN	_	54	com	_	_
53	-LSB-for	-lsb-for	NN	_	54	com	_	_
54	drug2	drug0	NN	_	17	conj	_	_
55	,	,	,	_	54	p	_	_
56	0.42	0	CD	_	58	num	_	_
57	(	-lrb-	-LRB-	_	58	p	_	_
58	0.19-0.93	0	CD	_	54	appo	_	_
59	)	-rrb-	-RRB-	_	58	p	_	_
60	and	and	CC	_	58	cc	_	_
61	0.31	0	CD	_	63	num	_	_
62	(	-lrb-	-LRB-	_	63	p	_	_
63	0.12-0.80	0	CD	_	58	conj	_	_
64	)	-rrb-	-RRB-	_	63	p	_	_
65	]	-rsb-	-RRB-	_	54	p	_	_
66	,	,	,	_	90	p	_	_
67	and	and	CC	_	70	cc	_	_
68	with	with	IN	_	70	case	_	_
69	increased	increase	VBN	_	70	attr	_	_
70	abstinence	abstinence	NN	_	90	ppmod	_	_
71	in	in	IN	_	74	case	_	_
72	the	the	DT	_	74	det	_	_
73	NRT	nrt	NN	_	74	com	_	_
74	PG	pg	NN	_	70	ppmod	_	_
75	at	at	IN	_	78	case	_	_
76	6MO	0mo	NN	_	78	com	_	_
77	-LSB-for	-lsb-for	NN	_	78	com	_	_
78	drug3	drug0	NN	_	70	ppmod	_	_
79	,	,	,	_	70	p	_	_
80	2.07	0	CD	_	70	appo	_	_
81	(	-lrb-	-LRB-	_	82	p	_	_
82	1.11-3.87	0	CD	_	80	num	_	_
83	)	-rrb-	-RRB-	_	82	p	_	_
84	and	and	CC	_	70	cc	_	_
85	for	for	IN	_	86	case	_	_
86	drug4	drug0	NN	_	70	conj	_	_
87	,	,	,	_	90	p	_	_
88	2.54	0	CD	_	90	num	_	_
89	(	-lrb-	-LRB-	_	90	p	_	_
90	1.29-4.99	0	CD	_	14	num	_	_
91	)	-rrb-	-RRB-	_	90	p	_	_
92	]	-rsb-	-RRB-	_	90	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	This	this	DT	_	4	det	_	_
4	meta-analysis	meta-analysis	NN	_	5	dep	_	_
5	suggests	suggest	VBZ	_	1	acl	_	_
6	that	that	IN	_	14	mark	_	_
7	the	the	DT	_	12	det	_	_
8	drug1	drug0	NN	_	12	attr	_	_
9	and	and	CC	_	8	cc	_	_
10	-308	0	CD	_	8	conj	_	_
11	promoter	promoter	NN	_	12	com	_	_
12	polymorphisms	polymorphism	NNS	_	14	dep	_	_
13	may	may	MD	_	14	modal	_	_
14	play	play	VB	_	5	comp	_	_
15	different	different	JJ	_	16	attr	_	_
16	roles	role	NNS	_	14	obj	_	_
17	in	in	IN	_	18	case	_	_
18	conferring	confer	VBG	_	14	ppmod	_	_
19	susceptibility	susceptibility	NN	_	18	obj	_	_
20	to	to	TO	_	21	aux	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	genotyped	genotyped	VBN	_	0	root	_	_
3	and	and	CC	_	2	cc	_	_
4	analyzed	analyze	VBD	_	2	conj	_	_
5	4	0	CD	_	6	num	_	_
6	SNPs	snp	NNS	_	4	obj	_	_
7	in	in	IN	_	9	case	_	_
8	3	0	CD	_	9	num	_	_
9	genes	gene	NNS	_	6	ppmod	_	_
10	:	:	:	_	6	p	_	_
11	PTPN22	ptpn0	NN	_	12	com	_	_
12	C1858T	c0t	NN	_	6	appo	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug1	drug0	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	,	,	,	_	12	p	_	_
17	TNFA	tnfa	NN	_	18	com	_	_
18	G-308A	g-0a	NN	_	12	conj	_	_
19	,	,	,	_	18	p	_	_
20	G-238A	g-0a	NN	_	12	conj	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	drug2	drug0	NN	_	20	prn	_	_
23	,	,	,	_	22	p	_	_
24	drug3	drug0	NN	_	22	appo	_	_
25	)	-rrb-	-RRB-	_	22	p	_	_
26	and	and	CC	_	20	cc	_	_
27	MIF	mif	NN	_	28	com	_	_
28	G-173C	g-0c	NN	_	12	conj	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	drug4	drug0	NN	_	28	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	in	in	IN	_	35	case	_	_
33	647	0	CD	_	35	num	_	_
34	drug5	drug0	NN	_	35	com	_	_
35	cases	case	NNS	_	4	ppmod	_	_
36	and	and	CC	_	35	cc	_	_
37	751	0	CD	_	39	num	_	_
38	healthy	healthy	JJ	_	39	attr	_	_
39	controls	control	NNS	_	35	conj	_	_
40	.	.	.	_	2	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	We	we	PRP	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	confirmed	confirm	VBN	_	1	acl	_	_
6	associations	association	NNS	_	5	obj	_	_
7	between	between	IN	_	8	case	_	_
8	drug3	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug1	drug0	NN	_	8	conj	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	.	.	.	_	1	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	found	find	VBN	_	1	acl	_	_
7	to	to	TO	_	8	aux	_	_
8	be	be	VB	_	6	comp	_	_
9	predictive	predictive	JJ	_	8	dep	_	_
10	of	of	IN	_	12	case	_	_
11	clinical	clinical	JJ	_	12	attr	_	_
12	response	response	NN	_	9	ppmod	_	_
13	and	and	CC	_	6	cc	_	_
14	was	be	VBD	_	6	conj	_	_
15	more	more	RBR	_	16	com	_	_
16	likely	likely	RB	_	14	adv	_	_
17	to	to	TO	_	18	aux	_	_
18	predict	predict	VB	_	14	comp	_	_
19	long-term	long-term	JJ	_	20	attr	_	_
20	survival	survival	NN	_	18	obj	_	_
21	in	in	IN	_	24	case	_	_
22	Japanese	japanese	NN	_	24	com	_	_
23	drug2	drug0	NN	_	24	com	_	_
24	patients	patient	NNS	_	20	ppmod	_	_
25	receiving	receive	VBG	_	24	acl	_	_
26	definitive	definitive	JJ	_	28	attr	_	_
27	5-FU/CDDP-based	0-fu/cddp-based	JJ	_	28	attr	_	_
28	CRT	crt	NN	_	25	obj	_	_
29	.	.	.	_	1	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	8	dep	_	_
4	compared	compare	VBN	_	7	adv	_	_
5	to	to	TO	_	7	aux	_	_
6	healthy	healthy	JJ	_	7	attr	_	_
7	individuals	individual	NNS	_	3	ppmod	_	_
8	demonstrated	demonstrate	VBD	_	1	acl	_	_
9	a	a	DT	_	12	det	_	_
10	statistically	statistically	RB	_	11	adv	_	_
11	significant	significant	JJ	_	12	attr	_	_
12	increase	increase	NN	_	8	obj	_	_
13	in	in	IN	_	15	case	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	allele	allele	NN	_	12	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	p	p	NN	_	15	prn	_	_
18	=	=	VBG	_	17	acl	_	_
19	0.037	0	CD	_	18	obj	_	_
20	,	,	,	_	17	p	_	_
21	OR	or	CC	_	17	cc	_	_
22	=	=	JJ	_	27	attr	_	_
23	2.12	0	CD	_	25	num	_	_
24	,	,	,	_	25	p	_	_
25	95	0	CD	_	22	num	_	_
26	%	%	NN	_	25	meta	_	_
27	CI	ci	NN	_	17	conj	_	_
28	1.29-3.4	0	CD	_	27	num	_	_
29	)	-rrb-	-RRB-	_	27	p	_	_
30	.	.	.	_	1	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Genome-wide	genome-wide	JJ	_	4	attr	_	_
4	significance	significance	NN	_	21	dep	_	_
5	in	in	IN	_	8	case	_	_
6	fully	fully	RB	_	7	adv	_	_
7	adjusted	adjust	VBN	_	8	attr	_	_
8	models	model	NNS	_	4	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	sex	sex	NN	_	8	prn	_	_
11	,	,	,	_	10	p	_	_
12	age	age	NN	_	10	appo	_	_
13	,	,	,	_	10	p	_	_
14	APOE	apoe	NN	_	15	com	_	_
15	genotype	genotype	NN	_	10	appo	_	_
16	,	,	,	_	10	p	_	_
17	population	population	NN	_	18	com	_	_
18	stratification	stratification	NN	_	10	appo	_	_
19	)	-rrb-	-RRB-	_	10	p	_	_
20	was	be	VBD	_	21	aux	_	_
21	observed	observe	VBN	_	1	acl	_	_
22	for	for	IN	_	24	case	_	_
23	a	a	DT	_	24	det	_	_
24	SNP	snp	NN	_	21	ppmod	_	_
25	in	in	IN	_	26	case	_	_
26	drug1	drug0	NN	_	24	ppmod	_	_
27	(	-lrb-	-LRB-	_	42	p	_	_
28	drug2	drug0	NN	_	42	dep	_	_
29	,	,	,	_	42	p	_	_
30	allele	allele	NN	_	32	attr	_	_
31	=	=	JJ	_	32	attr	_	_
32	G	g	NN	_	42	dep	_	_
33	;	;	:	_	42	p	_	_
34	frequency	frequency	NN	_	42	dep	_	_
35	,	,	,	_	42	p	_	_
36	0.09	0	CD	_	37	num	_	_
37	cases	case	NNS	_	42	dep	_	_
38	and	and	CC	_	37	cc	_	_
39	0.06	0	CD	_	40	num	_	_
40	controls	control	NNS	_	37	conj	_	_
41	;	;	:	_	42	p	_	_
42	odds	odds	NNS	_	26	prn	_	_
43	ratio	ratio	NN	_	44	advnp	_	_
44	-LSB-OR	-lsb-or	JJ	_	42	attr	_	_
45	]	-rsb-	-RRB-	_	42	p	_	_
46	,	,	,	_	52	p	_	_
47	1.79	0	CD	_	52	num	_	_
48	-LSB-95	-lsb-0	CD	_	52	num	_	_
49	%	%	NN	_	52	meta	_	_
50	CI	ci	CD	_	52	num	_	_
51	,	,	,	_	52	p	_	_
52	1.47-2.12	0	CD	_	26	num	_	_
53	]	-rsb-	-RRB-	_	52	p	_	_
54	;	;	:	_	52	p	_	_
55	P	p	NN	_	56	dep	_	_
56	=	=	JJ	_	52	advcl	_	_
57	2.2	0	CD	_	58	num	_	_
58	*	*	NN	_	56	obj	_	_
59	10	0	CD	_	58	num	_	_
60	(	-lrb-	-LRB-	_	58	p	_	_
61	-9	0	CD	_	58	num	_	_
62	)	-rrb-	-RRB-	_	58	p	_	_
63	)	-rrb-	-RRB-	_	52	p	_	_
64	,	,	,	_	24	p	_	_
65	which	which	WDT	_	66	dep	_	_
66	is	be	VBZ	_	24	relcl	_	_
67	in	in	IN	_	69	case	_	_
68	linkage	linkage	NN	_	69	com	_	_
69	disequilibrium	disequilibrium	NN	_	66	ppmod	_	_
70	with	with	IN	_	71	case	_	_
71	SNPs	snp	NNS	_	69	ppmod	_	_
72	previously	previously	RB	_	73	adv	_	_
73	associated	associate	VBN	_	71	acl	_	_
74	with	with	IN	_	76	case	_	_
75	drug3	drug0	NN	_	76	com	_	_
76	disease	disease	NN	_	73	ppmod	_	_
77	in	in	FW	_	78	adv	_	_
78	Europeans	europeans	FW	_	73	adv	_	_
79	(	-lrb-	-LRB-	_	83	p	_	_
80	0.8	0	CD	_	83	num	_	_
81	<	<	NN	_	83	com	_	_
82	D'	d'	NN	_	83	com	_	_
83	<	<	NN	_	78	prn	_	_
84	0.9	0	CD	_	83	num	_	_
85	)	-rrb-	-RRB-	_	83	p	_	_
86	.	.	.	_	1	p	_	_

1	Genotyping	genotyping	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	performed	performed	VBN	_	0	root	_	_
4	for	for	IN	_	7	case	_	_
5	five	#crd#	CD	_	7	num	_	_
6	single-nucleotide	single-nucleotide	JJ	_	7	attr	_	_
7	polymorphisms	polymorphism	NNS	_	3	ppmod	_	_
8	that	that	WDT	_	11	dep	_	_
9	have	have	VBP	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	associated	associate	VBN	_	7	relcl	_	_
12	with	with	IN	_	13	case	_	_
13	drug6	drug0	NN	_	11	ppmod	_	_
14	:	:	:	_	7	p	_	_
15	drug1	drug0	NN	_	7	appo	_	_
16	,	,	,	_	15	p	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug3	drug0	NN	_	15	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug4	drug0	NN	_	15	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	CLSTN2	clstn0	NN	_	15	conj	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	drug5	drug0	NN	_	15	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	.	.	.	_	3	p	_	_

1	Three	#crd#	CD	_	3	num	_	_
2	SNPs-LSB-	snps-lsb-	JJ	_	3	attr	_	_
3	drug1	drug0	NN	_	60	dep	_	_
4	in	in	IN	_	5	case	_	_
5	APOE	apoe	NN	_	3	ppmod	_	_
6	:	:	:	_	56	p	_	_
7	odds	odds	NNS	_	8	com	_	_
8	ratio	ratio	NN	_	56	dep	_	_
9	(	-lrb-	-LRB-	_	8	p	_	_
10	OR	or	CC	_	8	cc	_	_
11	)	-rrb-	-RRB-	_	21	p	_	_
12	=4.24	0	CD	_	17	num	_	_
13	,	,	,	_	17	p	_	_
14	95	0	CD	_	17	num	_	_
15	%	%	NN	_	17	meta	_	_
16	confidence	confidence	NN	_	17	com	_	_
17	interval	interval	NN	_	21	attr	_	_
18	(	-lrb-	-LRB-	_	21	p	_	_
19	CI	ci	CD	_	21	num	_	_
20	)	-rrb-	-RRB-	_	21	p	_	_
21	=3.01-5.96	0	CD	_	8	conj	_	_
22	,	,	,	_	56	p	_	_
23	P=1.23	p=0	NNP	_	24	com	_	_
24	*	*	NNP	_	56	dep	_	_
25	10	0	CD	_	24	num	_	_
26	;	;	:	_	56	p	_	_
27	drug2	drug0	NN	_	56	dep	_	_
28	in	in	IN	_	29	case	_	_
29	APOE	apoe	NN	_	27	ppmod	_	_
30	:	:	:	_	27	p	_	_
31	OR=3.57	or=0	CD	_	35	num	_	_
32	,	,	,	_	35	p	_	_
33	95	0	CD	_	35	num	_	_
34	%	%	NN	_	35	meta	_	_
35	CI=2.51-5.06	ci=0	CD	_	27	appo	_	_
36	,	,	,	_	56	p	_	_
37	P=1.23	p=0	NNP	_	38	com	_	_
38	*	*	NNP	_	56	dep	_	_
39	10	0	CD	_	38	num	_	_
40	;	;	:	_	38	p	_	_
41	and	and	CC	_	38	cc	_	_
42	drug3	drug0	NN	_	38	conj	_	_
43	in	in	IN	_	44	case	_	_
44	PICALM	picalm	NN	_	42	ppmod	_	_
45	:	:	:	_	56	p	_	_
46	OR=0.63	or=0	NNP	_	56	dep	_	_
47	,	,	,	_	46	p	_	_
48	95	0	CD	_	46	num	_	_
49	%	%	NN	_	46	meta	_	_
50	CI=0.49-0.81	ci=0	CD	_	46	num	_	_
51	,	,	,	_	46	p	_	_
52	P=0.00036	p=0	CD	_	46	num	_	_
53	,	,	,	_	56	p	_	_
54	log	log	NN	_	56	attr	_	_
55	additive	additive	JJ	_	56	attr	_	_
56	model	model	NN	_	60	prn	_	_
57	]	-rsb-	-RRB-	_	56	p	_	_
58	were	be	VBD	_	60	aux	_	_
59	significantly	significantly	RB	_	60	adv	_	_
60	associated	associate	VBN	_	0	root	_	_
61	with	with	IN	_	63	case	_	_
62	drug4	drug0	NN	_	63	com	_	_
63	susceptibility	susceptibility	NN	_	60	ppmod	_	_
64	after	after	IN	_	65	case	_	_
65	correction	correction	NN	_	60	ppmod	_	_
66	for	for	IN	_	68	case	_	_
67	multiple	multiple	JJ	_	68	attr	_	_
68	testing	testing	NN	_	65	ppmod	_	_
69	.	.	.	_	60	p	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Single	single	JJ	_	5	attr	_	_
4	nucleotide	nucleotide	NN	_	5	com	_	_
5	polymorphisms	polymorphism	NNS	_	38	dep	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	SNPs	snp	NNS	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	drug1	drug0	NN	_	5	appo	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	e4	e0	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	and	and	CC	_	9	cc	_	_
14	drug2	drug0	NN	_	9	conj	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	e2	e0	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	,	,	,	_	5	p	_	_
19	both	both	CC	_	5	cc	_	_
20	invoking	invoke	VBG	_	21	attr	_	_
21	changes	change	NNS	_	5	conj	_	_
22	in	in	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	amino-acid	amino-acid	JJ	_	25	attr	_	_
25	sequence	sequence	NN	_	21	ppmod	_	_
26	of	of	IN	_	33	case	_	_
27	the	the	DT	_	33	det	_	_
28	apolipoprotein	apolipoprotein	NN	_	33	attr	_	_
29	E	e	NN	_	33	attr	_	_
30	(	-lrb-	-LRB-	_	33	p	_	_
31	APOE	apoe	NN	_	33	attr	_	_
32	)	-rrb-	-RRB-	_	33	p	_	_
33	gene	gene	NN	_	25	ppmod	_	_
34	,	,	,	_	21	p	_	_
35	have	have	VBP	_	38	aux	_	_
36	previously	previously	RB	_	38	adv	_	_
37	been	be	VBN	_	38	aux	_	_
38	tested	test	VBN	_	1	acl	_	_
39	for	for	IN	_	40	case	_	_
40	association	association	NN	_	38	ppmod	_	_
41	with	with	IN	_	46	case	_	_
42	drug3	drug0	NN	_	46	attr	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	MS	ms	NN	_	42	prn	_	_
45	)	-rrb-	-RRB-	_	44	p	_	_
46	risk	risk	NN	_	40	ppmod	_	_
47	.	.	.	_	1	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Despite	despite	IN	_	5	case	_	_
4	sufficient	sufficient	JJ	_	5	attr	_	_
5	power	power	NN	_	23	ppmod	_	_
6	to	to	TO	_	7	aux	_	_
7	detect	detect	VB	_	5	acl	_	_
8	associations	association	NNS	_	7	obj	_	_
9	at	at	IN	_	12	case	_	_
10	genome-wide	genome-wide	NN	_	12	com	_	_
11	significance	significance	NN	_	12	com	_	_
12	thresholds	threshold	NNS	_	7	ppmod	_	_
13	across	across	IN	_	15	case	_	_
14	a	a	DT	_	15	det	_	_
15	range	range	NN	_	7	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	ORs	or	NNS	_	15	ppmod	_	_
18	,	,	,	_	23	p	_	_
19	our	our	PRP$	_	20	poss	_	_
20	analyses	analysis	NNS	_	23	dep	_	_
21	did	do	VBD	_	23	aux	_	_
22	not	not	RB	_	23	neg	_	_
23	support	support	VB	_	1	acl	_	_
24	a	a	DT	_	25	det	_	_
25	role	role	NN	_	23	obj	_	_
26	of	of	IN	_	27	case	_	_
27	drug1	drug0	NN	_	25	ppmod	_	_
28	or	or	CC	_	27	cc	_	_
29	drug2	drug0	NN	_	27	conj	_	_
30	on	on	IN	_	32	case	_	_
31	drug3	drug0	NN	_	32	com	_	_
32	susceptibility	susceptibility	NN	_	25	ppmod	_	_

1	The	the	DT	_	2	det	_	_
2	distributions	distribution	NNS	_	53	dep	_	_
3	of	of	IN	_	4	case	_	_
4	SNPs	snp	NNS	_	2	ppmod	_	_
5	relating	relate	VBG	_	4	acl	_	_
6	to	to	TO	_	10	aux	_	_
7	the	the	DT	_	10	det	_	_
8	amyloid	amyloid	JJ	_	10	attr	_	_
9	cascade	cascade	NN	_	10	com	_	_
10	hypothesis	hypothesis	NN	_	5	ppmod	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	TOMM40	tomm0	CD	_	14	num	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	G	g	NN	_	10	prn	_	_
15	and	and	CC	_	14	cc	_	_
16	TOMM40	tomm0	CD	_	18	num	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	G	g	NN	_	14	conj	_	_
19	)	-rrb-	-RRB-	_	14	p	_	_
20	,	,	,	_	10	p	_	_
21	to	to	TO	_	23	aux	_	_
22	the	the	DT	_	23	det	_	_
23	drug8	drug0	NN	_	10	conj	_	_
24	(	-lrb-	-LRB-	_	27	p	_	_
25	ApoE	apoe	NN	_	27	com	_	_
26	drug3	drug0	NN	_	27	com	_	_
27	C	c	NN	_	23	prn	_	_
28	,	,	,	_	27	p	_	_
29	LDLR	ldlr	NN	_	31	com	_	_
30	drug4	drug0	NN	_	31	com	_	_
31	G	g	NN	_	27	conj	_	_
32	and	and	CC	_	31	cc	_	_
33	CH25H	ch0h	NN	_	35	com	_	_
34	drug5	drug0	NN	_	35	com	_	_
35	T	t	NN	_	27	conj	_	_
36	and	and	CC	_	35	cc	_	_
37	PLAU	plau	NN	_	39	com	_	_
38	drug6	drug0	NN	_	39	com	_	_
39	CT	ct	NN	_	27	conj	_	_
40	)	-rrb-	-RRB-	_	27	p	_	_
41	and	and	CC	_	23	cc	_	_
42	to	to	TO	_	45	aux	_	_
43	the	the	DT	_	45	det	_	_
44	tau	tau	JJ	_	45	attr	_	_
45	hypothesis	hypothesis	NN	_	10	conj	_	_
46	(	-lrb-	-LRB-	_	49	p	_	_
47	MAPT/STH	mapt/sth	NN	_	49	com	_	_
48	drug7	drug0	NN	_	49	com	_	_
49	GG	gg	NN	_	45	prn	_	_
50	)	-rrb-	-RRB-	_	49	p	_	_
51	in	in	IN	_	52	case	_	_
52	aMCI	amci	NN	_	45	ppmod	_	_
53	were	be	VBD	_	0	root	_	_
54	significantly	significantly	RB	_	55	adv	_	_
55	different	different	JJ	_	53	dep	_	_
56	than	than	IN	_	57	case	_	_
57	those	those	DT	_	55	ppmod	_	_
58	in	in	IN	_	60	case	_	_
59	normal	normal	JJ	_	60	attr	_	_
60	controls	control	NNS	_	57	ppmod	_	_
61	.	.	.	_	53	p	_	_

1	The	the	DT	_	2	det	_	_
2	authors	author	NNS	_	4	dep	_	_
3	then	then	RB	_	4	adv	_	_
4	performed	performed	VBD	_	0	root	_	_
5	a	a	DT	_	7	det	_	_
6	large	large	JJ	_	7	attr	_	_
7	meta-analysis	meta-analysis	NN	_	4	obj	_	_
8	of	of	IN	_	10	case	_	_
9	36	0	CD	_	10	num	_	_
10	studies	study	NNS	_	7	ppmod	_	_
11	examining	examine	VBG	_	10	acl	_	_
12	the	the	DT	_	13	det	_	_
13	association	association	NN	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug5	drug0	NN	_	13	ppmod	_	_
16	with	with	IN	_	17	case	_	_
17	polymorphisms	polymorphism	NNS	_	13	ppmod	_	_
18	in	in	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	TCF7L2	tcf0l0	NN	_	21	com	_	_
21	gene	gene	NN	_	17	ppmod	_	_
22	in	in	IN	_	24	case	_	_
23	various	various	JJ	_	24	attr	_	_
24	ethnicities	ethnicity	NNS	_	11	ppmod	_	_
25	,	,	,	_	7	p	_	_
26	containing	contain	VBG	_	7	acl	_	_
27	drug1	drug0	NN	_	26	obj	_	_
28	C-to-T	c-to-t	JJ	_	27	attr	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	IVS3C>T	ivs0c>t	NN	_	27	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	,	,	,	_	27	p	_	_
33	drug2	drug0	NN	_	34	com	_	_
34	T-to-C	t-to-c	NN	_	27	conj	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	IVS3T>C	ivs0t>c	NN	_	34	prn	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	,	,	,	_	34	p	_	_
39	a	a	DT	_	40	det	_	_
40	drug3	drug0	NN	_	27	conj	_	_
41	G-to-T	g-to-t	JJ	_	40	attr	_	_
42	(	-lrb-	-LRB-	_	43	p	_	_
43	IVS4G>T	ivs0g>t	NN	_	40	prn	_	_
44	)	-rrb-	-RRB-	_	43	p	_	_
45	,	,	,	_	40	p	_	_
46	and	and	CC	_	40	cc	_	_
47	drug4	drug0	NN	_	48	com	_	_
48	G-to-C	g-to-c	NN	_	52	attr	_	_
49	(	-lrb-	-LRB-	_	50	p	_	_
50	IVS4G>C	ivs0g>c	NN	_	48	prn	_	_
51	)	-rrb-	-RRB-	_	50	p	_	_
52	polymorphisms	polymorphism	NNS	_	27	conj	_	_
53	and	and	CC	_	4	cc	_	_
54	toevaluate	toevaluate	VBP	_	4	conj	_	_
55	the	the	DT	_	56	det	_	_
56	size	size	NN	_	54	obj	_	_
57	of	of	IN	_	59	case	_	_
58	gene	gene	NN	_	59	com	_	_
59	effect	effect	NN	_	56	ppmod	_	_
60	and	and	CC	_	56	cc	_	_
61	the	the	DT	_	64	det	_	_
62	possible	possible	JJ	_	64	attr	_	_
63	genetic	genetic	JJ	_	64	attr	_	_
64	mode	mode	NN	_	56	conj	_	_
65	of	of	IN	_	66	case	_	_
66	action	action	NN	_	64	ppmod	_	_

1	Carbohydrate	carbohydrate	NN	_	2	com	_	_
2	quality	quality	NN	_	5	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	quantity	quantity	NN	_	2	conj	_	_
5	modified	modify	VBD	_	0	root	_	_
6	risk	risk	NN	_	5	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	associated	associate	VBN	_	6	acl	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	which	which	WDT	_	14	dep	_	_
14	suggests	suggest	VBZ	_	11	relcl	_	_
15	that	that	IN	_	25	mark	_	_
16	changes	change	NNS	_	25	dep	_	_
17	in	in	IN	_	18	case	_	_
18	risk	risk	NN	_	16	ppmod	_	_
19	attributable	attributable	JJ	_	18	attr	_	_
20	to	to	TO	_	23	aux	_	_
21	the	the	DT	_	23	det	_	_
22	TCF7L2	tcf0l0	NN	_	23	com	_	_
23	variant	variant	NN	_	19	ppmod	_	_
24	are	be	VBP	_	25	aux	_	_
25	magnified	magnify	VBN	_	14	comp	_	_
26	under	under	IN	_	27	case	_	_
27	conditions	condition	NNS	_	25	ppmod	_	_
28	of	of	IN	_	31	case	_	_
29	increased	increase	VBN	_	31	attr	_	_
30	insulin	insulin	NN	_	31	com	_	_
31	demand	demand	NN	_	27	ppmod	_	_
32	.	.	.	_	5	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	genotyped	genotyped	VBD	_	0	root	_	_
3	the	the	DT	_	7	det	_	_
4	TCF7L2	tcf0l0	NN	_	7	attr	_	_
5	single	single	JJ	_	7	attr	_	_
6	nucleotide	nucleotide	NN	_	7	com	_	_
7	polymorphisms	polymorphism	NNS	_	2	obj	_	_
8	drug1	drug0	NN	_	7	appo	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	(	-lrb-	-LRB-	_	7	p	_	_
12	previously	previously	RB	_	13	adv	_	_
13	associated	associate	VBN	_	7	acl	_	_
14	with	with	IN	_	15	case	_	_
15	drug5	drug0	NN	_	13	ppmod	_	_
16	)	-rrb-	-RRB-	_	7	p	_	_
17	and	and	CC	_	7	cc	_	_
18	drug3	drug0	NN	_	20	com	_	_
19	nd	nd	NN	_	20	com	_	_
20	drug4	drug0	NN	_	7	conj	_	_
21	(	-lrb-	-LRB-	_	20	p	_	_
22	which	which	WDT	_	26	dep	_	_
23	tag	tag	NN	_	26	com	_	_
24	haplotype	haplotype	NN	_	26	com	_	_
25	A	a	NN	_	26	com	_	_
26	-LSB-HapA	-lsb-hapa	NN	_	20	relcl	_	_
27	]	-rsb-	-RRB-	_	20	p	_	_
28	,	,	,	_	20	p	_	_
29	a	a	DT	_	30	det	_	_
30	haplotype	haplotype	NN	_	20	appo	_	_
31	reported	report	VBN	_	30	acl	_	_
32	to	to	TO	_	34	aux	_	_
33	be	be	VB	_	34	aux	_	_
34	associated	associate	VBN	_	31	comp	_	_
35	with	with	IN	_	36	case	_	_
36	drug6	drug0	NN	_	34	ppmod	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	in	in	IN	_	41	case	_	_
39	2,512	0	NN	_	41	num	_	_
40	FHS	fhs	NN	_	41	com	_	_
41	participants	participant	NNS	_	36	ppmod	_	_
42	.	.	.	_	2	p	_	_

1	As	as	IN	_	2	mark	_	_
2	expected	expect	VBN	_	11	advcl	_	_
3	,	,	,	_	11	p	_	_
4	the	the	DT	_	7	det	_	_
5	T	t	NN	_	7	com	_	_
6	risk	risk	NN	_	7	com	_	_
7	allele	allele	NN	_	11	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	was	be	VBD	_	11	aux	_	_
11	associated	associate	VBN	_	0	root	_	_
12	with	with	IN	_	14	case	_	_
13	higher	high	JJR	_	14	attr	_	_
14	drug2	drug0	NN	_	11	ppmod	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	p	p	NN	_	17	dep	_	_
17	=	=	JJ	_	11	prn	_	_
18	0.01	0	CD	_	17	obj	_	_
19	)	-rrb-	-RRB-	_	17	p	_	_
20	.	.	.	_	11	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	association	association	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	4	ppmod	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	p	p	NN	_	12	attr	_	_
11	=	=	JJ	_	12	attr	_	_
12	0.98	0	NN	_	8	num	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	,	,	,	_	8	p	_	_
15	drug3	drug0	NN	_	8	conj	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	p	p	NN	_	15	prn	_	_
18	=	=	JJ	_	17	attr	_	_
19	0.89	0	CD	_	17	num	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	,	,	,	_	15	p	_	_
22	drug4	drug0	NN	_	8	conj	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	p	p	NN	_	22	prn	_	_
25	=	=	JJ	_	24	attr	_	_
26	0.32	0	CD	_	25	num	_	_
27	)	-rrb-	-RRB-	_	24	p	_	_
28	or	or	CC	_	22	cc	_	_
29	drug5	drug0	NN	_	8	conj	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	p	p	NN	_	29	prn	_	_
32	=	=	JJ	_	31	attr	_	_
33	0.92	0	CD	_	32	num	_	_
34	)	-rrb-	-RRB-	_	31	p	_	_
35	.	.	.	_	2	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	confirmed	confirm	VBD	_	0	root	_	_
3	that	that	IN	_	10	mark	_	_
4	the	the	DT	_	6	det	_	_
5	risk	risk	NN	_	6	com	_	_
6	allele	allele	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	associated	associate	VBN	_	2	comp	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	a	a	NN	_	15	com	_	_
15	drug3	drug0	NN	_	12	conj	_	_
16	.	.	.	_	2	p	_	_

1	We	we	PRP	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	detect	detect	VB	_	0	root	_	_
5	any	any	DT	_	6	det	_	_
6	association	association	NN	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	6	ppmod	_	_
12	,	,	.	_	4	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	investigated	investigate	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	of	of	IN	_	8	case	_	_
6	single	single	JJ	_	8	attr	_	_
7	nucleotide	nucleotide	NN	_	8	com	_	_
8	polymorphisms	polymorphism	NNS	_	4	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	SNP	snp	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	,	,	,	_	8	p	_	_
13	drug1	drug0	NN	_	8	appo	_	_
14	and	and	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	,	,	,	_	8	p	_	_
17	within	within	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	TCF7L2	tcf0l0	NN	_	20	com	_	_
20	locus	locus	NN	_	8	ppmod	_	_
21	on	on	IN	_	22	case	_	_
22	drug3	drug0	NN	_	4	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	other	other	JJ	_	25	attr	_	_
25	drug4	drug0	NNS	_	22	conj	_	_
26	and	and	CC	_	22	cc	_	_
27	their	their	PRP$	_	28	poss	_	_
28	modulation	modulation	NN	_	22	conj	_	_
29	by	by	IN	_	31	case	_	_
30	dietary	dietary	NN	_	31	com	_	_
31	fat	fat	NN	_	28	ppmod	_	_
32	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	summary	summary	NN	_	16	ppmod	_	_
3	,	,	,	_	16	p	_	_
4	drug2	drug0	CD	_	16	num	_	_
5	(	-lrb-	-LRB-	_	9	p	_	_
6	>	>	JJ	_	9	attr	_	_
7	or	or	CC	_	6	cc	_	_
8	=	=	JJ	_	6	conj	_	_
9	6.62	0	CD	_	4	num	_	_
10	%	%	NN	_	9	meta	_	_
11	of	of	IN	_	13	case	_	_
12	energy	energy	NN	_	13	com	_	_
13	intake	intake	NN	_	9	ppmod	_	_
14	)	-rrb-	-RRB-	_	9	p	_	_
15	were	be	VBD	_	16	aux	_	_
16	associated	associate	VBN	_	0	root	_	_
17	with	with	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	in	in	IN	_	20	case	_	_
20	carriers	carrier	NNS	_	18	ppmod	_	_
21	of	of	IN	_	25	case	_	_
22	the	the	DT	_	25	det	_	_
23	minor	minor	JJ	_	25	attr	_	_
24	T	t	NN	_	25	com	_	_
25	allele	allele	NN	_	20	ppmod	_	_
26	at	at	IN	_	30	case	_	_
27	the	the	DT	_	30	det	_	_
28	TCF7L2	tcf0l0	NN	_	30	com	_	_
29	drug1	drug0	NN	_	30	com	_	_
30	SNP	snp	NN	_	25	ppmod	_	_
31	and	and	CC	_	16	cc	_	_
32	may	may	MD	_	33	modal	_	_
33	predispose	predispose	VB	_	16	conj	_	_
34	them	them	PRP	_	33	obj	_	_
35	to	to	TO	_	36	aux	_	_
36	MetS	met	NNS	_	33	ppmod	_	_
37	,	,	,	_	36	p	_	_
38	diabetes	diabetes	NNS	_	36	conj	_	_
39	,	,	,	_	38	p	_	_
40	and	and	CC	_	38	cc	_	_
41	cardiovascular	cardiovascular	JJ	_	42	attr	_	_
42	disease	disease	NN	_	36	conj	_	_
43	.	.	.	_	16	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	found	find	VBD	_	0	root	_	_
3	that	that	IN	_	18	mark	_	_
4	SNPs	snp	NNS	_	18	dep	_	_
5	drug1	drug0	NN	_	4	attr	_	_
6	,	,	,	_	5	p	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	5	conj	_	_
10	and	and	CC	_	9	cc	_	_
11	drug4	drug0	NN	_	5	conj	_	_
12	in	in	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	TCF7L2	tcf0l0	NN	_	15	com	_	_
15	gene	gene	NN	_	4	ppmod	_	_
16	were	be	VBD	_	18	aux	_	_
17	strongly	strongly	RB	_	18	adv	_	_
18	associated	associate	VBN	_	2	comp	_	_
19	with	with	IN	_	20	case	_	_
20	drug5	drug0	NN	_	18	ppmod	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	p<0.004	p<0	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	drug1	drug0	NN	_	11	ppmod	_	_
3	,	,	,	_	11	p	_	_
4	T2D	t0d	NN	_	5	com	_	_
5	patients	patient	NNS	_	11	dep	_	_
6	carrying	carry	VBG	_	5	acl	_	_
7	genotypes	genotype	NNS	_	6	obj	_	_
8	CT	ct	NN	_	7	attr	_	_
9	or	or	CC	_	8	cc	_	_
10	TT	tt	NN	_	8	conj	_	_
11	had	have	VBD	_	0	root	_	_
12	drug2	drug0	NN	_	16	attr	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	FPG	fpg	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	levels	level	NNS	_	11	obj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	p=0.042	p=0	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	and	and	CC	_	16	cc	_	_
21	drug3	drug0	NN	_	16	conj	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	p=0.015	p=0	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	and	and	CC	_	21	cc	_	_
26	drug4	drug0	NN	_	16	conj	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	p=0.015	p=0	NN	_	26	prn	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	compared	compare	VBN	_	33	adv	_	_
31	to	to	TO	_	33	aux	_	_
32	the	the	DT	_	33	det	_	_
33	patients	patient	NNS	_	11	ppmod	_	_
34	carrying	carry	VBG	_	33	acl	_	_
35	CC	cc	NN	_	36	com	_	_
36	genotype	genotype	NN	_	34	obj	_	_
37	.	.	.	_	11	p	_	_

1	Furthermore	furthermore	RB	_	30	adv	_	_
2	,	,	,	_	30	p	_	_
3	the	the	DT	_	5	det	_	_
4	risk	risk	NN	_	5	com	_	_
5	alleles	allele	NNS	_	30	dep	_	_
6	from	from	IN	_	9	case	_	_
7	TCF7L2	tcf0l0	NN	_	9	com	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	polymorphism	polymorphism	NN	_	5	ppmod	_	_
10	either	either	CC	_	13	cc	_	_
11	with	with	IN	_	13	case	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	polymorphism	polymorphism	NN	_	9	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	p=0.0257	p=0	NN	_	13	prn	_	_
16	,	,	,	_	15	p	_	_
17	OR=1.398	or=0	NN	_	15	appo	_	_
18	)	-rrb-	-RRB-	_	15	p	_	_
19	or	or	CC	_	13	cc	_	_
20	with	with	IN	_	22	case	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	polymorphism	polymorphism	NN	_	13	conj	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	p=0.0024	p=0	NN	_	22	prn	_	_
25	,	,	,	_	24	p	_	_
26	OR=1.514	or=0	NN	_	24	appo	_	_
27	)	-rrb-	-RRB-	_	24	p	_	_
28	were	be	VBD	_	30	aux	_	_
29	significantly	significantly	RB	_	30	adv	_	_
30	associated	associate	VBN	_	0	root	_	_
31	with	with	IN	_	32	case	_	_
32	drug4	drug0	NN	_	30	ppmod	_	_
33	.	.	.	_	30	p	_	_

1	The	the	DT	_	2	det	_	_
2	allele	allele	NN	_	12	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	genotype	genotype	NN	_	5	com	_	_
5	frequencies	frequency	NNS	_	2	conj	_	_
6	of	of	IN	_	9	case	_	_
7	two	#crd#	CD	_	9	num	_	_
8	SNP	snp	NN	_	9	com	_	_
9	drug1	drug0	NN	_	2	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	showed	show	VBD	_	0	root	_	_
13	that	that	IN	_	16	mark	_	_
14	these	these	DT	_	16	dep	_	_
15	are	be	VBP	_	16	aux	_	_
16	associated	associate	VBN	_	12	comp	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	odds	odds	NNS	_	16	prn	_	_
19	ratio	ratio	NN	_	18	attr	_	_
20	up	up	RB	_	22	adv	_	_
21	to	to	TO	_	22	attr	_	_
22	4	0	CD	_	19	num	_	_
23	)	-rrb-	-RRB-	_	18	p	_	_
24	with	with	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	development	development	NN	_	16	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	drug3	drug0	NN	_	26	ppmod	_	_
29	in	in	IN	_	33	case	_	_
30	the	the	DT	_	33	det	_	_
31	autoantibody-negative	autoantibody-negative	JJ	_	33	attr	_	_
32	diabetic	diabetic	JJ	_	33	attr	_	_
33	cohort	cohort	NN	_	26	ppmod	_	_
34	,	,	,	_	33	p	_	_
35	but	but	CC	_	33	cc	_	_
36	not	not	RB	_	41	neg	_	_
37	in	in	IN	_	41	case	_	_
38	the	the	DT	_	41	det	_	_
39	autoantibody-positive	autoantibody-positive	JJ	_	41	attr	_	_
40	diabetic	diabetic	JJ	_	41	attr	_	_
41	cohort	cohort	NN	_	33	conj	_	_
42	.	.	.	_	12	p	_	_

1	In	in	IN	_	4	case	_	_
2	our	our	PRP$	_	4	poss	_	_
3	case-control	case-control	JJ	_	4	attr	_	_
4	subjects	subject	NNS	_	10	ppmod	_	_
5	,	,	,	_	10	p	_	_
6	susceptibility	susceptibility	NN	_	10	dep	_	_
7	to	to	TO	_	8	aux	_	_
8	drug9	drug0	NN	_	6	ppmod	_	_
9	was	be	VBD	_	10	aux	_	_
10	replicated	replicate	VBN	_	0	root	_	_
11	in	in	IN	_	13	case	_	_
12	TCF7L2	tcf0l0	NN	_	13	com	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	CDKAL1	cdkal0	NN	_	16	com	_	_
16	drug2	drug0	NN	_	13	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	13	conj	_	_
19	,	,	,	_	18	p	_	_
20	HHEX	hhex	NN	_	13	conj	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	drug4	drug0	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	,	,	,	_	20	p	_	_
25	IGF2BP2	igf0bp0	NN	_	13	conj	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	drug5	drug0	NN	_	25	prn	_	_
28	and	and	CC	_	27	cc	_	_
29	drug6	drug0	NN	_	27	conj	_	_
30	)	-rrb-	-RRB-	_	27	p	_	_
31	,	,	,	_	25	p	_	_
32	CDKN2A/B	cdkn0a/b	NN	_	13	conj	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	drug7	drug0	NN	_	32	prn	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	,	,	,	_	32	p	_	_
37	and	and	CC	_	32	cc	_	_
38	SLC30A8	slc0a0	NN	_	13	conj	_	_
39	(	-lrb-	-LRB-	_	40	p	_	_
40	drug8	drug0	NN	_	38	prn	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	.	.	.	_	10	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	8	ppmod	_	_
3	to	to	TO	_	5	aux	_	_
4	these	these	DT	_	5	det	_	_
5	polymorphisms	polymorphism	NNS	_	2	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	meta-analysis	meta-analysis	NN	_	8	dep	_	_
8	confirmed	confirm	VBD	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	association	association	NN	_	8	obj	_	_
11	of	of	IN	_	13	case	_	_
12	drug4	drug0	NN	_	13	com	_	_
13	susceptibility	susceptibility	NN	_	10	ppmod	_	_
14	with	with	IN	_	16	case	_	_
15	KCNJ11	kcnj0	NN	_	16	com	_	_
16	drug1	drug0	NN	_	10	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	TCF7L2	tcf0l0	NN	_	19	com	_	_
19	drug2	drug0	NN	_	16	conj	_	_
20	,	,	,	_	19	p	_	_
21	and	and	CC	_	19	cc	_	_
22	HHEX	hhex	NN	_	23	com	_	_
23	drug3	drug0	NN	_	16	conj	_	_
24	.	.	.	_	8	p	_	_

1	The	the	DT	_	4	det	_	_
2	TCF7L2	tcf0l0	NN	_	4	com	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	polymorphism	polymorphism	NN	_	5	dep	_	_
5	showed	show	VBD	_	0	root	_	_
6	the	the	DT	_	9	det	_	_
7	highest	high	JJS	_	9	attr	_	_
8	odds	odds	NNS	_	9	com	_	_
9	ratio	ratio	NN	_	5	obj	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	OR	or	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	for	for	IN	_	14	case	_	_
14	drug2	drug0	NN	_	9	ppmod	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	OR	or	CC	_	17	cc	_	_
17	1.714	0	NN	_	14	num	_	_
18	-LSB-1.298-2.263	-lsb-0	CD	_	17	num	_	_
19	]	-rsb-	-RRB-	_	17	p	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	.	.	.	_	5	p	_	_

1	Odds	odds	NNS	_	2	com	_	_
2	ratio	ratio	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	other	other	JJ	_	5	attr	_	_
5	polymorphisms	polymorphism	NNS	_	2	ppmod	_	_
6	ranged	range	VBD	_	19	advcl	_	_
7	from	from	IN	_	10	case	_	_
8	1.13	0	CD	_	10	num	_	_
9	to	to	TO	_	10	attr	_	_
10	1.41.	0.	CD	_	6	ppmod	_	_
11	The	the	DT	_	13	det	_	_
12	risk	risk	NN	_	13	com	_	_
13	allele	allele	NN	_	19	dep	_	_
14	of	of	IN	_	16	case	_	_
15	CDKAL1	cdkal0	NN	_	16	com	_	_
16	drug1	drug0	NN	_	13	ppmod	_	_
17	was	be	VBD	_	19	aux	_	_
18	significantly	significantly	RB	_	19	adv	_	_
19	associated	associate	VBN	_	0	root	_	_
20	with	with	IN	_	22	case	_	_
21	drug2	drug0	NN	_	22	com	_	_
22	patients	patient	NNS	_	19	ppmod	_	_
23	after	after	IN	_	24	case	_	_
24	adjustment	adjustment	NN	_	22	ppmod	_	_
25	for	for	IN	_	28	case	_	_
26	other	other	JJ	_	28	attr	_	_
27	confounding	confound	VBG	_	28	attr	_	_
28	factors	factor	NNS	_	24	ppmod	_	_
29	.	.	.	_	19	p	_	_

1	Compared	compare	VBN	_	3	adv	_	_
2	with	with	IN	_	3	case	_	_
3	controls	control	NNS	_	13	ppmod	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	men	man	NNS	_	3	prn	_	_
6	and	and	CC	_	5	cc	_	_
7	women	woman	NNS	_	5	conj	_	_
8	combined	combine	VBN	_	5	acl	_	_
9	)	-rrb-	-RRB-	_	5	p	_	_
10	,	,	,	_	13	p	_	_
11	drug10	drug0	NN	_	13	dep	_	_
12	was	be	VBD	_	13	aux	_	_
13	associated	associate	VBN	_	0	root	_	_
14	with	with	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	(	-lrb-	-LRB-	_	24	p	_	_
19	OR	or	CC	_	24	cc	_	_
20	1.55	0	CD	_	24	num	_	_
21	,	,	,	_	24	p	_	_
22	95	0	CD	_	24	num	_	_
23	%	%	NN	_	24	meta	_	_
24	CI	ci	NN	_	17	prn	_	_
25	1.34-1.79	0	CD	_	24	num	_	_
26	,	,	,	_	24	p	_	_
27	p	p	NN	_	24	appo	_	_
28	=	=	JJ	_	27	attr	_	_
29	4.17	0	CD	_	28	num	_	_
30	x	x	CC	_	29	cc	_	_
31	10	0	CD	_	29	conj	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	-9	0	NN	_	29	num	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	)	-rrb-	-RRB-	_	24	p	_	_
36	in	in	IN	_	37	case	_	_
37	CDKAL1	cdkal0	NN	_	15	ppmod	_	_
38	;	;	:	_	37	p	_	_
39	drug3	drug0	NN	_	37	appo	_	_
40	(	-lrb-	-LRB-	_	42	p	_	_
41	OR	or	CC	_	42	cc	_	_
42	1.49	0	NN	_	39	num	_	_
43	,	,	,	_	42	p	_	_
44	95	0	CD	_	46	num	_	_
45	%	%	NN	_	46	meta	_	_
46	CI	ci	NN	_	42	appo	_	_
47	1.29-1.72	0	CD	_	46	num	_	_
48	,	,	,	_	42	p	_	_
49	p	p	NN	_	42	appo	_	_
50	=	=	JJ	_	49	attr	_	_
51	1.05	0	CD	_	50	num	_	_
52	x	x	CC	_	51	cc	_	_
53	10	0	CD	_	51	conj	_	_
54	(	-lrb-	-LRB-	_	55	p	_	_
55	-7	0	CD	_	51	num	_	_
56	)	-rrb-	-RRB-	_	55	p	_	_
57	)	-rrb-	-RRB-	_	42	p	_	_
58	in	in	IN	_	61	case	_	_
59	the	the	DT	_	61	det	_	_
60	CDKN2A-CDKN2B	cdkn0a-cdkn0b	NN	_	61	com	_	_
61	region	region	NN	_	39	ppmod	_	_
62	;	;	:	_	37	p	_	_
63	drug4	drug0	NN	_	37	appo	_	_
64	(	-lrb-	-LRB-	_	70	p	_	_
65	OR	or	CC	_	70	cc	_	_
66	1.27	0	CD	_	70	num	_	_
67	,	,	,	_	70	p	_	_
68	95	0	CD	_	70	num	_	_
69	%	%	NN	_	70	meta	_	_
70	CI	ci	NN	_	37	prn	_	_
71	1.09-1.49	0	CD	_	70	num	_	_
72	,	,	,	_	70	p	_	_
73	p	p	NN	_	70	appo	_	_
74	=	=	JJ	_	73	attr	_	_
75	0.003	0	CD	_	73	num	_	_
76	)	-rrb-	-RRB-	_	70	p	_	_
77	,	,	,	_	37	p	_	_
78	drug5	drug0	NN	_	37	conj	_	_
79	,	,	,	_	78	p	_	_
80	and	and	CC	_	78	cc	_	_
81	drug6	drug0	NN	_	37	conj	_	_
82	in	in	IN	_	83	case	_	_
83	HHEX	hhex	NN	_	15	ppmod	_	_
84	;	;	:	_	15	p	_	_
85	drug7	drug0	NN	_	15	conj	_	_
86	(	-lrb-	-LRB-	_	92	p	_	_
87	OR	or	CC	_	92	cc	_	_
88	1.18	0	CD	_	92	num	_	_
89	,	,	,	_	92	p	_	_
90	95	0	CD	_	92	num	_	_
91	%	%	NN	_	92	meta	_	_
92	CI	ci	NN	_	85	prn	_	_
93	1.01-1.38	0	CD	_	92	num	_	_
94	,	,	,	_	92	p	_	_
95	p	p	NN	_	92	appo	_	_
96	=	=	JJ	_	95	attr	_	_
97	0.03	0	CD	_	95	num	_	_
98	)	-rrb-	-RRB-	_	92	p	_	_
99	in	in	IN	_	100	case	_	_
100	IGF2BP2	igf0bp0	NN	_	85	ppmod	_	_
101	;	;	:	_	85	p	_	_
102	drug8	drug0	NN	_	15	conj	_	_
103	(	-lrb-	-LRB-	_	109	p	_	_
104	OR	or	CC	_	109	cc	_	_
105	1.24	0	CD	_	109	num	_	_
106	,	,	,	_	109	p	_	_
107	95	0	CD	_	109	num	_	_
108	%	%	NN	_	109	meta	_	_
109	CI	ci	NN	_	102	prn	_	_
110	1.07-1.43	0	CD	_	109	num	_	_
111	,	,	,	_	109	p	_	_
112	p	p	NN	_	109	appo	_	_
113	=	=	JJ	_	112	attr	_	_
114	0.005	0	CD	_	112	num	_	_
115	)	-rrb-	-RRB-	_	109	p	_	_
116	in	in	IN	_	117	case	_	_
117	SLC30A8	slc0a0	NN	_	102	ppmod	_	_
118	;	;	:	_	102	p	_	_
119	and	and	CC	_	102	cc	_	_
120	drug9	drug0	NN	_	15	conj	_	_
121	(	-lrb-	-LRB-	_	127	p	_	_
122	OR	or	CC	_	127	cc	_	_
123	1.58	0	CD	_	127	num	_	_
124	,	,	,	_	127	p	_	_
125	95	0	CD	_	127	num	_	_
126	%	%	NN	_	127	meta	_	_
127	CI	ci	NN	_	120	prn	_	_
128	1.03-2.43	0	CD	_	127	num	_	_
129	,	,	,	_	127	p	_	_
130	p	p	NN	_	127	appo	_	_
131	=	=	JJ	_	130	attr	_	_
132	0.038	0	CD	_	130	num	_	_
133	)	-rrb-	-RRB-	_	127	p	_	_
134	in	in	IN	_	135	case	_	_
135	TCF7L2	tcf0l0	NN	_	120	ppmod	_	_
136	.	.	.	_	13	p	_	_

1	The	the	DT	_	3	det	_	_
2	risk	risk	NN	_	3	com	_	_
3	alleles	allele	NNS	_	28	dep	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	SNPs	snp	NNS	_	3	ppmod	_	_
7	drug1	drug0	NN	_	6	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	in	in	IN	_	11	case	_	_
11	CDKAL1	cdkal0	NN	_	6	ppmod	_	_
12	;	;	:	_	11	p	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	in	in	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	CDKN2A-CDKN2B	cdkn0a-cdkn0b	NN	_	17	com	_	_
17	region	region	NN	_	13	ppmod	_	_
18	;	;	:	_	13	p	_	_
19	and	and	CC	_	13	cc	_	_
20	drug4	drug0	NN	_	11	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug5	drug0	NN	_	20	conj	_	_
23	and	and	CC	_	22	cc	_	_
24	drug6	drug0	NN	_	20	conj	_	_
25	in	in	IN	_	26	case	_	_
26	HHEX	hhex	NN	_	20	ppmod	_	_
27	were	be	VBD	_	28	aux	_	_
28	associated	associate	VBN	_	0	root	_	_
29	with	with	IN	_	31	case	_	_
30	drug7	drug0	NN	_	31	com	_	_
31	AUC	auc	NN	_	28	ppmod	_	_
32	during	during	IN	_	36	case	_	_
33	a	a	DT	_	36	det	_	_
34	100	0	CD	_	36	num	_	_
35	g	g	NN	_	36	com	_	_
36	OGTT	ogtt	NN	_	31	ppmod	_	_
37	performed	performed	VBN	_	36	acl	_	_
38	at	at	IN	_	40	case	_	_
39	the	the	DT	_	40	det	_	_
40	time	time	NN	_	37	ppmod	_	_
41	of	of	IN	_	42	case	_	_
42	diagnosis	diagnosis	NN	_	40	ppmod	_	_
43	of	of	IN	_	44	case	_	_
44	drug8	drug0	NN	_	42	ppmod	_	_
45	.	.	.	_	28	p	_	_

1	The	the	DT	_	3	det	_	_
2	risk	risk	NN	_	3	com	_	_
3	alleles	allele	NNS	_	15	dep	_	_
4	of	of	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	TCF7L2	tcf0l0	NN	_	7	com	_	_
7	gene	gene	NN	_	3	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	drug1	drug0	NN	_	7	prn	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	)	-rrb-	-RRB-	_	9	p	_	_
13	were	be	VBD	_	15	aux	_	_
14	strongly	strongly	RB	_	15	adv	_	_
15	associated	associate	VBN	_	0	root	_	_
16	with	with	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	15	p	_	_
19	even	even	RB	_	21	adv	_	_
20	after	after	IN	_	21	case	_	_
21	controlling	control	VBG	_	15	ppmod	_	_
22	for	for	IN	_	25	case	_	_
23	traditional	traditional	JJ	_	25	attr	_	_
24	risk	risk	NN	_	25	com	_	_
25	factors	factor	NNS	_	21	ppmod	_	_
26	in	in	IN	_	32	case	_	_
27	both	both	CC	_	32	cc	_	_
28	a	a	DT	_	32	det	_	_
29	cross-sectional	cross-sectional	JJ	_	32	attr	_	_
30	and	and	CC	_	29	cc	_	_
31	prospective	prospective	JJ	_	29	conj	_	_
32	setting	setting	NN	_	25	ppmod	_	_
33	.	.	.	_	15	p	_	_

1	The	the	DT	_	4	det	_	_
2	minor	minor	JJ	_	4	attr	_	_
3	allele	allele	NN	_	4	com	_	_
4	frequency	frequency	NN	_	11	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	and	and	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	6	conj	_	_
11	was	be	VBD	_	0	root	_	_
12	significantly	significantly	RB	_	13	adv	_	_
13	higher	high	JJR	_	11	dep	_	_
14	in	in	IN	_	16	case	_	_
15	drug4	drug0	NN	_	16	com	_	_
16	patients	patient	NNS	_	11	ppmod	_	_
17	compared	compare	VBN	_	19	adv	_	_
18	with	with	IN	_	19	case	_	_
19	that	that	DT	_	11	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	non-diabetic	non-diabetic	JJ	_	22	attr	_	_
22	individuals	individual	NNS	_	19	ppmod	_	_
23	.	.	.	_	11	p	_	_

1	The	the	DT	_	6	det	_	_
2	T	t	NN	_	6	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	minor	minor	JJ	_	6	attr	_	_
5	)	-rrb-	-RRB-	_	6	p	_	_
6	allele	allele	NN	_	13	dep	_	_
7	of	of	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	variant	variant	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	6	ppmod	_	_
11	was	be	VBD	_	13	aux	_	_
12	significantly	significantly	RB	_	13	adv	_	_
13	associated	associate	VBN	_	0	root	_	_
14	with	with	IN	_	17	case	_	_
15	a	a	DT	_	17	det	_	_
16	greater	great	JJR	_	17	attr	_	_
17	OR	or	NN	_	13	ppmod	_	_
18	for	for	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	adjusted	adjust	VBN	_	17	acl	_	_
21	for	for	IN	_	22	case	_	_
22	age	age	NN	_	20	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	sex	sex	NN	_	22	conj	_	_
25	and	and	CC	_	24	cc	_	_
26	BMI	bmi	NN	_	22	conj	_	_
27	in	in	IN	_	30	case	_	_
28	logistic	logistic	JJ	_	30	attr	_	_
29	regression	regression	NN	_	30	com	_	_
30	analysis	analysis	NN	_	20	ppmod	_	_
31	:	:	:	_	13	p	_	_

1	No	no	DT	_	4	det	_	_
2	statistically	statistically	RB	_	3	adv	_	_
3	significant	significant	JJ	_	4	attr	_	_
4	association	association	NN	_	9	dep	_	_
5	of	of	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	SNPs	snp	NNS	_	4	ppmod	_	_
8	was	be	VBD	_	9	aux	_	_
9	observed	observe	VBN	_	0	root	_	_
10	with	with	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	drug4	drug0	NN	_	11	conj	_	_
14	or	or	CC	_	11	cc	_	_
15	between	between	IN	_	16	case	_	_
16	carriers	carrier	NNS	_	11	conj	_	_
17	and	and	CC	_	16	cc	_	_
18	non-carriers	non-carriers	NNS	_	16	conj	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	16	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	drug2	drug0	NN	_	23	com	_	_
23	mutations	mutation	NNS	_	20	conj	_	_
24	.	.	.	_	9	p	_	_

1	while	while	IN	_	4	case	_	_
2	,	,	,	_	4	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	showed	show	VBD	_	0	root	_	_
5	a	a	DT	_	8	det	_	_
6	statistically	statistically	RB	_	7	adv	_	_
7	significant	significant	JJ	_	8	attr	_	_
8	association	association	NN	_	4	obj	_	_
9	between	between	IN	_	13	case	_	_
10	drug2	drug0	NN	_	13	attr	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	patients	patient	NNS	_	8	ppmod	_	_
14	carrying	carry	VBG	_	13	acl	_	_
15	the	the	DT	_	17	det	_	_
16	26V	0v	NN	_	17	com	_	_
17	allele	allele	NN	_	14	obj	_	_
18	(	-lrb-	-LRB-	_	31	p	_	_
19	OR	or	CC	_	31	cc	_	_
20	=	=	JJ	_	25	attr	_	_
21	1.69	0	CD	_	25	num	_	_
22	,	,	,	_	25	p	_	_
23	95	0	CD	_	25	num	_	_
24	%	%	NN	_	25	meta	_	_
25	CI	ci	NN	_	31	dep	_	_
26	=	=	JJ	_	25	attr	_	_
27	1.11-2.56	0	CD	_	25	num	_	_
28	,	,	,	_	31	p	_	_
29	P	p	NN	_	31	attr	_	_
30	=	=	JJ	_	31	attr	_	_
31	0.013	0	NN	_	17	num	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	.	.	.	_	4	p	_	_

1	The	the	DT	_	5	det	_	_
2	drug1	drug0	NN	_	5	attr	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	variants	variant	NNS	_	11	dep	_	_
6	of	of	IN	_	7	case	_	_
7	TCF7L2	tcf0l0	NN	_	5	ppmod	_	_
8	have	have	VBP	_	11	aux	_	_
9	been	be	VBN	_	11	aux	_	_
10	strongly	strongly	RB	_	11	adv	_	_
11	associated	associate	VBN	_	0	root	_	_
12	with	with	IN	_	14	case	_	_
13	drug3	drug0	NN	_	14	com	_	_
14	risk	risk	NN	_	11	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	most	most	JJS	_	17	attr	_	_
17	populations	population	NNS	_	14	ppmod	_	_
18	studied	study	VBN	_	17	acl	_	_
19	to	to	TO	_	20	aux	_	_
20	date	date	NN	_	18	ppmod	_	_
21	.	.	.	_	11	p	_	_

1	Comparison	comparison	NN	_	14	dep	_	_
2	between	between	IN	_	3	case	_	_
3	allele	allele	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	genotype	genotype	NN	_	6	com	_	_
6	frequencies	frequency	NNS	_	3	conj	_	_
7	of	of	IN	_	9	case	_	_
8	these	these	DT	_	9	det	_	_
9	SNPs	snp	NNS	_	1	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	controls	control	NNS	_	11	conj	_	_
14	showed	show	VBD	_	0	root	_	_
15	marginal	marginal	JJ	_	16	attr	_	_
16	association	association	NN	_	14	obj	_	_
17	for	for	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug2	drug0	NN	_	18	conj	_	_
21	with	with	IN	_	22	case	_	_
22	drug3	drug0	NN	_	16	ppmod	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	p	p	NN	_	14	prn	_	_
25	=	=	JJ	_	24	attr	_	_
26	0.063	0	CD	_	25	num	_	_
27	,	,	,	_	26	p	_	_
28	OR	or	CC	_	26	cc	_	_
29	1.982	0	CD	_	26	conj	_	_
30	,	,	,	_	26	p	_	_
31	95	0	CD	_	26	appo	_	_
32	%	%	NN	_	31	meta	_	_
33	CI	ci	RB	_	34	adv	_	_
34	1.128-3.485	0	CD	_	31	num	_	_
35	;	;	:	_	24	p	_	_
36	p	p	NN	_	37	dep	_	_
37	=	=	JJ	_	24	comp	_	_
38	0.071	0	CD	_	37	obj	_	_
39	,	,	,	_	37	p	_	_
40	OR	or	CC	_	37	cc	_	_
41	1.237	0	CD	_	43	num	_	_
42	,	,	,	_	43	p	_	_
43	95	0	CD	_	45	num	_	_
44	%	%	NN	_	43	meta	_	_
45	CI	ci	JJ	_	37	conj	_	_
46	0.983-1.557	0	CD	_	45	obj	_	_
47	,	,	,	_	45	p	_	_
48	respectively	respectively	RB	_	45	adv	_	_
49	)	-rrb-	-RRB-	_	24	p	_	_
50	.	.	.	_	14	p	_	_

1	No	no	DT	_	2	det	_	_
2	association	association	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	found	find	VBN	_	0	root	_	_
5	for	for	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	c.1,637C>A	c.0c>a	NN	_	6	conj	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	6	conj	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	p	p	NN	_	15	dep	_	_
15	=	=	JJ	_	4	prn	_	_
16	0.278-1.000	0	CD	_	15	obj	_	_
17	)	-rrb-	-RRB-	_	15	p	_	_
18	.	.	.	_	4	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	evaluated	evaluate	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	association	association	NN	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	a	a	DT	_	7	det	_	_
7	polymorphism	polymorphism	NN	_	4	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	TCF7L2	tcf0l0	NN	_	10	com	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	in	in	IN	_	15	case	_	_
12	the	the	DT	_	15	det	_	_
13	WNT	wnt	NN	_	15	com	_	_
14	signaling	signaling	NN	_	15	com	_	_
15	pathway	pathway	NN	_	10	ppmod	_	_
16	,	,	,	_	10	p	_	_
17	which	which	WDT	_	22	dep	_	_
18	previously	previously	RB	_	22	adv	_	_
19	has	have	VBZ	_	22	aux	_	_
20	been	be	VBN	_	22	aux	_	_
21	strongly	strongly	RB	_	22	adv	_	_
22	associated	associate	VBN	_	10	relcl	_	_
23	with	with	IN	_	24	case	_	_
24	risk	risk	NN	_	22	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	,	,	,	_	22	p	_	_
28	with	with	IN	_	29	case	_	_
29	drug3	drug0	NN	_	22	ppmod	_	_
30	and	and	CC	_	29	cc	_	_
31	drug4	drug0	NN	_	29	conj	_	_
32	in	in	IN	_	38	case	_	_
33	the	the	DT	_	38	det	_	_
34	prospective	prospective	JJ	_	38	attr	_	_
35	Nurses	nurses	NN	_	38	attr	_	_
36	'	'	``	_	38	p	_	_
37	Health	health	NN	_	38	com	_	_
38	Study	study	NN	_	29	ppmod	_	_
39	(	-lrb-	-LRB-	_	40	p	_	_
40	NHS	nhs	NN	_	38	prn	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	and	and	CC	_	38	cc	_	_
43	Health	health	NN	_	45	com	_	_
44	ProfessionalsFollow-up	professionalsfollow-up	NN	_	45	com	_	_
45	Study	study	NN	_	49	attr	_	_
46	(	-lrb-	-LRB-	_	47	p	_	_
47	HPFS	hpfs	NN	_	45	prn	_	_
48	)	-rrb-	-RRB-	_	47	p	_	_
49	cohorts	cohort	NNS	_	38	conj	_	_
50	.	.	.	_	2	p	_	_

1	Overall	overall	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	in	in	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	NHS	nhs	NN	_	10	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	HPFS	hpfs	NN	_	5	conj	_	_
8	,	,	,	_	10	p	_	_
9	there	there	EX	_	10	dep	_	_
10	was	be	VBD	_	0	root	_	_
11	suggestive	suggestive	JJ	_	12	attr	_	_
12	evidence	evidence	NN	_	10	obj	_	_
13	for	for	IN	_	16	case	_	_
14	an	an	DT	_	16	det	_	_
15	inverse	inverse	JJ	_	16	attr	_	_
16	association	association	NN	_	12	ppmod	_	_
17	associated	associate	VBN	_	16	acl	_	_
18	with	with	IN	_	19	case	_	_
19	homozygosity	homozygosity	NN	_	17	ppmod	_	_
20	for	for	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	minor	minor	JJ	_	23	attr	_	_
23	allele	allele	NN	_	19	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug1	drug0	NN	_	23	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	drug2	drug0	NN	_	25	conj	_	_
28	(	-lrb-	-LRB-	_	39	p	_	_
29	conditional	conditional	JJ	_	39	attr	_	_
30	and	and	CC	_	29	cc	_	_
31	covariate	covariate	NN	_	32	advnp	_	_
32	adjusted	adjust	VBN	_	29	conj	_	_
33	OR	or	CC	_	32	cc	_	_
34	=	=	JJ	_	32	conj	_	_
35	0.63	0	CD	_	37	num	_	_
36	,	,	,	_	37	p	_	_
37	95	0	CD	_	34	num	_	_
38	%	%	NN	_	37	meta	_	_
39	CI	ci	NN	_	25	prn	_	_
40	:	:	:	_	39	p	_	_
41	0.37-1.08	0	CD	_	39	appo	_	_
42	;	;	:	_	39	p	_	_
43	P	p	NN	_	39	appo	_	_
44	for	for	IN	_	45	case	_	_
45	heterogeneity	heterogeneity	NN	_	43	ppmod	_	_
46	0.52	0	CD	_	45	num	_	_
47	for	for	IN	_	49	case	_	_
48	the	the	DT	_	49	det	_	_
49	association	association	NN	_	43	ppmod	_	_
50	in	in	IN	_	51	case	_	_
51	women	woman	NNS	_	49	ppmod	_	_
52	and	and	CC	_	51	cc	_	_
53	men	man	NNS	_	51	conj	_	_
54	)	-rrb-	-RRB-	_	39	p	_	_
55	.	.	.	_	10	p	_	_

1	This	this	DT	_	2	det	_	_
2	result	result	NN	_	3	dep	_	_
3	suggests	suggest	VBZ	_	0	root	_	_
4	that	that	IN	_	12	mark	_	_
5	the	the	DT	_	7	det	_	_
6	increased	increase	VBN	_	7	attr	_	_
7	drug2	drug0	NN	_	12	dep	_	_
8	associated	associate	VBN	_	7	acl	_	_
9	with	with	IN	_	11	case	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	genotype	genotype	NN	_	8	ppmod	_	_
12	is	be	VBZ	_	3	comp	_	_
13	specific	specific	JJ	_	12	dep	_	_
14	to	to	TO	_	15	aux	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	Specifically	specifically	RB	_	27	adv	_	_
2	,	,	,	_	27	p	_	_
3	the	the	DT	_	6	det	_	_
4	same	same	JJ	_	6	attr	_	_
5	risk	risk	NN	_	6	com	_	_
6	allele	allele	NN	_	27	dep	_	_
7	of	of	IN	_	14	case	_	_
8	single	single	JJ	_	10	attr	_	_
9	nucleotide	nucleotide	NN	_	10	com	_	_
10	polymorphism	polymorphism	NN	_	14	attr	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	SNP	snp	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	drug1	drug0	NN	_	6	ppmod	_	_
15	that	that	WDT	_	17	dep	_	_
16	is	be	VBZ	_	17	aux	_	_
17	associated	associate	VBN	_	14	relcl	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	T	t	NN	_	22	com	_	_
22	allele	allele	NN	_	19	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	has	have	VBZ	_	27	aux	_	_
25	recently	recently	RB	_	27	adv	_	_
26	been	be	VBN	_	27	aux	_	_
27	associated	associate	VBN	_	0	root	_	_
28	with	with	IN	_	31	case	_	_
29	an	an	DT	_	31	det	_	_
30	increased	increase	VBN	_	31	attr	_	_
31	risk	risk	NN	_	27	ppmod	_	_
32	of	of	IN	_	33	case	_	_
33	drug3	drug0	NN	_	31	ppmod	_	_
34	.	.	.	_	27	p	_	_

1	The	the	DT	_	3	det	_	_
2	minor	minor	JJ	_	3	attr	_	_
3	allele	allele	NN	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	each	each	DT	_	6	det	_	_
6	variant	variant	NN	_	3	ppmod	_	_
7	was	be	VBD	_	9	aux	_	_
8	significantly	significantly	RB	_	9	adv	_	_
9	associated	associate	VBN	_	21	advcl	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	;	;	:	_	21	p	_	_
13	the	the	DT	_	15	det	_	_
14	greatest	great	JJS	_	15	attr	_	_
15	risk	risk	NN	_	21	dep	_	_
16	of	of	IN	_	17	case	_	_
17	developing	develop	VBG	_	15	ppmod	_	_
18	the	the	DT	_	19	det	_	_
19	disease	disease	NN	_	17	obj	_	_
20	was	be	VBD	_	21	aux	_	_
21	conferred	confer	VBN	_	0	root	_	_
22	by	by	IN	_	23	case	_	_
23	drug1	drug0	NN	_	21	ppmod	_	_
24	,	,	,	_	21	p	_	_
25	with	with	IN	_	29	case	_	_
26	an	an	DT	_	29	det	_	_
27	allelic	allelic	JJ	_	29	attr	_	_
28	odds	odds	NNS	_	29	com	_	_
29	ratio	ratio	NN	_	21	ppmod	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	OR	or	NN	_	29	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	of	of	IN	_	34	case	_	_
34	1.31	0	CD	_	29	ppmod	_	_
35	(	-lrb-	-LRB-	_	40	p	_	_
36	95	0	CD	_	38	num	_	_
37	%	%	NN	_	38	meta	_	_
38	CI	ci	NN	_	40	dep	_	_
39	:	:	:	_	40	p	_	_
40	1.11	0	CD	_	34	num	_	_
41	-	-	CC	_	40	cc	_	_
42	1.56	0	CD	_	40	conj	_	_
43	,	,	,	_	40	p	_	_
44	p	p	NN	_	45	dep	_	_
45	=	=	JJ	_	40	advcl	_	_
46	1.96	0	CD	_	47	num	_	_
47	x	x	NN	_	45	obj	_	_
48	10	0	CD	_	47	num	_	_
49	(	-lrb-	-LRB-	_	47	p	_	_
50	-3	0	CD	_	47	num	_	_
51	)	-rrb-	-RRB-	_	47	p	_	_
52	)	-rrb-	-RRB-	_	40	p	_	_
53	.	.	.	_	21	p	_	_

1	drug3	drug0	NN	_	3	com	_	_
2	disease	disease	NN	_	3	com	_	_
3	stage	stage	NN	_	7	dep	_	_
4	was	be	VBD	_	7	aux	_	_
5	marginally	marginally	RB	_	7	adv	_	_
6	significantly	significantly	RB	_	7	adv	_	_
7	associated	associate	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	frequency	frequency	NN	_	7	ppmod	_	_
11	of	of	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	T	t	NN	_	14	com	_	_
14	variant	variant	NN	_	10	ppmod	_	_
15	at	at	IN	_	16	case	_	_
16	drug1	drug0	NN	_	10	ppmod	_	_
17	(	-lrb-	-LRB-	_	21	p	_	_
18	p=0.057	p=0	NN	_	21	dep	_	_
19	;	;	:	_	21	p	_	_
20	adjusted	adjust	VBN	_	21	attr	_	_
21	p=0.017	p=0	NN	_	16	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	but	but	CC	_	16	cc	_	_
24	not	not	RB	_	26	neg	_	_
25	at	at	IN	_	26	case	_	_
26	drug2	drug0	NN	_	16	conj	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	p=0.5	p=0	CD	_	26	num	_	_
29	;	;	:	_	28	p	_	_
30	adjusted	adjust	VBN	_	31	attr	_	_
31	p=0.2	p=0	CD	_	28	appo	_	_
32	)	-rrb-	-RRB-	_	28	p	_	_
33	.	.	.	_	7	p	_	_

1	Comparison	comparison	NN	_	10	dep	_	_
2	between	between	IN	_	3	case	_	_
3	subjects	subject	NNS	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug3	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	the	the	DT	_	9	det	_	_
8	combined	combined	JJ	_	9	attr	_	_
9	drug4	drug0	NN	_	5	conj	_	_
10	showed	show	VBD	_	0	root	_	_
11	a	a	DT	_	13	det	_	_
12	significant	significant	JJ	_	13	attr	_	_
13	association	association	NN	_	10	obj	_	_
14	with	with	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	(	-lrb-	-LRB-	_	20	p	_	_
17	OR	or	CC	_	20	cc	_	_
18	1.47	0	NN	_	20	num	_	_
19	,	,	,	_	20	p	_	_
20	CI	ci	NN	_	15	prn	_	_
21	1.04-2.08	0	CD	_	20	num	_	_
22	;	;	:	_	20	p	_	_
23	p=0.03	p=0	CD	_	20	appo	_	_
24	)	-rrb-	-RRB-	_	20	p	_	_
25	but	but	CC	_	15	cc	_	_
26	not	not	RB	_	28	neg	_	_
27	with	with	IN	_	28	case	_	_
28	drug2	drug0	NN	_	15	conj	_	_
29	(	-lrb-	-LRB-	_	31	p	_	_
30	OR	or	CC	_	31	cc	_	_
31	1.16	0	CD	_	28	num	_	_
32	,	,	,	_	31	p	_	_
33	CI	ci	NNP	_	31	appo	_	_
34	0.81-1.64	0	CD	_	33	num	_	_
35	;	;	:	_	33	p	_	_
36	p=0.4	p=0	CD	_	33	num	_	_
37	)	-rrb-	-RRB-	_	31	p	_	_
38	.	.	.	_	10	p	_	_

1	These	these	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	are	be	VBP	_	7	aux	_	_
7	associated	associate	VBN	_	3	comp	_	_
8	with	with	IN	_	10	case	_	_
9	increased	increase	VBN	_	10	attr	_	_
10	risk	risk	NN	_	7	ppmod	_	_
11	for	for	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	Emirati	emirati	NN	_	15	com	_	_
15	subjects	subject	NNS	_	10	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	minor	minor	JJ	_	3	attr	_	_
3	alleles	allele	NNS	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	drug3	drug0	NN	_	5	conj	_	_
11	showed	show	VBD	_	0	root	_	_
12	significant	significant	JJ	_	13	attr	_	_
13	associations	association	NNS	_	11	obj	_	_
14	with	with	IN	_	15	case	_	_
15	drug6	drug0	NN	_	13	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	OR=1.48	or=0	CD	_	15	num	_	_
18	,	,	,	_	17	p	_	_
19	P=2.7	p=0	CD	_	17	conj	_	_
20	x	x	CC	_	19	cc	_	_
21	10	0	CD	_	23	num	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	-4	0	CD	_	17	conj	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	;	;	:	_	17	p	_	_
26	OR=1.39	or=0	CD	_	17	appo	_	_
27	,	,	,	_	26	p	_	_
28	P=4.6	p=0	CD	_	26	conj	_	_
29	x	x	CC	_	28	cc	_	_
30	10	0	CD	_	32	num	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	-4	0	CD	_	26	conj	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	;	;	:	_	32	p	_	_
35	OR=1.70	or=0	CD	_	26	conj	_	_
36	,	,	,	_	35	p	_	_
37	P=9.8	p=0	CD	_	26	conj	_	_
38	x	x	CC	_	37	cc	_	_
39	10	0	CD	_	41	num	_	_
40	(	-lrb-	-LRB-	_	41	p	_	_
41	-5	0	CD	_	26	conj	_	_
42	)	-rrb-	-RRB-	_	41	p	_	_
43	,	,	,	_	17	p	_	_
44	respectively	respectively	RB	_	17	adv	_	_
45	)	-rrb-	-RRB-	_	17	p	_	_
46	in	in	IN	_	50	case	_	_
47	the	the	DT	_	50	det	_	_
48	combined	combined	JJ	_	50	attr	_	_
49	sample	sample	NN	_	50	com	_	_
50	sets	set	NNS	_	15	ppmod	_	_
51	,	,	,	_	13	p	_	_
52	However	however	RB	_	13	adv	_	_
53	,	,	,	_	13	p	_	_
54	neither	neither	CC	_	13	cc	_	_
55	drug4	drug0	NN	_	13	conj	_	_
56	nor	nor	CC	_	11	cc	_	_
57	drug5	drug0	NN	_	58	dep	_	_
58	showed	show	VBD	_	11	conj	_	_
59	a	a	DT	_	61	det	_	_
60	significant	significant	JJ	_	61	attr	_	_
61	association	association	NN	_	58	obj	_	_
62	.	.	.	_	11	p	_	_

1	Significant	significant	JJ	_	2	attr	_	_
2	evidence	evidence	NN	_	6	dep	_	_
3	for	for	IN	_	4	case	_	_
4	association	association	NN	_	2	ppmod	_	_
5	was	be	VBD	_	6	aux	_	_
6	observed	observe	VBN	_	37	advcl	_	_
7	for	for	IN	_	9	case	_	_
8	high	high	JJ	_	9	attr	_	_
9	TG	tg	NN	_	6	ppmod	_	_
10	for	for	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	T	t	NN	_	13	com	_	_
13	alleles	allele	NNS	_	6	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	p	p	NN	_	15	prn	_	_
20	=	=	VBG	_	19	acl	_	_
21	0.005	0	CD	_	20	obj	_	_
22	and	and	CC	_	19	cc	_	_
23	p	p	NN	_	19	conj	_	_
24	=	=	VBG	_	23	acl	_	_
25	0.01	0	CD	_	24	obj	_	_
26	)	-rrb-	-RRB-	_	19	p	_	_
27	in	in	IN	_	30	case	_	_
28	Mexican	mexican	NN	_	30	com	_	_
29	drug3	drug0	NN	_	30	com	_	_
30	families	family	NNS	_	15	ppmod	_	_
31	,	,	,	_	37	p	_	_
32	No	no	DT	_	33	det	_	_
33	evidence	evidence	NN	_	37	dep	_	_
34	for	for	IN	_	35	case	_	_
35	association	association	NN	_	33	ppmod	_	_
36	was	be	VBD	_	37	aux	_	_
37	observed	observe	VBN	_	0	root	_	_
38	for	for	IN	_	39	case	_	_
39	drug4	drug0	NN	_	37	ppmod	_	_
40	,	,	,	_	39	p	_	_
41	drug5	drug0	NN	_	39	appo	_	_
42	,	,	,	_	39	p	_	_
43	drug6	drug0	NN	_	39	appo	_	_
44	in	in	IN	_	45	case	_	_
45	Mexicans	mexicans	NNP	_	37	ppmod	_	_
46	.	.	.	_	37	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	testing	test	VBG	_	18	advcl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	for	for	IN	_	7	case	_	_
7	replication	replication	NN	_	2	ppmod	_	_
8	in	in	IN	_	11	case	_	_
9	Finnish	finnish	NN	_	11	com	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	families	family	NNS	_	7	ppmod	_	_
12	,	,	,	_	18	p	_	_
13	these	these	DT	_	16	det	_	_
14	single	single	JJ	_	16	attr	_	_
15	nucleotide	nucleotide	NN	_	16	com	_	_
16	polymorphisms	polymorphism	NNS	_	18	dep	_	_
17	were	be	VBD	_	18	aux	_	_
18	associated	associate	VBN	_	0	root	_	_
19	with	with	IN	_	20	case	_	_
20	drug4	drug0	NN	_	18	ppmod	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	p	p	NN	_	18	prn	_	_
23	=	=	JJ	_	22	attr	_	_
24	0.01	0	CD	_	23	num	_	_
25	and	and	CC	_	22	cc	_	_
26	p	p	NN	_	22	conj	_	_
27	=	=	JJ	_	22	attr	_	_
28	0.007	0	CD	_	27	num	_	_
29	)	-rrb-	-RRB-	_	22	p	_	_
30	.	.	.	_	18	p	_	_

1	These	these	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	show	show	VBP	_	0	root	_	_
4	that	that	IN	_	10	mark	_	_
5	drug1	drug0	NN	_	10	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	are	be	VBP	_	10	aux	_	_
9	significantly	significantly	RB	_	10	adv	_	_
10	associated	associate	VBN	_	3	comp	_	_
11	with	with	IN	_	13	case	_	_
12	high	high	JJ	_	13	attr	_	_
13	drug3	drug0	NN	_	10	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	drug4	drug0	NN	_	16	com	_	_
16	families	family	NNS	_	13	ppmod	_	_
17	from	from	IN	_	20	case	_	_
18	two	#crd#	CD	_	20	num	_	_
19	different	different	JJ	_	20	attr	_	_
20	populations	population	NNS	_	16	ppmod	_	_
21	.	.	.	_	3	p	_	_

1	These	these	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	11	mark	_	_
5	the	the	DT	_	9	det	_	_
6	TCF7L2	tcf0l0	NN	_	9	attr	_	_
7	drug1	drug0	NN	_	9	attr	_	_
8	genetic	genetic	JJ	_	9	attr	_	_
9	variation	variation	NN	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	associated	associate	VBN	_	3	comp	_	_
12	with	with	IN	_	15	case	_	_
13	an	an	DT	_	15	det	_	_
14	increased	increase	VBN	_	15	attr	_	_
15	risk	risk	NN	_	11	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	One	#crd#	CD	_	3	num	_	_
2	representative	representative	JJ	_	3	attr	_	_
3	variant	variant	NN	_	9	dep	_	_
4	,	,	,	_	3	p	_	_
5	drug1	drug0	NN	_	3	appo	_	_
6	,	,	,	_	3	p	_	_
7	was	be	VBD	_	9	aux	_	_
8	nominally	nominally	RB	_	9	adv	_	_
9	associated	associate	VBN	_	0	root	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	in	in	IN	_	15	case	_	_
13	a	a	DT	_	15	det	_	_
14	general	general	JJ	_	15	attr	_	_
15	model	model	NN	_	11	ppmod	_	_
16	(	-lrb-	-LRB-	_	18	p	_	_
17	additive	additive	JJ	_	18	attr	_	_
18	P	p	NN	_	15	prn	_	_
19	=	=	JJ	_	18	attr	_	_
20	0.03	0	CD	_	19	num	_	_
21	,	,	,	_	18	p	_	_
22	dominant	dominant	JJ	_	23	attr	_	_
23	P	p	NN	_	24	dep	_	_
24	=	=	JJ	_	18	advcl	_	_
25	0.005	0	CD	_	24	obj	_	_
26	)	-rrb-	-RRB-	_	18	p	_	_
27	but	but	CC	_	15	cc	_	_
28	not	not	RB	_	32	neg	_	_
29	in	in	IN	_	32	case	_	_
30	a	a	DT	_	32	det	_	_
31	within-family	within-family	JJ	_	32	attr	_	_
32	analysis	analysis	NN	_	15	conj	_	_
33	(	-lrb-	-LRB-	_	35	p	_	_
34	additive	additive	JJ	_	35	attr	_	_
35	P	p	NN	_	32	prn	_	_
36	=	=	JJ	_	35	attr	_	_
37	0.2	0	CD	_	36	num	_	_
38	,	,	,	_	35	p	_	_
39	dominant	dominant	JJ	_	40	attr	_	_
40	P	p	NN	_	41	dep	_	_
41	=	=	JJ	_	35	advcl	_	_
42	0.07	0	CD	_	41	obj	_	_
43	)	-rrb-	-RRB-	_	35	p	_	_
44	.	.	.	_	9	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	several	several	JJ	_	4	attr	_	_
4	variants	variant	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	associated	associate	VBN	_	15	advcl	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	;	;	:	_	15	p	_	_
10	in	in	IN	_	11	case	_	_
11	particular	particular	JJ	_	15	ppmod	_	_
12	,	,	,	_	15	p	_	_
13	drug1	drug0	NN	_	15	dep	_	_
14	was	be	VBD	_	15	aux	_	_
15	associated	associate	VBN	_	0	root	_	_
16	in	in	IN	_	21	case	_	_
17	both	both	CC	_	18	cc	_	_
18	general	general	JJ	_	21	attr	_	_
19	and	and	CC	_	18	cc	_	_
20	within-family	within-family	JJ	_	18	conj	_	_
21	analyses	analysis	NNS	_	15	ppmod	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	both	both	CC	_	24	cc	_	_
24	P	p	NN	_	15	prn	_	_
25	=	=	JJ	_	24	attr	_	_
26	0.0007	0	CD	_	25	num	_	_
27	)	-rrb-	-RRB-	_	24	p	_	_
28	.	.	.	_	15	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	association	association	NN	_	2	obj	_	_
5	between	between	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	in	in	IN	_	13	case	_	_
10	the	the	DT	_	13	det	_	_
11	UK	uk	JJ	_	13	attr	_	_
12	case-control	case-control	JJ	_	13	attr	_	_
13	study	study	NN	_	2	ppmod	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	Cochran-Armitage	cochran-armitage	NN	_	16	com	_	_
16	test	test	NN	_	13	prn	_	_
17	,	,	,	_	16	p	_	_
18	p	p	NN	_	19	dep	_	_
19	=	=	JJ	_	16	advcl	_	_
20	0.51	0	CD	_	19	obj	_	_
21	)	-rrb-	-RRB-	_	16	p	_	_
22	;	;	:	_	13	p	_	_
23	nor	nor	CC	_	13	cc	_	_
24	with	with	IN	_	26	case	_	_
25	symptomatic	symptomatic	JJ	_	26	attr	_	_
26	status	status	NN	_	13	conj	_	_
27	in	in	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	Finnish	finnish	JJ	_	30	attr	_	_
30	cohort	cohort	NN	_	26	ppmod	_	_
31	(	-lrb-	-LRB-	_	34	p	_	_
32	p	p	NN	_	34	attr	_	_
33	=	=	JJ	_	34	attr	_	_
34	0.36	0	NN	_	30	num	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	5	ppmod	_	_
3	,	,	,	_	5	p	_	_
4	there	there	EX	_	5	dep	_	_
5	were	be	VBD	_	0	root	_	_
6	no	no	DT	_	7	det	_	_
7	relationships	relationship	NNS	_	5	obj	_	_
8	between	between	IN	_	14	case	_	_
9	the	the	DT	_	13	det	_	_
10	TCF7L2	tcf0l0	NN	_	13	attr	_	_
11	single	single	JJ	_	13	attr	_	_
12	nucleotide	nucleotide	NN	_	13	com	_	_
13	polymorphism	polymorphism	NN	_	14	com	_	_
14	drug1	drug0	NN	_	7	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	(	-lrb-	-LRB-	_	36	p	_	_
18	UK	uk	JJ	_	19	attr	_	_
19	cases	case	NNS	_	36	dep	_	_
20	,	,	,	_	36	p	_	_
21	p	p	NN	_	36	dep	_	_
22	=	=	JJ	_	21	attr	_	_
23	0.99	0	CD	_	22	num	_	_
24	;	;	:	_	36	p	_	_
25	Finnish	finnish	NN	_	26	com	_	_
26	controls	control	NNS	_	36	dep	_	_
27	,	,	,	_	36	p	_	_
28	p	p	NN	_	36	dep	_	_
29	=	=	JJ	_	28	attr	_	_
30	0.57	0	CD	_	29	num	_	_
31	;	;	:	_	36	p	_	_
32	Finnish	finnish	JJ	_	34	attr	_	_
33	symptomatic	symptomatic	JJ	_	34	attr	_	_
34	cases	case	NNS	_	36	dep	_	_
35	,	,	,	_	36	p	_	_
36	p	p	NN	_	5	prn	_	_
37	=	=	JJ	_	36	attr	_	_
38	0.80	0	CD	_	37	num	_	_
39	)	-rrb-	-RRB-	_	36	p	_	_
40	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	frequency	frequency	NN	_	13	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	T	t	NN	_	6	com	_	_
6	allele	allele	NN	_	2	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	both	both	DT	_	9	det	_	_
9	drug1	drug0	NN	_	2	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	polymorphisms	polymorphism	NNS	_	9	conj	_	_
13	was	be	VBD	_	0	root	_	_
14	significantly	significantly	RB	_	15	adv	_	_
15	higher	high	JJR	_	13	dep	_	_
16	in	in	IN	_	18	case	_	_
17	drug3	drug0	NN	_	18	com	_	_
18	subjects	subject	NNS	_	13	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	23	0	CD	_	18	num	_	_
21	%	%	NN	_	20	meta	_	_
22	and	and	CC	_	20	cc	_	_
23	33	0	CD	_	20	conj	_	_
24	%	%	NN	_	23	meta	_	_
25	)	-rrb-	-RRB-	_	20	p	_	_
26	compared	compare	VBN	_	28	adv	_	_
27	to	to	TO	_	28	aux	_	_
28	that	that	DT	_	13	ppmod	_	_
29	in	in	IN	_	32	case	_	_
30	normal	normal	JJ	_	32	attr	_	_
31	glucose-tolerant	glucose-tolerant	JJ	_	32	attr	_	_
32	subjects	subject	NNS	_	28	ppmod	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	19	0	CD	_	13	num	_	_
35	%	%	NN	_	34	meta	_	_
36	and	and	CC	_	34	cc	_	_
37	28	0	CD	_	34	conj	_	_
38	%	%	NN	_	37	meta	_	_
39	;	;	:	_	34	p	_	_
40	P	p	NN	_	45	dep	_	_
41	=	=	JJ	_	40	attr	_	_
42	.001	0	CD	_	41	num	_	_
43	and	and	CC	_	40	cc	_	_
44	P	p	NN	_	40	conj	_	_
45	=	=	JJ	_	34	advcl	_	_
46	.0001	0	CD	_	45	obj	_	_
47	,	,	,	_	45	p	_	_
48	respectively	respectively	RB	_	45	adv	_	_
49	)	-rrb-	-RRB-	_	34	p	_	_
50	.	.	.	_	13	p	_	_

1	Normal	normal	JJ	_	3	attr	_	_
2	glucose-tolerant	glucose-tolerant	JJ	_	3	attr	_	_
3	subjects	subject	NNS	_	10	dep	_	_
4	with	with	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	TT	tt	NN	_	7	com	_	_
7	genotype	genotype	NN	_	3	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	had	have	VBD	_	0	root	_	_
11	significantly	significantly	RB	_	12	adv	_	_
12	higher	high	JJR	_	13	attr	_	_
13	drug2	drug0	NN	_	10	obj	_	_
14	(	-lrb-	-LRB-	_	22	p	_	_
15	mean	mean	NN	_	22	dep	_	_
16	+/-	+/-	CC	_	15	cc	_	_
17	SD	sd	NN	_	15	conj	_	_
18	,	,	,	_	22	p	_	_
19	6.1	0	CD	_	22	num	_	_
20	+/-	+/-	CC	_	19	cc	_	_
21	1.4	0	CD	_	19	conj	_	_
22	mmol/L	mmol/l	NN	_	13	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	than	than	IN	_	25	case	_	_
25	those	those	DT	_	10	ppmod	_	_
26	with	with	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	GG	gg	NN	_	29	com	_	_
29	genotype	genotype	NN	_	25	ppmod	_	_
30	(	-lrb-	-LRB-	_	34	p	_	_
31	5.6	0	CD	_	34	num	_	_
32	+/-	+/-	CC	_	31	cc	_	_
33	1.0	0	CD	_	31	conj	_	_
34	mmol/L	mmol/l	NN	_	29	prn	_	_
35	,	,	,	_	34	p	_	_
36	P	p	NN	_	37	dep	_	_
37	=	=	JJ	_	34	advcl	_	_
38	.011	0	CD	_	37	obj	_	_
39	)	-rrb-	-RRB-	_	34	p	_	_
40	.	.	.	_	10	p	_	_

1	Normal	normal	JJ	_	3	attr	_	_
2	glucose-tolerant	glucose-tolerant	JJ	_	3	attr	_	_
3	subjects	subject	NNS	_	11	dep	_	_
4	with	with	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	TT	tt	NN	_	7	com	_	_
7	genotype	genotype	NN	_	3	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	polymorphism	polymorphism	NN	_	7	ppmod	_	_
11	had	have	VBD	_	0	root	_	_
12	significantly	significantly	RB	_	13	adv	_	_
13	higher	high	JJR	_	14	attr	_	_
14	drug2	drug0	NN	_	11	obj	_	_
15	(	-lrb-	-LRB-	_	23	p	_	_
16	mean	mean	NN	_	23	dep	_	_
17	+/-	+/-	CC	_	16	cc	_	_
18	SD	sd	NN	_	16	conj	_	_
19	,	,	,	_	23	p	_	_
20	6.0	0	CD	_	23	num	_	_
21	+/-	+/-	CC	_	20	cc	_	_
22	1.3	0	CD	_	20	conj	_	_
23	mmol/L	mmol/l	NN	_	14	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	than	than	IN	_	26	case	_	_
26	those	those	DT	_	11	ppmod	_	_
27	with	with	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	CC	cc	NN	_	30	com	_	_
30	genotype	genotype	NN	_	26	ppmod	_	_
31	(	-lrb-	-LRB-	_	35	p	_	_
32	5.6	0	CD	_	35	num	_	_
33	+/-	+/-	CC	_	32	cc	_	_
34	1.0	0	CD	_	32	conj	_	_
35	mmol/L	mmol/l	NN	_	30	prn	_	_
36	,	,	,	_	35	p	_	_
37	P	p	NN	_	38	dep	_	_
38	=	=	JJ	_	35	advcl	_	_
39	.004	0	CD	_	38	obj	_	_
40	)	-rrb-	-RRB-	_	35	p	_	_
41	.	.	.	_	11	p	_	_

1	In	in	IN	_	2	case	_	_
2	conclusion	conclusion	NN	_	16	ppmod	_	_
3	,	,	,	_	16	p	_	_
4	the	the	DT	_	6	det	_	_
5	T	t	NN	_	6	com	_	_
6	allele	allele	NN	_	16	dep	_	_
7	of	of	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	polymorphisms	polymorphism	NNS	_	9	conj	_	_
13	of	of	IN	_	15	case	_	_
14	TCF7L2	tcf0l0	NN	_	15	com	_	_
15	gene	gene	NN	_	9	ppmod	_	_
16	confer	confer	VBP	_	0	root	_	_
17	susceptibility	susceptibility	NN	_	16	obj	_	_
18	to	to	TO	_	19	aux	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	Asian	asian	NNP	_	22	com	_	_
22	Indians	indians	NNP	_	16	ppmod	_	_
23	.	.	.	_	16	p	_	_

1	The	the	DT	_	3	det	_	_
2	CT/TT	ct/tt	NN	_	3	com	_	_
3	genotypes	genotype	NNS	_	8	dep	_	_
4	of	of	IN	_	6	case	_	_
5	SNP	snp	NN	_	6	com	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	strongly	strongly	RB	_	8	adv	_	_
8	predicted	predict	VBD	_	0	root	_	_
9	future	future	JJ	_	10	attr	_	_
10	drug2	drug0	NN	_	8	obj	_	_
11	in	in	IN	_	14	case	_	_
12	2	0	CD	_	14	num	_	_
13	independent	independent	JJ	_	14	attr	_	_
14	cohorts	cohort	NNS	_	10	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	Swedish	swedish	NNP	_	14	prn	_	_
17	and	and	CC	_	16	cc	_	_
18	Finnish	finnish	NNP	_	16	conj	_	_
19	)	-rrb-	-RRB-	_	16	p	_	_
20	.	.	.	_	8	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	extend	extend	VBP	_	0	root	_	_
4	previous	previous	JJ	_	5	attr	_	_
5	observations	observation	NNS	_	3	obj	_	_
6	to	to	TO	_	9	aux	_	_
7	other	other	JJ	_	9	attr	_	_
8	ethnic	ethnic	JJ	_	9	attr	_	_
9	groups	group	NNS	_	3	ppmod	_	_
10	,	,	,	_	3	p	_	_
11	and	and	CC	_	3	cc	_	_
12	strongly	strongly	RB	_	13	adv	_	_
13	confirm	confirm	VBP	_	3	conj	_	_
14	that	that	IN	_	17	mark	_	_
15	drug1	drug0	NN	_	16	com	_	_
16	genotype	genotype	NN	_	17	dep	_	_
17	is	be	VBZ	_	13	comp	_	_
18	a	a	DT	_	21	det	_	_
19	major	major	JJ	_	21	attr	_	_
20	risk	risk	NN	_	21	com	_	_
21	factor	factor	NN	_	17	obj	_	_
22	for	for	IN	_	23	case	_	_
23	development	development	NN	_	21	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	3	p	_	_

1	However	however	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	GLP-1-infusion	glp-0-infusion	NN	_	9	dep	_	_
4	combined	combine	VBN	_	3	acl	_	_
5	with	with	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	hyperglycaemic	hyperglycaemic	JJ	_	8	attr	_	_
8	clamp	clamp	NN	_	4	ppmod	_	_
9	showed	show	VBD	_	0	root	_	_
10	a	a	DT	_	12	det	_	_
11	significant	significant	JJ	_	12	attr	_	_
12	reduction	reduction	NN	_	9	obj	_	_
13	in	in	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	carriers	carrier	NNS	_	12	ppmod	_	_
17	of	of	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	risk	risk	NN	_	20	com	_	_
20	allele	allele	NN	_	16	ppmod	_	_
21	in	in	IN	_	23	case	_	_
22	two	#crd#	CD	_	23	num	_	_
23	variants	variant	NNS	_	20	ppmod	_	_
24	(	-lrb-	-LRB-	_	28	p	_	_
25	drug1	drug0	NN	_	28	com	_	_
26	drug2	drug0	NN	_	28	com	_	_
27	p	p	NN	_	28	com	_	_
28	<	<	NN	_	23	prn	_	_
29	0.02	0	CD	_	28	num	_	_
30	)	-rrb-	-RRB-	_	28	p	_	_
31	,	,	,	_	9	p	_	_

1	we	we	PRP	_	2	dep	_	_
2	analysed	analyse	VBD	_	0	root	_	_
3	two	#crd#	CD	_	6	num	_	_
4	single	single	JJ	_	6	attr	_	_
5	nucleotide	nucleotide	NN	_	6	com	_	_
6	polymorphisms	polymorphism	NNS	_	2	obj	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	SNPs	snp	NNS	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	,	,	,	_	6	p	_	_
11	drug1	drug0	NN	_	6	appo	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	,	,	,	_	6	p	_	_
15	in	in	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	transcription	transcription	NN	_	18	com	_	_
18	factor	factor	NN	_	6	ppmod	_	_
19	7-like	0-like	NN	_	21	attr	_	_
20	2	0	CD	_	21	num	_	_
21	gene	gene	NN	_	18	attr	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	TCF7L2	tcf0l0	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	,	,	,	_	6	p	_	_
26	which	which	WDT	_	28	dep	_	_
27	are	be	VBP	_	28	aux	_	_
28	associated	associate	VBN	_	6	relcl	_	_
29	with	with	IN	_	32	case	_	_
30	an	an	DT	_	32	det	_	_
31	increased	increase	VBN	_	32	attr	_	_
32	risk	risk	NN	_	28	ppmod	_	_
33	of	of	IN	_	34	case	_	_
34	drug3	drug0	NN	_	32	ppmod	_	_
35	.	.	.	_	2	p	_	_

1	Both	both	DT	_	3	det	_	_
2	TCF7L2	tcf0l0	NN	_	3	com	_	_
3	SNPs	snp	NNS	_	10	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug1	drug0	NN	_	3	prn	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	)	-rrb-	-RRB-	_	5	p	_	_
9	were	be	VBD	_	10	aux	_	_
10	found	find	VBN	_	0	root	_	_
11	to	to	TO	_	14	aux	_	_
12	be	be	VB	_	14	aux	_	_
13	significantly	significantly	RB	_	14	adv	_	_
14	associated	associate	VBN	_	10	comp	_	_
15	with	with	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	when	when	WRB	_	18	adv	_	_
18	adjusting	adjust	VBG	_	10	advcl	_	_
19	for	for	IN	_	21	case	_	_
20	insulin	insulin	NN	_	21	com	_	_
21	sensitivity	sensitivity	NN	_	18	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	both	both	CC	_	21	cc	_	_
24	in	in	IN	_	27	case	_	_
25	the	the	DT	_	27	det	_	_
26	whole	whole	JJ	_	27	attr	_	_
27	cohort	cohort	NN	_	21	conj	_	_
28	and	and	CC	_	18	cc	_	_
29	when	when	WRB	_	34	adv	_	_
30	the	the	DT	_	32	det	_	_
31	diabetic	diabetic	JJ	_	32	attr	_	_
32	subjects	subject	NNS	_	34	dep	_	_
33	were	be	VBD	_	34	aux	_	_
34	excluded	exclude	VBN	_	18	conj	_	_
35	.	.	.	_	10	p	_	_

1	The	the	DT	_	4	det	_	_
2	most	most	RBS	_	3	adv	_	_
3	significant	significant	JJ	_	4	attr	_	_
4	associations	association	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	observed	observe	VBN	_	69	advcl	_	_
7	with	with	IN	_	12	case	_	_
8	TCF7L2	tcf0l0	NN	_	12	attr	_	_
9	intron	intron	NN	_	12	attr	_	_
10	3	0	CD	_	12	num	_	_
11	SNPs	snps	NN	_	12	com	_	_
12	drug1	drug0	NN	_	6	ppmod	_	_
13	(	-lrb-	-LRB-	_	31	p	_	_
14	additive	additive	JJ	_	15	attr	_	_
15	P	p	NN	_	31	dep	_	_
16	=	=	JJ	_	15	attr	_	_
17	4.10	0	CD	_	16	num	_	_
18	x	x	CC	_	17	cc	_	_
19	10	0	CD	_	17	conj	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	-6	0	CD	_	17	num	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	,	,	,	_	31	p	_	_
24	odds	odds	NNS	_	31	dep	_	_
25	ratio	ratio	NN	_	26	com	_	_
26	-LSB-OR	-lsb-or	NN	_	24	attr	_	_
27	]	-rsb-	-RRB-	_	26	p	_	_
28	1.51	0	CD	_	26	num	_	_
29	;	;	:	_	31	p	_	_
30	admixture-adjusted	admixture-adjusted	JJ	_	31	attr	_	_
31	P	p	NN	_	12	prn	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	a	a	NN	_	31	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	=	=	JJ	_	31	attr	_	_
36	3.77	0	CD	_	35	num	_	_
37	x	x	CC	_	36	cc	_	_
38	10	0	CD	_	36	conj	_	_
39	(	-lrb-	-LRB-	_	40	p	_	_
40	-6	0	CD	_	36	num	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	)	-rrb-	-RRB-	_	31	p	_	_
43	and	and	CC	_	12	cc	_	_
44	drug2	drug0	NN	_	12	conj	_	_
45	(	-lrb-	-LRB-	_	58	p	_	_
46	P	p	NN	_	58	dep	_	_
47	=	=	VBG	_	46	acl	_	_
48	0.001	0	CD	_	47	obj	_	_
49	,	,	,	_	46	p	_	_
50	OR	or	CC	_	46	cc	_	_
51	1.30	0	CD	_	46	conj	_	_
52	;	;	:	_	58	p	_	_
53	P	p	NN	_	57	advnp	_	_
54	(	-lrb-	-LRB-	_	57	p	_	_
55	a	a	NN	_	57	advnp	_	_
56	)	-rrb-	-RRB-	_	57	p	_	_
57	=	=	JJ	_	58	attr	_	_
58	0.003	0	CD	_	6	num	_	_
59	)	-rrb-	-RRB-	_	58	p	_	_
60	,	,	,	_	69	p	_	_
61	The	the	DT	_	63	det	_	_
62	2-SNP	0-snp	JJ	_	63	attr	_	_
63	haplotype	haplotype	NN	_	69	dep	_	_
64	containing	contain	VBG	_	63	acl	_	_
65	these	these	DT	_	66	det	_	_
66	SNPs	snp	NNS	_	64	obj	_	_
67	was	be	VBD	_	69	aux	_	_
68	also	also	RB	_	69	adv	_	_
69	associated	associate	VBN	_	0	root	_	_
70	with	with	IN	_	71	case	_	_
71	drug3	drug0	NN	_	69	ppmod	_	_
72	(	-lrb-	-LRB-	_	74	p	_	_
73	P	p	NN	_	74	dep	_	_
74	=	=	JJ	_	69	prn	_	_
75	3	0	CD	_	76	num	_	_
76	x	x	NN	_	74	obj	_	_
77	10	0	CD	_	76	num	_	_
78	(	-lrb-	-LRB-	_	76	p	_	_
79	-5	0	CD	_	76	num	_	_
80	)	-rrb-	-RRB-	_	76	p	_	_
81	)	-rrb-	-RRB-	_	74	p	_	_

1	The	the	DT	_	4	det	_	_
2	previously	previously	RB	_	3	adv	_	_
3	reported	report	VBN	_	4	attr	_	_
4	SNPs	snp	NNS	_	12	dep	_	_
5	drug1	drug0	NN	_	4	appo	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	of	of	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	TCF7L2	tcf0l0	NN	_	11	com	_	_
11	gene	gene	NN	_	4	ppmod	_	_
12	were	be	VBD	_	0	root	_	_
13	rare	rare	JJ	_	12	dep	_	_
14	and	and	CC	_	12	cc	_	_
15	were	be	VBD	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	associated	associate	VBN	_	12	conj	_	_
18	with	with	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	in	in	IN	_	23	case	_	_
21	a	a	DT	_	23	det	_	_
22	Chinese	chinese	JJ	_	23	attr	_	_
23	population	population	NN	_	19	ppmod	_	_
24	,	,	,	_	19	p	_	_
25	which	which	WDT	_	27	dep	_	_
26	may	may	MD	_	27	modal	_	_
27	attribute	attribute	VB	_	19	relcl	_	_
28	to	to	TO	_	31	aux	_	_
29	the	the	DT	_	31	det	_	_
30	low	low	JJ	_	31	attr	_	_
31	frequencies	frequency	NNS	_	27	ppmod	_	_
32	of	of	IN	_	35	case	_	_
33	these	these	DT	_	35	det	_	_
34	two	#crd#	CD	_	35	num	_	_
35	SNPs	snp	NNS	_	31	ppmod	_	_
36	.	.	.	_	12	p	_	_

1	SNP	snp	NN	_	2	com	_	_
2	drug1	drug0	NN	_	18	dep	_	_
3	located	located	JJ	_	2	attr	_	_
4	in	in	IN	_	7	case	_	_
5	an	an	DT	_	7	det	_	_
6	LD	ld	NN	_	7	com	_	_
7	block	block	NN	_	3	ppmod	_	_
8	close	close	JJ	_	7	attr	_	_
9	to	to	TO	_	13	aux	_	_
10	the	the	DT	_	13	det	_	_
11	3	0	CD	_	13	num	_	_
12	'	'	``	_	13	p	_	_
13	end	end	NN	_	8	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	gene	gene	NN	_	13	ppmod	_	_
17	was	be	VBD	_	18	aux	_	_
18	associated	associate	VBN	_	0	root	_	_
19	with	with	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	(	-lrb-	-LRB-	_	29	p	_	_
22	allele-specific	allele-specific	JJ	_	23	attr	_	_
23	P	p	NN	_	24	dep	_	_
24	=	=	JJ	_	29	advcl	_	_
25	0.0021	0	CD	_	24	obj	_	_
26	;	;	:	_	29	p	_	_
27	permuted	permuted	JJ	_	28	attr	_	_
28	P	p	NN	_	29	dep	_	_
29	=	=	JJ	_	18	prn	_	_
30	0.03	0	CD	_	29	obj	_	_
31	)	-rrb-	-RRB-	_	29	p	_	_
32	.	.	.	_	18	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	studied	study	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	TCF7L2	tcf0l0	NN	_	7	com	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	genotypes	genotype	NNS	_	7	conj	_	_
11	on	on	IN	_	12	case	_	_
12	drug3	drug0	NN	_	4	ppmod	_	_

1	We	we	PRP	_	2	dep	_	_
2	observed	observe	VBD	_	0	root	_	_
3	a	a	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	association	association	NN	_	2	obj	_	_
6	between	between	IN	_	13	case	_	_
7	the	the	DT	_	13	det	_	_
8	single-nucleotide	single-nucleotide	JJ	_	9	attr	_	_
9	polymorphism	polymorphism	NN	_	13	attr	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	SNP	snp	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	drug1	drug0	NN	_	5	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	the	the	DT	_	17	det	_	_
16	microsatellite	microsatellite	NN	_	17	com	_	_
17	drug2	drug0	NN	_	13	conj	_	_
18	with	with	IN	_	19	case	_	_
19	drug3	drug0	NN	_	5	ppmod	_	_
20	in	in	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	Mexican	mexican	NN	_	23	com	_	_
23	sample	sample	NN	_	2	ppmod	_	_

1	The	the	DT	_	3	det	_	_
2	SNP	snp	NN	_	3	com	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	shows	show	VBZ	_	0	root	_	_
5	similar	similar	JJ	_	6	attr	_	_
6	trends	trend	NNS	_	4	obj	_	_
7	,	,	,	_	4	p	_	_
8	but	but	CC	_	4	cc	_	_
9	its	its	PRP$	_	10	poss	_	_
10	association	association	NN	_	13	dep	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	is	be	VBZ	_	4	conj	_	_
14	not	not	RB	_	13	neg	_	_
15	as	as	RB	_	16	adv	_	_
16	strong	strong	JJ	_	13	dep	_	_
17	(	-lrb-	-LRB-	_	20	p	_	_
18	OR	or	NN	_	19	advnp	_	_
19	=	=	JJ	_	20	attr	_	_
20	1.39	0	CD	_	16	num	_	_
21	,	,	,	_	20	p	_	_
22	p	p	NN	_	23	dep	_	_
23	=	=	JJ	_	20	advcl	_	_
24	0.152	0	CD	_	23	obj	_	_
25	)	-rrb-	-RRB-	_	20	p	_	_
26	.	.	.	_	4	p	_	_

1	In	in	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	DPS	dps	NN	_	12	ppmod	_	_
4	,	,	,	_	12	p	_	_
5	the	the	DT	_	7	det	_	_
6	TT	tt	NN	_	7	com	_	_
7	genotype	genotype	NN	_	12	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	was	be	VBD	_	12	aux	_	_
11	significantly	significantly	RB	_	12	adv	_	_
12	associated	associate	VBN	_	0	root	_	_
13	with	with	IN	_	17	case	_	_
14	an	an	DT	_	17	det	_	_
15	adjusted	adjust	VBN	_	17	attr	_	_
16	2.85-fold	0-fold	JJ	_	17	attr	_	_
17	risk	risk	NN	_	12	ppmod	_	_
18	(	-lrb-	-LRB-	_	26	p	_	_
19	95	0	CD	_	21	num	_	_
20	%	%	NN	_	21	meta	_	_
21	CI	ci	NN	_	26	dep	_	_
22	1.17-6.95	0	CD	_	21	num	_	_
23	,	,	,	_	26	p	_	_
24	p	p	NN	_	26	attr	_	_
25	=	=	JJ	_	26	attr	_	_
26	0.021	0	NN	_	17	num	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	of	of	IN	_	30	case	_	_
29	incident	incident	JJ	_	30	attr	_	_
30	drug2	drug0	NNS	_	17	ppmod	_	_
31	in	in	IN	_	34	case	_	_
32	the	the	DT	_	34	det	_	_
33	control	control	JJ	_	34	attr	_	_
34	group	group	NN	_	30	ppmod	_	_
35	,	,	,	_	34	p	_	_
36	but	but	CC	_	34	cc	_	_
37	not	not	RB	_	41	neg	_	_
38	in	in	IN	_	41	case	_	_
39	the	the	DT	_	41	det	_	_
40	intervention	intervention	NN	_	41	com	_	_
41	group	group	NN	_	34	conj	_	_
42	.	.	.	_	12	p	_	_

1	The	the	DT	_	3	det	_	_
2	T	t	NN	_	3	com	_	_
3	allele	allele	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	was	be	VBD	_	8	aux	_	_
7	significantly	significantly	RB	_	8	adv	_	_
8	associated	associate	VBN	_	0	root	_	_
9	with	with	IN	_	11	case	_	_
10	decreased	decrease	VBN	_	11	attr	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	Studies	study	NNS	_	8	prn	_	_
14	II	ii	CD	_	13	num	_	_
15	,	,	,	_	13	p	_	_
16	III	iii	CD	_	13	appo	_	_
17	)	-rrb-	-RRB-	_	13	p	_	_
18	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	variant	variant	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	TCF7L2	tcf0l0	NN	_	4	ppmod	_	_
7	was	be	VBD	_	8	aux	_	_
8	associated	associate	VBN	_	0	root	_	_
9	with	with	IN	_	11	case	_	_
10	incident	incident	JJ	_	11	attr	_	_
11	drug2	drug0	NNS	_	8	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	DPS	dps	NN	_	11	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	in	in	IN	_	21	case	_	_
17	a	a	DT	_	21	det	_	_
18	separate	separate	JJ	_	21	attr	_	_
19	population-based	population-based	JJ	_	21	attr	_	_
20	cross-sectional	cross-sectional	JJ	_	21	attr	_	_
21	study	study	NN	_	14	conj	_	_
22	.	.	.	_	8	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	genotyped	genotyped	VBD	_	0	root	_	_
3	6,516	0	NN	_	4	num	_	_
4	participants	participant	NNS	_	2	obj	_	_
5	for	for	IN	_	6	case	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	and	and	CC	_	2	cc	_	_
10	analysed	analyse	VBN	_	2	conj	_	_
11	the	the	DT	_	12	det	_	_
12	role	role	NN	_	10	obj	_	_
13	in	in	IN	_	15	case	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	susceptibility	susceptibility	NN	_	12	ppmod	_	_
16	using	use	VBG	_	10	comp	_	_
17	binary	binary	JJ	_	19	attr	_	_
18	logistic	logistic	NN	_	19	com	_	_
19	regression.	regression.	NN	_	16	obj	_	_
20	Age	age	NN	_	27	dep	_	_
21	,	,	,	_	20	p	_	_
22	sex	sex	NN	_	20	conj	_	_
23	and	and	CC	_	22	cc	_	_
24	obesity	obesity	NN	_	25	com	_	_
25	status	status	NN	_	20	conj	_	_
26	were	be	VBD	_	27	aux	_	_
27	examined	examine	VBN	_	16	comp	_	_
28	as	as	IN	_	29	case	_	_
29	covariates	covariate	NNS	_	27	ppmod	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	All	all	DT	_	5	det	_	_
4	investigated	investigate	VBN	_	5	attr	_	_
5	polymorphisms	polymorphism	NNS	_	8	dep	_	_
6	were	be	VBD	_	8	aux	_	_
7	significantly	significantly	RB	_	8	adv	_	_
8	associated	associate	VBN	_	1	acl	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	8	p	_	_
12	and	and	CC	_	8	cc	_	_
13	drug1	drug0	NN	_	14	dep	_	_
14	showed	show	VBD	_	8	conj	_	_
15	the	the	DT	_	17	det	_	_
16	strongest	strong	JJS	_	17	attr	_	_
17	association	association	NN	_	14	obj	_	_
18	(	-lrb-	-LRB-	_	32	p	_	_
19	T	t	NN	_	32	dep	_	_
20	vs	vs	CC	_	19	cc	_	_
21	G	g	NN	_	19	conj	_	_
22	,	,	,	_	32	p	_	_
23	chi2	chi0	NN	_	32	dep	_	_
24	=	=	JJ	_	23	attr	_	_
25	9.20	0	CD	_	24	num	_	_
26	,	,	,	_	32	p	_	_
27	p	p	NN	_	29	attr	_	_
28	=	=	JJ	_	29	attr	_	_
29	0.0024	0	NN	_	32	num	_	_
30	,	,	,	_	32	p	_	_
31	odds	odds	NNS	_	32	com	_	_
32	ratio	ratio	NN	_	17	prn	_	_
33	=	=	JJ	_	32	attr	_	_
34	1.70	0	CD	_	33	num	_	_
35	,	,	,	_	32	p	_	_
36	95	0	CD	_	38	num	_	_
37	%	%	NN	_	38	meta	_	_
38	CI	ci	CD	_	39	num	_	_
39	=	=	JJ	_	32	advcl	_	_
40	1.20-2.41	0	CD	_	39	obj	_	_
41	)	-rrb-	-RRB-	_	32	p	_	_
42	,	,	,	_	1	p	_	_

1	However	however	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	showed	show	VBD	_	0	root	_	_
5	association	association	NN	_	4	obj	_	_
6	with	with	IN	_	9	case	_	_
7	30	0	CD	_	9	num	_	_
8	'	'	``	_	9	p	_	_
9	Deltainsulin	deltainsulin	NN	_	5	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug2	drug0	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	in	in	IN	_	15	case	_	_
14	an	an	DT	_	15	det	_	_
15	interaction	interaction	NN	_	4	ppmod	_	_
16	with	with	IN	_	17	case	_	_
17	percentage	percentage	NN	_	15	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	body	body	NN	_	20	com	_	_
20	fat	fat	NN	_	17	ppmod	_	_
21	(	-lrb-	-LRB-	_	25	p	_	_
22	Bonferroni-corrected	bonferroni-corrected	JJ	_	25	attr	_	_
23	P	p	NN	_	25	attr	_	_
24	=	=	JJ	_	25	attr	_	_
25	0.027	0	NN	_	20	num	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	also	also	RB	_	3	adv	_	_
3	showed	show	VBD	_	0	root	_	_
4	an	an	DT	_	5	det	_	_
5	association	association	NN	_	3	obj	_	_
6	with	with	IN	_	8	case	_	_
7	beta-cell	beta-cell	NN	_	8	com	_	_
8	compensation	compensation	NN	_	5	ppmod	_	_
9	for	for	IN	_	10	case	_	_
10	drug2	drug0	NNS	_	8	ppmod	_	_
11	based	base	VBN	_	10	acl	_	_
12	on	on	IN	_	15	case	_	_
13	30	0	CD	_	15	num	_	_
14	'	'	``	_	15	p	_	_
15	Deltainsulin	deltainsulin	NN	_	11	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	an	an	DT	_	18	det	_	_
18	interaction	interaction	NN	_	15	ppmod	_	_
19	with	with	IN	_	20	case	_	_
20	percentage	percentage	NN	_	18	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	body	body	NN	_	23	com	_	_
23	fat	fat	NN	_	20	ppmod	_	_
24	(	-lrb-	-LRB-	_	28	p	_	_
25	Bonferroni-corrected	bonferroni-corrected	JJ	_	28	attr	_	_
26	P	p	NN	_	28	attr	_	_
27	=	=	JJ	_	28	attr	_	_
28	0.014	0	NN	_	23	num	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	was	be	VBD	_	4	aux	_	_
3	also	also	RB	_	4	adv	_	_
4	associated	associate	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	(	-lrb-	-LRB-	_	12	p	_	_
8	odds	odds	NNS	_	12	attr	_	_
9	ratio	ratio	NN	_	12	attr	_	_
10	-LSB-OR	-lsb-or	NN	_	12	attr	_	_
11	]	-rsb-	-RRB-	_	12	p	_	_
12	2.49	0	NN	_	4	num	_	_
13	-LSB-95	-lsb-0	CD	_	12	num	_	_
14	%	%	NN	_	12	meta	_	_
15	CI	ci	NN	_	12	appo	_	_
16	1.17-5.31	0	CD	_	15	num	_	_
17	]	-rsb-	-RRB-	_	15	p	_	_
18	;	;	:	_	12	p	_	_
19	P	p	NN	_	20	dep	_	_
20	=	=	JJ	_	12	advcl	_	_
21	0.018	0	CD	_	20	obj	_	_
22	)	-rrb-	-RRB-	_	12	p	_	_
23	in	in	IN	_	26	case	_	_
24	our	our	PRP$	_	26	poss	_	_
25	case-control	case-control	JJ	_	26	attr	_	_
26	sample	sample	NN	_	4	ppmod	_	_
27	.	.	.	_	4	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	observed	observe	VBD	_	0	root	_	_
3	nominal	nominal	JJ	_	4	attr	_	_
4	association	association	NN	_	2	obj	_	_
5	between	between	IN	_	7	case	_	_
6	four	#crd#	CD	_	7	num	_	_
7	SNPs	snp	NNS	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	drug1	drug0	NN	_	7	prn	_	_
10	,	,	,	_	9	p	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	9	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	drug4	drug0	NN	_	9	conj	_	_
17	)	-rrb-	-RRB-	_	9	p	_	_
18	in	in	IN	_	21	case	_	_
19	three	#crd#	CD	_	21	num	_	_
20	haplotype	haplotype	NN	_	21	com	_	_
21	blocks	block	NNS	_	7	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	drug5	drug0	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	age	age	NN	_	23	conj	_	_
26	at	at	IN	_	27	case	_	_
27	diagnosis	diagnosis	NN	_	25	ppmod	_	_
28	,	,	,	_	25	p	_	_
29	and	and	CC	_	25	cc	_	_
30	2-h	0-h	JJ	_	32	attr	_	_
31	glucose	glucose	NN	_	32	com	_	_
32	levels	level	NNS	_	23	conj	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	P	p	NN	_	23	prn	_	_
35	=	=	JJ	_	34	attr	_	_
36	0.001-0.055	0	CD	_	34	num	_	_
37	)	-rrb-	-RRB-	_	34	p	_	_
38	.	.	.	_	2	p	_	_

